memantine has been researched along with Acute Confusional Senile Dementia in 838 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD." | 9.19 | Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. ( Arroyo, LM; Asthana, S; Bakshi, RS; Chen, P; Chopra, MP; Craft, S; Cruz, AR; Dysken, MW; Gordon, K; Guarino, PD; Heidebrink, JL; Kowall, NW; Llorente, M; Loreck, DJ; Love, S; Malphurs, J; McCarten, JR; Mintzer, JE; Monnell, KA; Pallaki, M; Peduzzi, PN; Prieto, S; Sano, M; Schellenberg, GD; Segal, Y; Thielke, S; Tomaska, J; Trapp, G; Turvey, CL; Vertrees, JE; Vidal-Cardona, A; Woodman, C; Zachariah, S, 2014) |
| "The primary objective of this study was to evaluate the rate of total brain atrophy (TBA) with serial magnetic resonance imaging (MRI), using the Brain Boundary Shift Integral (BBSI), in patients with probable Alzheimer's disease (AD) over the course of 52 weeks of treatment with memantine or placebo." | 9.16 | Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial. ( Barkhof, F; Fox, NC; Lemming, O; Phul, R; Scheltens, P; Wilkinson, D, 2012) |
| "The aim of the study was to determine whether changes in agitation and aggression would follow memantine treatment and, if so, be associated with changes in nursing burden in institutionalized patients with moderate to severe AD." | 9.15 | Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study. ( Cappell, J; Eryavec, GM; Herrmann, N; Lanctôt, KL, 2011) |
| "To study the feasibility of multimodal neuroimaging in mild to moderate Alzheimer disease (AD) and to estimate the size of possible treatment effects of memantine on potential functional, structural and metabolic biomarkers of disease progression." | 9.13 | Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. ( Berghold, A; Enzinger, C; Fazekas, F; Kolassa, H; Ofner, P; Pendl, B; Ropele, S; Schmidt, H; Schmidt, R; Windisch, M, 2008) |
| " The current retrospective analysis evaluated the efficacy and safety of memantine in a subpopulation of patients with Alzheimer's disease exhibiting behavioral symptoms of agitation/aggression or psychosis at baseline." | 9.13 | Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. ( Ballard, CG; Cooper, JA; Loft, H; Wilcock, GK, 2008) |
| "To evaluate the effects of withdrawal or continuation of cholinesterase inhibitors or memantine, or both, in people with dementia on: cognitive, neuropsychiatric and functional outcomes, rates of institutionalisation, adverse events, dropout from trials, mortality, quality of life and carer-related outcomes." | 9.12 | Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. ( Hughes, C; Lim, WY; Loy, C; McGuinness, B; Parsons, C; Passmore, P; Ward, SA, 2021) |
| "This study is an extension of a 28-week, randomized, double-blind, placebo-controlled study of memantine in 252 patients with moderate to severe Alzheimer disease." | 9.12 | A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. ( Doody, R; Ferris, S; Möbius, HJ; Reisberg, B; Schmitt, F; Stöffler, A, 2006) |
| "The objective of this study was to examine the clinical utility of memantine for moderate-to-severe Alzheimer disease (AD) using responder analyses." | 9.12 | A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. ( Olin, JT; Schmitt, FA; van Dyck, CH, 2006) |
| "To evaluate the clinical efficacy and safety of akatinol memantine in the treatment of patients with mild to moderate Alzheimer disease (AD)." | 9.12 | [Clinical efficacy and safety of akatinol memantine in treatment of mild to moderate Alzheimer disease: a donepezil-controlled, randomized trial]. ( Hu, HT; Ji, CJ; Tang, HC; Wang, YH; Xu, T; Yao, JL; Yu, HZ; Zhang, ZX, 2006) |
| "To investigate the behavioral effects of memantine in moderate to severe Alzheimer disease (AD)." | 9.12 | Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. ( Cummings, JL; Graham, SM; Schneider, E; Tariot, PN, 2006) |
| "The objective of this study was to compare the efficacy and safety of the moderate-affinity, uncompetitive N-methyl-d-aspartate receptor antagonist, memantine, versus placebo in patients with mild to moderate Alzheimer disease (AD)." | 9.12 | Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. ( Graham, SM; McDonald, S; Olin, JT; Ott, BR; Peskind, ER; Pomara, N; Potkin, SG, 2006) |
| "To determine efficacy and safety of memantine for people with dementia." | 9.01 | Memantine for dementia. ( Debarros, J; Farrimond, LE; Maayan, N; McShane, R; Minakaran, N; Roberts, E; Schneider, L; Ware, J; Westby, MJ, 2019) |
| "Similar to observational studies, many participants in AD clinical trials receiving ChEIs or memantine experience greater cognitive decline." | 8.98 | Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis. ( Cutter, GR; Fowler, ME; Kennedy, RE; Schneider, LS, 2018) |
| "This is the first meta-analysis to compare the treatment effects and safety of administering donepezil alone versus a combination of memantine and donepezil to treat patients with moderate to severe Alzheimer Disease, particularly regarding cognitive functions, behavioral and psychological symptoms in dementia (BPSD), and global functions." | 8.95 | Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis. ( Chan, PT; Chang, PC; Chen, CY; Chen, R; Chou, KR; Chu, H; Lin, YC, 2017) |
| "We directly assessed the clinical trials' evidence for memantine's efficacy in mild Alzheimer disease (AD)." | 8.87 | Lack of evidence for the efficacy of memantine in mild Alzheimer disease. ( Dagerman, KS; Higgins, JP; McShane, R; Schneider, LS, 2011) |
| "Memantine, a low affinity antagonist to glutamate NMDA receptors, may prevent excitatory neurotoxicity in dementia." | 8.83 | Memantine for dementia. ( Areosa Sastre, A; McShane, R; Minakaran, N, 2006) |
| "To determine the clinical efficacy and safety of memantine for people with Alzheimer's disease, vascular, or mixed dementia." | 8.82 | Memantine for dementia. ( Areosa, SA; Sherriff, F, 2003) |
| "There is a beneficial effect of memantine (20 mg/day) for patients with moderate to severe Alzheimer disease on cognition and functional decline but not in the clinical impression of change." | 8.82 | Memantine for dementia. ( Areosa, SA; Sherriff, F, 2003) |
| ":Memantine 20 mg/day caused a clinically noticeable reduction in deterioration over 28 weeks in patients with moderate to severe Alzheimer disease." | 8.82 | Memantine for dementia. ( Areosa Sastre, A; McShane, R; Sherriff, F, 2004) |
| "Memantine, a low affinity antagonist to glutamate NMDA receptors, may prevent excitatory neurotoxicity in dementia." | 8.82 | Memantine for dementia. ( Areosa, SA; McShane, R; Sherriff, F, 2005) |
| "Memantine, a low affinity antagonist to glutamate NMDA receptors, may prevent excitatory neurotoxicity in dementia." | 8.82 | Memantine for dementia. ( Areosa, SA; McShane, R; Sherriff, F, 2005) |
| "Memantine, a non-competitive NMDA antagonist, has been approved for use in the treatment of dementia in Germany for over ten years." | 8.80 | Evaluation of memantine for neuroprotection in dementia. ( Jain, KK, 2000) |
| "Providing evidence on donepezil and memantine administration as extemporaneous combination (DM-EXT) to treat Alzheimer Disease (AD) in Italy, and describing demographic and clinical features of AD patients prescribed DM-EXT." | 8.31 | Extemporaneous combination of donepezil and memantine to treat dementia in Alzheimer disease: evidence from Italian real-world data. ( Falato, S; Padovani, A; Pegoraro, V, 2023) |
| " Treatment with memantine prevented the chorea movement and the progression of Huntington's disease." | 8.31 | Memantine administration prevented chorea movement in Huntington's disease: a case report. ( Hirano, M; Ikegawa, A; Kusunoki, S; Mitsui, Y; Nagai, Y; Oda, I; Saigoh, K; Samukawa, M; Yamagishi, Y; Yoshikawa, K, 2023) |
| "When compared to patients prescribed donepezil, galantamine, or memantine, individuals prescribed rivastigmine were almost twice as likely to report dysphagia as an adverse event." | 8.12 | Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. ( Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022) |
| "we made animal models in the natural environment of the Qinghai-Tibet Plateau at an altitude of 4300 m, and used animal behavior, morphology, molecular biology and other methods to evaluate the impact of chronic hypoxia exposure on cognitive function and the neuroprotective effect of Memantine." | 8.02 | Memantine ameliorates cognitive impairment induced by exposure to chronic hypoxia environment at high altitude by inhibiting excitotoxicity. ( Ge, RL; Ji, W; Liu, J; Luo, J; Wan, Y; Zhang, Y, 2021) |
| "We conducted a disproportionality analysis using the Japanese Adverse Drug Event Report (JADER) database reported between April 2004 and March 2019 for detecting the neuropsychiatric adverse event (AE) signals associated with memantine and other potentially interactive drugs including amantadine, dextromethorphan, cimetidine, ranitidine, procainamide, quinidine, acetazolamide, citrate, and bicarbonate." | 8.02 | Safety of Memantine in Combination with Potentially Interactive Drugs in the Real World: A Pharmacovigilance Study Using the Japanese Adverse Drug Event Report (JADER) Database. ( Iwata, A; Mano, T; Sato, K; Toda, T, 2021) |
| " In our study, we investigated the potent anti-cancer effect of Alzheimer's drug Memantine on 4T1 breast cancer cells." | 7.96 | Alzheimer's drug Memantine inhibits metastasis and p-Erk protein expression on 4T1 breast cancer cells. ( Albayrak, G; Korkmaz, FD, 2020) |
| "Cholinesterase inhibitors and memantine are the only classes of drugs approved for the treatment of dementia due to Alzheimer's disease." | 7.83 | Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine. ( Wong, CW, 2016) |
| "To determine whether treatment with memantine plus vitamin D is more effective than memantine or vitamin D alone in improving cognition among patients with Alzheimer disease (AD)." | 7.78 | Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study. ( Annweiler, C; Beauchet, O; Brugg, B; Fantino, B; Herrmann, FR, 2012) |
| "An observational study showed that combining memantine with a cholinesterase inhibitor (ChEI) treatment significantly delayed admission to nursing homes in patients with Alzheimer disease (AD)." | 7.77 | Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease. ( Beauchemin, C; Bineau, S; Lachaine, J; Legault, M, 2011) |
| " There are no long-term studies of the effects of memantine in combination with ChEIs use in Alzheimer disease (AD)." | 7.75 | Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. ( Becker, JT; Dekosky, ST; Klunk, W; Lopez, OL; Saxton, J; Sweet, RA; Wahed, AS; Wolk, DA, 2009) |
| "Although memantine is widely used and generally considered safe, an abrupt cessation of memantine may result in discontinuation syndrome that can be distressing and result in decline of natural course." | 7.75 | Two cases of discontinuation syndrome following cessation of memantine. ( Han, IW; Koo, MS; Kwak, YT; Suk, SH, 2009) |
| "In this study, we proposed a hypothesis to explain the mechanisms of memantine action in treating Alzheimer disease (AD)." | 7.75 | Dual action of memantine in Alzheimer disease: a hypothesis. ( Chen, CP; Wu, TY, 2009) |
| "In in vitro experiments, amiridine in concentration of 100, 200, and 300 microM restored disturbed structure of microtubules assembled from tubulin and microtubule-associated proteins isolated from the brain of patients with Alzheimer disease." | 7.74 | Effect of tacrine, amiridine, akatinol memantine, and triazolam on phosphorylation, structure, and assembly of microtubules from brain microtubular proteins in Alzheimer diseases. ( Burbaeva, GSh; Shevtsov, PN; Shevtsova, EF, 2008) |
| "To conduct a cost-effectiveness analysis comparing the addition of memantine to standard care (that is, without acetylcholinesterase inhibitors) with standard care alone in moderate-to-severe Alzheimer disease (AD) in Canada." | 7.74 | Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. ( Gagnon, M; Guilhaume, C; Hux, M; Rive, B, 2007) |
| "Prevalence of Alzheimer's disease in people with Down's syndrome is very high, and many such individuals who are older than 40 years have pathological changes characteristic of Alzheimer's disease." | 6.77 | Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. ( Aarsland, D; Ballard, C; Bullock, R; Corbett, A; Francis, PT; Hanney, M; Johnson, T; Jones, EL; Lawrence, D; Prasher, V; Tyrer, S; Williams, N; Yu, LM, 2012) |
| "Memantine was significantly better than placebo for cognition." | 6.77 | Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. ( Auestad, BH; Ballard, C; Boustani, M; Coulton, S; Crugel, M; Fox, C; Katona, C; Livingston, G; Maidment, I; Treloar, A, 2012) |
| "Treatment with memantine appeared to have differential effects on cognitive performance in a population of women with putative risk factors for AD." | 6.74 | Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study. ( Holcomb, M; Kenna, HA; Lazzeroni, L; Powers, BN; Rasgon, NL; Williams, KE; Wroolie, TE, 2009) |
| "Memantine is used in Alzheimer's disease treatment as a non-competitive modern-affinity strong voltage-dependent N-methyl-D-aspartate receptor antagonist." | 6.72 | Memantine in neurological disorders - schizophrenia and depression. ( Chuchmacz, J; Czarnecka, K; Szymański, P; Wójtowicz, P, 2021) |
| "Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist." | 6.71 | Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. ( Farlow, MR; Gergel, I; Graham, SM; Grossberg, GT; McDonald, S; Tariot, PN, 2004) |
| "Memantine is a US Food and Drug Administration approved drug for the treatment of Alzheimer's disease." | 6.61 | Memantine for the treatment of ischemic stroke: experimental benefits and clinical lack of studies. ( F Kallmes, D; Seyedsaadat, SM, 2019) |
| "Memantine hydrochloride is a first-line therapeutic drug approved by the US Food and Drug Administration for the management of moderate to severe Alzheimer's disease (AD)." | 6.49 | Memantine hydrochloride in the treatment of dementia subtypes. ( Peng, D; Yuan, X; Zhu, R, 2013) |
| "Memantine acts as an antagonist of N-methyl-D-aspartate (NMDA) type receptors, which is thought to reduce abnormal activation of glutamate neurotransmission." | 6.45 | Memantine for dementia in people with Down syndrome. ( Bennett, C; Carpenter, PK; Mohan, M, 2009) |
| "Memantine is an uncompetitive N-methyl-D-aspartate receptor antagonist with moderate affinity." | 6.45 | Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. ( Grossberg, GT; Thomas, SJ, 2009) |
| "Patients had probable Alzheimer's disease and received treatment with memantine for at least one month." | 6.44 | Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. ( Boustani, M; Brown, RC; Fox, CG; Katona, CL; Maidment, ID; Rodriguez, J, 2008) |
| "The management of dementia in Alzheimer's disease has dramatically changed since the development of anti-dementia drugs." | 6.42 | Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. ( Prasher, VP, 2004) |
| " This was not observed when memantine treatment was combined with vitamin D enrichment." | 5.62 | Effect of Memantine Treatment and Combination with Vitamin D Supplementation on Body Composition in the APP/PS1 Mouse Model of Alzheimer's Disease Following Chronic Vitamin D Deficiency. ( Annweiler, C; Bartha, R; Beauchet, O; Bellyou, M; Broberg, DN; Doad, J; Holdsworth, DW; Montero-Odasso, M; Norley, CJD; Umoh, JU; Wong, D, 2021) |
| "Memantine (Mem) is a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist used in the treatment of Alzheimer's disease." | 5.62 | [Effects of Yokukansankachimpihange on Memantine-induced Dizziness in Mice with Memory Impairment]. ( Aoki, Y; Han, LK; Kaneda, M; Michihara, S; Shimoyama, T; Takahashi, R, 2021) |
| "Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD." | 5.19 | Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. ( Arroyo, LM; Asthana, S; Bakshi, RS; Chen, P; Chopra, MP; Craft, S; Cruz, AR; Dysken, MW; Gordon, K; Guarino, PD; Heidebrink, JL; Kowall, NW; Llorente, M; Loreck, DJ; Love, S; Malphurs, J; McCarten, JR; Mintzer, JE; Monnell, KA; Pallaki, M; Peduzzi, PN; Prieto, S; Sano, M; Schellenberg, GD; Segal, Y; Thielke, S; Tomaska, J; Trapp, G; Turvey, CL; Vertrees, JE; Vidal-Cardona, A; Woodman, C; Zachariah, S, 2014) |
| "We sought to determine whether the extended MAPT haplotype was associated with the worsening of delusions and hallucinations in a combined cohort of 95 patients who participated in 2 clinical trials of treatment with memantine." | 5.19 | Role of the extended MAPT haplotype in the worsening of psychotic symptoms and treatment response in Alzheimer disease. ( Ballard, C; Corbett, A; Creese, B; Fox, C; Jones, E, 2014) |
| "Patients with moderate-to-severe AD with Neuropsychiatric Inventory (NPI) total score ≥13 and NPI agitation/aggression score ≥1 were randomized to placebo or 20-mg memantine in a double-blind, 24-week trial." | 5.17 | A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease. ( Boneva, N; Gauthier, S; Herrmann, N; Lemming, OM, 2013) |
| "A total of 120 demented patients with mild-to-moderate ADRD were prospectively included in this pre-post quasi-experimental study with two intervention groups (43 patients taking CEIs, and 41 taking memantine) and a control group (36 age- and gender matched patients without any anti-dementia drugs)." | 5.17 | Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study. ( Allali, G; Annweiler, C; Beauchet, O; Gallouj, K; Herrmann, FR; Launay, CP; Watfa, G, 2013) |
| "The primary objective of this study was to evaluate the rate of total brain atrophy (TBA) with serial magnetic resonance imaging (MRI), using the Brain Boundary Shift Integral (BBSI), in patients with probable Alzheimer's disease (AD) over the course of 52 weeks of treatment with memantine or placebo." | 5.16 | Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial. ( Barkhof, F; Fox, NC; Lemming, O; Phul, R; Scheltens, P; Wilkinson, D, 2012) |
| "To assess the clinical characteristics and course of patients with mild cognitive impairment (MCI) and mild Alzheimer disease (AD) treated with cholinesterase inhibitors (ChEIs) and memantine hydrochloride." | 5.15 | Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. ( Insel, PS; Schneider, LS; Weiner, MW, 2011) |
| "The aim of the study was to determine whether changes in agitation and aggression would follow memantine treatment and, if so, be associated with changes in nursing burden in institutionalized patients with moderate to severe AD." | 5.15 | Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study. ( Cappell, J; Eryavec, GM; Herrmann, N; Lanctôt, KL, 2011) |
| "To compare memantine with the most prescribed cholinesterase inhibitor (donepezil) from a clinical viewpoint when administered in early phases of Alzheimer disease (AD), and to find out whether memantine may produce changes in brain metabolite concentrations in comparison with donepezil." | 5.14 | Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. ( Errea, JM; Fayed, N; Modrego, PJ; Pina, MA; Rios, C; Sarasa, M, 2010) |
| "To study the feasibility of multimodal neuroimaging in mild to moderate Alzheimer disease (AD) and to estimate the size of possible treatment effects of memantine on potential functional, structural and metabolic biomarkers of disease progression." | 5.13 | Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. ( Berghold, A; Enzinger, C; Fazekas, F; Kolassa, H; Ofner, P; Pendl, B; Ropele, S; Schmidt, H; Schmidt, R; Windisch, M, 2008) |
| " The current retrospective analysis evaluated the efficacy and safety of memantine in a subpopulation of patients with Alzheimer's disease exhibiting behavioral symptoms of agitation/aggression or psychosis at baseline." | 5.13 | Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. ( Ballard, CG; Cooper, JA; Loft, H; Wilcock, GK, 2008) |
| "To evaluate the effects of withdrawal or continuation of cholinesterase inhibitors or memantine, or both, in people with dementia on: cognitive, neuropsychiatric and functional outcomes, rates of institutionalisation, adverse events, dropout from trials, mortality, quality of life and carer-related outcomes." | 5.12 | Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. ( Hughes, C; Lim, WY; Loy, C; McGuinness, B; Parsons, C; Passmore, P; Ward, SA, 2021) |
| "This study is an extension of a 28-week, randomized, double-blind, placebo-controlled study of memantine in 252 patients with moderate to severe Alzheimer disease." | 5.12 | A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. ( Doody, R; Ferris, S; Möbius, HJ; Reisberg, B; Schmitt, F; Stöffler, A, 2006) |
| "The objective of this study was to examine the clinical utility of memantine for moderate-to-severe Alzheimer disease (AD) using responder analyses." | 5.12 | A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. ( Olin, JT; Schmitt, FA; van Dyck, CH, 2006) |
| "To evaluate the clinical efficacy and safety of akatinol memantine in the treatment of patients with mild to moderate Alzheimer disease (AD)." | 5.12 | [Clinical efficacy and safety of akatinol memantine in treatment of mild to moderate Alzheimer disease: a donepezil-controlled, randomized trial]. ( Hu, HT; Ji, CJ; Tang, HC; Wang, YH; Xu, T; Yao, JL; Yu, HZ; Zhang, ZX, 2006) |
| "To investigate the behavioral effects of memantine in moderate to severe Alzheimer disease (AD)." | 5.12 | Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. ( Cummings, JL; Graham, SM; Schneider, E; Tariot, PN, 2006) |
| "The objective of this study was to compare the efficacy and safety of the moderate-affinity, uncompetitive N-methyl-d-aspartate receptor antagonist, memantine, versus placebo in patients with mild to moderate Alzheimer disease (AD)." | 5.12 | Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. ( Graham, SM; McDonald, S; Olin, JT; Ott, BR; Peskind, ER; Pomara, N; Potkin, SG, 2006) |
| "To determine efficacy and safety of memantine for people with dementia." | 5.01 | Memantine for dementia. ( Debarros, J; Farrimond, LE; Maayan, N; McShane, R; Minakaran, N; Roberts, E; Schneider, L; Ware, J; Westby, MJ, 2019) |
| "Similar to observational studies, many participants in AD clinical trials receiving ChEIs or memantine experience greater cognitive decline." | 4.98 | Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis. ( Cutter, GR; Fowler, ME; Kennedy, RE; Schneider, LS, 2018) |
| "This is the first meta-analysis to compare the treatment effects and safety of administering donepezil alone versus a combination of memantine and donepezil to treat patients with moderate to severe Alzheimer Disease, particularly regarding cognitive functions, behavioral and psychological symptoms in dementia (BPSD), and global functions." | 4.95 | Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis. ( Chan, PT; Chang, PC; Chen, CY; Chen, R; Chou, KR; Chu, H; Lin, YC, 2017) |
| "The purpose of this systematic review was to review the current place in therapy of the 4 medications, donepezil, rivastigmine, galantamine, and memantine, approved for the treatment of Alzheimer disease (AD) since the publication of Phase III trials." | 4.91 | Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials? ( Chamberlin, KW; Ehret, MJ, 2015) |
| "Cholinesterase inhibitors and memantine are marketed for the treatment of Alzheimer disease." | 4.89 | Alzheimer disease pharmacologic treatment and treatment research. ( Schneider, LS, 2013) |
| "Current approved drug treatments for Alzheimer disease (AD) include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and the NMDA receptor antagonist memantine." | 4.88 | New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. ( Caraci, F; Drago, F; Fedotova, J; Leggio, GM; Salomone, S, 2012) |
| "We directly assessed the clinical trials' evidence for memantine's efficacy in mild Alzheimer disease (AD)." | 4.87 | Lack of evidence for the efficacy of memantine in mild Alzheimer disease. ( Dagerman, KS; Higgins, JP; McShane, R; Schneider, LS, 2011) |
| "In addition to donepezil, 2 other cholinesterase inhibitors galantamine and rivastigmine, and an N-methyl-D-aspartic acid receptor antagonist, memantine, have been recently approved for the treatment of Alzheimer disease patients at mild to moderately severe and moderately severe to severe stages of the disease, respectively, in Japan." | 4.87 | [Newly approved drugs for Alzheimer disease: effectiveness and limitation]. ( Yanagisawa, K, 2011) |
| "Cholinesterase inhibitors and memantine are widely used for the treatment of Alzheimer disease (AD) and other non-AD dementia worldwide." | 4.86 | [Drug therapy for Alzheimer's disease]. ( Shoji, M, 2010) |
| "Memantine, a low affinity antagonist to glutamate NMDA receptors, may prevent excitatory neurotoxicity in dementia." | 4.83 | Memantine for dementia. ( Areosa Sastre, A; McShane, R; Minakaran, N, 2006) |
| "The aim of this article is to discuss new data on presently approved drugs for dementia, such as cholinesterase inhibitors and memantine, and concerns regarding the use of antipsychotics for treating neuropsychiatric symptoms, as well as to summarize some relevant studies recently published on emerging therapies with potential disease-modifying effects." | 4.83 | Treatment of dementia: anything new? ( Caramelli, P; Machado, JC, 2006) |
| "To determine the clinical efficacy and safety of memantine for people with Alzheimer's disease, vascular, or mixed dementia." | 4.82 | Memantine for dementia. ( Areosa, SA; Sherriff, F, 2003) |
| "There is a beneficial effect of memantine (20 mg/day) for patients with moderate to severe Alzheimer disease on cognition and functional decline but not in the clinical impression of change." | 4.82 | Memantine for dementia. ( Areosa, SA; Sherriff, F, 2003) |
| "Memantine is a relatively new drug specially developed for use in moderate-to-severe dementia." | 4.82 | Memantine: pharmacological properties and clinical uses. ( Kumar, S, 2004) |
| ":Memantine 20 mg/day caused a clinically noticeable reduction in deterioration over 28 weeks in patients with moderate to severe Alzheimer disease." | 4.82 | Memantine for dementia. ( Areosa Sastre, A; McShane, R; Sherriff, F, 2004) |
| "Memantine, a low affinity antagonist to glutamate NMDA receptors, may prevent excitatory neurotoxicity in dementia." | 4.82 | Memantine for dementia. ( Areosa, SA; McShane, R; Sherriff, F, 2005) |
| "Memantine, a low affinity antagonist to glutamate NMDA receptors, may prevent excitatory neurotoxicity in dementia." | 4.82 | Memantine for dementia. ( Areosa, SA; McShane, R; Sherriff, F, 2005) |
| "Memantine, a non-competitive NMDA antagonist, has been approved for use in the treatment of dementia in Germany for over ten years." | 4.80 | Evaluation of memantine for neuroprotection in dementia. ( Jain, KK, 2000) |
| "Providing evidence on donepezil and memantine administration as extemporaneous combination (DM-EXT) to treat Alzheimer Disease (AD) in Italy, and describing demographic and clinical features of AD patients prescribed DM-EXT." | 4.31 | Extemporaneous combination of donepezil and memantine to treat dementia in Alzheimer disease: evidence from Italian real-world data. ( Falato, S; Padovani, A; Pegoraro, V, 2023) |
| " Treatment with memantine prevented the chorea movement and the progression of Huntington's disease." | 4.31 | Memantine administration prevented chorea movement in Huntington's disease: a case report. ( Hirano, M; Ikegawa, A; Kusunoki, S; Mitsui, Y; Nagai, Y; Oda, I; Saigoh, K; Samukawa, M; Yamagishi, Y; Yoshikawa, K, 2023) |
| " The cholinesterase inhibitor rivastigmine and the NMDA receptor antagonist memantine were used to investigate the effects of drugs, used to treat AD cognitive dysfunction, on breathing in hypoxia and hypercapnia." | 4.12 | Hypoxic and Hypercapnic Responses in Transgenic Murine Model of Alzheimer's Disease Overexpressing Human AβPP: The Effects of Pretreatment with Memantine and Rivastigmine. ( Andrzejewski, K; Conde, SV; Jampolska, M; Kaczyńska, K; Mojzych, I, 2022) |
| "When compared to patients prescribed donepezil, galantamine, or memantine, individuals prescribed rivastigmine were almost twice as likely to report dysphagia as an adverse event." | 4.12 | Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. ( Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022) |
| "we made animal models in the natural environment of the Qinghai-Tibet Plateau at an altitude of 4300 m, and used animal behavior, morphology, molecular biology and other methods to evaluate the impact of chronic hypoxia exposure on cognitive function and the neuroprotective effect of Memantine." | 4.02 | Memantine ameliorates cognitive impairment induced by exposure to chronic hypoxia environment at high altitude by inhibiting excitotoxicity. ( Ge, RL; Ji, W; Liu, J; Luo, J; Wan, Y; Zhang, Y, 2021) |
| "We conducted a disproportionality analysis using the Japanese Adverse Drug Event Report (JADER) database reported between April 2004 and March 2019 for detecting the neuropsychiatric adverse event (AE) signals associated with memantine and other potentially interactive drugs including amantadine, dextromethorphan, cimetidine, ranitidine, procainamide, quinidine, acetazolamide, citrate, and bicarbonate." | 4.02 | Safety of Memantine in Combination with Potentially Interactive Drugs in the Real World: A Pharmacovigilance Study Using the Japanese Adverse Drug Event Report (JADER) Database. ( Iwata, A; Mano, T; Sato, K; Toda, T, 2021) |
| "Memantine was favored over AChEIs as first-line treatment to AD in persons with asthma/COPD compared to those without asthma/COPD (odds ratio 1." | 3.96 | Asthma and Chronic Obstructive Pulmonary Disease as a Comorbidity and Association with the Choice of Antidementia Medication Among Persons with Alzheimer's Disease. ( Hartikainen, S; Koponen, M; Lampela, P; Taipale, H; Tanskanen, A; Tiihonen, J; Tolppanen, AM, 2020) |
| " In our study, we investigated the potent anti-cancer effect of Alzheimer's drug Memantine on 4T1 breast cancer cells." | 3.96 | Alzheimer's drug Memantine inhibits metastasis and p-Erk protein expression on 4T1 breast cancer cells. ( Albayrak, G; Korkmaz, FD, 2020) |
| "To compare time to SNF admission and cardiovascular events between acetylcholinesterase inhibitor (AChEI) monotherapy, memantine hydrochloride monotherapy, and combination therapy with an AChEI and memantine in treating elderly adults with Alzheimer disease." | 3.91 | Association of Antidementia Therapies With Time to Skilled Nursing Facility Admission and Cardiovascular Events Among Elderly Adults With Alzheimer Disease. ( He, M; Hernandez, I; San-Juan-Rodriguez, A; Zhang, Y, 2019) |
| "Memantine is a symptomatic treatment that partially prevents cognitive decline in Alzheimer disease (AD)." | 3.88 | Cognitive changes under memantine according to vitamin D status in Alzheimer patients: An exposed/unexposed cohort pilot study. ( Annweiler, C; Beaudenon, M; Brangier, A; Duval, GT; Lemire, P, 2018) |
| "The risk of pneumonia was higher in persons using rivastigmine patch (n = 9709) (adjusted hazard ratio (HR) 1." | 3.85 | Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease. ( Hartikainen, S; Lampela, P; Lavikainen, P; Taipale, H; Tanskanen, A; Tiihonen, J; Tolppanen, AM, 2017) |
| "Cholinesterase inhibitors and memantine are the only classes of drugs approved for the treatment of dementia due to Alzheimer's disease." | 3.83 | Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine. ( Wong, CW, 2016) |
| "Memantine is approved for treatment of moderate to severe Alzheimer disease (AD) but is also investigated as a treatment option for a number of different conditions, and even though there are reports of a number of adverse effects, including new-onset seizures and psychosis, it is considered to be generally well tolerated." | 3.79 | Two cases of loss of consciousness after long-term memantine treatment. ( Mimica, N; Savić, A, 2013) |
| "All four dementia drugs available on the Swedish market (three cholinesterase inhibitors [donepezil, rivastigmine and galantamine] and memantine) were prescribed at the two dementia clinics." | 3.79 | Is drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centres. ( Johnell, K; Sonde, L, 2013) |
| "To determine whether treatment with memantine plus vitamin D is more effective than memantine or vitamin D alone in improving cognition among patients with Alzheimer disease (AD)." | 3.78 | Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study. ( Annweiler, C; Beauchet, O; Brugg, B; Fantino, B; Herrmann, FR, 2012) |
| "An observational study showed that combining memantine with a cholinesterase inhibitor (ChEI) treatment significantly delayed admission to nursing homes in patients with Alzheimer disease (AD)." | 3.77 | Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease. ( Beauchemin, C; Bineau, S; Lachaine, J; Legault, M, 2011) |
| "The primary objective was to assess the safety and tolerability of rivastigmine capsules 6-12 mg/day plus memantine (5-20 mg/day) as measured by the incidences of vomiting and nausea compared with those reported in the rivastigmine United States Prescribing Information (US PI)." | 3.76 | Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). ( Bhatnagar, V; Brannan, S; Koumaras, B; Meng, X; Olin, JT; Reyes, P, 2010) |
| "To determine the factors associated with receiving specific treatment (cholinesterase inhibitors or/and memantine) for Alzheimer disease (AD) in elderly patients." | 3.76 | Lower Barthel Index scores predict less prescription of pharmacological therapy in elderly patients with Alzheimer disease. ( Formiga, F; Fort, I; Regalado, P; Robles, MJ; Rodriguez, D, 2010) |
| " There are no long-term studies of the effects of memantine in combination with ChEIs use in Alzheimer disease (AD)." | 3.75 | Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. ( Becker, JT; Dekosky, ST; Klunk, W; Lopez, OL; Saxton, J; Sweet, RA; Wahed, AS; Wolk, DA, 2009) |
| "Although memantine is widely used and generally considered safe, an abrupt cessation of memantine may result in discontinuation syndrome that can be distressing and result in decline of natural course." | 3.75 | Two cases of discontinuation syndrome following cessation of memantine. ( Han, IW; Koo, MS; Kwak, YT; Suk, SH, 2009) |
| "In this study, we proposed a hypothesis to explain the mechanisms of memantine action in treating Alzheimer disease (AD)." | 3.75 | Dual action of memantine in Alzheimer disease: a hypothesis. ( Chen, CP; Wu, TY, 2009) |
| "In in vitro experiments, amiridine in concentration of 100, 200, and 300 microM restored disturbed structure of microtubules assembled from tubulin and microtubule-associated proteins isolated from the brain of patients with Alzheimer disease." | 3.74 | Effect of tacrine, amiridine, akatinol memantine, and triazolam on phosphorylation, structure, and assembly of microtubules from brain microtubular proteins in Alzheimer diseases. ( Burbaeva, GSh; Shevtsov, PN; Shevtsova, EF, 2008) |
| "To conduct a cost-effectiveness analysis comparing the addition of memantine to standard care (that is, without acetylcholinesterase inhibitors) with standard care alone in moderate-to-severe Alzheimer disease (AD) in Canada." | 3.74 | Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. ( Gagnon, M; Guilhaume, C; Hux, M; Rive, B, 2007) |
| " After memantine was started he developed severe fluctuations in awareness, visual hallucinations, agitation, and worsened parkinsonism." | 3.73 | Exacerbation of Lewy bodies dementia due to memantine. ( Blazquez-Menes, B; Calatayud, MT; Menendez-Gonzalez, M, 2005) |
| "Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, reduces the clinical deterioration in moderate-to-severe Alzheimer disease (AD) for which other treatments are not available." | 3.72 | Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. ( Grundke-Iqbal, I; Haque, N; Iqbal, K; Li, L; Sengupta, A, 2004) |
| "Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia)." | 3.30 | Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial. ( Doskas, T; Dubois, B; Hermine, O; Lipschitz, S; López-Arrieta, J; Mansfield, CD; Moroz, S; Moussy, A; Spiru, L; Tsolaki, M; Venger, O; Vermersch, P, 2023) |
| "Early AD (eAD) includes mild cognitive impairment (MCI) due to AD and mild AD dementia." | 3.01 | Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease. ( Ballard, C; Garcia, MJ; Gsteiger, S; Lang, S; Leadley, R; Ross, J; Vinand, E, 2023) |
| "Memantine is an important addition to the psychopharmacological armamentarium." | 3.01 | Clinical Indications of Memantine in Psychiatry-Science or Art? ( Alayadhi, N; Aljuwaiser, M; Naguy, A; Ozidu, V; Rushdy, R; Shafik Zakhari, SA, 2023) |
| "In an ever-increasing aged world, Alzheimer's disease (AD) represents the first cause of dementia and one of the first chronic diseases in elderly people." | 3.01 | Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies. ( Buccellato, FR; D'Anca, M; Del Fabbro, M; Galimberti, D; Scarpini, E; Tartaglia, GM, 2023) |
| "Baseline Alzheimer's disease assessment scale-cognitive (ADAS-Cog) and Clinical Global Impression of Change were assessed." | 2.94 | Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer's disease. ( Agronin, ME; Alva, G; Armon, C; Baror, E; Bernick, C; Karantzoulis, S; Keegan, AP; Pascual-Leone, A; Ploznik, M; Sabbagh, M; Sadowsky, C; Tousi, B, 2020) |
| "We included trials assessing cognition with the Mini-Mental State Examination (MMSE), and adverse events." | 2.82 | Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis. ( Ashoor, HM; Clarke, M; Hemmelgarn, BR; Holroyd-Leduc, J; Mavridis, D; Rios, P; Seitidis, G; Stewart, L; Straus, SE; Tricco, AC; Tudur-Smith, C; Veroniki, AA, 2022) |
| " Improvements to the approved therapies, such as easier routes of administration and reduced dosing frequencies, along with the developments of new strategies and combined treatments are expected to occur within the next decade and will positively impact the way the disease is managed." | 2.82 | Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach. ( Boada, M; Jofresa, S; Morató, X; Pytel, V; Ruiz, A, 2022) |
| "Treatment with memantine significantly decreased the NPI score (5." | 2.82 | The effect of memantine on sleep architecture and psychiatric symptoms in patients with Alzheimer's disease. ( Ando, N; Ishikawa, I; Mori, T; Nakamura, Y; Shinno, H, 2016) |
| "Memantine-treated patients were younger than those not receiving memantine (mean 75." | 2.80 | Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor. ( Farlow, MR; Grossberg, GT; Meng, X; Velting, DM, 2015) |
| " A new fixed-dose combination (FDC) capsule containing 28 mg memantine extended release (ER) and 10 mg donepezil was evaluated for bioequivalence with co-administered commercially available memantine ER and donepezil, and for bioavailability with regard to food intake." | 2.80 | A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer's disease: two phase I studies in healthy volunteers. ( Boinpally, R; Chen, L; Hofbauer, RK; McClure, N; Periclou, A; Zukin, SR, 2015) |
| "Donepezil was used as the standard control treatment." | 2.80 | The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients. ( Cheng, Y; Du, H; Shi, FD; Wei, C; Zhang, N, 2015) |
| " Original memantine and generic medication dosage (5 mg daily) was titrated according to the manufacturer's recommendations." | 2.80 | [A comparison of the efficacy and safety of memantal and original memantine in the treatment of mild and moderate dementia in Alzheimer's disease]. ( Cherenkova, EV; Fedorova, EY; Goncharova, OV; Kuznetsova, NA; Polozova, TM; Shapovalov, DL; Shiryaev, OY, 2015) |
| "The mean Alzheimer's Disease Cooperative Study/Activities of Daily Living Inventory score at entry was 57 and the mean Mini-Mental State Examination score at entry was 21." | 2.79 | Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. ( Arroyo, LM; Asthana, S; Bakshi, RS; Carney, S; Chen, P; Chopra, MP; Craft, S; Cruz, AR; Dysken, MW; Gordon, K; Guarino, PD; Heidebrink, JL; Kowall, NW; Llorente, M; Loreck, DJ; Love, S; Malphurs, J; McCarten, JR; Mintzer, JE; Monnell, KA; Pallaki, M; Prieto, S; Sano, M; Schellenberg, GD; Thielke, S; Tomaska, J; Trapp, G; Turvey, CL; Vatassery, G; Vertrees, JE; Vidal-Cardona, A; Woodman, C, 2014) |
| "Memantine is an N-methyl-D-aspartate receptor antagonist used to treat AD in > 80 countries worldwide, and studies in the USA and Europe have shown it to be effective in improving language deficits; however, there are currently no data on language improvements in Japanese patients treated with memantine." | 2.79 | Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan. ( Homma, A; Kitamura, S; Matsui, D; Nakamura, Y; Shiosakai, K, 2014) |
| "A link between poor sleep quality and Alzheimer's disease (AD) has recently been suggested." | 2.79 | Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial. ( Farmer, M; Frydman-Marom, A; Fund, N; Harari, G; Laudon, M; Nir, T; Wade, AG; Zisapel, N, 2014) |
| " Participants were evaluated every month by Severe Cognitive Impairment Rating Scale (SCIRS) and Functional Assessment Staging (FAST) in addition to recording the probable adverse events." | 2.79 | Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial. ( Akhondzadeh, S; Alimardani, R; Farokhnia, M; Farsad, F; Gougol, A; Iranpour, N; Kamalipour, M; Shafiee Sabet, M; Yekehtaz, H, 2014) |
| " Safety and tolerability were assessed through adverse events and physical and laboratory examinations." | 2.78 | The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. ( Allegri, RF; Gloger, S; Graham, SM; Grossberg, GT; Gutiérrez-Robledo, LM; Jia, XD; Manes, F; Miller, ML; Pejović, V; Perhach, JL; Xie, L, 2013) |
| "The Relevant Outcome Scale for Alzheimer's disease (ROSA) is a novel, valid, and reliable instrument for multidimensional assessment of Alzheimer's disease (AD) symptoms across all severity stages." | 2.78 | Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open-label, single-arm, multicenter clinical study. ( Ferris, S; Gauthier, S; Holthoff, V; Ihl, R; Robert, P; Sternberg, K; Tennigkeit, F; Winblad, B, 2013) |
| "Prevalence of Alzheimer's disease in people with Down's syndrome is very high, and many such individuals who are older than 40 years have pathological changes characteristic of Alzheimer's disease." | 2.77 | Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. ( Aarsland, D; Ballard, C; Bullock, R; Corbett, A; Francis, PT; Hanney, M; Johnson, T; Jones, EL; Lawrence, D; Prasher, V; Tyrer, S; Williams, N; Yu, LM, 2012) |
| "In patients with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with cognitive benefits that exceeded the minimum clinically important difference and with significant functional benefits over the course of 12 months." | 2.77 | Donepezil and memantine for moderate-to-severe Alzheimer's disease. ( Adams, J; Baldwin, A; Ballard, C; Banerjee, S; Barber, R; Bentham, P; Brown, R; Burns, A; Dening, T; Findlay, D; Gray, R; Griffin, M; Hills, R; Holmes, C; Howard, R; Hughes, A; Jacoby, R; Johnson, T; Jones, R; Juszczak, E; Katona, C; Knapp, M; Lindesay, J; Macharouthu, A; McKeith, I; McShane, R; O'Brien, J; Onions, C; Passmore, P; Phillips, P; Ritchie, C; Sheehan, B, 2012) |
| "0) on stable donepezil dosing participated in two task-related fMRI sessions consisting of a face-name paired associative encoding memory paradigm 24 weeks apart during a randomized placebo-controlled pharmaco-fMRI drug study." | 2.77 | Tracking cognitive change over 24 weeks with longitudinal functional magnetic resonance imaging in Alzheimer's disease. ( Atri, A; Deluca, AN; Diamond, EL; McLaren, DG; Mitchell, MB; O'Brien, JL; Rentz, DM; Sperling, RA; Sreenivasan, A; Van Dijk, KR, 2012) |
| "Memantine was significantly better than placebo for cognition." | 2.77 | Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. ( Auestad, BH; Ballard, C; Boustani, M; Coulton, S; Crugel, M; Fox, C; Katona, C; Livingston, G; Maidment, I; Treloar, A, 2012) |
| "Donepezil 23 mg was generally safe and well tolerated among patients receiving donepezil alone and among patients receiving a combination of donepezil and memantine therapy." | 2.77 | Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. ( Doody, RS; Farlow, MR; Geldmacher, DS; Mackell, J; Moline, M; Sun, Y, 2012) |
| "Memantine is an approved symptomatic treatment for moderate to severe Alzheimer's disease that reduces the excitotoxic effects of hyperactive glutamatergic transmission." | 2.76 | Effect of memantine on resting state default mode network activity in Alzheimer's disease. ( Alessandrini, F; Beltramello, A; Caltagirone, C; Canu, E; Costardi, D; Cotelli, M; Frisoni, GB; Lorenzi, M; Mercuri, NB; Pizzini, FB; Rosini, S; Zoccatelli, G, 2011) |
| "Memantine treatment was also associated with superior performances on the Boston Naming Test (P = ." | 2.76 | Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer's disease. ( Fridman, M; Graham, SM; Hofbauer, RK; Hsu, HA; Li, S; Perhach, JL; Sadowsky, C; Saxton, J; Suhy, J; Weiner, MW; Yu, SY, 2011) |
| "Current treatments for Alzheimer's disease and related disorders (ADRD) are symptomatic and can only temporarily slow down ADRD." | 2.76 | Alzheimer's disease--input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial. ( Annweiler, C; Beauchet, O; Fantino, B; Gautier, J; Parot-Schinkel, E; Thiery, S, 2011) |
| "Treatment with memantine was safe and effective." | 2.75 | [Memantine in the pharmacologic treatment of moderately severe to severe Alzheimer's disease in Spain (MEMORY study)]. ( Agüera-Ortiz, LF, 2010) |
| "Treatment with memantine appeared to have differential effects on cognitive performance in a population of women with putative risk factors for AD." | 2.74 | Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study. ( Holcomb, M; Kenna, HA; Lazzeroni, L; Powers, BN; Rasgon, NL; Williams, KE; Wroolie, TE, 2009) |
| " Safety and tolerability were assessed by the number of withdrawals, adverse events (AEs) and monitoring of vital signs." | 2.73 | Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. ( Barker, A; Bayer, A; Inglis, F; Jones, RW; Phul, R, 2007) |
| "Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to be safe and to have beneficial effects on cognition, function, behavior, and global patient status in patients with Alzheimer's disease (AD) in studies lasting 3-6 months." | 2.73 | Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. ( Blake, LM; Kagan, E; Ott, BR; Resnick, M, 2007) |
| "Subscales of the Alzheimer's Disease Assessment Scale (ADAS-cog), the Mini-Mental State Examination (MMSE) and additional neuropsychological tests (e." | 2.73 | Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine. ( Adler, G; Gunay, I; Ibach, B; Riepe, MW; Tracik, F; Weinkauf, B, 2007) |
| "Memantine-treated patients showed statistically significant improvement relative to placebo at weeks 12 and 18, and numerical superiority at week 24 on both efficacy scales." | 2.73 | Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. ( Bakchine, S; Loft, H, 2007) |
| "Donepezil was effective and well tolerated in moderate-to-severe AD patients who discontinued memantine monotherapy, including those with previous exposure to ChE inhibitors." | 2.73 | Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy. ( Hager, K; Hort, J; Li, C; López Pousa, S; Sakka, P; Schwam, E; Soininen, H; Tsolaki, M, 2007) |
| "Memantine-treated patients showed statistically significant improvement relative to placebo at weeks 12 and 18, and numerical superiority at week 24 on both efficacy scales." | 2.73 | Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. ( Bakchine, S; Loft, H, 2008) |
| "This study consisted of 2 phases: development of a liquid chromatography-tandem mass spectrometry (LC/MS) method for determination of memantine in human plasma and characterization of single-dose and multiple-dose pharmacokinetic profiles of memantine in healthy Chinese volunteers using the LC/MS method." | 2.73 | Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ( Liu, MY; Meng, SN; Wang, S; Wei, MJ; Wu, HZ, 2008) |
| "Memantine is used in Alzheimer's disease treatment as a non-competitive modern-affinity strong voltage-dependent N-methyl-D-aspartate receptor antagonist." | 2.72 | Memantine in neurological disorders - schizophrenia and depression. ( Chuchmacz, J; Czarnecka, K; Szymański, P; Wójtowicz, P, 2021) |
| "Memantine was not associated with a significant frequency of adverse events." | 2.71 | Memantine in moderate-to-severe Alzheimer's disease. ( Doody, R; Ferris, S; Möbius, HJ; Reisberg, B; Schmitt, F; Stöffler, A, 2003) |
| "Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist." | 2.71 | Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. ( Farlow, MR; Gergel, I; Graham, SM; Grossberg, GT; McDonald, S; Tariot, PN, 2004) |
| "Memantine treatment also has demonstrated significant improvement of cognitive performance in patients suffering from vascular dementia." | 2.71 | Memantine hydrochloride: pharmacological and clinical profile. ( Graham, SM; Möbius, HJ; Stöffler, A, 2004) |
| "The cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog) was a primary endpoint in both trials, and in both trials a statistically significant difference was seen between treatment groups after 28 weeks." | 2.71 | Memantine in vascular dementia. ( Möbius, HJ; Stöffler, A, 2003) |
| " Given the renal tubular transport and extensive urinary excretion of memantine and metformin, it was of interest to assess the pharmacokinetic and pharmacodynamic interaction with glyburide/metformin." | 2.71 | Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. ( Abramowitz, W; Chou, T; Rao, N; Ventura, D, 2005) |
| "16 patients with Alzheimer's disease were treated with akatinol memantine." | 2.69 | [Akatinol memantin in Alzheimer's disease: clinico-immunological correlates]. ( Androsova, LV; Selezneva, ND, 2000) |
| " Besides, transdermal drug delivery systems seem to provide hope for the management of various diseases, due to the advantages that they offer in comparison with oral dosage forms." | 2.66 | Transdermal Drug Delivery Systems and their Potential in Alzheimer's Disease Management. ( Bülbül, EÖ; Karantas, ID; Mutlu, G; Okur, ME; Okur, NÜ; Siafaka, PI, 2020) |
| "Memantine was more acceptable than placebo (MD 0." | 2.66 | Memantine, Donepezil, or Combination Therapy-What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis. ( Guo, J; Huang, Y; Liu, R; Wang, Z; Zhang, N; Zhang, R, 2020) |
| "Dementia is an acquired loss of cognition in multiple cognitive domains sufficiently severe to affect social or occupational function." | 2.61 | Diagnosis and Management of Dementia: Review. ( Arvanitakis, Z; Bennett, DA; Shah, RC, 2019) |
| "Memantine is a US Food and Drug Administration approved drug for the treatment of Alzheimer's disease." | 2.61 | Memantine for the treatment of ischemic stroke: experimental benefits and clinical lack of studies. ( F Kallmes, D; Seyedsaadat, SM, 2019) |
| "Meta-analyses were conducted for Alzheimer's Disease Assessment Scale-cognitive subscale and/or Mini-Mental State Examination (MMSE)." | 2.58 | Comparisons between traditional medicines and pharmacotherapies for Alzheimer disease: A systematic review and meta-analysis of cognitive outcomes. ( Chang, SY; Dong, L; Feng, M; Guo, X; Hügel, H; Hyde, AJ; Lu, C; May, BH; Xue, CC; Zhang, AL, 2018) |
| "Memantine is an NMDA receptor antagonist clinically used for the treatment of moderate to severe Alzheimer's disease." | 2.58 | Studies on the interaction of NMDA receptor antagonist memantine with cell membranes: A mini-review. ( Jemiola-Rzeminska, M; Strzalka, K; Suwalsky, M; Zambrano, P, 2018) |
| "Memantine is a viable treatment option for patients with AD presenting not only with cognitive impairment, but also with a broader range of symptoms, including the behavioral and psychological symptoms of dementia." | 2.58 | Memantine in Japanese patients with moderate to severe Alzheimer's disease: meta-analysis of multiple-index responder analyses. ( Fukuchi, Y; Kamata, T; Matsui, D; Matsumoto, T; Okuizumi, K; Saito, K, 2018) |
| " Primary outcomes were all-cause discontinuation, discontinuation due to adverse events (AE) and efficacy on cognitive function." | 2.58 | Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer's disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients. ( Blanco-Silvente, L; Capellà, D; Castells, X; Garre-Olmo, J; Vilalta-Franch, J, 2018) |
| " Although memantine monotherapy and combination therapy are associated with a few individual adverse events such as somnolence, it is well-tolerated and its safety (all-cause discontinuation) is comparable or superior to that of the placebo (agitation)." | 2.58 | The efficacy and safety of memantine for the treatment of Alzheimer's disease. ( Ikuta, T; Iwata, N; Kishi, T; Matsunaga, S; Nomura, I; Okuya, M; Sakuma, K, 2018) |
| " Based on these studies, donepezil has been shown to be effective and safe in Chinese AD patients and may impact AD biomarkers, such as hippocampal atrophy, Aβ, and tau." | 2.58 | Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients. ( Gordon, ML; Zhang, N, 2018) |
| "The increasing prevalence of Alzheimer's disease (AD) demands more effective drugs, which are still unclear." | 2.58 | Identification of the optimal cognitive drugs among Alzheimer's disease: a Bayesian meta-analytic review. ( Hang, L; Jia, R; Li, J; Liang, J; Wang, Y; Wu, R; Xu, Y; Zhang, H, 2018) |
| " The primary outcomes were the mean overall changes in cognitive function and responders who had any adverse events." | 2.58 | Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials. ( Cao, XP; Dou, KX; Guo, QH; Hou, XH; Mok, V; Tan, CC; Tan, L; Tan, MS; Yu, JT, 2018) |
| "Alzheimer's disease is a neurodegenerative disorder with insidious onset and slow progression." | 2.55 | [Alzheimer's disease]. ( Høgh, P, 2017) |
| "Memantine was the first breakthrough medication for the treatment of moderate to severe Alzheimer's disease (AD) patients and represents a fundamentally new mechanism of action (moderate-affinity, uncompetitive, voltage-dependent, N-methyl-d-aspartate (NMDA) receptor antagonist that exhibits fast on/off kinetics) to modulate glutamatergic dysfunction." | 2.55 | Classics in Chemical Neuroscience: Memantine. ( Alam, S; Bender, AM; Lindsley, CW; Lingenfelter, KS, 2017) |
| "The clinical benefit of memantine for Alzheimer's disease (AD) remains inconclusive." | 2.55 | Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis. ( Ikuta, T; Iwata, N; Kishi, T; Matsunaga, S; Nomura, I; Oya, K, 2017) |
| "In fact, Alzheimer's disease is a complex multifactorial disease." | 2.55 | Recent Progress in the Pharmacotherapy of Alzheimer's Disease. ( Gold, J; Grossberg, GT; Hinds, S; Khoury, R; Patel, K, 2017) |
| "Apathy is highly prevalent in Alzheimer's disease (AD), but whether pharmacotherapy is effective in managing apathy is unclear." | 2.55 | Pharmacological Therapy for Apathy in Alzheimer's Disease: A Systematic Review and Meta-Analysis. ( Hsiung, GR; Sarai, M; Sepehry, AA, 2017) |
| "The most prevalent of all dementias is Alzheimer's disease, a progressive neurodegenerative disease that presents with deficits in memory, cognition, motor skills, and a general decline in the quality of life." | 2.55 | Alzheimer's disease in the zebrafish: where can we take it? ( Caramillo, EM; Echevarria, DJ, 2017) |
| "Kynurenic acid (KYNA) is an endogenous antagonist of NMDA receptors which has been demonstrated under experimental conditions to be neuroprotective." | 2.53 | Memantine and Kynurenic Acid: Current Neuropharmacological Aspects. ( Majláth, Z; Toldi, J; Török, N; Vécsei, L, 2016) |
| "Whilst dementia has long been synonymous with AD, it is becoming more widely accepted as part of the clinical spectrum in PD (PDD)." | 2.53 | Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia. ( Lewis, SJ; Szeto, JY, 2016) |
| "Memantine is an uncompetitive N-methyl-d-aspartic acid receptor antagonist and is approved for the management of moderate-to-severe AD." | 2.53 | Pharmacotherpy and Alzheimer's Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach. ( Daulatzai, MA, 2016) |
| " To alleviate the pill burden and swallowing difficulties associated with the condition, a fixed drug combination of extended-release memantine and donepezil was developed." | 2.53 | Memantine and donepezil: a fixed drug combination for the treatment of moderate to severe Alzheimer's dementia. ( Owen, RT, 2016) |
| "Using Alzheimer's disease as an example, this review employs a networks-based method to assess repeatability of outcomes across species, by intervention and mechanism." | 2.52 | Improving the predictive value of interventional animal models data. ( Zeiss, CJ, 2015) |
| "While the neuropathological features of Alzheimer's disease are recognized but the intricacies of the mechanism have not been clearly defined." | 2.52 | A review on Alzheimer's disease pathophysiology and its management: an update. ( Kumar, A; Singh, A, 2015) |
| "Memantine was superior to placebo in terms of discontinuation because of inefficacy [risk ratio (RR)=0." | 2.52 | Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. ( Iwata, N; Kishi, T; Matsunaga, S, 2015) |
| " In clinical trials, a high dropout rate and numerous adverse events associated with memantine have been observed." | 2.52 | Efficacy and adverse effects of memantine treatment for Alzheimer's disease from randomized controlled trials. ( Jiang, H; Jiang, J, 2015) |
| "Memantine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that is a well-established treatment option for moderate to severe dementia of the Alzheimer's type, either alone or in combination with cholinesterase inhibitors." | 2.52 | Memantine extended release (28 mg once daily): a review of its use in Alzheimer's disease. ( Plosker, GL, 2015) |
| " In this setting, drug-drug interaction may represent a serious and even life-threatening clinical condition." | 2.52 | Potential drug-drug interactions in Alzheimer patients with behavioral symptoms. ( Calsolaro, V; Monzani, F; Pasqualetti, G; Polini, A; Tognini, S, 2015) |
| "The modern era of drug development for Alzheimer's disease began with the proposal of the cholinergic hypothesis of memory impairment and the 1984 research criteria for Alzheimer's disease." | 2.50 | Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. ( Andreasen, N; Feldman, H; Giacobini, E; Jones, R; Kivipelto, M; Mangialasche, F; Mantua, V; Mecocci, P; Pani, L; Schneider, LS; Winblad, B, 2014) |
| " Compared with placebo, more dropouts and adverse events occurred with the cholinesterase inhibitors, but not with memantine." | 2.50 | Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. ( Jiang, T; Meng, XF; Tan, CC; Tan, L; Tan, MS; Wang, C; Wang, HF; Yu, JT; Zhu, XC, 2014) |
| "Memantine is a non-competitive low-affinity antagonist of the NMDA receptor with a t(1/2) of 70 h." | 2.49 | Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. ( Eap, CB; Noetzli, M, 2013) |
| "During the course of Alzheimer's disease (AD), cognitive processes, including language and communication, become increasingly impaired." | 2.49 | Aspects of communication in Alzheimer's disease: clinical features and treatment options. ( Woodward, M, 2013) |
| " Memantine did not significantly affect discontinuation caused by serious adverse events but did increase the risk for somnolence, weight gain, confusion, hypertension, nervous system disorders, and falling." | 2.49 | Effectiveness and safety of memantine treatment for Alzheimer's disease. ( Yang, Z; Zhang, Q; Zhou, X, 2013) |
| "Memantine hydrochloride is a first-line therapeutic drug approved by the US Food and Drug Administration for the management of moderate to severe Alzheimer's disease (AD)." | 2.49 | Memantine hydrochloride in the treatment of dementia subtypes. ( Peng, D; Yuan, X; Zhu, R, 2013) |
| "Treatment with memantine/ChEI combination therapy in moderate-to-severe AD produces consistent benefits that appear to increase over time, and that are beyond those of ChEI treatment alone." | 2.49 | Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. ( Gauthier, S; Molinuevo, JL, 2013) |
| "The first drugs developed for Alzheimer's disease (AD), anticholinesterase inhibitors (AchEI), increase acetylcholine levels, previously demonstrated to be reduced in AD." | 2.49 | Immunotherapy against amyloid pathology in Alzheimer's disease. ( Galimberti, D; Ghezzi, L; Scarpini, E, 2013) |
| "Memantine now has a considerable database of published studies and is associated with benefits in aspects of behaviour, cognition and communication, and on clinical progression." | 2.48 | A review of the effects of memantine on clinical progression in Alzheimer's disease. ( Wilkinson, D, 2012) |
| "Treatment with memantine in addition to donepezil versus treatment with donepezil alone showed an ICER range from a dominant value to 6818." | 2.48 | Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses. ( Dams, J; Dodel, R; Neumann, A; Pouryamout, L; Wasem, J, 2012) |
| "Even though the etiology of Alzheimer's disease is unknown, several different therapeutic approaches are being investigated." | 2.48 | [Intended pharmacotherapeutical approaches of Alzheimer's disease therapy]. ( Hrubá, E; Korábecný, J; Kuca, K; Musílek, K; Nepovímová, E; Opletalová, V; Soukup, O; Spilovská, K; Zemek, F, 2012) |
| "However, unlike stroke, treatment of hyperlipidemia with statin class drugs or treatment of blood clotting abnormalities with acetylsalicylic acid do not appear to have an effect on VaD incidence or progression." | 2.48 | Pharmacological prevention and treatment of vascular dementia: approaches and perspectives. ( Baskys, A; Cheng, JX, 2012) |
| "The symptomatic treatment of Alzheimer's disease is currently carried out using a twofold therapeutic approach involving acetylcholinesterase inhibitors, whose mechanism of action is based on the selective inhibition of this enzyme, and memantine, which acts by blocking the pathological tonic activation of NMDA receptors." | 2.47 | [Memantine: the value of combined therapy]. ( Molinuevo, JL, 2011) |
| "Memantine is a low- to moderate-affinity, non-competitive NMDA receptor antagonist that is currently approved for the treatment of moderate to severe AD." | 2.47 | Memantine in dementia: a review of the current evidence. ( Herrmann, N; Lanctôt, K; Li, A, 2011) |
| "There is no dedicated therapy for frontotemporal dementia (FTD)." | 2.47 | Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia. ( Boxer, A; Kerchner, GA; Tartaglia, MC, 2011) |
| "Memantine was found to have a favourable tolerability profile when used as monotherapy or in combination with other agents." | 2.46 | A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. ( Jones, RW, 2010) |
| "Recent studies with add-on therapies in Alzheimer's disease, apart from expanding our clinical knowledge, have also provided some new insights to guide future studies and therapeutic approaches." | 2.46 | Combination treatments in Alzheimer's disease: risks and benefits. ( Sobow, T, 2010) |
| "Dementia is characterised by chronic, global, non-reversible deterioration in memory, executive function, and personality." | 2.46 | Dementia. ( Butler, R; Gupta, S; Warner, JP, 2010) |
| "Memantine acts as an antagonist of N-methyl-D-aspartate (NMDA) type receptors, which is thought to reduce abnormal activation of glutamate neurotransmission." | 2.45 | Memantine for dementia in people with Down syndrome. ( Bennett, C; Carpenter, PK; Mohan, M, 2009) |
| "Memantine is a moderate-affinity, uncompetitive antagonist of N-methyl-D-aspartate receptors, approved for the treatment of moderate to severe Alzheimer's disease (AD)." | 2.45 | Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease. ( Graham, SM; Grossberg, GT; Miller, ML; Pejović, V, 2009) |
| "The pharmacological treatment of dementias aims to improve cognitive deficits, activities of daily living and behavioural and psychiatric symptoms." | 2.45 | [Antidementia drugs]. ( Müller-Spahn, F; Sollberger, D; Wollmer, MA, 2009) |
| "Memantine (which is an inhibitor of the N-metil-D-aspartate receptor) is used in the middle and severe stages of AD and it can be effectively combined with AChEIs." | 2.45 | [Therapy of Alzheimer disease]. ( Kovács, T, 2009) |
| "Memantine is an uncompetitive, moderate-affinity NMDA receptor antagonist that is indicated for the treatment of moderate to severe Alzheimer's disease." | 2.45 | Memantine: a review of its use in moderate to severe Alzheimer's disease. ( McKeage, K, 2009) |
| "Memantine is an uncompetitive N-methyl-D-aspartate receptor antagonist with moderate affinity." | 2.45 | Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. ( Grossberg, GT; Thomas, SJ, 2009) |
| "Moderate-to-severe stage Alzheimer's disease (AD) is a clinically diagnosable entity that represents a substantial burden to our healthcare system in terms of its prevalence, symptomatology, caregiver stress and economics." | 2.44 | Pharmacological treatment in moderate-to-severe Alzheimer's disease. ( Feldman, HH; Hsiung, GY, 2008) |
| " Furthermore, published reports support reduced dosing in patients with significant renal disease." | 2.44 | A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer's disease. ( Cooper, G; Ryan, M; Schmitt, F, 2007) |
| "Memantine was well tolerated, and the overall incidence rates of adverse events were comparable to placebo." | 2.44 | Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. ( Jones, RW; Möbius, HJ; Stöffler, A; Winblad, B; Wirth, Y, 2007) |
| "Alzheimer's disease (AD) and Vascular dementia represent the most common forms of dementia." | 2.44 | Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. ( Lipton, SA, 2007) |
| "Memantine is a non-competitive, low-affinity N-methyl-D-aspartate receptor antagonist of glutamate that offers a very attractive efficacy and safety profile for treating moderate to severe AD." | 2.44 | [Alzheimer Disease]. ( Massoud, F, 2007) |
| "Memantine is a moderate affinity, uncompetitive NMDA receptor antagonist with strong voltage-dependency and fast kinetics." | 2.44 | Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. ( Danysz, W; Parsons, CG; Stöffler, A, 2007) |
| "Patients had probable Alzheimer's disease and received treatment with memantine for at least one month." | 2.44 | Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. ( Boustani, M; Brown, RC; Fox, CG; Katona, CL; Maidment, ID; Rodriguez, J, 2008) |
| "(iii) The use of transgenic models of Alzheimer's disease." | 2.44 | The use of the hippocampal slice preparation in the study of Alzheimer's disease. ( Collingridge, GL; Doherty, AJ; Fitzjohn, SM, 2008) |
| "At present, the therapy of Alzheimer's disease is aimed at improving both, cognitive and behavioural symptoms and thereby, quality of life for the patients." | 2.43 | Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope. ( Kaul, CL; Ramarao, P; Sonkusare, SK, 2005) |
| "Memantine was also associated with a small gain in quality-adjusted life expectancy in the UK model." | 2.43 | Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease. ( Lyseng-Williamson, KA; Plosker, GL, 2005) |
| "Memantine treatment showed a significant beneficial effect in comparison to placebo treatment in the NPI agitation/aggression domain in both studies (p = 0." | 2.43 | Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. ( Gauthier, S; Möbius, HJ; Wirth, Y, 2005) |
| "Memantine could be a treatment for some patients with moderate to severe degrees of dementia, while acetylcholinesterase inhibitors could be useful for some patients with mild to moderate degrees of dementia of the Alzheimer type." | 2.43 | [Assessment of dementia and use of anti-dementia drugs in nursing homes]. ( Engedal, K, 2005) |
| "Although FDA-approved Alzheimer's disease (AD) treatment strategies (cholinesterase inhibitors and memantine) offer proven benefits, providers recognize unmet needs beyond what is currently available." | 2.43 | Combination drug therapy for Alzheimer's disease: what is evidence-based, and what is not? ( Doraiswamy, PM; Xiong, G, 2005) |
| "In western countries, Alzheimer's disease (AD) is the most common form of dementia." | 2.43 | The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. ( Lipton, SA, 2005) |
| "Alzheimer's disease is a chronic, progressive illness that requires long-term management." | 2.43 | Alzheimer's disease care management plan: maximizing patient care. ( Treinkman, A, 2005) |
| "Pharmacological therapy in Alzheimer's disease." | 2.43 | [Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands]. ( Schölzel-Dorenbos, CJ, 2005) |
| "Memantine acts as an uncompetitive antagonist of NMDA receptors and therefore compensates for this overactivation." | 2.43 | Memantine: a therapeutic approach in treating Alzheimer's and vascular dementia. ( Fischer-Barnicol, D; Koch, HJ; Uyanik, G, 2005) |
| "Memantine is a clinically useful drug in many neurological disorders, including Alzheimer's disease." | 2.43 | Mechanism of action of memantine. ( Johnson, JW; Kotermanski, SE, 2006) |
| "Managing Alzheimer's disease (AD) continues to challenge long-term care physicians and administrators." | 2.43 | Alzheimer's treatment in nursing homes: room for improvement. ( Bright-Long, L, 2006) |
| "The cognitive symptoms of Alzheimer's disease (AD) are believed to be caused not only by the loss of neurons in the cholinergic and glutamatergic neural systems but also by the irregular functioning of surviving neurons in these 2 systems." | 2.43 | Neuropathologic changes in Alzheimer's disease: potential targets for treatment. ( Wenk, GL, 2006) |
| "The search for effective treatments of Alzheimer's disease (AD) is one of the major challenges facing modern medicine." | 2.43 | Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease. ( Geerts, H; Grossberg, GT, 2006) |
| "Alzheimer's disease is the leading cause of dementia in the elderly, presenting itself clinically by progressive loss of memory and learning." | 2.43 | Altered synaptic function in Alzheimer's disease. ( Bell, KF; Claudio Cuello, A, 2006) |
| "Memantine is an effective pharmacotherapeutic agent, and currently the only approved option, for the treatment of moderate to severe Alzheimer's disease." | 2.43 | Memantine: a review of its use in Alzheimer's disease. ( Keating, GM; Robinson, DM, 2006) |
| "Specific treatments for Alzheimer's disease (AD) were first introduced in the 1990s using the acetyl-cholinesterase inhibitors." | 2.43 | New pathways in drug discovery for Alzheimer's disease. ( Dean, RA; Demattos, R; May, PC; Siemers, ER, 2006) |
| "The main symptom of Alzheimer's disease is a gradual loss of cognitive function." | 2.42 | The glutamatergic system and Alzheimer's disease: therapeutic implications. ( Butterfield, DA; Pocernich, CB, 2003) |
| "Current treatments for Alzheimer's disease focus on deficits in the cholinergic neurochemical pathway." | 2.42 | The search for better noncholinergic treatment options for Alzheimer's disease. ( Mintzer, JE, 2003) |
| "Memantine is an uncompetitive (channel blocking) NMDA receptor antagonist." | 2.42 | The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. ( Rogawski, MA; Wenk, GL, 2003) |
| "Memantine was recently approved in Europe for the treatment of moderately severe to severe AD and is an investigational drug in the United States." | 2.42 | Alzheimer's disease and the glutamate NMDA receptor. ( Doraiswamy, PM, 2003) |
| "Memantine has been shown to improve symptoms and reduce the rate of clinical deterioration among patients with moderate-to-severe AD and was approved in the US for this indication in October 2003." | 2.42 | Evaluation of memantine for the treatment of Alzheimer's disease. ( Ferris, SH, 2003) |
| "Memantine acts as a neuroprotective agent in various animal models based on both neurodegenerative and vascular processes as it ameliorates cognitive and memory deficits." | 2.42 | NMDA-antagonism (memantine): an alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia. ( Haen, E; Koch, HJ; Szecsey, A, 2004) |
| "The management of dementia in Alzheimer's disease has dramatically changed since the development of anti-dementia drugs." | 2.42 | Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. ( Prasher, VP, 2004) |
| "By some estimates moderate-to-severe Alzheimer's disease accounts for 50% of all patients with Alzheimer's disease." | 2.42 | What are the treatment options for patients with severe Alzheimer's disease? ( Feldman, H; Portet, F; Reynish, E; Vellas, B; Voisin, T, 2004) |
| "Research into Alzheimer's disease (AD) pathology has identified several underlying disease processes that are potential targets for drug discovery and development." | 2.42 | NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease. ( Farlow, MR, 2004) |
| "Memantine is a similar uncompetitive NMDA-receptor antagonist to MK-801 and phencyclidine (PCP), and it prevents nerve cell death induced by the ischemia which induces as excessive release of glutamate." | 2.42 | [Memantine: a therapeutic drug for Alzheimer's disease and the comparison with MK-801]. ( Kato, T, 2004) |
| " Three head-to-head trials of ChEIs in the treatment of AD have been published to date, but are limited due to their open-label design, rates of titration, and the drug dosage levels utilised." | 2.42 | The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. ( Herrmann, N; Lanctôt, KL; Thompson, S, 2004) |
| "Vascular dementia is the second cause of dementia after Alzheimer's disease." | 2.42 | [Diagnosis and treatment of vascular dementia]. ( Gold, G, 2004) |
| "The pathophysiology of Alzheimer's disease (AD) includes the deposition of amyloid beta protein (Abeta) and the ensuing initiation of a variety of secondary processes, including tau hyperphosphorylation, excitotoxicity, oxidation, and inflammation." | 2.42 | Treatment of Alzheimer's disease: current and future therapeutic approaches. ( Cummings, JL, 2004) |
| "The pathophysiology of Alzheimer's disease is complex and involves several different biochemical pathways." | 2.41 | Non-cholinergic strategies for treating and preventing Alzheimer's disease. ( Doraiswamy, PM, 2002) |
| "Memantine was recently recommended for central European approval." | 2.41 | Glutamate receptors as a target for Alzheimer's disease--are clinical results supporting the hope? ( Möbius, HJ; Stöffler, A; Winblad, B, 2002) |
| "The arrival of these new treatments for Alzheimer's disease has focused attention on the management of dementia in general and has provided the catalyst for the widespread development of memory clinics to enable proper assessment of patients with dementing disorders, providing hope for both patients and carers." | 2.41 | Drugs for treatment of Alzheimer's disease. ( Wilkinson, D, 2001) |
| "MEM is used to treat Alzheimer's disease (AD); conceivably, its acute impact on PPI might be used to predict a patient's sensitivity to MEM's therapeutic effects." | 1.91 | Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer's Disease. ( Delano-Wood, L; Huege, S; Iwanaga, D; Joshi, YB; Kotz, JE; Léger, GC; Light, GA; Molina, JL; Sprock, J; Swerdlow, NR; Talledo, J, 2023) |
| "Memantine consumption was nearly 4 DDD/1000 inhabitants per day, representing 40% of ADD consumption." | 1.91 | Anti-dementia drugs: a descriptive study of the prescription pattern in Italy. ( Ancidoni, A; Da Cas, R; Ippoliti, I; Pierantozzi, A; Trotta, F; Vanacore, N, 2023) |
| "Hydromethylthionine (HMT) is a potent inhibitor of tau aggregation in vitro and in vivo and is being developed as a possible anti-dementia medication." | 1.91 | Mitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice. ( Baddeley, TC; Harrington, CR; Klein, J; Kondak, C; Leith, M; Riedel, G; Santos, RX; Wischik, CM, 2023) |
| "A cohort of 214 Alzheimer's disease (AD) patients was used as a neurodegenerative disease reference group." | 1.91 | Psychopharmacological Medication Use in Frontotemporal Dementia at the Time of Diagnosis: Comparison with Alzheimer's Disease. ( Haapasalo, A; Hartikainen, P; Katisko, K; Krüger, J; Remes, AM; Solje, E; Soppela, H, 2023) |
| "As of 2022, according to the Alzheimer's Disease Association, there were over 6." | 1.91 | A causal inference study: The impact of the combined administration of Donepezil and Memantine on decreasing hospital and emergency department visits of Alzheimer's disease patients. ( Ehwerhemuepha, L; Lu, H; Patel, YM; Pierce, A; Rakovski, C; Rezaie, A; Sajjadi, SA; Yaghmaei, E, 2023) |
| " Unfortunately, it showed a suboptimal pharmacokinetic profile, which required intracerebroventricular administration for in vivo studies." | 1.91 | Galantamine-memantine hybrids for Alzheimer's disease: The influence of linker rigidity in biological activity and pharmacokinetic properties. ( Armirotti, A; Bartolini, M; Basagni, F; Bedeschi, M; Bertorelli, R; Bertozzi, SM; Bottegoni, G; Cavalli, A; Lembo, V; Mellor, IR; Minarini, A; Ortega, JA; Rosini, M; Summa, M, 2023) |
| "Donepezil and memantine were the most consumed drugs, with the highest growth in consumption from 2014 to 2020." | 1.91 | Consumption of drugs for Alzheimer's disease on the Brazilian private market. ( Calil-Elias, S; Erbisti, RS; Freitas, EL; Grinberg-Weller, B; Miranda, ES, 2023) |
| "Thymoquinone (TQ) has broad biological functions, including antiinflammatory, antioxidant, neuroprotective properties." | 1.91 | Effects of thymoquinone and memantine alone and in combination on memory and hippocampal morphology in rats with streptozotocin-induced Alzheimer's disease. ( Akçay, E; Çakir, Z; Gevrek, F; Özsoy, Ş, 2023) |
| "Treatment with memantine and vitamin D can protect cortical axons from exposure to amyloid-β and glutamate toxicity, suggesting this combination may mitigate altered gait in AD." | 1.72 | Effects of Memantine and High Dose Vitamin D on Gait in Male APP/PS1 Alzheimer's Disease Mice Following Vitamin D Deprivation. ( Annweiler, C; Bartha, R; Beauchet, O; Bellyou, M; Broberg, DN; Montero-Odasso, M; Wong, D, 2022) |
| "We observed a correlation between Alzheimer's disease (AD) and anti-AD drug (AAD) groups from 2010 to 2019 on the National Health Insurance System (NHIS) of South Korea." | 1.72 | The listed, delisted, and sustainability of therapeutic medicines for dementia patients: the study is specific to South Korea. ( Lee, JH, 2022) |
| "In pre-clinical studies of Alzheimer's disease (AD) transgenic mice, bryostatin restored synaptic connections, prevented neuronal death, reduced amyloid plaques, and reduced neurofibrillary tangles." | 1.72 | Bryostatin Placebo-Controlled Trials Indicate Cognitive Restoration Above Baseline for Advanced Alzheimer's Disease in the Absence of Memantine1. ( Alkon, DL; Thompson, RE; Tuchman, AJ, 2022) |
| "Alzheimer's disease is a chronic disease, and the long-term treatment of chronic diseases has always been a concern." | 1.72 | Insoluble Salt of Memantine with a Unique Fluorescence Phenomenon. ( Gong, J; Kuang, W; Lin, X; Liu, J; Wang, J; Wu, S; Yin, Q, 2022) |
| "To assess the impact of long-term use of different drugs commonly prescribed in Alzheimer's disease (AD) on its clinical course and to identify clinical and therapeutic factors associated with a delay in AD progression." | 1.72 | Long-term use of pharmacological treatment in Alzheimer's disease: a retrospective cohort study in real-world clinical practice. ( Bagnoli, S; Berti, V; Bessi, V; Bettiol, A; Crescioli, G; Ferrari, C; Lombardi, G; Lombardi, N; Lucidi, G; Nacmias, B; Polito, C; Sorbi, S; Vannacci, A, 2022) |
| "Memantine was used at a clinically relevant dose (20 mg daily oral administration) from 4 (asymptomatic phase) to 10 (mild cognitive impairment phase) months of age." | 1.72 | Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer's Disease Predementia. ( Alves, S; Audrain, M; Billard, JM; Braudeau, J; Cartier, N; Dutar, P; Fol, R; Orefice, NS; Potier, B; Souchet, B; Tada, S, 2022) |
| "Drug delivery systems that not only show efficacy through multiple therapeutic pathways but also facilitate patient drug use and exhibit a high bioavailability profile represent a promising strategy in the treatment of Alzheimer's disease (AD)." | 1.72 | A novel multi-target strategy for Alzheimer's disease treatment via sublingual route: Donepezil/memantine/curcumin-loaded nanofibers. ( Aydemir, O; Bocekci, VG; Cam, ME; Duruksu, G; Ertas, B; Guler, E; Gunduz, O; Gurbuz, F; Ozcan, GS; Sahin Cam, C; Topal, F; Yazir, Y, 2022) |
| " The gamma scintigraphy studies showed higher uptake of the drug in the target site through the intranasal route and pharmacodynamic studies indicated that nanoparticles were able to inhibit the spatial memory impairment significantly as compared to the control group." | 1.72 | A Preliminary Pharmacodynamic Study for the Management of Alzheimer's Disease Using Memantine-Loaded PLGA Nanoparticles. ( Dang, S; Kaur, A; Nigam, K; Tyagi, A, 2022) |
| "Alzheimer's disease is one of the most common neurodegenerative diseases worldwide and carries a huge social burden." | 1.72 | [Capabilities of combined therapy of Alzheimer's disease]. ( Levin, OS; Vasenina, EE; Veryugina, NI, 2022) |
| "Memantine is an orally administrative N-methyl-d-aspartate glutamate receptor antagonist used to slow the progression of moderate-to-severe Alzheimer's disease (AD) and dementia." | 1.62 | Spectroscopic, calorimetric and in silico insight into the molecular interactions of Memantine with human transferrin: Implications of Alzheimer's drugs. ( Al Abdulmonem, W; Alhumaydhi, FA; Aljasir, MA; Alsagaby, SA; Alwashmi, ASS; Hassan, MI; Islam, A; Shahwan, M; Shamsi, A, 2021) |
| "Memantine's benefits in Alzheimer's disease (AD) are modest and heterogeneous." | 1.62 | Using Biomarkers to Predict Memantine Effects in Alzheimer's Disease: A Proposal and Proof-Of-Concept Demonstration. ( Delano-Wood, L; Huege, SF; Huisa, B; Joshi, YB; Kotz, JE; Light, GA; Molina, JL; Romero, JA; Sprock, J; Swerdlow, NR; Talledo, J; Walsh, MJ, 2021) |
| "Current therapies in Alzheimer's disease (AD), including Memantine, have proven to be only symptomatic but not curative or disease modifying." | 1.62 | Anti-Amnesic and Neuroprotective Effects of Fluoroethylnormemantine in a Pharmacological Mouse Model of Alzheimer's Disease. ( Bouchet, M; Couly, S; Denus, M; Maurice, T; Rubinstenn, G, 2021) |
| " T-006 improved cognitive ability after long-term administration in two AD mouse models and targeted mitochondrial-related protein alpha-F1-ATP synthase (ATP5A)." | 1.62 | The Tetramethylpyrazine Analogue T-006 Alleviates Cognitive Deficits by Inhibition of Tau Expression and Phosphorylation in Transgenic Mice Modeling Alzheimer's Disease. ( Chen, H; Cheng, J; Guo, B; Huang, C; Su, Z; Sun, Y; Wang, Y; Wu, J; Wu, L; Yang, X; Zhang, G; Zhang, Z; Zhu, Z, 2021) |
| "The hallmarks of Alzheimer's disease (AD) pathology include senile plaques accumulation and neurofibrillary tangles, which is thought to underlie synaptic failure." | 1.62 | Hippocampal Degeneration and Behavioral Impairment During Alzheimer-Like Pathogenesis Involves Glutamate Excitotoxicity. ( Adeniyi, PA; Adigun, OO; Arietarhire, LO; Arogundade, T; Asogwa, NT; Bamisi, O; Gbadamosi, IT; Idowu, OK; Kareem, R; Lambe, E; Lewu, FS; Ogunrinola, KY; Olajide, OJ; Oluyomi, OO; Yawson, EO, 2021) |
| "The pathophysiology of Alzheimer's disease (AD) is related to neuroinflammatory responses mediated by microglia." | 1.62 | Effect of memantine, an anti-Alzheimer's drug, on rodent microglial cells in vitro. ( Haraguchi, Y; Mizoguchi, Y; Monji, A; Murakawa-Hirachi, T; Ohgidani, M, 2021) |
| " This was not observed when memantine treatment was combined with vitamin D enrichment." | 1.62 | Effect of Memantine Treatment and Combination with Vitamin D Supplementation on Body Composition in the APP/PS1 Mouse Model of Alzheimer's Disease Following Chronic Vitamin D Deficiency. ( Annweiler, C; Bartha, R; Beauchet, O; Bellyou, M; Broberg, DN; Doad, J; Holdsworth, DW; Montero-Odasso, M; Norley, CJD; Umoh, JU; Wong, D, 2021) |
| "Memantine (Mem) is a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist used in the treatment of Alzheimer's disease." | 1.62 | [Effects of Yokukansankachimpihange on Memantine-induced Dizziness in Mice with Memory Impairment]. ( Aoki, Y; Han, LK; Kaneda, M; Michihara, S; Shimoyama, T; Takahashi, R, 2021) |
| "The current drugs for Alzheimer's disease (AD) are only used to slow or delay the progression of the pathology." | 1.56 | Neuroprotective Effect of New Nanochelating-Based Nano Complex, ALZc3, Against Aβ ( Ashiri, M; Fakharzadeh, S; Hafizi, M; Kalanaky, S; Karimi-Sales, R; Maghsoudi, AH; Maghsoudi, N; Nazaran, MH, 2020) |
| "Alzheimer's disease is type of dementia in which cognitive functions get declined." | 1.56 | Multiple target-based combination therapy of galantamine, memantine and lycopene for the possible treatment of Alzheimer's disease. ( Awasthi, A; Corrie, L; Gulati, M; Kumar Singh, S; Vishwas, S, 2020) |
| " Medical charts were reviewed, including diagnosis, dosage of antidementia medicines, neuropsychological testing scores, and the further questionnaires were conducted via face-to-face or telephone, included duration of treatment, types of antidementia drugs, and reasons for treatment discontinuation." | 1.56 | Usage and adherence of antidementia drugs in a memory clinic cohort in Chongqing, Southwest China. ( Lü, Y; Yang, W; Yu, W; Yu, X, 2020) |
| "Dementia was diagnosed in 132 (32." | 1.56 | Dementia Diagnoses and Treatment in Geriatric Ward Patients: A Cross-Sectional Study in Poland. ( Wojszel, ZB, 2020) |
| "Background Tauopathies, including Alzheimer's disease (AD), are multifactorial diseases with strong phenotypic and genetic heterogeneity." | 1.51 | Pore-former enabled seeding of tau in rats: Alleviation by memantine and lithium chloride. ( Gasiorowska, A; Koss, DJ; Mietelska-Porowska, A; Niewiadomska, G; Palasz, E; Riedel, G, 2019) |
| " In the dog model, relative memantine bioavailability approaches 100% with sustained plasma levels of memantine over seven days and profiles that can be tuned by varying components of the formulation." | 1.51 | A pharmaceutical answer to nonadherence: Once weekly oral memantine for Alzheimer's disease. ( Bellinger, AM; Bhise, N; Bishoff, M; Carter, B; DeBenedictis, B; Grant, T; Kanasty, R; Low, S; Moorthy, S; Peeke, E; Schwarz, M; Simses, C; Wright, J; Yang, J, 2019) |
| "Overall the number of Alzheimer's disease outpatients of sampling days increased from 10 239 in 2012 to 20 546 in 2017." | 1.51 | Trends of antidementia drugs use in outpatients with Alzheimer's disease in six major cities of China: 2012-2017. ( Chen, X; Yu, L; Yu, Z, 2019) |
| "Potential predictors of disease progression, including age, gender, the type of ChEI, and Apolipoprotein E (APOE) genotype, were also analyzed." | 1.48 | Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication. ( Chou, PS; Lin, SH; Su, HC; Sung, PS; Wu, MN; Yang, YH, 2018) |
| "Memantine followed a slower release profile from the NPs against the free drug solution, allowing to reduce drug administration frequency in vivo." | 1.48 | Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization. ( Calpena, AC; Camins, A; Cano, A; Carmona, N; Egea, MA; Espina, M; Ettcheto, M; García, ML; Sánchez-López, E; Silva, AM; Souto, EB, 2018) |
| "Background Alzheimer's disease (AD) medications have been suggested to positively affect behavior, though not universally in all studies." | 1.48 | The Impact of Cholinesterase Inhibitors with or without Memantine on Antipsychotic Prescribing. ( Blaszczyk, AT; Garza, H; Mang, BH; Mathys, M, 2018) |
| " A transdermal physiologically based pharmacokinetic (TPBPK) model was developed and was integrated in a compartmental pharmacokinetic model to predict the plasma drug concentrations in rats." | 1.48 | In Depth Analysis of Pressure-Sensitive Adhesive Patch-Assisted Delivery of Memantine and Donepezil Using Physiologically Based Pharmacokinetic Modeling and in Vitro/in Vivo Correlations. ( Arfi, S; Bhatta, RS; Mishra, PR; Mittapelly, N; Pandey, G; Tulsankar, SL, 2018) |
| "Alzheimer's disease is the most common form of dementia and is a major contributor to morbidity and mortality in older Australians." | 1.48 | Current approaches to the pharmacological treatment of Alzheimer's disease. ( Bell, JS; Garcia-Ptacek, S; Hilmer, SN; Tan, EC, 2018) |
| "Memantine is a NMDA antagonist receptor clinically used for treating Alzheimer's disease." | 1.46 | In vitro effects of the anti-Alzheimer drug memantine on the human erythrocyte membrane and molecular models. ( Jemiola-Rzeminska, M; Strzalka, K; Suwalsky, M; Villena, F; Zambrano, P, 2017) |
| "A total of 551 Alzheimer's disease patients (201 men and 350 women) were divided into four subgroups based on their PVH severity (0-III)." | 1.46 | Different clinical effect of four antidementia drugs for Alzheimer's disease patients depending on white matter severity. ( Abe, K; Fukui, Y; Hishikawa, N; Ichinose, J; Morihara, R; Nakano, Y; Ohta, Y; Sato, K; Yamashita, T, 2017) |
| "Memantine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist used to treat Alzheimer's disease." | 1.43 | Pharmacokinetics of Memantine after a Single and Multiple Dose of Oral and Patch Administration in Rats. ( Bae, CS; Cho, IH; Choi, BM; Kim, EJ; Kim, SH; Lee, SH; Noh, GJ; Noh, YH; Park, WD, 2016) |
| "Metabolic syndrome (MetS) and Type 2 diabetes mellitus (T2DM) increase risk for Alzheimer's disease (AD)." | 1.43 | Elevated glucose and oligomeric β-amyloid disrupt synapses via a common pathway of aberrant protein S-nitrosylation. ( Akhtar, MW; Ambasudhan, R; Chon, K; Dolatabadi, N; Lee, MS; Lipton, SA; McKercher, SR; Nakamura, T; Parker, J; Sanz-Blasco, S; Soussou, W, 2016) |
| "Currently available treatments for Alzheimer's disease (AD) are disappointing and their modest benefits do not reflect the increased understanding of the condition that has arisen from the last 50 years of research or the huge investments made by the pharmaceutical industry and academia in developing therapies." | 1.43 | The importance of high quality trials of cognitive interventions in Alzheimer's disease. ( Howard, R; Huntley, J, 2016) |
| "Beneficiaries aged 65 and older with Alzheimer's disease or related dementia (ADRD) before 2009 and no fills for antidementia medications in the first half of 2009 (N = 84,043)." | 1.43 | Racial and Ethnic Differences in Initiation and Discontinuation of Antidementia Drugs by Medicare Beneficiaries. ( Fowler, NR; Gellad, WF; Hanlon, JT; Harrigan, K; Kang, Y; Schleiden, LJ; Thorpe, CT; Thorpe, JM; Zhao, X, 2016) |
| "Memantine (MEM) has been indicated to dramatically increase hippocampal neurogenesis by promoting the proliferation of RGLs." | 1.42 | Protection of Radial Glial-Like Cells in the Hippocampus of APP/PS1 Mice: a Novel Mechanism of Memantine in the Treatment of Alzheimer's Disease. ( Bao, X; Cai, Y; Chen, J; Fan, X; Huang, J; Huang, W; Sun, D; Xu, H; Zhao, J, 2015) |
| " They shall help to ensure proper dosage switching among various formulations." | 1.42 | Discontinuation of memantine standard release and its impact on patient therapy. ( Lam, S; Mondiello, T, 2015) |
| "Memantine treatment showed similar effects, regardless of the baseline cognitive functions, but showed better effects on ABS for higher baseline cognitive functions." | 1.42 | Clinical Benefits of Memantine Treatment for Alzheimer's Disease in the Okayama Memantine Study II (OMS II). ( Abe, K; Deguchi, K; Hishikawa, N; Koike, M; Kono, S; Matsuzono, K; Nakano, Y; Ohta, Y; Sato, K; Yamashita, T, 2015) |
| "Memantine is a low-affinity voltage-dependent noncompetitive antagonist at glutamatergic NMDA receptors." | 1.42 | Protective effects of NMDA receptor antagonist, memantine, against senescence of PC12 cells: A possible role of nNOS and combined effects with donepezil. ( Akishita, M; Ogawa, S; Ota, H; Ouchi, Y, 2015) |
| "Treatment with memantine, a noncompetitive NMDA receptor antagonist which is an approved drug for treatment of Alzheimer's disease, rescued protein phosphatase-2A activity by decreasing its demethylation at Leu309 selectively and attenuated Alzheimer's disease-like pathology and cognitive impairment in adeno-associated virus vector-1-I1PP2A rats." | 1.42 | Memantine Attenuates Alzheimer's Disease-Like Pathology and Cognitive Impairment. ( Blanchard, J; Grundke-Iqbal, I; Iqbal, K; Wang, X, 2015) |
| "The currently available therapies for Alzheimer's disease (AD) and related forms of dementia are limited by modest efficacy, adverse side effects, and the fact that they do not prevent the relentless progression of the illness." | 1.40 | Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease. ( Adam, BL; Gao, J; Terry, AV, 2014) |
| "The costs associated with the care of Alzheimer's disease patients are very high, particularly those associated with nursing home placement." | 1.40 | The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France. ( Beauchemin, C; Bineau, S; Granghaud, A; Lachaine, J; Rive, B; Touchon, J, 2014) |
| " Further longitudinal studies may be required to assess dose-response relationships regarding treatment with psychotropics for patients with dementia." | 1.40 | Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease. ( Bertolucci, PH; Chen, ES; de Oliveira, FF; Smith, Mde A, 2014) |
| "The use and type of medication in Alzheimer's disease (AD) patients and association with falls is limited." | 1.40 | Medication for Alzheimer's disease and associated fall hazard: a retrospective cohort study from the Alzheimer's Disease Neuroimaging Initiative. ( Epstein, NU; Farlow, MR; Fisher, M; Guo, R; Singh, JP, 2014) |
| "Alzheimer's disease is the most common form of dementia in the elderly." | 1.40 | Is memantine + acetylcholinesterase inhibitor treatment superior to either therapy alone in Alzheimer's disease? ( Mattace-Raso, F, 2014) |
| "The approved treatments for Alzheimer's disease (AD) exploit mainly a symptomatic approach based on the use of cholinesterase inhibitors or N-methyl-D-aspartate (NMDA) receptor antagonists." | 1.39 | Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer's disease. ( Cacciatore, I; Cerasa, LS; Cornacchia, C; Di Crescenzo, A; Di Filippo, ES; Di Stefano, A; Fontana, A; Fulle, S; Grilli, M; Laserra, S; Marchi, M; Sozio, P, 2013) |
| " In concert with other studies showing the anti-inflammatory and protective effect of FTY720 in some neurodegenerative disorders like ischemia, we have recently shown that FTY720 chronic administration prevents from impairment of spatial learning and memory in AD rats." | 1.39 | Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: comparison with memantine. ( Ahmadiani, A; Chik, Z; Dargahi, L; Hemmati, F; Mohamed, Z; Naidu, M; Nasoohi, S; Omidbakhsh, R, 2013) |
| "Memantine is an N-methyl-D-aspartate glutamate receptor antagonist that may improve cognitive functions in patients with Alzheimer's disease." | 1.39 | Memantine-associated hyperkalaemia in a patient with Alzheimer's disease. ( Tsukamoto, T; Uchimura, N; Yamada, H, 2013) |
| "Alzheimer's disease is characterized by a progressive decline in cognitive function and involves β-amyloid (Aβ) in its pathogenesis." | 1.39 | Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine. ( Matsuoka, N; Nagakura, A; Shitaka, Y; Yarimizu, J, 2013) |
| "Memantine use was associated with delayed time to death." | 1.39 | Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease. ( Albert, M; Blacker, D; Brandt, J; Livote, EE; Sano, M; Scarmeas, N; Stern, Y; Zhu, CW, 2013) |
| "Memantine efficacy was based on a meta-analysis of six large trials." | 1.38 | Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway. ( Aarsland, D; Cochran, J; Grishchenko, M; Lamure, M; Rive, B; Toumi, M, 2012) |
| "Current treatment of Alzheimer's disease rests on cholinergic and anti-glutamatergic substances." | 1.38 | Synergistic effects of antidementia drugs on spatial learning and recall in the APP23 transgenic mouse model of Alzheimer's disease. ( Neumeister, KL; Riepe, MW, 2012) |
| "Memantine is a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist that has been approved for the treatment of the cognitive deficits noted in Alzheimer's disease." | 1.38 | Memantine facilitates memory consolidation and reconsolidation in the day-old chick. ( Crowe, SF; Hazi, A; Samartgis, JR; Schachte, L, 2012) |
| "However, patients with Alzheimer's disease seem not only to forget events but also to express false confidence in remembering events that have never happened." | 1.38 | False recognition in a mouse model of Alzheimer's disease: rescue with sensory restriction and memantine. ( Bussey, TJ; Cho, K; Heath, CJ; McTighe, SM; Romberg, C; Saksida, LM; Whitcomb, DJ, 2012) |
| "Treatment with memantine delays clinical worsening in patients with moderate to severe AD when compared with placebo." | 1.38 | Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD. ( Hartmann, S; Hellweg, R; Janetzky, W; Wirth, Y, 2012) |
| "Memantine has the indication for moderate to severe AD, and can be prescribed with one choline esterase inhibitor." | 1.38 | [New anti-AD drugs--their possibilities and issues]. ( Nakamura, Y, 2012) |
| "Memantine was used by 17." | 1.38 | Use of antidementia drugs in frontotemporal lobar degeneration. ( Bisbe, J; Calvó-Perxas, L; Cullell, M; Garre-Olmo, J; Hernández, E; Lejarreta, S; López-Pousa, S; Manzano, A; Meléndez, R; Perkal, H; Roig, AM; Turró-Garriga, O; Vilalta-Franch, J, 2012) |
| "Memantine is an uncompetitive N-methyl-D-aspartate receptor antagonist." | 1.38 | Memantine in Alzheimer's disease: experience in an Alzheimer's disease assessment unit. ( Chiapella, L; Malinverni, P; Pasotti, C; Sinforiani, E; Zucchella, C, 2012) |
| "Treatment disparities in Alzheimer's disease (AD) have received little attention." | 1.38 | Racial and ethnic disparities in Alzheimer's disease pharmacotherapy exposure: an analysis across four state Medicaid populations. ( Armstrong, EP; Gilligan, AM; Malone, DC; Warholak, TL, 2012) |
| "The progression of Alzheimer's disease (AD) is accompanied by disturbances of the endosome/lysosome (EL) system and there is accumulation of peptides of the AD-associated amyloid beta (Abeta) type in EL vesicles of affected neurons." | 1.38 | Beneficial effects of lysosome-modulating and other pharmacological and nanocarrier agents on amyloid-beta-treated cells. ( Chen, L; Fuchs, PM; Kanazirska, MV; Lal, S; Vassilev, PM; Verma, J, 2012) |
| "Donepezil was the most widely used CED (66%), followed by galantamine (27%) then memantine (4%)." | 1.37 | Prescribing trends in cognition enhancing drugs in Australia. ( Byrne, GJ; Hollingworth, SA, 2011) |
| "Memantine is an N-methyl-D: -aspartate (NMDA) receptor antagonist, approved for the treatment of moderate to severe Alzheimer's disease (AD)." | 1.37 | Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study. ( Chirikdjian, JJ; Erb, C; Jagsch, C; Mucke, HA; Rainer, M; Wuschitz, A, 2011) |
| "Patients with Alzheimer's disease (AD) who deteriorate rapidly are likely to have a poorer prognosis." | 1.37 | Diagnosis of Alzheimer's disease patients with rapid cognitive decline in clinical practice: interest of the Deco questionnaire. ( Berrut, G; Bourdeix, I; Carcaillon, L; Dartigues, JF; Gillette, S; Pere, JJ; Sellal, F, 2011) |
| "Memantine treatment also was associated with a decline in the levels of total tau and hyperphosphorylated tau." | 1.36 | Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. ( Albrecht, M; Banerjee, P; Billings, LM; Green, KN; Gupta, S; Kitazawa, M; LaFerla, FM; Martinez-Coria, H; Parsons, CG; Rammes, G, 2010) |
| "Donepezil was the most frequently prescribed active ingredient (37." | 1.36 | Prescribing of drugs for Alzheimer's disease: a South African database analysis. ( Truter, I, 2010) |
| "Memantine efficacy was based on a meta-analysis of six large trials." | 1.36 | Cost effectiveness of memantine in Alzheimer's disease in the UK. ( François, C; Grishchenko, M; Guilhaume-Goulant, C; Katona, C; Lamure, M; Livingston, G; Rive, B; Toumi, M, 2010) |
| "The goal of this article is to review the once-daily memantine ER 28 mg formulation for the treatment of Alzheimer's disease, which, by simplifying the dosage regimen, decreases the problems of medication adherence." | 1.36 | Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease. ( Bassil, N; Grossberg, GT; Thaipisuttikul, P, 2010) |
| "Memantine is an NMDA receptor antagonist that has been recently approved in EU for the treatment of moderate to severe Alzheimer's disease." | 1.36 | Effects of the uncompetitive nmda receptor antagonist memantine on recognition memory in rats. ( Beselia, G; Burjanadze, M; Chkhikvishvili, N; Dashniani, M; Naneishvili, T, 2010) |
| "Memantine-treated patients had less decline from baseline on the ADL14 total score, compared with placebo (p < 0." | 1.36 | Memantine benefits functional abilities in moderate to severe Alzheimer's disease. ( Aström, D; Gauthier, S; Stender, K; Winblad, B, 2010) |
| "The analysis revealed that adverse events occurring during both short- and long-term memantine treatment were minimal, and similar in type and frequency to those reported for placebo-treated patients." | 1.35 | Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials. ( Alva, G; Farlow, MR; Graham, SM, 2008) |
| "Memantine has also been shown to reduce the levels of amyloid beta (A beta) peptides in human neuroblastoma cells as well as to inhibit A beta oligomer-induced synaptic loss." | 1.35 | Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. ( Banerjee, P; Douadi, M; Li, YS; Quartermain, D; Scholtzova, H; Sigurdsson, EM; Wadghiri, YZ; Wisniewski, T, 2008) |
| "Memantine treatment significantly protected cultured neurons against Abeta-induced toxicity by attenuating tau-phosphorylation and its associated signaling mechanisms." | 1.35 | Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation. ( Baker, GB; Kar, S; Rauw, G; Song, MS, 2008) |
| "Dementia with Lewy bodies and Parkinson's disease with dementia should be treated with rivastigmine." | 1.35 | [Treatment of degenerative dementia disorders--who should be treated?]. ( Hasselbalch, SG; Kampmann, JP, 2009) |
| "California Department of Public Health Alzheimer's Disease (AD) Research Centers of California." | 1.35 | Treatment practices of mild cognitive impairment in California Alzheimer's Disease Centers. ( Barton, C; Kramer, JH; Ross, L; Weinstein, AM; Yaffe, K, 2009) |
| "Co-treatment with memantine reversed the activation of the astrocytes and microglia, thus attenuating the PAD2 increment." | 1.35 | Increased expression of PAD2 after repeated intracerebroventricular infusions of soluble Abeta(25-35) in the Alzheimer's disease model rat brain: effect of memantine. ( Arif, M; Kato, T, 2009) |
| "Treatment with memantine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist significantly attenuated Abeta(25-35)-induced changes of neuropeptides, their metabolizing enzymes, glial marker proteins, and activation of iNOS." | 1.35 | Effects of memantine on soluble Alphabeta(25-35)-induced changes in peptidergic and glial cells in Alzheimer's disease model rat brain regions. ( Ahmed, MM; Arif, M; Chikuma, T; Kato, T; Nakazato, M; Smith, MA, 2009) |
| "Memantine treatment of AD patients results in significant benefits for language function." | 1.35 | Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients. ( Ferris, S; Gatz, G; Gauthier, S; Ihl, R; Robert, P; Tennigkeit, F; Winblad, B, 2009) |
| "To estimate the prevalence of Alzheimer's disease (AD) treatment in Aragon (Spain), analyzing differences according to age, gender and health area." | 1.35 | Variability in the prescription of cholinesterase inhibitors and memantine. ( Bjerrum, L; Feja, C; Rabanaque, MJ; Villar-Fernández, I, 2009) |
| "Many patients with early symptoms of Alzheimer's disease (AD) first seek help from their primary care providers (PCPs)." | 1.35 | Alzheimer's disease: Seeing the signs early. ( Leifer, BP, 2009) |
| "Treatment with memantine decreased Glu/Cr (creatine) ratio in the left hippocampal region." | 1.35 | Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study. ( de Leon, MJ; De Santi, S; Glodzik, L; Gonen, O; King, KG; Liu, S, 2008) |
| " The patients spent the baseline period and day 35 at the study centre, where plasma samples for pharmacokinetic evaluation were taken at specified time intervals over a 10-hour time period." | 1.35 | Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study. ( Athalye, S; Lefèvre, G; Picard, F; Pommier, F; Sedek, G; Shua-Haim, J; Smith, J, 2008) |
| "Cardiovascular disorders are the most frequently reported adverse effects of drugs used to treat Alzheimer's disease." | 1.34 | Anti-Alzheimer drugs: life-threatening adverse effects. ( , 2007) |
| "Memantine was extracted from biological samples by a standard liquid-liquid basic drug method followed by analysis utilizing a gas chromatograph-mass spectrometer operated in SIM mode." | 1.34 | Postmortem memantine concentrations. ( Bynum, N; Garside, D; Poklis, J; Winecker, R, 2007) |
| "Memantine is a moderate affinity N-methyl-D-aspartate receptor antagonist approved for treatment of Alzheimer's disease (AD)." | 1.34 | Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. ( Basun, H; Degerman Gunnarsson, M; Kilander, L; Lannfelt, L, 2007) |
| " Higher dosages often did not exert beneficial effects in accordance with inverted U-shaped dose-response curves described for cholinomimetics." | 1.33 | Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. ( Abramowski, D; De Deyn, PP; Staufenbiel, M; Van Dam, D, 2005) |
| "Formation of senile plaques composed of amyloid beta peptide, a pathological hallmark of Alzheimer disease, in human brains precedes disease onset by many years." | 1.33 | 19F and 1H MRI detection of amyloid beta plaques in vivo. ( Higuchi, M; Iwata, N; Matsuba, Y; Saido, TC; Sasamoto, K; Sato, K, 2005) |
| "Donepezil was well tolerated, with 85 of 913 (9." | 1.33 | Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study. ( Ibach, B; Kamleiter, M; Klinger, T; Mielke, R; Schoenknecht, P; Schroeder, J; Silver, G, 2005) |
| "Memantine was initiated, and the dose was titrated to 10 mg twice daily." | 1.33 | Antipsychotic dose-sparing effect with addition of memantine. ( Sleeper, RB, 2005) |
| "The memantine strategy was associated with an additional 2." | 1.33 | Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain. ( Antonanzas, F; Badenas, JM; Gomez-Lus, S; Guilhaume, C; Rive, B, 2006) |
| "Memantine use has shown some benefit in moderate-to-severe Alzheimer's disease or for vascular dementia." | 1.33 | Magnesium supplementation in the treatment of dementia patients. ( Cillier, AE; Ozturk, S, 2006) |
| "Since Alzheimer's disease is known to be associated with down-regulation of the cholinergic and N-methyl-D-aspartate (NMDA) systems, most of these drugs inhibit acetylcholinesterase, potentiate the activity of nicotinic acetylcholine receptors (nAChRs), or modulate NMDA receptors." | 1.33 | In vitro galantamine-memantine co-application: mechanism of beneficial action. ( Huang, J; Marszalec, W; Narahashi, T; Toth, PT; Yeh, JZ; Zhao, X, 2006) |
| "Other causes of dementia have overlapping presentations, but with important differences." | 1.32 | Does this patient have Alzheimer disease? Diagnosing and treating dementia. ( Messinger-Rapport, BJ, 2003) |
| "Most patients with advanced Alzheimer's disease need 24-hour supervision, often provided in a long-term care setting." | 1.32 | Diagnosis and management of Alzheimer's disease. ( Coll, PP; Fortinsky, RH; Kaplan, R; Song, C, 2003) |
| "The authors report 2 cases, in Alzheimer's disease and vascular dementia, in which erotomania emerged in the early stage of the underlying disorder." | 1.32 | Erotomania variants in dementia. ( Brüne, M; Schröder, SG, 2003) |
| "Memantine is a second-line option, as its adverse effects differ from those of anticholinesterases." | 1.32 | Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer's disease. ( , 2003) |
| "Memantine, shown to cause cognitive and functional improvement, is not an ChE inhibitor and does not interact with marketed ChE inhibitors." | 1.32 | What is the rationale for new treatment strategies in Alzheimer's disease? ( Rogawski, MA, 2004) |
| "Treatment of Alzheimer's disease (AD) that combats progressive functional deterioration can improve the patient's quality of life and reduce caregiver burden." | 1.32 | Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. ( Doody, R; Möbius, HJ; Schmitt, F; Wirth, Y, 2004) |
| "For each category of Alzheimer's disease patient examined, treatment with memantine was a cost-effective strategy." | 1.32 | Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective. ( Guilhaume, C; Jones, RW; McCrone, P, 2004) |
| "Memantine treated animals had significant reductions in the amount of neuronal degeneration, pyknotic nuclei, and GFAP immunostaining as compared with vehicle treated animals." | 1.31 | Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). ( Alvarez, XA; Cacabelos, R; Miguel-Hidalgo, JJ; Quack, G, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.12) | 18.7374 |
| 1990's | 3 (0.36) | 18.2507 |
| 2000's | 297 (35.44) | 29.6817 |
| 2010's | 409 (48.81) | 24.3611 |
| 2020's | 128 (15.27) | 2.80 |
| Authors | Studies |
|---|---|
| Rosini, M | 6 |
| Simoni, E | 4 |
| Bartolini, M | 3 |
| Cavalli, A | 5 |
| Ceccarini, L | 1 |
| Pascu, N | 1 |
| McClymont, DW | 1 |
| Tarozzi, A | 1 |
| Bolognesi, ML | 1 |
| Minarini, A | 5 |
| Tumiatti, V | 1 |
| Andrisano, V | 2 |
| Mellor, IR | 3 |
| Melchiorre, C | 2 |
| Rook, Y | 1 |
| Schmidtke, KU | 1 |
| Gaube, F | 2 |
| Schepmann, D | 1 |
| Wünsch, B | 1 |
| Heilmann, J | 1 |
| Lehmann, J | 1 |
| Winckler, T | 2 |
| Daniele, S | 2 |
| Bottegoni, G | 2 |
| Pizzirani, D | 1 |
| Trincavelli, ML | 1 |
| Goldoni, L | 1 |
| Tarozzo, G | 1 |
| Reggiani, A | 1 |
| Martini, C | 2 |
| Piomelli, D | 1 |
| Montolio, M | 1 |
| Gregori-Puigjané, E | 1 |
| Pineda, D | 1 |
| Mestres, J | 1 |
| Navarro, P | 1 |
| Gao, J | 1 |
| Adam, BL | 1 |
| Terry, AV | 2 |
| de Candia, M | 1 |
| Zaetta, G | 1 |
| Denora, N | 1 |
| Tricarico, D | 1 |
| Majellaro, M | 1 |
| Cellamare, S | 1 |
| Altomare, CD | 1 |
| Nirogi, R | 1 |
| Shinde, A | 1 |
| Kambhampati, RS | 1 |
| Mohammed, AR | 1 |
| Saraf, SK | 1 |
| Badange, RK | 1 |
| Bandyala, TR | 1 |
| Bhatta, V | 1 |
| Bojja, K | 1 |
| Reballi, V | 1 |
| Subramanian, R | 1 |
| Benade, V | 1 |
| Palacharla, RC | 1 |
| Bhyrapuneni, G | 1 |
| Jayarajan, P | 1 |
| Goyal, V | 1 |
| Jasti, V | 1 |
| Gonzalez, D | 1 |
| Arribas, RL | 1 |
| Viejo, L | 1 |
| Lajarin-Cuesta, R | 1 |
| de Los Rios, C | 1 |
| Zhang, P | 1 |
| Xu, S | 1 |
| Zhu, Z | 4 |
| Xu, J | 4 |
| Pérez-Areales, FJ | 1 |
| Turcu, AL | 4 |
| Barniol-Xicota, M | 1 |
| Pont, C | 1 |
| Pivetta, D | 1 |
| Espargaró, A | 1 |
| De Simone, A | 1 |
| Pérez, B | 2 |
| Sabate, R | 1 |
| Sureda, FX | 2 |
| Vázquez, S | 4 |
| Muñoz-Torrero, D | 1 |
| Jiang, X | 4 |
| Guo, J | 2 |
| Lv, Y | 2 |
| Yao, C | 2 |
| Zhang, C | 4 |
| Mi, Z | 1 |
| Shi, Y | 2 |
| Gu, J | 1 |
| Zhou, T | 1 |
| Bai, R | 1 |
| Xie, Y | 3 |
| Schwarthoff, S | 1 |
| Tischer, N | 1 |
| Sager, H | 1 |
| Schätz, B | 1 |
| Rohrbach, MM | 1 |
| Raztsou, I | 1 |
| Robaa, D | 1 |
| Arndt, HD | 1 |
| Companys-Alemany, J | 3 |
| Phillips, MB | 1 |
| Patel, DS | 1 |
| Griñán-Ferré, C | 3 |
| Loza, MI | 1 |
| Brea, JM | 1 |
| Soto, D | 1 |
| Kurnikova, MG | 1 |
| Johnson, JW | 3 |
| Pallàs, M | 3 |
| Lu, K | 1 |
| Wang, Y | 12 |
| Zhang, H | 4 |
| Tian, C | 1 |
| Wang, W | 3 |
| Yang, T | 1 |
| Qi, B | 1 |
| Wu, S | 4 |
| Knorz, AL | 1 |
| Quante, A | 1 |
| Shamsi, A | 1 |
| Shahwan, M | 1 |
| Alhumaydhi, FA | 1 |
| Alwashmi, ASS | 1 |
| Aljasir, MA | 1 |
| Alsagaby, SA | 1 |
| Al Abdulmonem, W | 1 |
| Hassan, MI | 1 |
| Islam, A | 2 |
| Swerdlow, NR | 4 |
| Kotz, JE | 4 |
| Joshi, YB | 4 |
| Talledo, J | 4 |
| Sprock, J | 4 |
| Molina, JL | 4 |
| Huisa, B | 1 |
| Huege, SF | 1 |
| Romero, JA | 1 |
| Walsh, MJ | 1 |
| Delano-Wood, L | 4 |
| Light, GA | 4 |
| Park, JS | 1 |
| Kim, T | 1 |
| Kim, D | 1 |
| Jeong, YI | 1 |
| Radulović, S | 1 |
| Sunkara, S | 1 |
| Maurer, C | 1 |
| Leitinger, G | 1 |
| Vallius, S | 1 |
| Taipale, H | 5 |
| Koponen, M | 3 |
| Tolppanen, AM | 4 |
| Tanskanen, A | 4 |
| Hartikainen, S | 6 |
| Tiihonen, M | 1 |
| Bago Rožanković, P | 1 |
| Rožanković, M | 1 |
| Badžak, J | 1 |
| Stojić, M | 1 |
| Šušak Sporiš, I | 1 |
| Balázs, N | 1 |
| Bereczki, D | 1 |
| Kovács, T | 2 |
| Gareri, P | 3 |
| Veronese, N | 1 |
| Cotroneo, AM | 3 |
| Broberg, DN | 2 |
| Wong, D | 2 |
| Bellyou, M | 2 |
| Montero-Odasso, M | 2 |
| Beauchet, O | 10 |
| Annweiler, C | 12 |
| Bartha, R | 3 |
| Shi, X | 3 |
| Ren, G | 1 |
| Cui, Y | 2 |
| Xu, Z | 1 |
| Lee, JH | 6 |
| Thompson, RE | 1 |
| Tuchman, AJ | 1 |
| Alkon, DL | 1 |
| Zhu, CW | 2 |
| Neugroschl, J | 1 |
| Barnes, LL | 1 |
| Sano, M | 6 |
| Nagata, T | 1 |
| Shinagawa, S | 1 |
| Nakajima, S | 1 |
| Noda, Y | 2 |
| Mimura, M | 1 |
| Kuang, W | 1 |
| Liu, J | 6 |
| Lin, X | 2 |
| Gong, J | 1 |
| Yin, Q | 1 |
| Wang, J | 8 |
| Saeedi, M | 1 |
| Mehranfar, F | 1 |
| Zhang, W | 2 |
| Kandel, N | 1 |
| Zhou, Y | 4 |
| Smith, N | 1 |
| C L B Ferreira, B | 1 |
| Perez, M | 1 |
| Claure, ML | 1 |
| Mintz, KJ | 1 |
| Wang, C | 5 |
| Leblanc, RM | 1 |
| de Oliveira, FF | 3 |
| de Almeida, SS | 1 |
| Chen, ES | 3 |
| Smith, MC | 2 |
| Bertolucci, PHF | 2 |
| Byun, J | 1 |
| Lee, DY | 1 |
| Jeong, CW | 1 |
| Kim, Y | 4 |
| Rhee, HY | 1 |
| Moon, KW | 1 |
| Heo, J | 1 |
| Hong, Y | 1 |
| Kim, WJ | 1 |
| Nam, SJ | 1 |
| Choi, HS | 1 |
| Park, JI | 2 |
| Chun, IK | 1 |
| Bak, SH | 1 |
| Lee, K | 1 |
| Byeon, GH | 1 |
| Kim, KL | 1 |
| Kim, JA | 1 |
| Park, YJ | 1 |
| Kim, JH | 1 |
| Lee, EJ | 2 |
| Lee, SA | 1 |
| Kwon, SO | 1 |
| Park, SW | 1 |
| Kasani, PH | 1 |
| Kim, JK | 1 |
| Kim, S | 1 |
| Jang, JW | 1 |
| Świetlik, D | 1 |
| Kusiak, A | 1 |
| Ossowska, A | 1 |
| Veroniki, AA | 1 |
| Ashoor, HM | 1 |
| Rios, P | 1 |
| Seitidis, G | 1 |
| Stewart, L | 1 |
| Clarke, M | 1 |
| Tudur-Smith, C | 1 |
| Mavridis, D | 1 |
| Hemmelgarn, BR | 1 |
| Holroyd-Leduc, J | 1 |
| Straus, SE | 1 |
| Tricco, AC | 1 |
| Lombardi, G | 1 |
| Lombardi, N | 1 |
| Bettiol, A | 1 |
| Crescioli, G | 1 |
| Ferrari, C | 1 |
| Lucidi, G | 1 |
| Polito, C | 1 |
| Berti, V | 1 |
| Bessi, V | 1 |
| Bagnoli, S | 1 |
| Nacmias, B | 1 |
| Vannacci, A | 1 |
| Sorbi, S | 2 |
| Souchet, B | 1 |
| Audrain, M | 1 |
| Alves, S | 1 |
| Fol, R | 1 |
| Tada, S | 1 |
| Orefice, NS | 1 |
| Potier, B | 1 |
| Dutar, P | 1 |
| Billard, JM | 1 |
| Cartier, N | 1 |
| Braudeau, J | 1 |
| Yamaguchi, F | 1 |
| Hayakawa, S | 1 |
| Kawashima, S | 1 |
| Asakura, T | 1 |
| Oishi, Y | 1 |
| Wiatrak, B | 1 |
| Balon, K | 1 |
| Jawień, P | 1 |
| Bednarz, D | 1 |
| Jęśkowiak, I | 1 |
| Szeląg, A | 1 |
| Moriguchi, S | 2 |
| Inagaki, R | 1 |
| Saito, T | 2 |
| Saido, TC | 3 |
| Fukunaga, K | 2 |
| Parsons, C | 1 |
| Lim, WY | 1 |
| Loy, C | 1 |
| McGuinness, B | 1 |
| Passmore, P | 6 |
| Ward, SA | 1 |
| Hughes, C | 1 |
| Andrzejewski, K | 1 |
| Jampolska, M | 1 |
| Mojzych, I | 1 |
| Conde, SV | 1 |
| Kaczyńska, K | 1 |
| Schneider, M | 1 |
| Müller, CE | 1 |
| Majidazar, R | 1 |
| Rezazadeh-Gavgani, E | 1 |
| Sadigh-Eteghad, S | 1 |
| Naseri, A | 1 |
| Yıldırım, ÖÇ | 1 |
| Arslan, ME | 1 |
| Öner, S | 1 |
| Cacciatore, I | 2 |
| Di Stefano, A | 2 |
| Mardinoglu, A | 1 |
| Turkez, H | 1 |
| Topal, F | 1 |
| Ertas, B | 1 |
| Guler, E | 1 |
| Gurbuz, F | 1 |
| Ozcan, GS | 1 |
| Aydemir, O | 1 |
| Bocekci, VG | 1 |
| Duruksu, G | 1 |
| Sahin Cam, C | 1 |
| Yazir, Y | 1 |
| Gunduz, O | 1 |
| Cam, ME | 1 |
| Bu, K | 1 |
| Patel, D | 1 |
| Morris, R | 1 |
| Han, W | 1 |
| Umeukeje, G | 1 |
| Zhu, T | 1 |
| Cheng, F | 1 |
| Liu, M | 3 |
| Chen, C | 1 |
| Gao, K | 2 |
| Gao, F | 2 |
| Qin, C | 1 |
| Yuan, Q | 2 |
| Zhuang, L | 1 |
| Wang, P | 2 |
| Morató, X | 1 |
| Pytel, V | 1 |
| Jofresa, S | 1 |
| Ruiz, A | 1 |
| Boada, M | 2 |
| Vieira, ADC | 1 |
| Medeiros, EB | 1 |
| Zabot, GC | 1 |
| Pereira, NS | 1 |
| do Nascimento, NB | 1 |
| Lidio, AV | 1 |
| Scheffer, ÂK | 1 |
| Rempel, LCT | 1 |
| Macarini, BMN | 1 |
| Costa, MA | 1 |
| Gonçalves, CL | 1 |
| Kucharska, E | 1 |
| Rodrigues, MS | 1 |
| Moreira, JCF | 1 |
| de Oliveira, J | 1 |
| Budni, J | 1 |
| Nguyen, HD | 1 |
| Kaur, A | 4 |
| Nigam, K | 4 |
| Tyagi, A | 4 |
| Dang, S | 4 |
| Fide, E | 3 |
| Polat, H | 3 |
| Yener, G | 3 |
| Özerdem, MS | 3 |
| Perlett, L | 3 |
| Smith, EE | 3 |
| Garcia, MJ | 3 |
| Leadley, R | 3 |
| Lang, S | 3 |
| Ross, J | 3 |
| Vinand, E | 3 |
| Ballard, C | 16 |
| Gsteiger, S | 3 |
| Iwanaga, D | 3 |
| Huege, S | 3 |
| Léger, GC | 4 |
| Vasenina, EE | 3 |
| Veryugina, NI | 3 |
| Levin, OS | 3 |
| Painuli, S | 2 |
| Semwal, P | 2 |
| Zam, W | 2 |
| Taheri, Y | 2 |
| Ezzat, SM | 2 |
| Zuo, P | 2 |
| Li, L | 8 |
| Kumar, D | 2 |
| Sharifi-Rad, J | 2 |
| Cruz-Martins, N | 2 |
| Anderson, A | 1 |
| Malone, M | 1 |
| Ippoliti, I | 1 |
| Ancidoni, A | 1 |
| Da Cas, R | 3 |
| Pierantozzi, A | 1 |
| Vanacore, N | 3 |
| Trotta, F | 1 |
| Müller, T | 1 |
| Riederer, P | 1 |
| Kuhn, W | 1 |
| Padovani, A | 2 |
| Falato, S | 1 |
| Pegoraro, V | 1 |
| Dubois, B | 2 |
| López-Arrieta, J | 1 |
| Lipschitz, S | 1 |
| Doskas, T | 1 |
| Spiru, L | 1 |
| Moroz, S | 1 |
| Venger, O | 1 |
| Vermersch, P | 1 |
| Moussy, A | 1 |
| Mansfield, CD | 1 |
| Hermine, O | 1 |
| Tsolaki, M | 2 |
| Aljuwaiser, M | 1 |
| Alayadhi, N | 1 |
| Ozidu, V | 1 |
| Shafik Zakhari, SA | 1 |
| Rushdy, R | 1 |
| Naguy, A | 1 |
| Fava, M | 1 |
| Stahl, SM | 1 |
| De Martin, S | 1 |
| Mattarei, A | 1 |
| Bettini, E | 1 |
| Comai, S | 1 |
| Alimonti, A | 1 |
| Bifari, F | 1 |
| Pani, L | 2 |
| Folli, F | 1 |
| Guidetti, C | 1 |
| Furlan, A | 1 |
| Sgrignani, J | 1 |
| Locatelli, P | 1 |
| O'Gorman, C | 1 |
| Traversa, S | 1 |
| Inturrisi, CE | 1 |
| Pappagallo, M | 1 |
| Manfredi, PL | 1 |
| Yamada, M | 2 |
| Prasad, P | 1 |
| Bagai, S | 1 |
| Khullar, D | 1 |
| Toccaceli Blasi, M | 1 |
| Valletta, M | 1 |
| Trebbastoni, A | 1 |
| D'Antonio, F | 1 |
| Talarico, G | 1 |
| Campanelli, A | 1 |
| Sepe Monti, M | 1 |
| Salati, E | 1 |
| Gasparini, M | 1 |
| Buscarnera, S | 1 |
| Salzillo, M | 1 |
| Canevelli, M | 1 |
| Bruno, G | 1 |
| Kondak, C | 1 |
| Leith, M | 1 |
| Baddeley, TC | 1 |
| Santos, RX | 1 |
| Harrington, CR | 1 |
| Wischik, CM | 1 |
| Riedel, G | 3 |
| Klein, J | 1 |
| Bhattarai, K | 1 |
| Rajaganapathy, S | 1 |
| Das, T | 1 |
| Chen, Y | 2 |
| Dai, Q | 1 |
| Li, X | 7 |
| Zong, N | 1 |
| Kerckhove, N | 1 |
| Bornier, N | 1 |
| Mulliez, A | 1 |
| Elyn, A | 1 |
| Teixeira, S | 1 |
| Authier, N | 1 |
| Bertin, C | 1 |
| Chenaf, C | 1 |
| Anoush, M | 1 |
| Bijani, S | 1 |
| Moslemifar, F | 1 |
| Jahanpour, F | 1 |
| Kalantari-Hesari, A | 1 |
| Hosseini, MJ | 1 |
| Schneider, LS | 9 |
| Olazarán, J | 1 |
| Carnero-Pardo, C | 1 |
| Fortea, J | 1 |
| Sánchez-Juan, P | 1 |
| García-Ribas, G | 1 |
| Viñuela, F | 1 |
| Martínez-Lage, P | 1 |
| Katisko, K | 1 |
| Krüger, J | 1 |
| Soppela, H | 1 |
| Hartikainen, P | 1 |
| Haapasalo, A | 1 |
| Remes, AM | 1 |
| Solje, E | 1 |
| Rani, V | 1 |
| Verma, R | 1 |
| Kumar, K | 1 |
| Chawla, R | 1 |
| Bandakinda, M | 1 |
| Mishra, A | 1 |
| Yaghmaei, E | 1 |
| Pierce, A | 1 |
| Lu, H | 1 |
| Patel, YM | 1 |
| Ehwerhemuepha, L | 1 |
| Rezaie, A | 1 |
| Sajjadi, SA | 1 |
| Rakovski, C | 1 |
| Basagni, F | 3 |
| Ortega, JA | 1 |
| Bertozzi, SM | 1 |
| Armirotti, A | 1 |
| Summa, M | 1 |
| Bertorelli, R | 1 |
| Bedeschi, M | 1 |
| Lembo, V | 1 |
| Buccellato, FR | 1 |
| D'Anca, M | 1 |
| Tartaglia, GM | 1 |
| Del Fabbro, M | 1 |
| Scarpini, E | 4 |
| Galimberti, D | 4 |
| Arkhipov, VI | 1 |
| Chernomorets, IY | 1 |
| Zhuikova, NS | 1 |
| Fedorov, DA | 1 |
| Pershina, EV | 1 |
| Saigoh, K | 1 |
| Hirano, M | 1 |
| Mitsui, Y | 1 |
| Oda, I | 1 |
| Ikegawa, A | 1 |
| Samukawa, M | 1 |
| Yoshikawa, K | 1 |
| Yamagishi, Y | 1 |
| Kusunoki, S | 1 |
| Nagai, Y | 1 |
| Freitas, EL | 1 |
| Calil-Elias, S | 1 |
| Erbisti, RS | 1 |
| Grinberg-Weller, B | 1 |
| Miranda, ES | 1 |
| Özsoy, Ş | 1 |
| Çakir, Z | 1 |
| Akçay, E | 1 |
| Gevrek, F | 1 |
| Mesiti, F | 1 |
| Chavarria, D | 1 |
| Gaspar, A | 1 |
| Alcaro, S | 1 |
| Borges, F | 1 |
| Blanco-Silvente, L | 2 |
| Castells, X | 2 |
| Garre-Olmo, J | 5 |
| Vilalta-Franch, J | 5 |
| Saez, M | 1 |
| Barceló, MA | 1 |
| Capellà, D | 2 |
| Linna, M | 2 |
| Vuoti, S | 1 |
| Silander, K | 1 |
| Hörhammer, I | 2 |
| Halminen, O | 2 |
| Mikkola, T | 2 |
| Koivuranta-Vaara, P | 1 |
| Virta, LJ | 2 |
| Koivusalo, M | 1 |
| Ylisaukko-Oja, T | 2 |
| Jürgenson, M | 1 |
| Zharkovskaja, T | 1 |
| Noortoots, A | 1 |
| Morozova, M | 1 |
| Beniashvili, A | 1 |
| Zapolski, M | 1 |
| Zharkovsky, A | 1 |
| Gothwal, A | 1 |
| Kumar, H | 1 |
| Nakhate, KT | 1 |
| Dutta, A | 1 |
| Borah, A | 1 |
| Gupta, U | 1 |
| Kabir, MT | 2 |
| Sufian, MA | 1 |
| Uddin, MS | 2 |
| Begum, MM | 1 |
| Akhter, S | 1 |
| Mathew, B | 2 |
| Islam, MS | 1 |
| Amran, MS | 1 |
| Md Ashraf, G | 1 |
| Arvanitakis, Z | 1 |
| Shah, RC | 2 |
| Bennett, DA | 1 |
| Radwan, RR | 1 |
| Abdel Ghaffar, AM | 1 |
| Ali, HE | 1 |
| Sharma, P | 1 |
| Tripathi, MK | 1 |
| Shrivastava, SK | 1 |
| Atri, A | 6 |
| Goldfarb, D | 1 |
| Sheard, S | 1 |
| Shaughnessy, L | 1 |
| Sabbagh, M | 1 |
| Sadowsky, C | 2 |
| Tousi, B | 1 |
| Agronin, ME | 1 |
| Alva, G | 3 |
| Armon, C | 1 |
| Bernick, C | 1 |
| Keegan, AP | 1 |
| Karantzoulis, S | 1 |
| Baror, E | 1 |
| Ploznik, M | 1 |
| Pascual-Leone, A | 1 |
| Wang, QJ | 1 |
| Shen, YE | 1 |
| Wang, X | 6 |
| Fu, S | 2 |
| Zhang, X | 7 |
| Zhang, YN | 1 |
| Wang, RT | 1 |
| Mak, S | 1 |
| Liu, Z | 5 |
| Wu, L | 3 |
| Guo, B | 2 |
| Luo, F | 1 |
| Hu, S | 2 |
| Cui, G | 1 |
| Sun, Y | 9 |
| Zhang, G | 5 |
| Han, Y | 2 |
| Zhang, Z | 5 |
| Lampela, P | 3 |
| Tiihonen, J | 3 |
| Binvignat, O | 1 |
| Olloquequi, J | 2 |
| Bures, J | 1 |
| Kvetina, J | 1 |
| Radochova, V | 1 |
| Tacheci, I | 1 |
| Peterova, E | 1 |
| Herman, D | 1 |
| Dolezal, R | 1 |
| Kopacova, M | 1 |
| Rejchrt, S | 1 |
| Douda, T | 1 |
| Sestak, V | 1 |
| Douda, L | 1 |
| Karasova, JZ | 1 |
| Karimi-Sales, R | 1 |
| Ashiri, M | 1 |
| Hafizi, M | 1 |
| Kalanaky, S | 1 |
| Maghsoudi, AH | 1 |
| Fakharzadeh, S | 1 |
| Maghsoudi, N | 1 |
| Nazaran, MH | 1 |
| Honjo, Y | 1 |
| Ide, K | 1 |
| Takechi, H | 1 |
| Cao, Y | 3 |
| Qian, L | 1 |
| Yu, W | 2 |
| Li, T | 1 |
| Mao, S | 1 |
| Han, G | 2 |
| Potasiewicz, A | 2 |
| Krawczyk, M | 1 |
| Gzielo, K | 1 |
| Popik, P | 2 |
| Nikiforuk, A | 2 |
| Halim, AA | 1 |
| Alsayed, B | 1 |
| Embarak, S | 1 |
| Yaseen, T | 1 |
| Dabbous, S | 1 |
| Fontaine, O | 1 |
| Dueluzeau, R | 1 |
| Raibaud, P | 1 |
| Chabanet, C | 1 |
| Popoff, MR | 1 |
| Badoual, J | 1 |
| Gabilan, JC | 1 |
| Andremont, A | 1 |
| Gómez, L | 1 |
| Andrés, S | 1 |
| Sánchez, J | 1 |
| Alonso, JM | 1 |
| Rey, J | 1 |
| López, F | 1 |
| Jiménez, A | 1 |
| Yan, Z | 1 |
| Zhou, L | 1 |
| Zhao, Y | 3 |
| Huang, L | 2 |
| Hu, K | 1 |
| Liu, H | 4 |
| Wang, H | 4 |
| Guo, Z | 1 |
| Song, Y | 1 |
| Huang, H | 4 |
| Yang, R | 1 |
| Owen, TW | 1 |
| Al-Kaysi, RO | 1 |
| Bardeen, CJ | 1 |
| Cheng, Q | 1 |
| Cheng, T | 1 |
| Zhou, X | 3 |
| Wang, B | 4 |
| Zhang, Q | 5 |
| Wu, X | 2 |
| Yao, Y | 3 |
| Ochiai, T | 1 |
| Ishiguro, H | 2 |
| Nakano, R | 2 |
| Kubota, Y | 2 |
| Hara, M | 1 |
| Sunada, K | 1 |
| Hashimoto, K | 1 |
| Kajioka, J | 1 |
| Fujishima, A | 1 |
| Jiao, J | 3 |
| Gai, QY | 3 |
| Zang, YP | 2 |
| Niu, LL | 2 |
| Fu, YJ | 3 |
| Yao, LP | 1 |
| Qin, QP | 1 |
| Wang, ZY | 1 |
| Aleksic Sabo, V | 1 |
| Knezevic, P | 1 |
| Borges-Argáez, R | 1 |
| Chan-Balan, R | 1 |
| Cetina-Montejo, L | 1 |
| Ayora-Talavera, G | 1 |
| Sansores-Peraza, P | 1 |
| Gómez-Carballo, J | 1 |
| Cáceres-Farfán, M | 1 |
| Jang, J | 1 |
| Akin, D | 1 |
| Bashir, R | 1 |
| Yu, Z | 2 |
| Zhu, J | 2 |
| Jiang, H | 3 |
| He, C | 2 |
| Xiao, Z | 1 |
| Sun, Q | 1 |
| Han, D | 1 |
| Lei, H | 1 |
| Zhao, K | 2 |
| Zhu, L | 2 |
| Fu, H | 2 |
| Wilson, BK | 1 |
| Step, DL | 1 |
| Maxwell, CL | 1 |
| Gifford, CA | 1 |
| Richards, CJ | 1 |
| Krehbiel, CR | 1 |
| Warner, JM | 1 |
| Doerr, AJ | 1 |
| Erickson, GE | 1 |
| Guretzky, JA | 1 |
| Rasby, RJ | 1 |
| Watson, AK | 1 |
| Klopfenstein, TJ | 1 |
| Pham, TD | 1 |
| Lee, BK | 1 |
| Yang, FC | 1 |
| Wu, KH | 1 |
| Lin, WP | 1 |
| Hu, MK | 1 |
| Lin, L | 4 |
| Shao, J | 1 |
| Sun, M | 1 |
| Xu, G | 1 |
| Xu, N | 1 |
| Wang, R | 1 |
| Liu, S | 2 |
| He, H | 1 |
| Dong, X | 2 |
| Yang, M | 2 |
| Yang, Q | 1 |
| Duan, S | 1 |
| Yu, Y | 2 |
| Han, J | 3 |
| Chen, L | 4 |
| Yang, X | 3 |
| Li, W | 3 |
| Wang, T | 3 |
| Campbell, DA | 1 |
| Zager, RA | 1 |
| Johnson, ACM | 1 |
| Guillem, A | 1 |
| Keyser, J | 1 |
| Singh, B | 1 |
| Steubl, D | 1 |
| Schneider, MP | 1 |
| Meiselbach, H | 1 |
| Nadal, J | 1 |
| Schmid, MC | 1 |
| Saritas, T | 1 |
| Krane, V | 1 |
| Sommerer, C | 1 |
| Baid-Agrawal, S | 1 |
| Voelkl, J | 1 |
| Kotsis, F | 1 |
| Köttgen, A | 1 |
| Eckardt, KU | 1 |
| Scherberich, JE | 1 |
| Li, H | 4 |
| Yao, L | 2 |
| Sun, L | 3 |
| Naren, N | 1 |
| Zhang, XX | 2 |
| Gentile, GL | 1 |
| Rupert, AS | 1 |
| Carrasco, LI | 1 |
| Garcia, EM | 1 |
| Kumar, NG | 1 |
| Walsh, SW | 1 |
| Jefferson, KK | 1 |
| Guest, RL | 1 |
| Samé Guerra, D | 1 |
| Wissler, M | 1 |
| Grimm, J | 1 |
| Silhavy, TJ | 1 |
| Yoo, JS | 1 |
| Kim, JS | 2 |
| Roe, JH | 1 |
| Delorme, M | 1 |
| Bouchard, PA | 1 |
| Simon, M | 1 |
| Simard, S | 1 |
| Lellouche, F | 1 |
| D'Urzo, KA | 1 |
| Mok, F | 1 |
| D'Urzo, AD | 1 |
| Koneru, B | 1 |
| Lopez, G | 1 |
| Farooqi, A | 1 |
| Conkrite, KL | 1 |
| Nguyen, TH | 1 |
| Macha, SJ | 1 |
| Modi, A | 1 |
| Rokita, JL | 1 |
| Urias, E | 1 |
| Hindle, A | 1 |
| Davidson, H | 1 |
| Mccoy, K | 1 |
| Nance, J | 1 |
| Yazdani, V | 1 |
| Irwin, MS | 1 |
| Yang, S | 1 |
| Wheeler, DA | 1 |
| Maris, JM | 1 |
| Diskin, SJ | 1 |
| Reynolds, CP | 1 |
| Abhilash, L | 1 |
| Kalliyil, A | 1 |
| Sheeba, V | 1 |
| Hartley, AM | 2 |
| Meunier, B | 2 |
| Pinotsis, N | 1 |
| Maréchal, A | 2 |
| Xu, JY | 1 |
| Genko, N | 1 |
| Haraux, F | 1 |
| Rich, PR | 1 |
| Kamalanathan, M | 1 |
| Doyle, SM | 1 |
| Xu, C | 1 |
| Achberger, AM | 1 |
| Wade, TL | 1 |
| Schwehr, K | 1 |
| Santschi, PH | 1 |
| Sylvan, JB | 1 |
| Quigg, A | 1 |
| Leong, W | 1 |
| Xu, W | 2 |
| Gao, S | 1 |
| Zhai, X | 1 |
| Gilson, E | 1 |
| Ye, J | 1 |
| Lu, Y | 2 |
| Yan, R | 1 |
| Zhang, Y | 8 |
| Hu, Z | 1 |
| You, Q | 1 |
| Cai, Q | 1 |
| Yang, D | 1 |
| Gu, S | 1 |
| Dai, H | 1 |
| Zhao, X | 3 |
| Gui, C | 1 |
| Gui, J | 1 |
| Wu, PK | 1 |
| Hong, SK | 1 |
| Starenki, D | 1 |
| Oshima, K | 1 |
| Shao, H | 1 |
| Gestwicki, JE | 1 |
| Tsai, S | 1 |
| Zhao, R | 1 |
| Gu, Z | 1 |
| Dong, C | 2 |
| Guo, G | 1 |
| Barrett, HE | 1 |
| Meester, EJ | 1 |
| van Gaalen, K | 1 |
| van der Heiden, K | 1 |
| Krenning, BJ | 1 |
| Beekman, FJ | 1 |
| de Blois, E | 1 |
| de Swart, J | 1 |
| Verhagen, HJ | 1 |
| Maina, T | 1 |
| Nock, BA | 1 |
| Norenberg, JP | 1 |
| de Jong, M | 1 |
| Gijsen, FJH | 1 |
| Bernsen, MR | 1 |
| Martínez-Milla, J | 1 |
| Galán-Arriola, C | 1 |
| Carnero, M | 1 |
| Cobiella, J | 1 |
| Pérez-Camargo, D | 1 |
| Bautista-Hernández, V | 1 |
| Rigol, M | 1 |
| Solanes, N | 1 |
| Villena-Gutierrez, R | 1 |
| Lobo, M | 1 |
| Mateo, J | 1 |
| Vilchez-Tschischke, JP | 1 |
| Salinas, B | 1 |
| Cussó, L | 1 |
| López, GJ | 1 |
| Fuster, V | 1 |
| Desco, M | 1 |
| Sanchez-González, J | 1 |
| Ibanez, B | 1 |
| van den Berg, P | 1 |
| Schweitzer, DH | 1 |
| van Haard, PMM | 1 |
| Geusens, PP | 1 |
| van den Bergh, JP | 1 |
| Zhu, X | 3 |
| Huang, X | 3 |
| Xu, H | 4 |
| Yang, G | 2 |
| Lin, Z | 2 |
| Salem, HF | 1 |
| Nafady, MM | 1 |
| Kharshoum, RM | 1 |
| Abd El-Ghafar, OA | 1 |
| Farouk, HO | 1 |
| Domiciano, D | 1 |
| Nery, FC | 1 |
| de Carvalho, PA | 1 |
| Prudente, DO | 1 |
| de Souza, LB | 1 |
| Chalfun-Júnior, A | 1 |
| Paiva, R | 1 |
| Marchiori, PER | 1 |
| Lu, M | 2 |
| An, Z | 1 |
| Jiang, J | 3 |
| Li, J | 8 |
| Du, S | 1 |
| Zhou, H | 1 |
| Cui, J | 1 |
| Wu, W | 1 |
| Liu, Y | 7 |
| Song, J | 1 |
| Lian, Q | 1 |
| Uddin Ahmad, Z | 1 |
| Gang, DD | 1 |
| Konggidinata, MI | 1 |
| Gallo, AA | 1 |
| Zappi, ME | 1 |
| Yang, TWW | 1 |
| Johari, Y | 1 |
| Burton, PR | 1 |
| Earnest, A | 1 |
| Shaw, K | 1 |
| Hare, JL | 1 |
| Brown, WA | 1 |
| Kim, GA | 1 |
| Han, S | 1 |
| Choi, GH | 1 |
| Choi, J | 1 |
| Lim, YS | 1 |
| Gallo, A | 1 |
| Cancelli, C | 1 |
| Ceron, E | 1 |
| Covino, M | 1 |
| Capoluongo, E | 1 |
| Pocino, K | 1 |
| Ianiro, G | 1 |
| Cammarota, G | 1 |
| Gasbarrini, A | 1 |
| Montalto, M | 1 |
| Somasundar, Y | 1 |
| Lu, IC | 1 |
| Mills, MR | 1 |
| Qian, LY | 1 |
| Olivares, X | 1 |
| Ryabov, AD | 1 |
| Collins, TJ | 1 |
| Zhao, L | 1 |
| Doddipatla, S | 1 |
| Thomas, AM | 1 |
| Nikolayev, AA | 1 |
| Galimova, GR | 1 |
| Azyazov, VN | 1 |
| Mebel, AM | 1 |
| Kaiser, RI | 1 |
| Guo, S | 1 |
| Yang, P | 1 |
| Yu, X | 4 |
| Wu, Y | 2 |
| Yu, B | 2 |
| Han, B | 1 |
| George, MW | 1 |
| Moor, MB | 1 |
| Bonny, O | 1 |
| Langenberg, E | 1 |
| Paik, H | 1 |
| Smith, EH | 1 |
| Nair, HP | 1 |
| Hanke, I | 1 |
| Ganschow, S | 1 |
| Catalan, G | 1 |
| Domingo, N | 1 |
| Schlom, DG | 1 |
| Assefa, MK | 1 |
| Wu, G | 2 |
| Hayton, TW | 1 |
| Becker, B | 1 |
| Enikeev, D | 1 |
| Netsch, C | 1 |
| Gross, AJ | 1 |
| Laukhtina, E | 1 |
| Glybochko, P | 1 |
| Rapoport, L | 1 |
| Herrmann, TRW | 1 |
| Taratkin, M | 1 |
| Dai, W | 1 |
| Shi, J | 2 |
| Carreno, J | 1 |
| Kloner, RA | 1 |
| Pickersgill, NA | 1 |
| Vetter, JM | 1 |
| Kim, EH | 1 |
| Cope, SJ | 1 |
| Du, K | 1 |
| Venkatesh, R | 1 |
| Giardina, JD | 1 |
| Saad, NES | 1 |
| Bhayani, SB | 1 |
| Figenshau, RS | 1 |
| Eriksson, J | 1 |
| Landfeldt, E | 1 |
| Ireland, S | 1 |
| Jackson, C | 1 |
| Wyatt, E | 1 |
| Gaudig, M | 1 |
| Stancill, JS | 1 |
| Happ, JT | 1 |
| Broniowska, KA | 1 |
| Hogg, N | 1 |
| Corbett, JA | 1 |
| Tang, LF | 1 |
| Bi, YL | 1 |
| Fan, Y | 2 |
| Sun, YB | 1 |
| Wang, AL | 1 |
| Xiao, BH | 1 |
| Wang, LF | 1 |
| Qiu, SW | 1 |
| Guo, SW | 1 |
| Wáng, YXJ | 1 |
| Sun, J | 2 |
| Chu, S | 1 |
| Pan, Q | 1 |
| Li, D | 2 |
| Zheng, S | 2 |
| Ma, L | 1 |
| Wang, L | 3 |
| Hu, T | 1 |
| Wang, F | 1 |
| Han, Z | 1 |
| Yin, Z | 1 |
| Ge, X | 1 |
| Xie, K | 1 |
| Lei, P | 1 |
| Dias-Santagata, D | 1 |
| Lennerz, JK | 1 |
| Sadow, PM | 1 |
| Frazier, RP | 1 |
| Govinda Raju, S | 1 |
| Henry, D | 1 |
| Chung, T | 1 |
| Kherani, J | 1 |
| Rothenberg, SM | 1 |
| Wirth, LJ | 1 |
| Marti, CN | 1 |
| Choi, NG | 1 |
| Bae, SJ | 1 |
| Ni, L | 1 |
| Luo, X | 1 |
| Dai, T | 1 |
| Yang, Y | 3 |
| Lee, R | 1 |
| Fleischer, AS | 1 |
| Wemhoff, AP | 1 |
| Ford, CR | 1 |
| Kleppinger, EL | 1 |
| Helms, K | 1 |
| Bush, AA | 1 |
| Luna-Abanto, J | 1 |
| García Ruiz, L | 1 |
| Laura Martinez, J | 1 |
| Álvarez Larraondo, M | 1 |
| Villoslada Terrones, V | 1 |
| Dukic, L | 1 |
| Maric, N | 1 |
| Simundic, AM | 1 |
| Chogtu, B | 1 |
| Ommurugan, B | 1 |
| Thomson, SR | 1 |
| Kalthur, SG | 1 |
| Benidir, M | 1 |
| El Massoudi, S | 1 |
| El Ghadraoui, L | 1 |
| Lazraq, A | 1 |
| Benjelloun, M | 1 |
| Errachidi, F | 1 |
| Cassar, M | 1 |
| Law, AD | 1 |
| Chow, ES | 1 |
| Giebultowicz, JM | 1 |
| Kretzschmar, D | 1 |
| Salonurmi, T | 1 |
| Nabil, H | 1 |
| Ronkainen, J | 1 |
| Hyötyläinen, T | 1 |
| Hautajärvi, H | 1 |
| Savolainen, MJ | 1 |
| Tolonen, A | 1 |
| Orešič, M | 1 |
| Känsäkoski, P | 1 |
| Rysä, J | 1 |
| Hakkola, J | 1 |
| Hukkanen, J | 1 |
| Zhu, N | 2 |
| Li, Y | 8 |
| Du, Q | 1 |
| Hao, P | 1 |
| Cao, X | 1 |
| Li, CX | 1 |
| Zhao, S | 1 |
| Luo, XM | 1 |
| Feng, JX | 1 |
| Gonzalez-Cotto, M | 1 |
| Guo, L | 1 |
| Karwan, M | 1 |
| Sen, SK | 1 |
| Barb, J | 1 |
| Collado, CJ | 1 |
| Elloumi, F | 1 |
| Palmieri, EM | 1 |
| Boelte, K | 1 |
| Kolodgie, FD | 1 |
| Finn, AV | 1 |
| Biesecker, LG | 1 |
| McVicar, DW | 1 |
| Qu, F | 1 |
| Deng, Z | 1 |
| Tang, J | 3 |
| Chen, Z | 2 |
| Luo, W | 1 |
| Xiong, D | 1 |
| Zhao, D | 1 |
| Fang, J | 1 |
| Zhou, Z | 1 |
| Niu, PP | 1 |
| Song, B | 1 |
| Xu, YM | 1 |
| Qiu, N | 1 |
| Yin, J | 1 |
| Zhang, J | 3 |
| Guo, W | 1 |
| Liu, T | 2 |
| Chen, D | 5 |
| Luo, K | 1 |
| He, Z | 2 |
| Zheng, G | 1 |
| Xu, F | 1 |
| Sun, W | 1 |
| Yin, F | 1 |
| van Hest, JCM | 1 |
| Du, L | 2 |
| Kang, S | 1 |
| Duan, W | 1 |
| Zhang, S | 2 |
| Feng, J | 2 |
| Qi, N | 1 |
| Shen, G | 1 |
| Ren, H | 1 |
| Shang, Q | 1 |
| Zhao, W | 2 |
| Yang, Z | 3 |
| Alame, M | 1 |
| Cornillot, E | 1 |
| Cacheux, V | 1 |
| Tosato, G | 1 |
| Four, M | 1 |
| De Oliveira, L | 1 |
| Gofflot, S | 1 |
| Delvenne, P | 1 |
| Turtoi, E | 1 |
| Cabello-Aguilar, S | 1 |
| Nishiyama, M | 1 |
| Turtoi, A | 1 |
| Costes-Martineau, V | 1 |
| Colinge, J | 1 |
| Guo, Q | 1 |
| Quan, M | 1 |
| Dong, J | 1 |
| Bai, J | 1 |
| Han, R | 1 |
| Cai, Y | 3 |
| Lv, YQ | 1 |
| Chen, Q | 1 |
| Lyu, HD | 1 |
| Deng, L | 1 |
| Zhou, D | 1 |
| Xiao, X | 1 |
| De Langhe, S | 1 |
| Billadeau, DD | 1 |
| Lou, Z | 1 |
| Zhang, JS | 1 |
| Xue, Z | 1 |
| Shen, XD | 1 |
| Busuttil, RW | 1 |
| Kupiec-Weglinski, JW | 1 |
| Ji, H | 1 |
| Otano, I | 1 |
| Alvarez, M | 1 |
| Minute, L | 1 |
| Ochoa, MC | 1 |
| Migueliz, I | 1 |
| Molina, C | 1 |
| Azpilikueta, A | 1 |
| de Andrea, CE | 1 |
| Etxeberria, I | 1 |
| Sanmamed, MF | 1 |
| Teijeira, Á | 1 |
| Berraondo, P | 1 |
| Melero, I | 1 |
| Zhong, Z | 1 |
| Xie, X | 1 |
| Yu, Q | 1 |
| Zhou, C | 1 |
| Liu, C | 2 |
| Liu, W | 2 |
| Chen, W | 1 |
| Yin, Y | 2 |
| Li, CW | 1 |
| Hsu, JL | 1 |
| Zhou, Q | 1 |
| Hu, B | 1 |
| Fu, P | 1 |
| Atyah, M | 1 |
| Ma, Q | 2 |
| Xu, Y | 2 |
| Dong, Q | 1 |
| Hung, MC | 1 |
| Ren, N | 1 |
| Huang, P | 1 |
| Liao, R | 1 |
| Chen, X | 5 |
| Cao, Q | 1 |
| Yuan, X | 2 |
| Nie, W | 1 |
| Yang, J | 3 |
| Shao, B | 1 |
| Ma, X | 1 |
| Bi, Z | 1 |
| Liang, X | 1 |
| Tie, Y | 1 |
| Mo, F | 1 |
| Xie, D | 1 |
| Wei, Y | 1 |
| Wei, X | 2 |
| Dokla, EME | 1 |
| Fang, CS | 1 |
| Chu, PC | 1 |
| Chang, CS | 1 |
| Abouzid, KAM | 1 |
| Chen, CS | 1 |
| Blaszczyk, R | 1 |
| Brzezinska, J | 1 |
| Dymek, B | 1 |
| Stanczak, PS | 1 |
| Mazurkiewicz, M | 1 |
| Olczak, J | 1 |
| Nowicka, J | 1 |
| Dzwonek, K | 1 |
| Zagozdzon, A | 1 |
| Golab, J | 1 |
| Golebiowski, A | 1 |
| Xin, Z | 1 |
| Himmelbauer, MK | 1 |
| Jones, JH | 1 |
| Enyedy, I | 1 |
| Gilfillan, R | 1 |
| Hesson, T | 1 |
| King, K | 1 |
| Marcotte, DJ | 1 |
| Murugan, P | 1 |
| Santoro, JC | 1 |
| Gonzalez-Lopez de Turiso, F | 1 |
| Pedron, J | 1 |
| Boudot, C | 1 |
| Brossas, JY | 1 |
| Pinault, E | 1 |
| Bourgeade-Delmas, S | 1 |
| Sournia-Saquet, A | 1 |
| Boutet-Robinet, E | 1 |
| Destere, A | 1 |
| Tronnet, A | 1 |
| Bergé, J | 1 |
| Bonduelle, C | 1 |
| Deraeve, C | 1 |
| Pratviel, G | 1 |
| Stigliani, JL | 1 |
| Paris, L | 1 |
| Mazier, D | 1 |
| Corvaisier, S | 1 |
| Since, M | 1 |
| Malzert-Fréon, A | 1 |
| Wyllie, S | 1 |
| Milne, R | 1 |
| Fairlamb, AH | 1 |
| Valentin, A | 1 |
| Courtioux, B | 1 |
| Verhaeghe, P | 1 |
| Fang, X | 1 |
| Gao, M | 1 |
| Gao, H | 1 |
| Bi, W | 1 |
| Tang, H | 1 |
| Zhang, L | 3 |
| Fan, H | 1 |
| Yu, H | 1 |
| Mathison, CJN | 1 |
| Chianelli, D | 1 |
| Rucker, PV | 1 |
| Nelson, J | 1 |
| Roland, J | 1 |
| Huang, Z | 2 |
| Xie, YF | 1 |
| Epple, R | 1 |
| Bursulaya, B | 1 |
| Lee, C | 1 |
| Gao, MY | 1 |
| Shaffer, J | 1 |
| Briones, S | 1 |
| Sarkisova, Y | 1 |
| Galkin, A | 1 |
| Li, N | 2 |
| Li, C | 4 |
| Hua, S | 1 |
| Kasibhatla, S | 1 |
| Kinyamu-Akunda, J | 1 |
| Kikkawa, R | 1 |
| Molteni, V | 1 |
| Tellew, JE | 1 |
| Jin, X | 1 |
| Pang, B | 1 |
| Liu, Q | 3 |
| Liu, X | 4 |
| Huang, Y | 3 |
| Josephine Fauci, A | 1 |
| Ma, Y | 1 |
| Soo Lee, M | 1 |
| Yuan, W | 1 |
| Gao, R | 1 |
| Qi, H | 1 |
| Zheng, W | 1 |
| Yang, F | 2 |
| Chua, H | 1 |
| Wang, K | 1 |
| Ou, Y | 1 |
| Huang, M | 1 |
| Zhu, Y | 1 |
| Yu, J | 1 |
| Tian, J | 1 |
| Zhao, M | 1 |
| Hu, J | 1 |
| Zhang, B | 1 |
| Usawachintachit, M | 1 |
| Tzou, DT | 1 |
| Washington, SL | 1 |
| Hu, W | 2 |
| Chi, T | 2 |
| Sorensen, MD | 1 |
| Bailey, MR | 1 |
| Hsi, RS | 1 |
| Cunitz, BW | 1 |
| Simon, J | 1 |
| Wang, YN | 1 |
| Dunmire, BL | 1 |
| Paun, M | 1 |
| Starr, F | 1 |
| Lu, W | 1 |
| Evan, AP | 1 |
| Harper, JD | 1 |
| Rodrigues, AE | 1 |
| Fouladvand, F | 1 |
| Falahi, E | 1 |
| Asbaghi, O | 1 |
| Abbasnezhad, A | 1 |
| Anigboro, AA | 1 |
| Avwioroko, OJ | 1 |
| Cholu, CO | 1 |
| Sonei, A | 1 |
| Fazelipour, S | 1 |
| Kanaani, L | 1 |
| Jahromy, MH | 1 |
| Jo, K | 1 |
| Hong, KB | 1 |
| Suh, HJ | 1 |
| Park, JH | 1 |
| Shin, E | 1 |
| Park, E | 1 |
| Kouakou-Kouamé, CA | 1 |
| N'guessan, FK | 1 |
| Montet, D | 1 |
| Djè, MK | 1 |
| Kim, GD | 1 |
| González-Fernández, D | 1 |
| Pons, EDC | 1 |
| Rueda, D | 1 |
| Sinisterra, OT | 1 |
| Murillo, E | 1 |
| Scott, ME | 1 |
| Koski, KG | 1 |
| Shete, PB | 1 |
| Gonzales, R | 1 |
| Ackerman, S | 1 |
| Cattamanchi, A | 1 |
| Handley, MA | 1 |
| Li, XX | 1 |
| Xiao, SZ | 1 |
| Gu, FF | 1 |
| He, WP | 1 |
| Ni, YX | 1 |
| Han, LZ | 1 |
| Heffernan, JK | 1 |
| Valgepea, K | 1 |
| de Souza Pinto Lemgruber, R | 1 |
| Casini, I | 1 |
| Plan, M | 1 |
| Tappel, R | 1 |
| Simpson, SD | 1 |
| Köpke, M | 1 |
| Nielsen, LK | 1 |
| Marcellin, E | 1 |
| Cen, YK | 1 |
| Lin, JG | 1 |
| Wang, YL | 1 |
| Wang, JY | 1 |
| Liu, ZQ | 1 |
| Zheng, YG | 1 |
| Spirk, D | 1 |
| Noll, S | 1 |
| Burnier, M | 1 |
| Rimoldi, S | 1 |
| Noll, G | 1 |
| Sudano, I | 1 |
| Penzhorn, BL | 1 |
| Oosthuizen, MC | 1 |
| Kobos, LM | 1 |
| Alqatani, S | 1 |
| Ferreira, CR | 1 |
| Aryal, UK | 1 |
| Hedrick, V | 1 |
| Sobreira, TJP | 1 |
| Shannahan, JH | 1 |
| Gale, P | 1 |
| Singhroy, DN | 1 |
| MacLean, E | 1 |
| Kohli, M | 1 |
| Lessem, E | 1 |
| Branigan, D | 1 |
| England, K | 1 |
| Suleiman, K | 1 |
| Drain, PK | 1 |
| Ruhwald, M | 1 |
| Schumacher, S | 1 |
| Denkinger, CM | 1 |
| Waning, B | 1 |
| Van Gemert, W | 1 |
| Pai, M | 1 |
| Myers, RK | 1 |
| Bonsu, JM | 1 |
| Carey, ME | 1 |
| Yerys, BE | 1 |
| Mollen, CJ | 1 |
| Curry, AE | 1 |
| Douglas, TA | 1 |
| Alinezhadbalalami, N | 1 |
| Balani, N | 1 |
| Schmelz, EM | 1 |
| Davalos, RV | 1 |
| Kamaldinov, T | 1 |
| Erndt-Marino, J | 1 |
| Levin, M | 1 |
| Kaplan, DL | 1 |
| Hahn, MS | 1 |
| Heidarimoghadam, R | 1 |
| Farmany, A | 1 |
| Lee, JJ | 1 |
| Kang, J | 1 |
| Park, S | 1 |
| Cho, JH | 1 |
| Oh, S | 1 |
| Park, DJ | 1 |
| Perez-Maldonado, R | 1 |
| Cho, JY | 1 |
| Park, IH | 1 |
| Kim, HB | 1 |
| Song, M | 1 |
| Mfarrej, B | 1 |
| Jofra, T | 1 |
| Morsiani, C | 1 |
| Gagliani, N | 1 |
| Fousteri, G | 1 |
| Battaglia, M | 1 |
| Giuliano, C | 1 |
| Levinger, I | 1 |
| Vogrin, S | 1 |
| Neil, CJ | 1 |
| Allen, JD | 1 |
| Yuan, R | 1 |
| Cai, B | 1 |
| Bahrami, B | 1 |
| Chowdhury, AH | 1 |
| Yang, C | 2 |
| Qiao, Q | 1 |
| Liu, SF | 1 |
| Zhang, WH | 1 |
| Kolano, L | 1 |
| Knappe, D | 1 |
| Volke, D | 1 |
| Sträter, N | 1 |
| Hoffmann, R | 1 |
| Coussens, M | 1 |
| Calders, P | 1 |
| Lapauw, B | 1 |
| Celie, B | 1 |
| Banica, T | 1 |
| De Wandele, I | 1 |
| Pacey, V | 1 |
| Malfait, F | 1 |
| Rombaut, L | 1 |
| Vieira, D | 1 |
| Angel, S | 1 |
| Honjol, Y | 1 |
| Gruenheid, S | 1 |
| Gbureck, U | 1 |
| Harvey, E | 1 |
| Merle, G | 1 |
| Seo, G | 1 |
| Lee, G | 1 |
| Kim, MJ | 1 |
| Baek, SH | 1 |
| Choi, M | 1 |
| Ku, KB | 1 |
| Lee, CS | 1 |
| Jun, S | 1 |
| Park, D | 1 |
| Kim, HG | 1 |
| Kim, SJ | 1 |
| Lee, JO | 1 |
| Kim, BT | 1 |
| Park, EC | 1 |
| Kim, SI | 1 |
| Ende, M | 1 |
| Kirkkala, T | 1 |
| Loitzenbauer, M | 1 |
| Talla, D | 1 |
| Wildner, M | 1 |
| Miletich, R | 1 |
| Criado, A | 1 |
| Lavela, P | 1 |
| Tirado, JL | 1 |
| Pérez-Vicente, C | 1 |
| Kang, D | 1 |
| Feng, D | 2 |
| Fang, Z | 1 |
| Wei, F | 1 |
| De Clercq, E | 1 |
| Pannecouque, C | 1 |
| Zhan, P | 1 |
| Guo, Y | 1 |
| Shen, Y | 1 |
| Wang, Q | 2 |
| Kawazoe, Y | 1 |
| Jena, P | 1 |
| Sun, Z | 1 |
| Li, Z | 3 |
| Liang, H | 1 |
| Xu, X | 1 |
| Ma, G | 1 |
| Huo, X | 1 |
| Church, JS | 1 |
| Chace-Donahue, F | 1 |
| Blum, JL | 1 |
| Ratner, JR | 1 |
| Zelikoff, JT | 1 |
| Schwartzer, JJ | 1 |
| Fiseha, T | 1 |
| Tamir, Z | 1 |
| Yao, W | 1 |
| Mi, K | 1 |
| Cheng, J | 2 |
| Gu, C | 1 |
| Huang, J | 4 |
| Sun, HB | 1 |
| Xing, WQ | 1 |
| Liu, XB | 1 |
| Zheng, Y | 1 |
| Yang, SJ | 1 |
| Wang, ZF | 1 |
| Liu, SL | 1 |
| Ba, YF | 1 |
| Zhang, RX | 1 |
| Liu, BX | 1 |
| Fan, CC | 1 |
| Chen, PN | 1 |
| Liang, GH | 1 |
| Yu, YK | 1 |
| Wang, HR | 1 |
| Li, HM | 1 |
| Li, ZX | 1 |
| Lalani, SS | 1 |
| Anasir, MI | 1 |
| Poh, CL | 1 |
| Khan, IT | 1 |
| Nadeem, M | 1 |
| Imran, M | 1 |
| Khalique, A | 1 |
| Raspini, B | 1 |
| Porri, D | 1 |
| De Giuseppe, R | 1 |
| Chieppa, M | 1 |
| Liso, M | 1 |
| Cerbo, RM | 1 |
| Civardi, E | 1 |
| Garofoli, F | 1 |
| Monti, MC | 1 |
| Vacca, M | 1 |
| De Angelis, M | 1 |
| Cena, H | 1 |
| Kong, D | 1 |
| Han, X | 1 |
| Xue, H | 1 |
| Ruan, Z | 1 |
| Li, S | 3 |
| Noer, PR | 1 |
| Kjaer-Sorensen, K | 1 |
| Juhl, AK | 1 |
| Goldstein, A | 1 |
| Ke, C | 1 |
| Oxvig, C | 1 |
| Duan, C | 1 |
| Kong, F | 1 |
| Lin, S | 1 |
| Wang, Z | 3 |
| Bhattacharya, R | 1 |
| Mazumder, D | 1 |
| Yan, X | 1 |
| Ma, C | 1 |
| Tang, Y | 2 |
| Kong, X | 1 |
| Lu, J | 1 |
| Zhang, M | 1 |
| Vital-Jacome, M | 1 |
| Cazares-Granillo, M | 1 |
| Carrillo-Reyes, J | 1 |
| Buitron, G | 1 |
| Jacob, SI | 1 |
| Douair, I | 1 |
| Maron, L | 1 |
| Ménard, G | 1 |
| Rusjan, P | 1 |
| Sabioni, P | 1 |
| Di Ciano, P | 1 |
| Mansouri, E | 1 |
| Boileau, I | 1 |
| Laveillé, A | 1 |
| Capet, M | 1 |
| Duvauchelle, T | 1 |
| Schwartz, JC | 1 |
| Robert, P | 6 |
| Le Foll, B | 1 |
| Xia, Y | 1 |
| Chen, S | 3 |
| Luo, M | 1 |
| Wu, J | 2 |
| Cai, S | 1 |
| He, Y | 2 |
| Garbacz, P | 1 |
| Misiak, M | 1 |
| Jackowski, K | 1 |
| Sherrell, PC | 1 |
| Chen, J | 3 |
| Bi, X | 1 |
| Nutho, B | 1 |
| Mahalapbutr, P | 1 |
| Hengphasatporn, K | 1 |
| Pattaranggoon, NC | 1 |
| Simanon, N | 1 |
| Shigeta, Y | 1 |
| Hannongbua, S | 1 |
| Rungrotmongkol, T | 1 |
| Caffrey, PJ | 1 |
| Kher, R | 1 |
| Bian, K | 1 |
| Delaney, S | 1 |
| Xue, J | 1 |
| Wu, P | 1 |
| Xu, L | 1 |
| Yuan, Y | 1 |
| Luo, J | 2 |
| Ye, S | 1 |
| Ustriyana, P | 1 |
| Wei, B | 1 |
| Raee, E | 1 |
| Hu, Y | 1 |
| Wesdemiotis, C | 1 |
| Sahai, N | 1 |
| Srivastava, S | 1 |
| Millar, JE | 1 |
| Bartnikowski, N | 1 |
| Passmore, MR | 1 |
| Obonyo, NG | 1 |
| Malfertheiner, MV | 1 |
| von Bahr, V | 1 |
| Redd, MA | 1 |
| See Hoe, L | 1 |
| Ki, KK | 1 |
| Pedersen, S | 1 |
| Boyle, AJ | 1 |
| Baillie, JK | 1 |
| Shekar, K | 1 |
| Palpant, N | 1 |
| Suen, JY | 1 |
| Matthay, MA | 1 |
| McAuley, DF | 1 |
| Fraser, JF | 1 |
| Settles, JA | 1 |
| Gerety, GF | 1 |
| Spaepen, E | 1 |
| Suico, JG | 1 |
| Child, CJ | 1 |
| Oh, BL | 1 |
| Lee, JS | 1 |
| Lee, EY | 1 |
| Lee, HY | 1 |
| Yu, HG | 1 |
| Leslie, I | 1 |
| Boos, LA | 1 |
| Larkin, J | 1 |
| Pickering, L | 1 |
| Lima, HK | 1 |
| Vogel, K | 1 |
| Hampel, D | 1 |
| Wagner-Gillespie, M | 1 |
| Fogleman, AD | 1 |
| Ferraz, SL | 1 |
| O'Connor, M | 1 |
| Mazzucchelli, TG | 1 |
| Kajiyama, H | 1 |
| Suzuki, S | 1 |
| Shimbo, A | 1 |
| Utsumi, F | 1 |
| Yoshikawa, N | 1 |
| Kikkawa, F | 1 |
| Javvaji, PK | 1 |
| Dhali, A | 1 |
| Francis, JR | 1 |
| Kolte, AP | 1 |
| Roy, SC | 1 |
| Selvaraju, S | 1 |
| Mech, A | 1 |
| Sejian, V | 1 |
| DeSilva, S | 1 |
| Vaidya, SS | 1 |
| Mao, C | 1 |
| Akhatayeva, Z | 1 |
| Cheng, H | 1 |
| Jiang, F | 1 |
| Meng, X | 4 |
| Elnour, IE | 1 |
| Lan, X | 1 |
| Song, E | 1 |
| Rohde, S | 1 |
| Antonides, CFJ | 1 |
| Muslem, R | 1 |
| de Woestijne, PCV | 1 |
| der Meulen, MHV | 1 |
| Kraemer, US | 1 |
| Dalinghaus, M | 1 |
| Bogers, AJJC | 1 |
| Pourmand, A | 1 |
| Ghassemi, M | 1 |
| Sumon, K | 1 |
| Amini, SB | 1 |
| Hood, C | 1 |
| Sikka, N | 1 |
| Duan, H | 1 |
| Chen, WP | 1 |
| Fan, M | 1 |
| Wang, WP | 1 |
| Yu, L | 2 |
| Tan, SJ | 1 |
| Xin, S | 1 |
| Wan, LJ | 1 |
| Guo, YG | 1 |
| Tanda, S | 1 |
| Gingl, K | 1 |
| Ličbinský, R | 1 |
| Hegrová, J | 1 |
| Goessler, W | 1 |
| Li, ZL | 1 |
| Zhou, YL | 1 |
| Yan, W | 1 |
| Luo, L | 1 |
| Su, ZZ | 1 |
| Fan, MZ | 1 |
| Wang, SR | 1 |
| Zhao, WG | 1 |
| Xu, D | 2 |
| Hassan, HM | 1 |
| Jiang, Z | 1 |
| Bachmann, KF | 1 |
| Haenggi, M | 1 |
| Jakob, SM | 1 |
| Takala, J | 1 |
| Gattinoni, L | 1 |
| Berger, D | 1 |
| Bentley, RF | 1 |
| Vecchiarelli, E | 1 |
| Banks, L | 1 |
| Gonçalves, PEO | 1 |
| Thomas, SG | 1 |
| Goodman, JM | 1 |
| Mather, K | 1 |
| Boachie, R | 1 |
| Anini, Y | 1 |
| Panahi, S | 1 |
| Anderson, GH | 1 |
| Luhovyy, BL | 1 |
| Nafie, MS | 1 |
| Arafa, K | 1 |
| Sedky, NK | 1 |
| Alakhdar, AA | 1 |
| Arafa, RK | 1 |
| Fan, S | 1 |
| Hu, H | 1 |
| Liang, J | 2 |
| Hu, BC | 1 |
| Wen, Z | 1 |
| Hu, D | 1 |
| Liu, YY | 1 |
| Chu, Q | 1 |
| Wu, MC | 1 |
| Lu, X | 1 |
| Wang, D | 1 |
| Hu, M | 1 |
| Shen, H | 1 |
| Yao, M | 1 |
| Dahlgren, RA | 1 |
| Vysloužil, J | 1 |
| Kulich, P | 1 |
| Zeman, T | 1 |
| Vaculovič, T | 1 |
| Tvrdoňová, M | 1 |
| Mikuška, P | 1 |
| Večeřa, Z | 1 |
| Stráská, J | 1 |
| Moravec, P | 1 |
| Balcar, VJ | 1 |
| Šerý, O | 1 |
| Qiao, L | 1 |
| Xiong, X | 1 |
| Peng, X | 1 |
| Zheng, J | 1 |
| Duan, J | 1 |
| Xiao, W | 1 |
| Zhou, HY | 1 |
| Sui, ZY | 1 |
| Zhao, FL | 1 |
| Sun, YN | 1 |
| Wang, HY | 1 |
| Han, BH | 1 |
| Jintao, X | 1 |
| Shasha, Y | 1 |
| Jincai, W | 1 |
| Chunyan, L | 1 |
| Mengya, Y | 1 |
| Yongli, S | 1 |
| Rasoanirina, BNV | 1 |
| Lassoued, MA | 1 |
| Miladi, K | 1 |
| Razafindrakoto, Z | 1 |
| Chaâbane-Banaoues, R | 1 |
| Ramanitrahasimbola, D | 1 |
| Cornet, M | 1 |
| Sfar, S | 1 |
| Liang, C | 1 |
| Xing, Q | 1 |
| Yi, JL | 1 |
| Zhang, YQ | 1 |
| Li, CY | 1 |
| Tang, SJ | 1 |
| Gao, C | 2 |
| Sun, X | 1 |
| Peng, M | 1 |
| Sun, XF | 1 |
| Zhang, T | 1 |
| Shi, JH | 1 |
| Liao, CX | 1 |
| Gao, WJ | 1 |
| Sun, LL | 1 |
| Gao, Y | 1 |
| Cao, WH | 1 |
| Lyu, J | 1 |
| Yu, CQ | 1 |
| Wang, SF | 1 |
| Pang, ZC | 1 |
| Cong, LM | 1 |
| Dong, Z | 1 |
| Wu, F | 1 |
| Wu, XP | 1 |
| Jiang, GH | 1 |
| Wang, XJ | 1 |
| Wang, BY | 1 |
| Li, LM | 1 |
| Pan, L | 1 |
| Wan, SP | 1 |
| Yi, HWL | 1 |
| He, HJ | 1 |
| Yong, ZP | 1 |
| Shan, GL | 1 |
| Weng, TT | 1 |
| Yan, SQ | 1 |
| Gao, GP | 1 |
| Wei, C | 2 |
| Tao, FB | 1 |
| Shao, ZH | 1 |
| Yao, T | 1 |
| Dong, S | 1 |
| Shi, S | 1 |
| Feng, YL | 1 |
| Zhang, YW | 1 |
| Wang, SP | 1 |
| Shi, AX | 1 |
| Operario, D | 1 |
| Zhang, ZH | 1 |
| Zhu, XF | 1 |
| Zaller, N | 1 |
| Gao, P | 1 |
| Sun, YH | 1 |
| Zhang, HB | 1 |
| Mamun, AA | 1 |
| Jeandet, P | 1 |
| Aleya, L | 1 |
| Mansouri, RA | 1 |
| Ashraf, GM | 1 |
| Bin-Jumah, MN | 1 |
| Abdel-Daim, MM | 1 |
| Vishwas, S | 1 |
| Awasthi, A | 1 |
| Corrie, L | 1 |
| Kumar Singh, S | 1 |
| Gulati, M | 1 |
| Giebel, C | 1 |
| Cations, M | 1 |
| Draper, B | 1 |
| Komuravelli, A | 1 |
| Yang, W | 1 |
| Barthold, D | 1 |
| Joyce, G | 1 |
| Ferido, P | 1 |
| Drabo, EF | 1 |
| Marcum, ZA | 1 |
| Gray, SL | 1 |
| Zissimopoulos, J | 1 |
| Siafaka, PI | 1 |
| Bülbül, EÖ | 1 |
| Mutlu, G | 1 |
| Okur, ME | 1 |
| Karantas, ID | 1 |
| Okur, NÜ | 1 |
| Azadfar, P | 1 |
| Noormohammadi, Z | 1 |
| Noroozian, M | 1 |
| Eidi, A | 1 |
| Mortazavi, P | 1 |
| Vaci, N | 1 |
| Koychev, I | 1 |
| Kim, CH | 1 |
| Kormilitzin, A | 1 |
| Lucas, C | 1 |
| Dehghan, A | 1 |
| Nenadic, G | 1 |
| Nevado-Holgado, A | 1 |
| Antonoglou, O | 1 |
| Giannousi, K | 1 |
| Mourdikoudis, S | 1 |
| Dendrinou-Samara, C | 1 |
| Övey, İS | 1 |
| Nazıroğlu, M | 1 |
| Koola, MM | 1 |
| Wong, RSY | 1 |
| Cheong, SK | 1 |
| Marotta, G | 1 |
| Stazi, M | 1 |
| Wirths, O | 1 |
| Liu, R | 2 |
| Zhang, N | 3 |
| Zhang, R | 1 |
| Couly, S | 1 |
| Denus, M | 1 |
| Bouchet, M | 1 |
| Rubinstenn, G | 1 |
| Maurice, T | 2 |
| Albayrak, G | 1 |
| Korkmaz, FD | 1 |
| Tencheva, A | 1 |
| Volkova, TV | 1 |
| Chayrov, R | 1 |
| Mitrev, Y | 1 |
| Štícha, M | 1 |
| Stankova, I | 1 |
| Perlovich, GL | 1 |
| Wojszel, ZB | 1 |
| Orsitto, G | 1 |
| Putignano, S | 2 |
| Coombs, SE | 1 |
| Banjade, S | 1 |
| Kriksunov, K | 1 |
| Clemente, N | 1 |
| Zhao, J | 3 |
| Gillilan, RE | 1 |
| Oswald, RE | 1 |
| Huang, C | 1 |
| Su, Z | 2 |
| Chen, H | 1 |
| Lee, HJ | 1 |
| Roughead, EE | 1 |
| Han, E | 1 |
| Lee, J | 1 |
| Kalisch Ellett, L | 1 |
| Olajide, OJ | 1 |
| Gbadamosi, IT | 1 |
| Yawson, EO | 1 |
| Arogundade, T | 1 |
| Lewu, FS | 1 |
| Ogunrinola, KY | 1 |
| Adigun, OO | 1 |
| Bamisi, O | 1 |
| Lambe, E | 1 |
| Arietarhire, LO | 1 |
| Oluyomi, OO | 1 |
| Idowu, OK | 1 |
| Kareem, R | 1 |
| Asogwa, NT | 1 |
| Adeniyi, PA | 1 |
| Ji, W | 1 |
| Wan, Y | 1 |
| Ge, RL | 1 |
| D'Onofrio, G | 1 |
| Nabavi, SM | 1 |
| Sancarlo, D | 1 |
| Greco, A | 1 |
| Pieretti, S | 1 |
| Czarnecka, K | 1 |
| Chuchmacz, J | 1 |
| Wójtowicz, P | 1 |
| Szymański, P | 1 |
| Castagna, A | 3 |
| Fabbo, A | 3 |
| Manzo, C | 2 |
| Lacava, R | 3 |
| Ruberto, C | 2 |
| Ruotolo, G | 2 |
| Murakawa-Hirachi, T | 1 |
| Mizoguchi, Y | 1 |
| Ohgidani, M | 1 |
| Haraguchi, Y | 1 |
| Monji, A | 2 |
| Doad, J | 1 |
| Umoh, JU | 1 |
| Norley, CJD | 1 |
| Holdsworth, DW | 1 |
| Vesikansa, A | 1 |
| Mehtälä, J | 1 |
| Mak, SH | 1 |
| Zha, L | 1 |
| Man Hoi, MP | 1 |
| Li, P | 1 |
| Gu, H | 1 |
| Peng, H | 1 |
| Zhuang, J | 1 |
| Sato, K | 5 |
| Mano, T | 1 |
| Iwata, A | 1 |
| Toda, T | 1 |
| Shimoyama, T | 1 |
| Aoki, Y | 1 |
| Kaneda, M | 1 |
| Han, LK | 1 |
| Michihara, S | 1 |
| Takahashi, R | 1 |
| Ju, C | 1 |
| Wong, ICK | 1 |
| Lau, WCY | 1 |
| Man, KKC | 1 |
| Brauer, R | 1 |
| Ma, TT | 1 |
| Alsharif, A | 1 |
| Alwafi, H | 1 |
| Lau, KK | 1 |
| Chan, EW | 1 |
| Chui, CSL | 1 |
| Wei, L | 1 |
| Bruszt, N | 1 |
| Bali, ZK | 1 |
| Tadepalli, SA | 1 |
| Nagy, LV | 1 |
| Hernádi, I | 1 |
| Høgh, P | 1 |
| Bachurin, SO | 3 |
| Shevtsova, EF | 3 |
| Makhaeva, GF | 1 |
| Grigoriev, VV | 1 |
| Boltneva, NP | 1 |
| Kovaleva, NV | 1 |
| Lushchekina, SV | 1 |
| Shevtsov, PN | 3 |
| Neganova, ME | 1 |
| Redkozubova, OM | 1 |
| Bovina, EV | 1 |
| Gabrelyan, AV | 1 |
| Fisenko, VP | 1 |
| Sokolov, VB | 1 |
| Aksinenko, AY | 1 |
| Echeverria, V | 1 |
| Barreto, GE | 1 |
| Aliev, G | 1 |
| Lawler, E | 1 |
| Avila, A | 1 |
| Havolli, E | 1 |
| Hill, MD | 1 |
| Godley, A | 1 |
| Goetghebeur, PJ | 1 |
| Ahmed, AS | 1 |
| Elgharabawy, RM | 1 |
| Al-Najjar, AH | 1 |
| Zala, D | 1 |
| Chan, D | 1 |
| McCrone, P | 2 |
| Zanforlin, E | 1 |
| Zagotto, G | 1 |
| Ribaudo, G | 1 |
| Alam, S | 1 |
| Lingenfelter, KS | 1 |
| Bender, AM | 1 |
| Lindsley, CW | 2 |
| Yu, EY | 1 |
| Liao, ZL | 1 |
| Tan, YF | 1 |
| Qiu, YJ | 1 |
| Zhu, JP | 1 |
| Lin, SS | 1 |
| Wu, MH | 1 |
| Chen, R | 1 |
| Chan, PT | 1 |
| Chu, H | 1 |
| Lin, YC | 2 |
| Chang, PC | 1 |
| Chen, CY | 1 |
| Chou, KR | 1 |
| Glynn-Servedio, BE | 1 |
| Ranola, TS | 1 |
| Kishi, T | 4 |
| Matsunaga, S | 4 |
| Oya, K | 1 |
| Nomura, I | 2 |
| Ikuta, T | 2 |
| Iwata, N | 5 |
| Rahman, A | 1 |
| Lamberty, Y | 1 |
| Schenker, E | 1 |
| Cella, M | 1 |
| Languille, S | 1 |
| Bordet, R | 2 |
| Richardson, J | 1 |
| Pifferi, F | 1 |
| Aujard, F | 1 |
| Blom, K | 1 |
| van den Elsen, GAH | 1 |
| Koek, HL | 1 |
| Sanders, JB | 1 |
| Kruithof, HC | 1 |
| Claassen, JAHR | 1 |
| Yang, YH | 2 |
| Wu, MN | 1 |
| Chou, PS | 1 |
| Su, HC | 1 |
| Lin, SH | 1 |
| Sung, PS | 1 |
| Hessmann, P | 1 |
| Dodel, R | 4 |
| Baum, E | 1 |
| Müller, MJ | 1 |
| Paschke, G | 1 |
| Kis, B | 1 |
| Zeidler, J | 1 |
| Klora, M | 1 |
| Reese, JP | 1 |
| Balzer-Geldsetzer, M | 1 |
| Khoury, R | 2 |
| Patel, K | 1 |
| Gold, J | 1 |
| Hinds, S | 1 |
| Grossberg, GT | 17 |
| Smith, LM | 1 |
| Zhu, R | 2 |
| Strittmatter, SM | 1 |
| May, BH | 1 |
| Feng, M | 1 |
| Hyde, AJ | 1 |
| Hügel, H | 1 |
| Chang, SY | 1 |
| Dong, L | 1 |
| Guo, X | 1 |
| Zhang, AL | 1 |
| Lu, C | 1 |
| Xue, CC | 1 |
| Dhull, DK | 1 |
| Kumar, A | 2 |
| Folch, J | 2 |
| Busquets, O | 2 |
| Ettcheto, M | 3 |
| Sánchez-López, E | 3 |
| Castro-Torres, RD | 1 |
| Verdaguer, E | 1 |
| Garcia, ML | 3 |
| Casadesús, G | 3 |
| Beas-Zarate, C | 2 |
| Pelegri, C | 1 |
| Vilaplana, J | 1 |
| Auladell, C | 2 |
| Camins, A | 3 |
| Dong, H | 2 |
| Hu, N | 1 |
| Xing, G | 1 |
| Kidana, K | 1 |
| Tatebe, T | 1 |
| Ito, K | 1 |
| Hara, N | 1 |
| Kakita, A | 1 |
| Takatori, S | 1 |
| Ouchi, Y | 2 |
| Ikeuchi, T | 1 |
| Makino, M | 1 |
| Akishita, M | 2 |
| Iwatsubo, T | 1 |
| Hori, Y | 1 |
| Tomita, T | 1 |
| Gómez-Mínguez, Y | 1 |
| Cabrera, H | 1 |
| Carro, E | 1 |
| Vázquez Carrera, M | 1 |
| Zambrano, P | 2 |
| Suwalsky, M | 2 |
| Jemiola-Rzeminska, M | 2 |
| Strzalka, K | 2 |
| Okuizumi, K | 1 |
| Kamata, T | 1 |
| Matsui, D | 2 |
| Saito, K | 1 |
| Matsumoto, T | 1 |
| Fukuchi, Y | 1 |
| Eady, N | 1 |
| Sheehan, R | 1 |
| Rantell, K | 1 |
| Sinai, A | 1 |
| Bernal, J | 1 |
| Bohnen, I | 1 |
| Bonell, S | 1 |
| Courtenay, K | 1 |
| Dodd, K | 1 |
| Gazizova, D | 1 |
| Hassiotis, A | 1 |
| Hillier, R | 1 |
| McBrien, J | 1 |
| Mukherji, K | 1 |
| Naeem, A | 1 |
| Perez-Achiaga, N | 1 |
| Sharma, V | 1 |
| Thomas, D | 1 |
| Walker, Z | 2 |
| McCarthy, J | 1 |
| Strydom, A | 1 |
| Ahn, BJ | 1 |
| Kwon, KY | 1 |
| Chang, W | 1 |
| Teng, J | 1 |
| Egea, MA | 1 |
| Espina, M | 1 |
| Cano, A | 1 |
| Calpena, AC | 1 |
| Carmona, N | 1 |
| Silva, AM | 1 |
| Souto, EB | 1 |
| Song, X | 1 |
| Jensen, MØ | 1 |
| Jogini, V | 1 |
| Stein, RA | 1 |
| Lee, CH | 1 |
| Mchaourab, HS | 1 |
| Shaw, DE | 1 |
| Gouaux, E | 1 |
| Hong, YJ | 1 |
| Choi, SH | 5 |
| Jeong, JH | 1 |
| Park, KW | 5 |
| Na, HR | 3 |
| Tsoi, KK | 2 |
| Chan, JY | 2 |
| Chan, FC | 1 |
| Hirai, HW | 2 |
| Kwok, TC | 2 |
| Wong, SY | 1 |
| Roeben, B | 1 |
| Zieschang, T | 2 |
| Maetzler, W | 1 |
| Knight, R | 1 |
| Khondoker, M | 1 |
| Magill, N | 1 |
| Stewart, R | 1 |
| Landau, S | 1 |
| Blaszczyk, AT | 1 |
| Mang, BH | 1 |
| Garza, H | 1 |
| Mathys, M | 1 |
| Mittapelly, N | 1 |
| Pandey, G | 1 |
| Tulsankar, SL | 1 |
| Arfi, S | 1 |
| Bhatta, RS | 1 |
| Mishra, PR | 1 |
| Wei, H | 1 |
| Ebrahem, AS | 1 |
| Oremus, M | 1 |
| Gravitz, L | 2 |
| Seyedsaadat, SM | 1 |
| F Kallmes, D | 1 |
| Rinaldi, A | 1 |
| Sakuma, K | 1 |
| Okuya, M | 1 |
| Tan, EC | 1 |
| Hilmer, SN | 1 |
| Garcia-Ptacek, S | 1 |
| Bell, JS | 2 |
| Calhoun, A | 1 |
| King, C | 1 |
| Kodis, EJ | 1 |
| Choi, S | 1 |
| Swanson, E | 1 |
| Ferreira, G | 1 |
| Bloom, GS | 1 |
| Gordon, ML | 1 |
| Jia, R | 1 |
| Wu, R | 1 |
| Hang, L | 1 |
| Silva, CFM | 1 |
| Pinto, DCGA | 1 |
| Silva, AMS | 1 |
| Mietelska-Porowska, A | 1 |
| Gasiorowska, A | 1 |
| Palasz, E | 1 |
| Koss, DJ | 1 |
| Niewiadomska, G | 1 |
| Torrez, VR | 2 |
| Zimmer, ER | 2 |
| Kalinine, E | 2 |
| Haas, CB | 2 |
| Zenki, KC | 1 |
| Muller, AP | 2 |
| Souza, DO | 2 |
| Portela, LV | 2 |
| Dou, KX | 1 |
| Tan, MS | 2 |
| Tan, CC | 2 |
| Cao, XP | 1 |
| Hou, XH | 1 |
| Guo, QH | 1 |
| Tan, L | 2 |
| Mok, V | 1 |
| Yu, JT | 2 |
| Huisa, BN | 1 |
| Thomas, RG | 2 |
| Jin, S | 1 |
| Oltersdorf, T | 1 |
| Taylor, C | 1 |
| Feldman, HH | 2 |
| Frölich, L | 5 |
| Tariot, PN | 7 |
| Molinuevo, JL | 5 |
| Boneva, N | 2 |
| Geist, MA | 1 |
| Raket, LL | 1 |
| Cummings, JL | 8 |
| Kennedy, RE | 1 |
| Cutter, GR | 1 |
| Fowler, ME | 1 |
| Hausner, L | 1 |
| Khalaf, SS | 1 |
| Hafez, MM | 1 |
| Mehanna, ET | 1 |
| Mesbah, NM | 1 |
| Abo-Elmatty, DM | 1 |
| Lin, M | 1 |
| Ma, J | 1 |
| Gao, L | 2 |
| Wei, S | 1 |
| Xue, Y | 1 |
| Shang, X | 1 |
| Kaniakova, M | 1 |
| Nepovimova, E | 3 |
| Kleteckova, L | 1 |
| Skrenkova, K | 1 |
| Holubova, K | 1 |
| Chrienova, Z | 1 |
| Hepnarova, V | 1 |
| Kucera, T | 1 |
| Kobrlova, T | 1 |
| Vales, K | 1 |
| Korabecny, J | 3 |
| Soukup, O | 2 |
| Horak, M | 1 |
| San-Juan-Rodriguez, A | 1 |
| He, M | 2 |
| Hernandez, I | 1 |
| Sestito, S | 1 |
| Pietrobono, D | 1 |
| Citi, V | 1 |
| Bellusci, L | 1 |
| Chiellini, G | 1 |
| Calderone, V | 1 |
| Rapposelli, S | 1 |
| McShane, R | 10 |
| Westby, MJ | 1 |
| Roberts, E | 1 |
| Minakaran, N | 2 |
| Schneider, L | 2 |
| Farrimond, LE | 1 |
| Maayan, N | 1 |
| Ware, J | 1 |
| Debarros, J | 1 |
| Kanasty, R | 1 |
| Low, S | 1 |
| Bhise, N | 1 |
| Peeke, E | 1 |
| Schwarz, M | 1 |
| Wright, J | 1 |
| Carter, B | 1 |
| Moorthy, S | 1 |
| Grant, T | 1 |
| DeBenedictis, B | 1 |
| Bishoff, M | 1 |
| Simses, C | 1 |
| Bellinger, AM | 1 |
| Thancharoen, O | 1 |
| Limwattananon, C | 1 |
| Waleekhachonloet, O | 1 |
| Rattanachotphanit, T | 1 |
| Limwattananon, P | 1 |
| Limpawattana, P | 1 |
| Müller, P | 1 |
| Fendt, M | 1 |
| Müller, NG | 1 |
| von Arnim, CAF | 1 |
| Bartsch, T | 1 |
| Jacobs, AH | 1 |
| Holbrook, J | 1 |
| Bergmann, P | 1 |
| Polidori, MC | 1 |
| Glinz, D | 1 |
| Gloy, VL | 1 |
| Monsch, AU | 1 |
| Kressig, RW | 2 |
| Patel, C | 1 |
| McCord, KA | 1 |
| Ademi, Z | 1 |
| Tomonaga, Y | 1 |
| Schwenkglenks, M | 1 |
| Bucher, HC | 1 |
| Raatz, H | 1 |
| Caporaso, R | 2 |
| Catanzaro, M | 1 |
| Abu, IF | 1 |
| Fagiani, F | 1 |
| Fusco, F | 1 |
| Masuzzo, S | 1 |
| Albani, D | 1 |
| Lanni, C | 1 |
| Kostev, K | 1 |
| Kurylo, P | 1 |
| Kosik, J | 1 |
| Jacob, L | 1 |
| Noetzli, M | 1 |
| Eap, CB | 1 |
| Di Santo, SG | 1 |
| Prinelli, F | 1 |
| Adorni, F | 1 |
| Caltagirone, C | 3 |
| Musicco, M | 2 |
| Savić, A | 1 |
| Mimica, N | 2 |
| Sonde, L | 1 |
| Johnell, K | 1 |
| Horikawa, N | 1 |
| Yamada, H | 2 |
| Uchimura, N | 2 |
| Rodda, J | 1 |
| Carter, J | 1 |
| Sozio, P | 1 |
| Cerasa, LS | 1 |
| Laserra, S | 1 |
| Cornacchia, C | 1 |
| Di Filippo, ES | 1 |
| Fulle, S | 1 |
| Fontana, A | 1 |
| Di Crescenzo, A | 1 |
| Grilli, M | 1 |
| Marchi, M | 1 |
| Herrmann, N | 6 |
| Gauthier, S | 14 |
| Lemming, OM | 2 |
| Woodward, M | 2 |
| Lachaine, J | 3 |
| Beauchemin, C | 3 |
| Crochard, A | 1 |
| Bineau, S | 3 |
| Dysken, MW | 2 |
| Guarino, PD | 2 |
| Vertrees, JE | 2 |
| Asthana, S | 2 |
| Llorente, M | 2 |
| Pallaki, M | 2 |
| Love, S | 2 |
| Schellenberg, GD | 2 |
| McCarten, JR | 2 |
| Malphurs, J | 2 |
| Prieto, S | 2 |
| Chen, P | 2 |
| Loreck, DJ | 2 |
| Carney, S | 1 |
| Trapp, G | 2 |
| Bakshi, RS | 2 |
| Mintzer, JE | 3 |
| Heidebrink, JL | 2 |
| Vidal-Cardona, A | 2 |
| Arroyo, LM | 2 |
| Cruz, AR | 2 |
| Kowall, NW | 2 |
| Chopra, MP | 2 |
| Craft, S | 2 |
| Thielke, S | 2 |
| Turvey, CL | 2 |
| Woodman, C | 2 |
| Monnell, KA | 2 |
| Gordon, K | 2 |
| Tomaska, J | 2 |
| Vatassery, G | 1 |
| Parsons, CG | 7 |
| Danysz, W | 6 |
| Dekundy, A | 1 |
| Pulte, I | 1 |
| Hattori, H | 1 |
| Lazzeroni, LC | 1 |
| Halbauer, JD | 1 |
| Ashford, JW | 2 |
| Noda, A | 2 |
| Hernandez, B | 2 |
| Azor, V | 1 |
| Hozack, N | 1 |
| Hasson, N | 1 |
| Henderson, VW | 1 |
| Yesavage, JA | 2 |
| Tinklenberg, JR | 1 |
| Manes, F | 1 |
| Allegri, RF | 1 |
| Gutiérrez-Robledo, LM | 1 |
| Gloger, S | 1 |
| Xie, L | 1 |
| Jia, XD | 1 |
| Pejović, V | 4 |
| Miller, ML | 4 |
| Perhach, JL | 3 |
| Graham, SM | 9 |
| Conde-Sala, JL | 1 |
| Llinàs-Reglà, J | 1 |
| Turró-Garriga, O | 3 |
| Lozano-Gallego, M | 2 |
| Hernández-Ferràndiz, M | 1 |
| Pericot-Nierga, I | 1 |
| López-Pousa, S | 2 |
| Rive, B | 7 |
| Costello, S | 1 |
| Marre, C | 1 |
| François, C | 3 |
| Hemmati, F | 1 |
| Dargahi, L | 1 |
| Nasoohi, S | 1 |
| Omidbakhsh, R | 1 |
| Mohamed, Z | 1 |
| Chik, Z | 1 |
| Naidu, M | 1 |
| Ahmadiani, A | 1 |
| Touchon, J | 1 |
| Granghaud, A | 1 |
| Huang, Q | 1 |
| Reiman, EM | 1 |
| Chen, K | 1 |
| Li, G | 1 |
| Xiao, S | 1 |
| Mehta, DC | 1 |
| Short, JL | 1 |
| Nicolazzo, JA | 1 |
| Brugg, B | 2 |
| Peyrin, JM | 1 |
| Peng, D | 1 |
| Trechot, P | 1 |
| Schmutz, JL | 1 |
| Wilkinson, D | 7 |
| Wirth, Y | 6 |
| Goebel, C | 1 |
| Sonali, N | 2 |
| Tripathi, M | 2 |
| Sagar, R | 2 |
| Velpandian, T | 2 |
| Subbiah, V | 2 |
| Cumbo, E | 1 |
| Ligori, LD | 1 |
| Bertolucci, PH | 1 |
| Smith, Mde A | 1 |
| Launay, CP | 2 |
| Allali, G | 4 |
| Watfa, G | 1 |
| Gallouj, K | 1 |
| Herrmann, FR | 2 |
| Molino, I | 1 |
| Colucci, L | 1 |
| Fasanaro, AM | 1 |
| Traini, E | 1 |
| Amenta, F | 1 |
| Ghezzi, L | 2 |
| Epstein, NU | 1 |
| Guo, R | 1 |
| Farlow, MR | 8 |
| Singh, JP | 1 |
| Fisher, M | 1 |
| Evans, DA | 1 |
| Morris, MC | 1 |
| Rajan, KB | 1 |
| Zachariah, S | 1 |
| Segal, Y | 1 |
| Peduzzi, PN | 1 |
| Aprahamian, I | 1 |
| Stella, F | 1 |
| Forlenza, OV | 1 |
| Araki, T | 1 |
| Wake, R | 1 |
| Miyaoka, T | 1 |
| Kawakami, K | 1 |
| Nagahama, M | 1 |
| Furuya, M | 1 |
| Limoa, E | 1 |
| Liaury, K | 1 |
| Hashioka, S | 1 |
| Murotani, K | 1 |
| Horiguchi, J | 1 |
| Wallesch, CW | 1 |
| Ahmed, MM | 3 |
| Dhanasekaran, AR | 1 |
| Block, A | 1 |
| Tong, S | 1 |
| Costa, AC | 2 |
| Gardiner, KJ | 1 |
| Rush, T | 1 |
| Buisson, A | 1 |
| Mangialasche, F | 1 |
| Andreasen, N | 1 |
| Feldman, H | 4 |
| Giacobini, E | 1 |
| Jones, R | 12 |
| Mantua, V | 1 |
| Mecocci, P | 4 |
| Winblad, B | 10 |
| Kivipelto, M | 2 |
| Ritchie, CW | 1 |
| Bajwa, J | 1 |
| Coleman, G | 1 |
| Hope, K | 1 |
| Jones, RW | 6 |
| Lawton, M | 1 |
| Marven, M | 1 |
| Corbett, A | 5 |
| Putignano, D | 1 |
| De Palo, G | 1 |
| Forgione, L | 1 |
| Giacummo, A | 1 |
| Marino, S | 1 |
| Simone, M | 1 |
| Zurlo, A | 1 |
| Wang, HF | 1 |
| Meng, XF | 1 |
| Jiang, T | 1 |
| Zhu, XC | 1 |
| Zádori, D | 1 |
| Veres, G | 1 |
| Szalárdy, L | 1 |
| Klivényi, P | 1 |
| Toldi, J | 2 |
| Vécsei, L | 2 |
| Nakamura, Y | 4 |
| Kitamura, S | 2 |
| Homma, A | 3 |
| Shiosakai, K | 1 |
| Kimura, N | 1 |
| Asami, Y | 1 |
| Mattace-Raso, F | 1 |
| Burbaeva, GSh | 2 |
| Zemek, F | 2 |
| Drtinova, L | 1 |
| Sepsova, V | 1 |
| Klimes, J | 1 |
| Kuca, K | 2 |
| Liu, MY | 2 |
| Wang, S | 2 |
| Yao, WF | 1 |
| Zhang, ZJ | 1 |
| Zhong, X | 1 |
| Sha, L | 1 |
| Zheng, ZH | 1 |
| Wei, MJ | 2 |
| Wade, AG | 1 |
| Farmer, M | 2 |
| Harari, G | 1 |
| Fund, N | 1 |
| Laudon, M | 1 |
| Nir, T | 1 |
| Frydman-Marom, A | 1 |
| Zisapel, N | 1 |
| Hermann, DM | 1 |
| Utsumi, K | 1 |
| Hori, K | 2 |
| Konishi, K | 2 |
| Akita, R | 1 |
| Tani, M | 2 |
| Tomioka, H | 2 |
| Kitajima, Y | 2 |
| Yokoyama, S | 1 |
| Azuma, K | 1 |
| Ikuse, D | 1 |
| Akashi, N | 2 |
| Yuda, H | 2 |
| Hachisu, M | 2 |
| Kurz, A | 2 |
| Grimmer, T | 1 |
| Gabryelewicz, T | 1 |
| Farokhnia, M | 1 |
| Shafiee Sabet, M | 1 |
| Iranpour, N | 1 |
| Gougol, A | 1 |
| Yekehtaz, H | 1 |
| Alimardani, R | 1 |
| Farsad, F | 1 |
| Kamalipour, M | 1 |
| Akhondzadeh, S | 1 |
| Takehara, H | 1 |
| Suzuki, Y | 1 |
| Someya, T | 1 |
| Sun, D | 1 |
| Bao, X | 1 |
| Huang, W | 1 |
| Fan, X | 2 |
| Creese, B | 2 |
| Jones, E | 1 |
| Fox, C | 2 |
| Han, HJ | 4 |
| Kwon, JC | 1 |
| Kim, JE | 1 |
| Kim, SG | 1 |
| Park, JM | 1 |
| Park, KC | 1 |
| Park, KH | 1 |
| Moon, SY | 1 |
| Seo, SW | 1 |
| Cho, SJ | 2 |
| Zeiss, CJ | 1 |
| Thomas, A | 3 |
| Gerry, S | 1 |
| Yu, LM | 2 |
| Aarsland, D | 4 |
| Merritt, C | 1 |
| Davison, C | 1 |
| Sharma, N | 1 |
| Khan, Z | 1 |
| Loughlin, P | 1 |
| Bannister, C | 1 |
| Burns, A | 10 |
| Win, SN | 1 |
| Velting, DM | 1 |
| Matsuzono, K | 3 |
| Hishikawa, N | 4 |
| Ohta, Y | 4 |
| Yamashita, T | 4 |
| Deguchi, K | 3 |
| Nakano, Y | 4 |
| Abe, K | 4 |
| Singh, A | 1 |
| Safer, U | 1 |
| Doruk, H | 1 |
| Tasci, I | 1 |
| Schmidt, R | 4 |
| Hofer, E | 1 |
| Bouwman, FH | 1 |
| Buerger, K | 1 |
| Cordonnier, C | 1 |
| Fladby, T | 1 |
| Georges, J | 1 |
| Heneka, MT | 1 |
| Hort, J | 2 |
| Laczó, J | 1 |
| O'Brien, JT | 4 |
| Religa, D | 1 |
| Scheltens, P | 3 |
| Schott, JM | 1 |
| Holmes, D | 1 |
| Plosker, GL | 2 |
| Tasi, YC | 1 |
| Chin, TY | 2 |
| Chen, YJ | 1 |
| Huang, CC | 1 |
| Lee, SL | 1 |
| Wu, TY | 3 |
| Li, Q | 1 |
| Yin, ZQ | 1 |
| Tsukamoto, T | 1 |
| Öncel, Ç | 1 |
| Dursun, B | 1 |
| Korkut, D | 1 |
| Başer, S | 1 |
| Mondiello, T | 1 |
| Lam, S | 1 |
| Boinpally, R | 1 |
| Zukin, SR | 1 |
| McClure, N | 1 |
| Hofbauer, RK | 4 |
| Periclou, A | 1 |
| Du, H | 1 |
| Shi, FD | 1 |
| Cheng, Y | 1 |
| Saint-Laurent Thibault, C | 1 |
| Özer Stillman, I | 1 |
| Getsios, D | 2 |
| Proskorovsky, I | 1 |
| Hernandez, L | 1 |
| Dixit, S | 1 |
| Birnbaum, JH | 1 |
| Bali, J | 1 |
| Rajendran, L | 1 |
| Nitsch, RM | 1 |
| Tackenberg, C | 1 |
| Ehret, MJ | 1 |
| Chamberlin, KW | 1 |
| Inamoto, A | 1 |
| Kurosawa, K | 1 |
| Hanashi, T | 1 |
| Ouchi, H | 1 |
| Hosoi, M | 1 |
| Clay, E | 1 |
| Toumi, M | 3 |
| Milea, D | 1 |
| Feng, MT | 1 |
| Price, FW | 1 |
| McKee, Y | 1 |
| Price, MO | 1 |
| Klusty, T | 1 |
| Lee, SH | 1 |
| Kim, SH | 1 |
| Noh, YH | 1 |
| Choi, BM | 1 |
| Noh, GJ | 1 |
| Park, WD | 1 |
| Kim, EJ | 3 |
| Cho, IH | 1 |
| Bae, CS | 1 |
| Nagasawa, S | 1 |
| Yajima, D | 1 |
| Torimitsu, S | 1 |
| Chiba, F | 1 |
| Iwase, H | 1 |
| Pasqualetti, G | 1 |
| Tognini, S | 1 |
| Calsolaro, V | 1 |
| Polini, A | 1 |
| Monzani, F | 1 |
| Koike, M | 1 |
| Kono, S | 2 |
| Ota, H | 1 |
| Ogawa, S | 1 |
| Törmälehto, SM | 1 |
| Martikainen, JA | 1 |
| Väätäinen, ST | 1 |
| Hallikainen, IT | 1 |
| Hallikainen, M | 1 |
| Koivisto, AM | 1 |
| Charkhkar, H | 1 |
| Meyyappan, S | 1 |
| Matveeva, E | 1 |
| Moll, JR | 1 |
| McHail, DG | 1 |
| Peixoto, N | 1 |
| Cliff, RO | 1 |
| Pancrazio, JJ | 1 |
| Song, G | 1 |
| Wimo, A | 3 |
| Howard, R | 6 |
| Lindesay, J | 5 |
| Ritchie, C | 6 |
| Baldwin, A | 5 |
| Barber, R | 4 |
| Dening, T | 5 |
| Findlay, D | 5 |
| Holmes, C | 6 |
| McKeith, I | 7 |
| Macharouthu, A | 5 |
| O'Brien, J | 5 |
| Sheehan, B | 5 |
| Juszczak, E | 3 |
| Katona, C | 6 |
| Hills, R | 2 |
| Knapp, M | 6 |
| Brown, RG | 3 |
| Banerjee, S | 5 |
| Adams, J | 5 |
| Johnson, T | 6 |
| Bentham, P | 5 |
| Phillips, PP | 1 |
| Magierski, R | 1 |
| Sobow, T | 2 |
| Greig, SL | 1 |
| Shiryaev, OY | 1 |
| Shapovalov, DL | 1 |
| Polozova, TM | 1 |
| Goncharova, OV | 1 |
| Kuznetsova, NA | 1 |
| Cherenkova, EV | 1 |
| Fedorova, EY | 1 |
| Majláth, Z | 1 |
| Török, N | 1 |
| Ishikawa, I | 1 |
| Shinno, H | 1 |
| Ando, N | 1 |
| Mori, T | 1 |
| Pai, MC | 1 |
| Aref, H | 1 |
| Bassil, N | 2 |
| Kandiah, N | 1 |
| Srinivasan, AV | 1 |
| diTommaso, S | 1 |
| Yuksel, O | 1 |
| Szeto, JY | 1 |
| Lewis, SJ | 1 |
| Blanchard, J | 1 |
| Grundke-Iqbal, I | 2 |
| Iqbal, K | 3 |
| Albert, M | 2 |
| Fox, N | 1 |
| Goedert, M | 1 |
| Mestre-Ferrandiz, J | 1 |
| Middleton, LT | 1 |
| Jelic, V | 1 |
| Akhtar, MW | 1 |
| Sanz-Blasco, S | 1 |
| Dolatabadi, N | 1 |
| Parker, J | 1 |
| Chon, K | 1 |
| Lee, MS | 1 |
| Soussou, W | 1 |
| McKercher, SR | 1 |
| Ambasudhan, R | 1 |
| Nakamura, T | 1 |
| Lipton, SA | 4 |
| Hu, R | 1 |
| Sun, N | 1 |
| Hao, J | 1 |
| Kajitani, K | 1 |
| Yanagimoto, K | 1 |
| Maruyama, T | 1 |
| Sil, S | 1 |
| Ghosh, T | 1 |
| Ghosh, R | 1 |
| Daulatzai, MA | 1 |
| Chong, TW | 1 |
| Loi, SM | 1 |
| Lautenschlager, NT | 1 |
| Ames, D | 1 |
| Devi, L | 1 |
| Ohno, M | 1 |
| Capati, VC | 1 |
| Kesselheim, AS | 1 |
| Gavrilova, SI | 3 |
| Kolykhalov, IV | 2 |
| Kulik, AS | 1 |
| Ponomareva, EV | 1 |
| Selezneva, ND | 3 |
| Fedorova, YB | 1 |
| Huntley, J | 1 |
| Lavaur, J | 1 |
| Lemaire, M | 1 |
| Pype, J | 1 |
| Le Nogue, D | 1 |
| Hirsch, EC | 1 |
| Michel, PP | 1 |
| Yoon, SJ | 2 |
| Shim, YS | 2 |
| Na, DL | 2 |
| Laver, K | 1 |
| Dyer, S | 1 |
| Whitehead, C | 1 |
| Clemson, L | 1 |
| Crotty, M | 1 |
| Wong, CW | 1 |
| Owen, RT | 1 |
| Koller, D | 2 |
| Hua, T | 1 |
| Bynum, JP | 1 |
| Kos, T | 1 |
| Deardorff, WJ | 2 |
| Lowinus, T | 1 |
| Bose, T | 1 |
| Busse, S | 1 |
| Busse, M | 1 |
| Reinhold, D | 1 |
| Schraven, B | 1 |
| Bommhardt, UH | 1 |
| Zhou, W | 2 |
| Zhong, G | 1 |
| Xie, H | 1 |
| Rao, X | 1 |
| Zeng, S | 1 |
| Sheng, G | 1 |
| Ji, X | 2 |
| Wu, D | 1 |
| Zou, L | 1 |
| Tortorella, M | 1 |
| Zhang, K | 1 |
| Thorpe, CT | 1 |
| Fowler, NR | 1 |
| Harrigan, K | 1 |
| Kang, Y | 1 |
| Hanlon, JT | 1 |
| Gellad, WF | 1 |
| Schleiden, LJ | 1 |
| Thorpe, JM | 1 |
| Barden, J | 1 |
| Liu-Ambrose, T | 1 |
| Chester, VL | 1 |
| Szturm, T | 1 |
| Grenier, S | 1 |
| Léonard, G | 1 |
| Bherer, L | 1 |
| Reggiani, AM | 1 |
| Meunier, J | 1 |
| Keller, E | 1 |
| Hommet, C | 2 |
| Novella, JL | 1 |
| Auriacombe, S | 3 |
| Vercelletto, M | 2 |
| Berrut, G | 2 |
| Belliard, S | 2 |
| Desmidt, T | 2 |
| Ceccaldi, M | 1 |
| Camus, V | 1 |
| Singh, N | 1 |
| Hroudová, J | 1 |
| Fišar, Z | 1 |
| King, D | 1 |
| Romeo, R | 1 |
| Phillips, PPJ | 1 |
| Ishizuka, T | 1 |
| Yabuki, Y | 1 |
| Shioda, N | 1 |
| Sasaki, Y | 1 |
| Tagashira, H | 1 |
| Yawo, H | 1 |
| Yeh, JZ | 2 |
| Sakagami, H | 1 |
| Narahashi, T | 2 |
| Lavikainen, P | 1 |
| Haussmann, R | 1 |
| Donix, M | 1 |
| Ruthirakuhan, M | 1 |
| Suridjan, I | 1 |
| Abraham, EH | 1 |
| Farber, I | 1 |
| Lanctôt, KL | 3 |
| Hager, K | 2 |
| Baseman, AS | 1 |
| Nye, JS | 1 |
| Brashear, HR | 1 |
| Davis, B | 1 |
| Richards, HM | 1 |
| Wang, CH | 1 |
| Wang, LS | 1 |
| Borges, LG | 1 |
| Bonakdarpour, B | 1 |
| Villena, F | 1 |
| Lemire, P | 1 |
| Brangier, A | 1 |
| Beaudenon, M | 1 |
| Duval, GT | 1 |
| Yasutaka, Y | 1 |
| Fujioka, S | 1 |
| Terasawa, M | 1 |
| Shibaguchi, H | 1 |
| Futagami, K | 1 |
| Ouma, S | 1 |
| Tsuboi, Y | 1 |
| Kamimura, H | 1 |
| Ford, AH | 1 |
| Almeida, OP | 1 |
| Graham, WV | 1 |
| Bonito-Oliva, A | 1 |
| Sakmar, TP | 1 |
| Jones, M | 1 |
| Livingston, G | 4 |
| Mittler, P | 1 |
| Robinson, L | 1 |
| Sampson, EL | 1 |
| Taylor, JP | 1 |
| Reisberg, B | 3 |
| Shao, Y | 1 |
| Golomb, J | 1 |
| Monteiro, I | 1 |
| Torossian, C | 1 |
| Boksay, I | 1 |
| Shulman, M | 1 |
| Heller, S | 1 |
| Atif, A | 1 |
| Sidhu, J | 1 |
| Vedvyas, A | 1 |
| Kenowsky, S | 1 |
| Sepehry, AA | 1 |
| Sarai, M | 1 |
| Hsiung, GR | 1 |
| Caramillo, EM | 1 |
| Echevarria, DJ | 1 |
| Calvó-Perxas, L | 2 |
| de Eugenio, R | 1 |
| Márquez, F | 1 |
| Carmona, O | 1 |
| Gich, J | 1 |
| Manzano, A | 2 |
| Viñas, M | 1 |
| Roig, AM | 2 |
| Fukui, Y | 1 |
| Ichinose, J | 1 |
| Morihara, R | 1 |
| Chen, CF | 1 |
| Hsu, HC | 1 |
| Ouyang, WC | 1 |
| Emre, M | 1 |
| Stender, K | 3 |
| Ropele, S | 1 |
| Pendl, B | 1 |
| Ofner, P | 1 |
| Enzinger, C | 1 |
| Schmidt, H | 1 |
| Berghold, A | 1 |
| Windisch, M | 1 |
| Kolassa, H | 1 |
| Fazekas, F | 1 |
| Scholtzova, H | 1 |
| Wadghiri, YZ | 1 |
| Douadi, M | 1 |
| Sigurdsson, EM | 1 |
| Li, YS | 1 |
| Quartermain, D | 1 |
| Banerjee, P | 3 |
| Wisniewski, T | 1 |
| Mackell, J | 3 |
| Kaufer, D | 1 |
| Chin, JJ | 1 |
| Wroolie, TE | 1 |
| Kenna, HA | 1 |
| Williams, KE | 1 |
| Powers, BN | 1 |
| Holcomb, M | 1 |
| Lazzeroni, L | 1 |
| Rasgon, NL | 1 |
| Ruis, J | 1 |
| Hsiung, GY | 1 |
| Vidal, JS | 1 |
| Lacombe, JM | 1 |
| Dartigues, JF | 2 |
| Pasquier, F | 1 |
| Tzourio, C | 1 |
| Alpérovitch, A | 1 |
| Neff, F | 1 |
| Lampl, C | 1 |
| Benke, T | 1 |
| Anditsch, M | 1 |
| Bancher, C | 1 |
| Dal-Bianco, P | 1 |
| Reisecker, F | 1 |
| Marksteiner, J | 1 |
| Rainer, M | 4 |
| Kapeller, P | 2 |
| Doody, RS | 5 |
| Song, MS | 1 |
| Rauw, G | 1 |
| Baker, GB | 2 |
| Kar, S | 2 |
| Nikisch, G | 1 |
| Hertel, A | 1 |
| Kiessling, B | 1 |
| Wagner, T | 1 |
| Krasz, D | 1 |
| Hofmann, E | 1 |
| Wiedemann, G | 1 |
| Namba, T | 1 |
| Maekawa, M | 1 |
| Yuasa, S | 1 |
| Kohsaka, S | 1 |
| Uchino, S | 1 |
| Mohan, M | 1 |
| Bennett, C | 1 |
| Carpenter, PK | 1 |
| Kyomen, HH | 1 |
| Whitfield, TH | 1 |
| Lopez, OL | 3 |
| Becker, JT | 1 |
| Wahed, AS | 1 |
| Saxton, J | 3 |
| Sweet, RA | 1 |
| Wolk, DA | 1 |
| Klunk, W | 1 |
| Dekosky, ST | 1 |
| Kotermanski, SE | 2 |
| Hasselbalch, SG | 1 |
| Kampmann, JP | 1 |
| Bladström, A | 1 |
| McClendon, MJ | 2 |
| Hernandez, S | 2 |
| Smyth, KA | 1 |
| Lerner, AJ | 2 |
| Roman, MW | 1 |
| Crutchfield, D | 1 |
| Weinstein, AM | 1 |
| Barton, C | 1 |
| Ross, L | 2 |
| Kramer, JH | 1 |
| Yaffe, K | 1 |
| Smith, DA | 1 |
| Clerici, F | 2 |
| Elia, A | 2 |
| Spila-Alegiani, S | 2 |
| Pomati, S | 2 |
| Raschetti, R | 2 |
| Mariani, C | 2 |
| Kwak, YT | 1 |
| Han, IW | 1 |
| Suk, SH | 1 |
| Koo, MS | 1 |
| Müller-Spahn, F | 1 |
| Sollberger, D | 1 |
| Wollmer, MA | 1 |
| Phillips, P | 3 |
| Barber, B | 1 |
| Brown, R | 2 |
| Gray, R | 3 |
| Griffin, M | 3 |
| Hughes, A | 3 |
| Jacoby, R | 3 |
| Onions, C | 2 |
| Raftery, J | 1 |
| Arif, M | 2 |
| Kato, T | 5 |
| Goñi-Oliver, P | 1 |
| Avila, J | 1 |
| Hernández, F | 1 |
| Glodzik, L | 2 |
| De Santi, S | 2 |
| Rich, KE | 1 |
| Brys, M | 1 |
| Pirraglia, E | 1 |
| Mistur, R | 1 |
| Switalski, R | 1 |
| Mosconi, L | 1 |
| Sadowski, M | 1 |
| Zetterberg, H | 1 |
| Blennow, K | 1 |
| de Leon, MJ | 2 |
| Olin, JT | 5 |
| Bhatnagar, V | 1 |
| Reyes, P | 1 |
| Koumaras, B | 1 |
| Brannan, S | 1 |
| Chitramohan, R | 1 |
| Chikuma, T | 2 |
| Nakazato, M | 1 |
| Smith, MA | 2 |
| Suh, GH | 1 |
| O'Connor, D | 1 |
| Ikeda, M | 1 |
| Dominguez, J | 1 |
| Yang, BM | 1 |
| Sevilla, C | 1 |
| Jiménez Caballero, PE | 1 |
| Alfonso, V | 1 |
| González-Adalid, M | 1 |
| McKeage, K | 2 |
| Ferris, S | 6 |
| Ihl, R | 5 |
| Gatz, G | 1 |
| Tennigkeit, F | 4 |
| Chen, CP | 2 |
| Thomas, SJ | 1 |
| Modrego, PJ | 1 |
| Fayed, N | 1 |
| Errea, JM | 1 |
| Rios, C | 1 |
| Pina, MA | 1 |
| Sarasa, M | 1 |
| Villar-Fernández, I | 1 |
| Bjerrum, L | 1 |
| Feja, C | 1 |
| Rabanaque, MJ | 1 |
| Leifer, BP | 1 |
| Hu, NW | 1 |
| Klyubin, I | 1 |
| Anwyl, R | 1 |
| Anwy, R | 1 |
| Rowan, MJ | 1 |
| Tabaton, M | 1 |
| Perry, G | 1 |
| Lee, HG | 1 |
| Martinez-Coria, H | 1 |
| Green, KN | 1 |
| Billings, LM | 1 |
| Kitazawa, M | 1 |
| Albrecht, M | 1 |
| Rammes, G | 1 |
| Gupta, S | 2 |
| LaFerla, FM | 1 |
| Truter, I | 1 |
| Supnet, C | 1 |
| Bezprozvanny, I | 1 |
| Zhou, XH | 1 |
| Sachs, M | 1 |
| Neuhaus, J | 1 |
| Knopman, D | 1 |
| Kramer, J | 1 |
| Boeve, B | 1 |
| Caselli, RJ | 2 |
| Graff-Radford, N | 1 |
| Mendez, MF | 1 |
| Miller, BL | 1 |
| Boxer, AL | 1 |
| Chen, TF | 1 |
| Huang, RF | 1 |
| Lin, SE | 1 |
| Lu, JF | 1 |
| Tang, MC | 1 |
| Chiu, MJ | 1 |
| Sultzer, DL | 1 |
| Melrose, RJ | 1 |
| Harwood, DG | 1 |
| Campa, O | 1 |
| Mandelkern, MA | 1 |
| Formiga, F | 1 |
| Fort, I | 1 |
| Robles, MJ | 1 |
| Rodriguez, D | 1 |
| Regalado, P | 1 |
| Yeh, HH | 1 |
| Chen, SH | 1 |
| Kiencke, P | 2 |
| Rychlik, R | 3 |
| Grimm, C | 2 |
| Daniel, D | 2 |
| Grishchenko, M | 2 |
| Guilhaume-Goulant, C | 1 |
| Lamure, M | 2 |
| Thaipisuttikul, P | 1 |
| Mayeux, R | 1 |
| Presecki, P | 1 |
| Borah, B | 1 |
| Sacco, P | 1 |
| Zarotsky, V | 1 |
| Baumhackl, U | 1 |
| Berek, K | 1 |
| Brücke, T | 1 |
| Lechner, A | 1 |
| Stögerer, EM | 1 |
| Criado-Alvarez, JJ | 1 |
| Romo Barrientos, C | 1 |
| Dashniani, M | 2 |
| Burjanadze, M | 2 |
| Beselia, G | 2 |
| Chkhikvishvili, N | 2 |
| Naneishvili, T | 1 |
| Canan, F | 1 |
| Ataoglu, A | 1 |
| Hollingworth, SA | 1 |
| Byrne, GJ | 1 |
| Shoji, M | 1 |
| Kubová, Z | 1 |
| Kremláček, J | 1 |
| Vališ, M | 1 |
| Szanyi, J | 1 |
| Langrová, J | 1 |
| Vít, F | 1 |
| Kuba, M | 1 |
| Gomolin, IH | 1 |
| Smith, C | 1 |
| Jeitner, TM | 1 |
| Osborn, GG | 1 |
| Saunders, AV | 1 |
| Galluzzi, KE | 1 |
| Appelt, DM | 1 |
| Balin, BJ | 1 |
| Agüera-Ortiz, LF | 1 |
| Fillit, H | 1 |
| Setyawan, J | 2 |
| Tourkodimitris, S | 1 |
| Fridman, M | 2 |
| Erder, MH | 2 |
| Lyketsos, C | 1 |
| Motawaj, M | 1 |
| Burban, A | 1 |
| Davenas, E | 1 |
| Arrang, JM | 1 |
| Aström, D | 1 |
| Isik, AT | 1 |
| Supprian, T | 2 |
| Höhl, W | 1 |
| Insel, PS | 1 |
| Weiner, MW | 3 |
| Lorenzi, M | 1 |
| Beltramello, A | 1 |
| Mercuri, NB | 1 |
| Canu, E | 1 |
| Zoccatelli, G | 1 |
| Pizzini, FB | 1 |
| Alessandrini, F | 1 |
| Cotelli, M | 1 |
| Rosini, S | 1 |
| Costardi, D | 1 |
| Frisoni, GB | 1 |
| Xie, MF | 1 |
| Tong, XY | 1 |
| Chen, YL | 1 |
| Duan, GL | 1 |
| Vandesquille, M | 1 |
| Krazem, A | 1 |
| Louis, C | 1 |
| Lestage, P | 1 |
| Béracochéa, D | 1 |
| Filali, M | 1 |
| Lalonde, R | 1 |
| Rivest, S | 1 |
| Bloudek, LM | 1 |
| Spackman, DE | 1 |
| Veenstra, DL | 1 |
| Sullivan, SD | 1 |
| Callahan, PM | 1 |
| Hall, B | 1 |
| Webster, SJ | 1 |
| Delrieu, J | 1 |
| Piau, A | 1 |
| Caillaud, C | 1 |
| Voisin, T | 2 |
| Vellas, B | 3 |
| Riordan, KC | 1 |
| Hoffman Snyder, CR | 1 |
| Wellik, KE | 1 |
| Wingerchuk, DM | 1 |
| Demaerschalk, BM | 1 |
| Li, A | 1 |
| Lanctôt, K | 1 |
| van den Bussche, H | 2 |
| Kaduszkiewicz, H | 1 |
| Eisele, M | 1 |
| Steinmann, S | 1 |
| Glaeske, G | 1 |
| Wiese, B | 1 |
| Bohlken, J | 1 |
| Selke, GW | 1 |
| Voigt-Radloff, S | 1 |
| Hüll, M | 3 |
| Wuschitz, A | 1 |
| Jagsch, C | 1 |
| Erb, C | 1 |
| Chirikdjian, JJ | 1 |
| Mucke, HA | 1 |
| Schulz, JB | 1 |
| Klünemann, HH | 1 |
| Wolf, S | 1 |
| Sternberg, K | 2 |
| Riepe, MW | 4 |
| Janetzky, W | 4 |
| Cappell, J | 1 |
| Eryavec, GM | 1 |
| Dagerman, KS | 1 |
| Higgins, JP | 1 |
| Carcaillon, L | 1 |
| Sellal, F | 1 |
| Gillette, S | 1 |
| Pere, JJ | 2 |
| Bourdeix, I | 2 |
| Howland, RH | 1 |
| Yu, SY | 1 |
| Hsu, HA | 2 |
| Suhy, J | 1 |
| Winslow, BT | 1 |
| Onysko, MK | 1 |
| Stob, CM | 1 |
| Hazlewood, KA | 1 |
| Patel, L | 1 |
| Warner, JP | 1 |
| Butler, R | 4 |
| Kerchner, GA | 1 |
| Tartaglia, MC | 1 |
| Boxer, A | 1 |
| Pesce, A | 1 |
| Robert, PH | 1 |
| Aisen, PS | 3 |
| Ancoli-Israel, S | 1 |
| Andrieu, S | 1 |
| Cedarbaum, J | 1 |
| Siemers, E | 1 |
| Spire, JP | 1 |
| May, TS | 1 |
| Bute, J | 1 |
| Waller, D | 1 |
| Mancuso, C | 1 |
| Siciliano, R | 1 |
| Barone, E | 1 |
| Butterfield, DA | 2 |
| Preziosi, P | 1 |
| Yanagisawa, K | 1 |
| Cochran, J | 2 |
| Takeda, M | 1 |
| Tanaka, T | 1 |
| Okochi, M | 1 |
| Olivares, D | 1 |
| Deshpande, VK | 1 |
| Lahiri, DK | 1 |
| Greig, NH | 1 |
| Rogers, JT | 1 |
| Iliffe, S | 2 |
| McGrath, T | 1 |
| Mitchell, D | 1 |
| Lo, D | 1 |
| Gilchrist, NL | 1 |
| Potocnik, F | 1 |
| Adamson, M | 1 |
| Beale, T | 1 |
| La, D | 1 |
| Rosen, A | 1 |
| O'Hara, R | 1 |
| Fairchild, JK | 1 |
| Spielman, D | 1 |
| Fantino, B | 3 |
| Parot-Schinkel, E | 1 |
| Thiery, S | 1 |
| Gautier, J | 1 |
| Massoud, F | 2 |
| Legault, M | 1 |
| Salomone, S | 1 |
| Caraci, F | 1 |
| Leggio, GM | 1 |
| Fedotova, J | 1 |
| Drago, F | 1 |
| Launay, C | 1 |
| Dominguez, E | 1 |
| Stefanacci, RG | 2 |
| Hanney, M | 1 |
| Prasher, V | 1 |
| Williams, N | 1 |
| Jones, EL | 1 |
| Lawrence, D | 1 |
| Tyrer, S | 1 |
| Francis, PT | 3 |
| Bullock, R | 2 |
| Förstl, H | 4 |
| Stamouli, SS | 1 |
| Galanopoulos, A | 1 |
| Karageorgiou, C | 1 |
| Tzanakaki, M | 1 |
| Fox, NC | 1 |
| Barkhof, F | 1 |
| Phul, R | 2 |
| Lemming, O | 1 |
| Mielke, MM | 1 |
| Leoutsakos, JM | 1 |
| Corcoran, CD | 1 |
| Green, RC | 1 |
| Norton, MC | 1 |
| Welsh-Bohmer, KA | 1 |
| Tschanz, JT | 1 |
| Lyketsos, CG | 2 |
| Kruashvili, L | 1 |
| Hartz, S | 1 |
| Tao, S | 1 |
| Blume, S | 1 |
| Maclaine, G | 1 |
| Rountree, SD | 2 |
| Cummings, J | 2 |
| Ritter, JM | 1 |
| Neumeister, KL | 1 |
| Samartgis, JR | 1 |
| Schachte, L | 1 |
| Hazi, A | 1 |
| Crowe, SF | 1 |
| Galasko, DR | 1 |
| Peskind, E | 1 |
| Clark, CM | 1 |
| Quinn, JF | 1 |
| Ringman, JM | 1 |
| Jicha, GA | 1 |
| Cotman, C | 1 |
| Cottrell, B | 1 |
| Montine, TJ | 1 |
| Aisen, P | 1 |
| McLaren, DG | 1 |
| Sreenivasan, A | 1 |
| Diamond, EL | 1 |
| Mitchell, MB | 1 |
| Van Dijk, KR | 1 |
| Deluca, AN | 1 |
| O'Brien, JL | 1 |
| Rentz, DM | 1 |
| Sperling, RA | 1 |
| Romberg, C | 1 |
| McTighe, SM | 1 |
| Heath, CJ | 1 |
| Whitcomb, DJ | 1 |
| Cho, K | 1 |
| Bussey, TJ | 1 |
| Saksida, LM | 1 |
| Pouryamout, L | 1 |
| Dams, J | 1 |
| Wasem, J | 1 |
| Neumann, A | 1 |
| Holthoff, V | 1 |
| Hellweg, R | 2 |
| Hartmann, S | 1 |
| Berghmans, R | 1 |
| Hrubá, E | 1 |
| Musílek, K | 1 |
| Spilovská, K | 1 |
| Opletalová, V | 1 |
| Bond, M | 2 |
| Rogers, G | 2 |
| Peters, J | 2 |
| Anderson, R | 2 |
| Hoyle, M | 2 |
| Miners, A | 1 |
| Moxham, T | 2 |
| Davis, S | 3 |
| Thokala, P | 2 |
| Wailoo, A | 1 |
| Jeffreys, M | 2 |
| Hyde, C | 2 |
| Crugel, M | 1 |
| Maidment, I | 1 |
| Auestad, BH | 1 |
| Coulton, S | 1 |
| Treloar, A | 1 |
| Boustani, M | 2 |
| Geldmacher, DS | 1 |
| Moline, M | 1 |
| Lejarreta, S | 1 |
| Cullell, M | 1 |
| Meléndez, R | 1 |
| Hernández, E | 1 |
| Bisbe, J | 1 |
| Perkal, H | 1 |
| Peters, O | 1 |
| Lorenz, D | 1 |
| Fesche, A | 1 |
| Schmidtke, K | 1 |
| Perneczky, R | 1 |
| Rüther, E | 3 |
| Möller, HJ | 3 |
| Jessen, F | 1 |
| Maier, W | 1 |
| Kornhuber, J | 3 |
| Jahn, H | 1 |
| Luckhaus, C | 1 |
| Gertz, HJ | 3 |
| Schröder, J | 1 |
| Pantel, J | 1 |
| Teipel, S | 1 |
| Wellek, S | 1 |
| Heuser, I | 2 |
| Chu, LW | 1 |
| Suzuki, T | 1 |
| Finucane, MM | 1 |
| Finucane, TE | 2 |
| Kalyn, IaB | 1 |
| Fedorova, IaB | 1 |
| Tifratene, K | 1 |
| Duff, FL | 1 |
| Pradier, C | 1 |
| Quetel, J | 1 |
| Lafay, P | 1 |
| Schück, S | 1 |
| Benzenine, E | 1 |
| Quantin, C | 1 |
| Baskys, A | 1 |
| Cheng, JX | 1 |
| Sinforiani, E | 1 |
| Pasotti, C | 1 |
| Chiapella, L | 1 |
| Malinverni, P | 1 |
| Zucchella, C | 1 |
| Chiu, HF | 1 |
| Li, SW | 1 |
| Revett, TJ | 1 |
| Jhamandas, J | 1 |
| Salloway, S | 1 |
| Mintzer, J | 2 |
| Geldmacher, D | 1 |
| Yardley, J | 1 |
| Schwarz, S | 1 |
| Froelich, L | 1 |
| Kim, BC | 1 |
| Lee, JY | 1 |
| Ryu, SH | 1 |
| Park, HY | 1 |
| Shin, JH | 1 |
| Yi, HA | 1 |
| Choi, MS | 1 |
| Heo, JH | 1 |
| Kim, KK | 1 |
| Gilligan, AM | 1 |
| Malone, DC | 1 |
| Warholak, TL | 1 |
| Armstrong, EP | 1 |
| Kanazirska, MV | 1 |
| Fuchs, PM | 1 |
| Lal, S | 1 |
| Verma, J | 1 |
| Vassilev, PM | 1 |
| Hamuro, A | 1 |
| Babiloni, C | 1 |
| Del Percio, C | 1 |
| Bourriez, JL | 1 |
| Bentivoglio, M | 1 |
| Payoux, P | 1 |
| Derambure, P | 1 |
| Dix, S | 1 |
| Infarinato, F | 1 |
| Lizio, R | 1 |
| Triggiani, AI | 1 |
| Richardson, JC | 1 |
| Rossini, PM | 1 |
| Shimohama, S | 1 |
| Pfeil, AM | 1 |
| Szucs, TD | 1 |
| Lyseng-Williamson, KA | 2 |
| Nagakura, A | 1 |
| Shitaka, Y | 1 |
| Yarimizu, J | 1 |
| Matsuoka, N | 1 |
| Livote, EE | 1 |
| Scarmeas, N | 1 |
| Brandt, J | 1 |
| Blacker, D | 1 |
| Stern, Y | 1 |
| Helmuth, L | 1 |
| Doraiswamy, PM | 3 |
| Grützner, L | 1 |
| Möbius, HJ | 9 |
| Stöffler, A | 8 |
| Miguel-Hidalgo, JJ | 1 |
| Alvarez, XA | 1 |
| Cacabelos, R | 1 |
| Quack, G | 1 |
| Nabeshima, T | 1 |
| Kamei, H | 1 |
| Brodaty, H | 1 |
| Green, A | 1 |
| Areosa, SA | 4 |
| Sherriff, F | 5 |
| Kohler, J | 1 |
| Jendroska, K | 1 |
| Pilartz, H | 1 |
| Adler, G | 2 |
| Berger, FM | 1 |
| Calabrese, P | 3 |
| Hampel, H | 4 |
| Haupt, M | 1 |
| Mielke, R | 2 |
| Paulus, HJ | 1 |
| Zedlick, D | 1 |
| Doody, R | 3 |
| Schmitt, F | 4 |
| Jarvis, B | 1 |
| Figgitt, DP | 1 |
| Lermontova, NN | 1 |
| Mukhina, TV | 1 |
| Van'kin, GI | 1 |
| Serkova, TP | 1 |
| Pocernich, CB | 1 |
| Bleich, S | 2 |
| Wiltfang, J | 2 |
| Skausig, OB | 1 |
| Laugesem, LP | 1 |
| Jensen, T | 1 |
| Messinger-Rapport, BJ | 1 |
| Doggrell, S | 1 |
| Rogawski, MA | 2 |
| Wenk, GL | 4 |
| Fuchsberger, T | 1 |
| Coll, PP | 1 |
| Fortinsky, RH | 1 |
| Kaplan, R | 1 |
| Song, C | 1 |
| Diehl, RR | 1 |
| Alhainen, K | 1 |
| Ferris, SH | 1 |
| Brüne, M | 1 |
| Schröder, SG | 1 |
| Underwood, A | 1 |
| McDonald, S | 2 |
| Gergel, I | 1 |
| Koch, HJ | 2 |
| Szecsey, A | 1 |
| Haen, E | 1 |
| Corey-Bloom, J | 1 |
| Small, GW | 1 |
| Witt, A | 1 |
| Macdonald, N | 1 |
| Kirkpatrick, P | 1 |
| Miller, MC | 1 |
| Ables, AZ | 1 |
| McGann-Gramling, K | 1 |
| Hauss-Wegrzyniak, B | 1 |
| Sengupta, A | 1 |
| Haque, N | 1 |
| Damier, FD | 1 |
| Sternon, J | 1 |
| Bier, JC | 1 |
| Hoshino, H | 1 |
| Minkeviciene, R | 1 |
| Tanila, H | 1 |
| Prasher, VP | 1 |
| Standridge, JB | 1 |
| Reynish, E | 1 |
| Portet, F | 1 |
| Engedal, K | 2 |
| Braekhus, A | 1 |
| Gjerstad, L | 1 |
| van Dyck, CH | 2 |
| Guilhaume, C | 3 |
| Marder, K | 1 |
| Thompson, S | 1 |
| Gold, G | 1 |
| Kumar, S | 1 |
| Areosa Sastre, A | 2 |
| Sonkusare, SK | 1 |
| Kaul, CL | 1 |
| Ramarao, P | 1 |
| Warner, J | 4 |
| Arya, P | 2 |
| Van Dam, D | 2 |
| Abramowski, D | 1 |
| Staufenbiel, M | 1 |
| De Deyn, PP | 2 |
| Schmitt, B | 1 |
| Diener, H | 1 |
| Hallauer, JF | 1 |
| Rieke, K | 1 |
| Riepe, M | 1 |
| Kmietowicz, Z | 1 |
| Perras, C | 1 |
| Higuchi, M | 1 |
| Matsuba, Y | 1 |
| Sasamoto, K | 1 |
| Small, SA | 1 |
| Huey, ED | 1 |
| Dustin, IH | 1 |
| Overman, GP | 1 |
| Mirza, N | 1 |
| Sunderland, T | 1 |
| Jouanny, P | 1 |
| Bentué-Ferrer, D | 1 |
| Michel, O | 1 |
| Allain, H | 1 |
| Rossom, R | 1 |
| Dysken, M | 1 |
| Füsgen, I | 1 |
| Xiong, G | 1 |
| Neumann, PJ | 1 |
| Cafiero, AC | 1 |
| Padberg, F | 1 |
| Bottlender, R | 1 |
| Klinger, T | 1 |
| Ibach, B | 2 |
| Schoenknecht, P | 1 |
| Kamleiter, M | 1 |
| Silver, G | 1 |
| Schroeder, J | 1 |
| Caban-Holt, A | 1 |
| Bottiggi, K | 1 |
| Schmitt, FA | 3 |
| Morris, JC | 1 |
| Treinkman, A | 1 |
| Sleeper, RB | 1 |
| Schölzel-Dorenbos, CJ | 1 |
| Scharf, SL | 1 |
| Parikh, S | 1 |
| Dillon, LC | 1 |
| Jönsson, L | 1 |
| O'Neill, MF | 1 |
| Olsen, CE | 1 |
| Poulsen, HD | 1 |
| Lublin, HK | 1 |
| Uyanik, G | 1 |
| Fischer-Barnicol, D | 1 |
| Potz-Biedermann, C | 1 |
| Molinuevo Guix, JL | 1 |
| Lladó Plarrumaní, A | 1 |
| Rao, N | 1 |
| Chou, T | 1 |
| Ventura, D | 1 |
| Abramowitz, W | 1 |
| Menendez-Gonzalez, M | 1 |
| Calatayud, MT | 1 |
| Blazquez-Menes, B | 1 |
| Dantoine, T | 1 |
| Sarazin, M | 1 |
| Becker, H | 1 |
| Loveman, E | 2 |
| Green, C | 3 |
| Kirby, J | 2 |
| Takeda, A | 2 |
| Picot, J | 2 |
| Payne, E | 2 |
| Clegg, A | 2 |
| Bright-Long, L | 1 |
| Wellhöfer, B | 1 |
| Bianchetti, A | 1 |
| Di Luca, M | 1 |
| Pirfo, E | 1 |
| Scapicchio, P | 1 |
| Senin, U | 1 |
| Trabucchi, M | 1 |
| Ladouceur, R | 1 |
| Alander, J | 1 |
| Lönnroos, E | 1 |
| Klaukka, T | 1 |
| Creeley, C | 1 |
| Wozniak, DF | 1 |
| Labruyere, J | 1 |
| Taylor, GT | 1 |
| Olney, JW | 1 |
| Wuntakal, B | 1 |
| Aupperle, PM | 1 |
| Antonanzas, F | 1 |
| Badenas, JM | 1 |
| Gomez-Lus, S | 1 |
| Dautzenberg, PL | 1 |
| Wouters, CJ | 1 |
| Bootsma, JE | 1 |
| Hu, HT | 1 |
| Zhang, ZX | 1 |
| Yao, JL | 1 |
| Yu, HZ | 1 |
| Wang, YH | 1 |
| Tang, HC | 1 |
| Ji, CJ | 1 |
| Xu, T | 1 |
| Nourhashémi, F | 1 |
| Ozturk, S | 1 |
| Cillier, AE | 1 |
| Ota, KS | 1 |
| Godwin, T | 1 |
| Geerts, H | 1 |
| Edwards, KR | 1 |
| Zhao, Q | 1 |
| Schneider, E | 1 |
| Peskind, ER | 1 |
| Potkin, SG | 1 |
| Pomara, N | 1 |
| Ott, BR | 2 |
| Preskorn, SH | 1 |
| Borges, S | 1 |
| Flockhart, D | 1 |
| Bell, KF | 1 |
| Claudio Cuello, A | 1 |
| Robinson, DM | 1 |
| Keating, GM | 1 |
| Siemers, ER | 1 |
| Dean, RA | 1 |
| Demattos, R | 1 |
| May, PC | 1 |
| Ferreri, F | 1 |
| Agbokou, C | 1 |
| Agokou, C | 1 |
| Verhey, FR | 1 |
| Beatty, GE | 1 |
| Chohan, MO | 1 |
| Marszalec, W | 1 |
| Toth, PT | 1 |
| Machado, JC | 1 |
| Caramelli, P | 1 |
| Monastero, R | 1 |
| Camarda, C | 1 |
| Pipia, C | 1 |
| Camarda, R | 1 |
| Johannsen, P | 1 |
| Zoladz, PR | 1 |
| Campbell, AM | 1 |
| Park, CR | 1 |
| Schaefer, D | 1 |
| Diamond, DM | 1 |
| Rabins, PV | 1 |
| Broich, K | 1 |
| Ford, G | 1 |
| McCaddon, A | 1 |
| Jacova, C | 1 |
| Lennon, S | 1 |
| Orgogozo, JM | 1 |
| Purandare, N | 1 |
| Richardson, M | 1 |
| Wilcock, G | 1 |
| Berger, M | 1 |
| Heneka, M | 1 |
| Kay, G | 1 |
| Crook, T | 1 |
| Heinen-Kammerer, T | 1 |
| Rulhoff, H | 1 |
| Nelles, S | 1 |
| Bayer, A | 1 |
| Inglis, F | 1 |
| Barker, A | 1 |
| Cosman, KM | 1 |
| Boyle, LL | 1 |
| Porsteinsson, AP | 2 |
| Ryan, M | 1 |
| Cooper, G | 1 |
| Beier, MT | 1 |
| Blake, LM | 1 |
| Kagan, E | 1 |
| Resnick, M | 1 |
| Weinkauf, B | 1 |
| Tracik, F | 1 |
| Gunay, I | 1 |
| Maggiore, C | 1 |
| Locatelli, L | 1 |
| Grandi, FC | 1 |
| Pizzolato, G | 1 |
| Villar Fernández, I | 1 |
| Rabaneque Hernández, MJ | 1 |
| Armesto Gómez, J | 1 |
| García Arilla, E | 1 |
| Izuel Rami, M | 1 |
| Weycker, D | 1 |
| Taneja, C | 1 |
| Edelsberg, J | 1 |
| Oster, G | 1 |
| Melnikova, I | 1 |
| Bynum, N | 1 |
| Poklis, J | 1 |
| Garside, D | 1 |
| Winecker, R | 1 |
| Belmin, J | 1 |
| Péquignot, R | 1 |
| Konrat, C | 1 |
| Pariel-Madjlessi, S | 1 |
| Essner, U | 1 |
| Andersen, HF | 1 |
| Papageorgiou, SG | 1 |
| Kontaxis, T | 1 |
| Antelli, A | 1 |
| Kalfakis, N | 1 |
| Bakchine, S | 2 |
| Loft, H | 4 |
| Semla, TP | 1 |
| Degerman Gunnarsson, M | 1 |
| Kilander, L | 1 |
| Basun, H | 1 |
| Lannfelt, L | 1 |
| Lexchin, J | 1 |
| Fellgiebel, A | 1 |
| Lang, CJ | 1 |
| Gagnon, M | 1 |
| Hux, M | 1 |
| Virta, L | 1 |
| Viramo, P | 1 |
| Sakka, P | 1 |
| Soininen, H | 1 |
| López Pousa, S | 1 |
| Schwam, E | 1 |
| Maidment, ID | 1 |
| Fox, CG | 1 |
| Rodriguez, J | 1 |
| Brown, RC | 1 |
| Katona, CL | 1 |
| Arai, T | 1 |
| Drever, BD | 1 |
| Anderson, WG | 1 |
| Johnson, H | 1 |
| O'Callaghan, M | 1 |
| Seo, S | 1 |
| Choi, DY | 1 |
| Platt, B | 1 |
| Waldemar, G | 1 |
| Hyvärinen, M | 1 |
| Josiassen, MK | 1 |
| Kørner, A | 1 |
| Lehto, H | 1 |
| Wetterberg, P | 1 |
| Wilcock, GK | 1 |
| Ballard, CG | 1 |
| Cooper, JA | 1 |
| Downey, D | 1 |
| King, KG | 1 |
| Gonen, O | 1 |
| Ferrara, N | 1 |
| Corbi, G | 1 |
| Capuano, A | 1 |
| Filippelli, A | 1 |
| Rossi, F | 1 |
| Yuede, CM | 1 |
| Coughlan, C | 1 |
| Lewis, B | 1 |
| Csernansky, JG | 1 |
| Fitzjohn, SM | 1 |
| Doherty, AJ | 1 |
| Collingridge, GL | 1 |
| Shua-Haim, J | 1 |
| Smith, J | 1 |
| Picard, F | 1 |
| Sedek, G | 1 |
| Athalye, S | 1 |
| Pommier, F | 1 |
| Lefèvre, G | 1 |
| van Marum, RJ | 1 |
| Meng, SN | 1 |
| Wu, HZ | 1 |
| Weller, M | 1 |
| Glaser, A | 1 |
| Degner, D | 1 |
| Poritis, N | 1 |
| Marx, J | 1 |
| Dresser, R | 1 |
| Marwick, C | 1 |
| Androsova, LV | 1 |
| Jain, KK | 1 |
| Zharikov, GA | 1 |
| Fleischhacker, WW | 1 |
| Buchgeher, A | 1 |
| Schubert, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study of Masitinib as add-on Therapy in Patients With Mild to Moderate Alzheimer's Disease[NCT05564169] | Phase 3 | 600 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| Comparison of Optical Coherence Tomography Angiographic Factors of Macula and Optic Disc in Patients With or Without Amyloid Pathology: A Prospective Study[NCT05475158] | 117 participants (Actual) | Observational | 2019-09-01 | Completed | |||
| Investigation of Factors Associated With Cognitive Status in the Elderly[NCT05051319] | 814 participants (Actual) | Observational [Patient Registry] | 2017-04-01 | Completed | |||
| Multi-targets, Single-lead GPi+NBM DBS in Parkinson's Disease With Mild Cognitive Impairment[NCT04571112] | 6 participants (Actual) | Interventional | 2017-12-04 | Completed | |||
| A Randomised, Double-Blind, Parallel-Group Study Examining the Efficacy and Safety of Memantine in Patients With Moderate to Severe Dementia of the Alzheimer's Type[NCT00857649] | Phase 3 | 369 participants (Actual) | Interventional | 2003-12-31 | Terminated | ||
| CSP #546 - A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD)[NCT00235716] | Phase 3 | 613 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Maladie d'Alzheimer et Maladies apparentées : Caractérisation Des Anomalies Cognitivo-motrices, et Des Effets Des médicaments Anti-démence et de la Vitamine D à Partir de la Mise en Place d'Une Base de données au CMRR du CHU d'Angers[NCT01315704] | 700 participants (Anticipated) | Observational | 2009-11-30 | Recruiting | |||
| A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor[NCT00940589] | Phase 2 | 73 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Pilot, Open-label Study to Evaluate the Effects of a Prostate Health Formulation on Scores Attained From the International Prostate Symptom Score (I-PSS) Questionnaire Among Overall Healthy Male Participants Who Report Lower Urinary Tract Complaints[NCT02886832] | 30 participants (Anticipated) | Interventional | 2016-09-21 | Completed | |||
| A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dement[NCT00948766] | Phase 4 | 716 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-Severe Alzheimer's Disease[NCT00679627] | Phase 3 | 2,051 participants (Actual) | Interventional | 2008-06-30 | Terminated (stopped due to Due to a pre-specified imbalance of deaths between treatment groups, the DSMB recommended early termination of the trial) | ||
| Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment[NCT01876823] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Memantine Versus Donepezil in Mild to Moderate Alzheimer's Disease. A Randomized Trial With Magnetic Resonance Spectroscopy.[NCT00505167] | Phase 4 | 64 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Prospective, 5-Week, Open-Label, Randomized, Multi-Center, Parallel-Group Study With a 20-Week, Open-Label Extension Evaluating the Tolerability and Safety of Switching From Donepezil to an Initial Dose of 5 cm2 Rivastigmine Patch Formulation in Patient[NCT00428389] | Phase 3 | 262 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Study: A Coverage With Evidence Development Longitudinal Cohort Study[NCT02420756] | 18,488 participants (Actual) | Observational [Patient Registry] | 2016-02-29 | Completed | |||
| Alzheimer's Disease Neuroimaging Initiative[NCT00106899] | 818 participants (Actual) | Observational | 2005-07-31 | Completed | |||
| Prospective, Single-arm, Multicenter, Open-label Study to Investigate the Efficacy and Tolerability of the Once Daily (OD) Memantine Treatment[NCT00624026] | Phase 3 | 107 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Phase IV-An Open-Label Prospective Study of Memantine in Institutionalized Patients With Severe Alzheimer's Disease and Significant Behavioural and Psychological Symptoms of Dementia[NCT00401167] | Phase 4 | 32 participants (Anticipated) | Interventional | 2006-11-30 | Completed | ||
| A Multicenter, Randomized, Open-label Study to Compare the Tolerability Between Rivastigmine Patch Monotherapy and Combination Therapy With Memantine in Patients With Alzheimer's Disease[NCT01025466] | Phase 4 | 206 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score ≥ B7 Cirrhosis and Hepatocellular Carcinoma[NCT06007846] | Phase 2/Phase 3 | 12 participants (Anticipated) | Interventional | 2023-07-31 | Recruiting | ||
| Evaluation d'Une stratégie thérapeutique d'Association médicamenteuse Pour la Prise en Charge de la Maladie d'Alzheimer et Des Maladies apparentées au Stade modéré[NCT01409694] | Phase 3 | 90 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Phase II Multicenter 16-Week Randomized Double Blind Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Adolescents and Young Adults With Down Syndrome[NCT02304302] | Phase 2 | 160 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| A 1-year Randomised, Double-blind Placebo-controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients With Alzheimer's Disease[NCT00862940] | Phase 4 | 277 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Evaluation of the Safety, Tolerability and Impact on Biomarkers of Anti-Oxidant Treatment of Mild to Moderate Alzheimer's Disease[NCT00117403] | Phase 1 | 75 participants (Anticipated) | Interventional | 2006-01-31 | Completed | ||
| Open Label, Single-Arm, Multi-Centre, Study to Validate a New Alzheimer's Disease Scale in Patients With DAT, Treated With Memantine[NCT00804271] | Phase 3 | 487 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| A 6 Months, Prospective, Open-label, Observational, Non-interventional Clinical Trial to Examine the Efficacy and Safety of Donepezil (Dementis®) Administration in Patients With Dementia.[NCT01772095] | 389 participants (Actual) | Observational | 2013-02-28 | Completed | |||
| Pragmatic Randomized Control Trial of Memantine For Agitation In Dementia[NCT00371059] | Phase 4 | 153 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease[NCT00478205] | Phase 3 | 1,467 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease[NCT00551161] | Phase 4 | 12 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Does Memantine Improve Verbal Memory Task Performance in Subjects With Localization-related Epilepsy and Memory Dysfunction? A Randomized, Double-Blind, Placebo-Controlled Trial[NCT01054599] | 29 participants (Actual) | Interventional | 2009-01-31 | Completed | |||
| A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia[NCT00545974] | Phase 4 | 81 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Namenda as Prevention for Post-Operative Delirium[NCT00303433] | Phase 4 | 30 participants | Interventional | 2006-03-31 | Terminated | ||
| Pilot Study of Memantine for Enhanced Stroke Recovery[NCT02144584] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2014-01-31 | Active, not recruiting | ||
| Efficacy of Memantine in the Treatment of Fibromyalgia: a Double-blind Randomized Trial[NCT01653457] | Phase 3 | 60 participants (Anticipated) | Interventional | 2012-09-30 | Not yet recruiting | ||
| Evaluation of [123I] IMPY and SPECT as a Marker of Beta-amyloid Protein Deposition in the Brain of Healthy Subjects and Patients With Alzheimer Disease[NCT00287248] | Phase 1 | 38 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Change from Baseline in Neuropsychiatric Inventory (NPI) total score.~NPI is a validated scale that assesses behavioural disturbances in patients with dementia. The 12 item version consists of 10 behavioural and 2 neurovegetative areas. It provides both a total score as well as scores for a number of sub-scales. The frequency, severity and caregiver distress for each domain are measured. The NPI is based upon responses obtained from the caregiver. The total score is from 0 to 144. A higher score reflects more frequency and severity of the disturbances." (NCT00857649)
Timeframe: Baseline to Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Memantine | -3.90 |
| Placebo | -5.13 |
"Change from Baseline in Severe Impairment Battery (SIB) total score.~SIB is a validated scale used to assess cognitive function in patients with moderate to severe dementia. Items are single words or one-step commands combined with gestures. Nine domains are assessed, and the total score is between 0 and 100. A lower total score reflects the loss of cognitive function." (NCT00857649)
Timeframe: Baseline to Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Memantine | -2.34 |
| Placebo | -1.86 |
"Change from Baseline on the Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) 19-item version total score.~ADCS-ADL- 19 items version for moderate to severe AD will measure patient's functioning. This battery of ADL questions is used here to measure the functional capabilities of patients with dementia. The inventory is done by interviewing a person in close contact with the patient and covers the most usual and consistent performance of the patient over the preceding 4 weeks. Total score is from 0 to 54. The higher score, the lower impairment." (NCT00857649)
Timeframe: Baseline to Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Memantine | -4.36 |
| Placebo | -2.56 |
"Change from Baseline on the Cohen-Mansfield Agitation Inventory (CMAI) - Long Form total score.~CMAI - Long Form looks specifically at agitated behaviour in patients with cognitive impairment. It is a seven-point rating scale assessing the frequency of up to 29 agitated behaviours, ranging from 1 = Never to 7 = Several times an hour. Rating is based on responses obtained from interviews with the caregiver. The total score ranges from 29 to 203, with a higher score reflecting more frequent behavioural disturbances." (NCT00857649)
Timeframe: Baseline to Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Memantine | -0.26 |
| Placebo | -1.16 |
"Clinician's Interview-Based Impression of Change-Plus Version (CIBIC-plus). Improvement evaluated with reference to Baseline.~CIBIC-plus is a global rating that is derived through an independent, comprehensive interview with the patient and caregiver by a rater who is barred from knowledge of all other psychometric test scores conducted as part of this protocol as well as from reported safety data. The rating is made on a 7-point scale ranging from 1 = marked improvement to 7 = marked worsening. A score of 4 indicates no change." (NCT00857649)
Timeframe: Baseline to Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Memantine | 4.68 |
| Placebo | 4.63 |
Survival analysis of death from any cause. (NCT00235716)
Timeframe: up to 4 years
| Intervention | participants (Number) |
|---|---|
| Vitamin E | 26 |
| Memantine | 39 |
| Vitamin E + Memantine | 32 |
| Placebo | 31 |
The Dependence Scale assesses the level of assistance needed by patients with Alzheimer's disease for activities of daily living. The scale yields six levels of dependence: no assistance required (Level 0); requires occasional reminders (Level 1); requires frequent reminders and/or help with household chores (Level 2); needs daily supervision (Level 3); needs to be dressed, toileted or fed (Level 4); needs to be transferred, diapered or tube fed (Level 5). (NCT00235716)
Timeframe: Every 6 months to a maximum of 4 years
| Intervention | participants (Number) |
|---|---|
| Vitamin E | 80 |
| Memantine | 87 |
| Vitamin E + Memantine | 87 |
| Placebo | 79 |
The Alzheimer's Disease Assessment Scale (ADAS) is a 21-item scale designed to assess the severity of cognitive and non-cognitive behavioral impairments in patients with Alzheimer's disease. The cognitive portion of the scale (ADAS-cog) consists of 11 items to assess memory, language, and praxis functions. The ADAS-cog total score ranges from 0 (no errors) to 70 (severe cognitive impairment). Outcome analysis is average least square means change from baseline. (NCT00235716)
Timeframe: 6, 12, 18, 24, 30, 36, 42 and 48 months minus baseline
| Intervention | units on a scale (Least Squares Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 6 months minus baseline | 12 months minus baseline | 18 months minus baseline | 24 months minus baseline | 30 months minus baseline | 36 months minus baseline | 42 months minus baseline | 48 months minus baseline | Average change from baseline | |
| Memantine | 1.11 | 3.32 | 5.69 | 6.73 | 7.64 | 8.31 | 8.24 | 11.74 | 6.38 |
| Placebo | 3.04 | 4.26 | 6.04 | 6.71 | 8.90 | 10.77 | 10.61 | 10.85 | 7.78 |
| Vitamin E | 1.38 | 2.40 | 4.34 | 4.32 | 7.87 | 9.00 | 10.35 | 10.73 | 5.97 |
| Vitamin E + Memantine | 1.53 | 2.48 | 3.46 | 5.76 | 5.85 | 8.26 | 7.97 | 9.70 | 6.13 |
The primary outcome of the study was the Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS/ADL) Inventory. The ADCS/ADL Inventory is designed to assess functional abilities to perform activities of daily living in Alzheimer patients with a broad range of dementia severity. The total score ranges from 0 to 78 with higher scores indicating greater abilities. Outcome analysis is average least square means change from baseline. (NCT00235716)
Timeframe: 6, 12, 18, 24, 30, 36, 42 and 48 months minus baseline
| Intervention | units on a scale (Least Squares Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 6 months minus baseline | 12 months minus baseline | 18 months minus baseline | 24 months minus baseline | 30 months minus baseline | 36 months minus baseline | 42 months minus baseline | 48 months minus baseline | Average change from baseline | |
| Memantine | -2.40 | -6.99 | -9.32 | -14.06 | -18.30 | -18.78 | -23.48 | -24.60 | -14.98 |
| Placebo | -4.52 | -8.11 | -10.21 | -16.18 | -19.67 | -24.82 | -28.13 | -27.55 | -16.96 |
| Vitamin E | -1.72 | -4.29 | -8.01 | -11.88 | -15.84 | -19.71 | -25.30 | -26.55 | -13.81 |
| Vitamin E + Memantine | -2.78 | -6.60 | -7.98 | -12.82 | -15.66 | -18.89 | -23.44 | -29.25 | -15.20 |
The Caregiver Activity Survey (CAS) was developed to measure the time caregivers spend aiding Alzheimer patients with their day-to-day activities. The CAS consists of six items that ask for an estimate in hours and minutes of the time that the caregiver spent during the previous 24 hours performing these particular activities. The six CAS items are as follows: 1) communication with the person, 2) using transportation, 3) dressing, 4) eating, 5) looking after one's appearance, and 6) supervising the person. The more caregiving hours the worse the patient's functioning level. Outcome analysis is average least square means change from baseline. (NCT00235716)
Timeframe: 6, 12, 18, 24, 30, 36, 42 and 48 months minus baseline
| Intervention | hours per day (Least Squares Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 6 months minus baseline | 12 months minus baseline | 18 months minus baseline | 24 months minus baseline | 30 months minus baseline | 36 months minus baseline | 42 months minus baseline | 48 months minus baseline | Average change from baseline | |
| Memantine | 0.99 | 2.72 | 3.77 | 3.06 | 5.22 | 5.72 | 9.46 | 9.27 | 5.52 |
| Placebo | 1.20 | 1.89 | 3.16 | 3.45 | 4.36 | 10.68 | 10.62 | 12.17 | 5.14 |
| Vitamin E | -0.93 | -0.18 | 2.12 | 1.60 | 4.14 | 7.69 | 4.95 | 10.17 | 3.35 |
| Vitamin E + Memantine | 1.08 | 1.39 | 2.69 | 2.82 | 3.41 | 4.90 | 5.48 | 13.80 | 5.00 |
The Mini-Mental State Examination (MMSE) briefly and objectively assess cognitive status in psychiatric patients with cognitive impairment. The MMSE questions are grouped into seven categories, each representing a different cognitive domain. The MMSE yields a total score that ranges from 0 for a patient who gives no correct response to a score of 30 for a patient who makes no errors. Outcome analysis is average least square means change from baseline. (NCT00235716)
Timeframe: 6, 12, 18, 24, 30, 36, 42 and 48 months minus baseline
| Intervention | units on a scale (Least Squares Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 6 months minus baseline | 12 months minus baseline | 18 months minus baseline | 24 months minus baseline | 30 months minus baseline | 36 months minus baseline | 42 months minus baseline | 48 months minus baseline | Average change from baseline | |
| Memantine | -0.24 | -1.09 | -2.62 | -3.44 | -3.79 | -4.26 | -4.59 | -5.98 | -3.05 |
| Placebo | -0.34 | -1.39 | -2.21 | -2.90 | -3.26 | -3.87 | -4.68 | -5.42 | -3.16 |
| Vitamin E | -0.35 | -0.95 | -2.00 | -2.62 | -3.67 | -4.97 | -4.84 | -5.26 | -2.97 |
| Vitamin E + Memantine | -0.20 | -0.65 | -1.22 | -2.29 | -3.16 | -3.69 | -3.80 | -5.70 | -2.80 |
The Neuropsychiatric Inventory (NPI) assesses psychological and behavioral problems in patients with dementia. For each of twelve domains, there are four scores: frequency, severity, total frequency x severity, and caregiver distress. The frequency x severity total scores from each domain are summed for an overall total score that ranges from 0 to 144. The total caregiver distress scores are also summed for an overall total caregiver distress score that ranges from 0 to 60. The secondary endpoint for the trial will be the overall frequency times severity total score. Outcome analysis is average least square means change from baseline. (NCT00235716)
Timeframe: 6, 12, 18, 24, 30, 36, 42 and 48 months minus baseline
| Intervention | units on a scale (Least Squares Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 6 months minus baseline | 12 months minus baseline | 18 months minus baseline | 24 months minus baseline | 30 months minus baseline | 36 months minus baseline | 42 months minus baseline | 48 months minus baseline | Average change from baseline | |
| Memantine | -0.20 | 0.31 | 1.18 | 4.29 | 2.62 | 3.24 | 3.63 | 2.79 | 1.87 |
| Placebo | 0.46 | 1.08 | 4.06 | 3.59 | 1.66 | 0.60 | 3.64 | 0.30 | 2.26 |
| Vitamin E | -1.24 | -1.04 | 0.93 | 2.16 | 3.21 | 2.15 | 0.81 | -0.60 | 0.79 |
| Vitamin E + Memantine | -0.47 | -0.17 | 0.41 | 1.98 | 2.16 | 2.79 | 1.85 | 5.14 | 1.79 |
ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale) is a cognitive testing instrument used in clinical trials. It consists of 11 tasks measuring the disturbances of memory, language, praxis, attention, and other cognitive abilities that are often referred to as the core symptoms of AD. The test comprises 11 items summed to a total score ranging from 0 to 70, with lower scores indicating less severe impairment. A negative change indicates an improvement from baseline. ADAS-cog was measured at base line and at end of treatment after 24 weeks. (NCT00940589)
Timeframe: 24 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Circadin | 0.45 |
| Placebo | 0.19 |
Instrumental Activities of Daily Living (iADL). The scale rates activities that represent key life tasks that people need to manage. These tasks are valuable for evaluating persons with early-stage disease, both to assess the level of disease and to determine the person's ability to care for himself or herself. Scores of 0 or 1 are given to every task (Bathing, Dressing, Tolieting, transferring, Continence and Feeding) to a total score of 6. , while 0 represents a patient who is very dependent and 6 represents patient who is independent. iADL was measured at base line and at end of treatment after 24 weeks. (NCT00940589)
Timeframe: 24 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Circadin | 0.77 |
| Placebo | 1.62 |
The Mini Mental State Examination (MMSE) is a brief assessment instrument used to assess cognitive function in elderly patients. The MMSE can be used to screen for cognitive impairment and as a measurement of cognition over time and with pharmacologic treatment. The instrument is divided into 2 sections. The first section measures orientation, memory, and attention: the maximum score is 21. The second section tests the ability of the patient to name objects, follow verbal and written commands, write a sentence, and copy figures: the maximum score is 9. The scoring range for the MMSE is 0-30. Higher score represents better performance. MMSE was measured at base line and at end of treatment after 24 weeks. (NCT00940589)
Timeframe: 24 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Circadin | -0.3 |
| Placebo | -1.9 |
"The ADCS-ADL-SIV is designed to assess the patient's performance of both basic and instrumental activities of daily living such as those necessary for personal care, communicating and interacting with other people, maintaining a household, conducting hobbies and interests, and making judgments and decisions. For each of the 19 questions in the ADCS-ADL-SIV, there was either a forced choice of best response or a yes or no question with additional sub-questions. Responses for each item were obtained from the caregiver through an interview. Higher numbered scores and answers of yes reflected a more self-sufficient individual. The total score was calculated as the sum of all items and sub-questions and ranged from 0 to 54. A higher total score represented a higher functioning patient. A positive change score indicates improvement." (NCT00948766)
Timeframe: Baseline of the core study to Week 24 of the core study
| Intervention | Units on a scale (Mean) |
|---|---|
| Rivastigmine 13.3 mg/24 h Transdermal Patch | -2.6 |
| Rivastigmine 4.6 mg/24 h Transdermal Patch | -3.6 |
The NPI-12 assesses a wide range of behaviors encountered in patients with dementia to provide a means of distinguishing the frequency and severity of behavioral changes over time. Ten behavioral and 2 neurovegetative domains were evaluated in an interview with the caregiver given by a mental health professional. The scale included both frequency and severity ratings of each domain as well as a composite domain score (frequency x severity). The sum of the composite scores for the 12 domains yielded the NPI-12 total score. The NPI-12 was scored from 0 to 144, with lower scores reflecting improvement in psychiatric behavior. A negative change score indicates improvement. (NCT00948766)
Timeframe: Baseline of the core study to Week 24 of the core study
| Intervention | Units on a scale (Mean) |
|---|---|
| Rivastigmine 13.3 mg/24 h Transdermal Patch | -0.4 |
| Rivastigmine 4.6 mg/24 h Transdermal Patch | 1.2 |
The SIB is a 40-item scale developed for the evaluation of the severity of cognitive dysfunction in more advanced Alzheimer Disease patients. The domains assessed included social interaction, memory, language, attention, orientation, praxis, visuo-spatial ability, construction, and orienting to name. The items of the SIB were developed as simple 1-step commands which are presented by a trained rater with gestural cues and repeated if necessary. The SIB was scored from 0 to 100, with higher scores reflecting higher levels of cognitive ability. A positive change score indicates improvement. (NCT00948766)
Timeframe: Baseline of the core study to Week 24 of the core study
| Intervention | Units on a scale (Mean) |
|---|---|
| Rivastigmine 13.3 mg/24 h Transdermal Patch | -1.6 |
| Rivastigmine 4.6 mg/24 h Transdermal Patch | -6.4 |
"The ADCS-ADL-SIV is designed to assess the patient's performance of both basic and instrumental activities of daily living such as those necessary for personal care, communicating and interacting with other people, maintaining a household, conducting hobbies and interests, and making judgments and decisions. For each of the 19 questions in the ADCS-ADL-SIV, there was either a forced choice of best response or a yes or no question with additional sub-questions. Responses for each item were obtained from the caregiver through an interview. Higher numbered scores and answers of yes reflected a more self-sufficient individual. The total score was calculated as the sum of all items and sub-questions and ranged from 0 to 54. A higher total score represented a higher functioning patient. A positive change score indicates improvement." (NCT00948766)
Timeframe: Baseline of the core study to Week 24 of the extension study
| Intervention | Units on a scale (Mean) |
|---|---|
| Rivastigmine 13.3 mg/24 h Transdermal Patch | -4.3 |
The SIB is a 40-item scale developed for the evaluation of the severity of cognitive dysfunction in more advanced Alzheimer Disease patients. The domains assessed included social interaction, memory, language, attention, orientation, praxis, visuo-spatial ability, construction, and orienting to name. The items of the SIB were developed as simple 1-step commands which are presented by a trained rater with gestural cues and repeated if necessary. The SIB was scored from 0 to 100, with higher scores reflecting higher levels of cognitive ability. A positive change score indicates improvement. (NCT00948766)
Timeframe: Baseline of the core study to Week 24 of the extension study
| Intervention | Units on a scale (Mean) |
|---|---|
| Rivastigmine 13.3 mg/24 h Transdermal Patch | -5.9 |
The ADCS-CGIC assesses the clinical meaningfulness of a treatment based on the clinician's rating of change. The rating is provided by a trained clinician or psychometrician blinded to the patient's treatment. The rater interviewed the patient and caregiver separately at Baseline using a worksheet that provided space for notes and comments. At baseline, raters had access to all of the patient's available records and evaluations. The rater used a similar worksheet at follow-up visits, and referred to the baseline worksheet prior to making a rating of change. The worksheets were divided into 3 domains: mental/cognitive state, behavior, and functioning. Change ratings were based on a 7-point scale: Marked (1), moderate (2), and minimal improvement (3), no change (4), and marked (5), moderate (6), and minimal worsening (7). The percentage of patients in each of the 7 categories is reported. (NCT00948766)
Timeframe: Baseline of the core study to Week 24 of the core study
| Intervention | Percentage of patients (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Marked improvement | Moderate improvement | Minimal improvement | No change | Minimal worsening | Moderate worsening | Marked worsening | |
| Rivastigmine 13.3 mg/24 h Transdermal Patch | 1.0 | 3.5 | 20.1 | 34.2 | 24.3 | 14.1 | 2.9 |
| Rivastigmine 4.6 mg/24 h Transdermal Patch | 1.3 | 3.5 | 11.4 | 29.2 | 31.4 | 19.0 | 4.1 |
The ADCS-CGIC assesses the clinical meaningfulness of a treatment based on the clinician's rating of change. The rating is provided by a trained clinician or psychometrician blinded to the patient's treatment. The rater interviewed the patient and caregiver separately at Baseline using a worksheet that provided space for notes and comments. At baseline, raters had access to all of the patient's available records and evaluations. The rater used a similar worksheet at follow-up visits, and referred to the baseline worksheet prior to making a rating of change. The worksheets were divided into 3 domains: mental/cognitive state, behavior, and functioning. Change ratings were based on a 7-point scale: Marked (1), moderate (2), and minimal improvement (3), no change (4), and marked (5), moderate (6), and minimal worsening (7). The percentage of patients in each of the 7 categories is reported. (NCT00948766)
Timeframe: Baseline of the core study to Week 24 of the extension study
| Intervention | Percentage of patients (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Marked improvement | Moderate improvement | Minimal improvement | No change | Minimal worsening | Moderate worsening | Marked worsening | |
| Rivastigmine 13.3 mg/24 h Transdermal Patch | 1.8 | 5.0 | 9.7 | 26.2 | 31.5 | 21.5 | 4.2 |
The DAD assesses physical activities of daily living and instrumental-activities of daily livings of participants with Alzheimer disease. This measure is a validated, disability assessment scale that collects information regarding the ability of a participant to initiate, plan, organize, and perform activities of daily living, as based on a structured interview with the caregiver. The maximum scores were 13 for initiation, 10 for planning and organizing, and 17 for effective performance in order to yield a total maximum score of 40. These scores were normalized to a scale of 100 for analysis.A higher score, or percentage of items that can be performed represents fewer disabilities in carrying out activities of daily living while a lower percentage indicates an increase in disabilities. (NCT00679627)
Timeframe: Baseline, Month 24
| Intervention | Scores on scale (Mean) |
|---|---|
| Placebo | -10.81 |
| Galantamine | -8.16 |
The MMSE is a brief 30-point questionnaire test that is used or the assessment of dementia patients' cognitive impairment. Evaluation of points are as follows: 24 to 30 = no cognitive impairment, 18 to 23 = mild cognitive impairment, 0 to 17 = severe cognitive impairment. Lower scores indicate worsening. (NCT00679627)
Timeframe: Baseline, Month 24
| Intervention | Scores on scale (Mean) |
|---|---|
| Placebo | -2.14 |
| Galantamine | -1.41 |
The MMSE is a brief 30-point questionnaire test that is used or the assessment of dementia patients' cognitive impairment. Evaluation of points are as follows: 24 to 30 = no cognitive impairment, 18 to 23 = mild cognitive impairment, 0 to 17 = severe cognitive impairment. Lower scores indicate worsening. (NCT00679627)
Timeframe: Baseline, Month 6
| Intervention | Scores on scale (Mean) |
|---|---|
| Placebo | -0.28 |
| Galantamine | 0.15 |
An external Data Safety Monitoring Board (DSMB) was assigned for this study to monitor the progress of the study and to ensure that the safety of participants was not compromised. (NCT00679627)
Timeframe: Up to 2 years
| Intervention | Number of Participants (Number) |
|---|---|
| Placebo | 56 |
| Galantamine | 33 |
The table below presents the number of days that caregiving activities were provided during the past week. (NCT00679627)
Timeframe: Baseline, Months 12 and 24
| Intervention | Days (Mean) | ||
|---|---|---|---|
| Provided caregiving during past week - Baseline | Provided caregiving during past week - Month 12 | Provided caregiving during past week - Month 24 | |
| Galantamine | 5.77 | 6.07 | 6.20 |
| Placebo | 5.91 | 6.06 | 6.13 |
This table describes the number of participants who were reported as institutionalized at baseline and Month 24. (NCT00679627)
Timeframe: Baseline, Month 24
| Intervention | Number of Participants (Number) | |
|---|---|---|
| Baseline | Month 24 | |
| Galantamine | 0 | 6 |
| Placebo | 1 | 5 |
"The APAS-CarB is a measure used to evaluate participant status and caregiver burden. The table below presents Patient Accommodation assessed as the percentage of participants home with friend or relative using the APAS-CarB." (NCT00679627)
Timeframe: Baseline, Months 12 and 24
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Home with friend or relative - Baseline | Home with friend or relative - Month 12 | Home with friend or relative - Month 24 | |
| Galantamine | 62.8 | 61.8 | 60.1 |
| Placebo | 62.1 | 61.4 | 55.3 |
The DAD assesses physical activities of daily living and instrumental-activities of daily livings of participants with Alzheimer disease. This measure is a validated, disability assessment scale that collects information regarding the ability of a participant to initiate, plan, organize, and perform activities of daily living, as based on a structured interview with the caregiver. The maximum scores were 13 for initiation, 10 for planning and organizing, and 17 for effective performance in order to yield a total maximum score of 40. These scores were normalized to a scale of 100 for analysis.A higher score, or percentage of items that can be performed represents fewer disabilities in carrying out activities of daily living while a lower percentage indicates an increase in disabilities. (NCT00679627)
Timeframe: Baseline, Month 24
| Intervention | Scores on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Initiation | Planning and Organization | Effective Performance | Basic | Instrumental | Leisure | |
| Galantamine | -9.60 | -9.96 | -10.82 | -9.84 | -10.72 | -10.46 |
| Placebo | -13.53 | -13.14 | -13.82 | -14.24 | -13.52 | -13.02 |
The MMSE, is a validated, brief examination that rates subjects on orientation (total score, 10), registration (total score, 3), attention (total score, 5), calculation (total score, 5), recall (total score, 3), and language (total score, 9). The maximum score is 30 (only the higher of the two scores for attention and calculation [each with a maximum score of 5] was used). A higher score compared with baseline indicates less impairment. (NCT00679627)
Timeframe: Baseline, Month 24
| Intervention | Scores on scale (Mean) | ||||
|---|---|---|---|---|---|
| Orientation | Registration | Attention and Calculation | Recall | Language | |
| Galantamine | -0.76 | -0.16 | -0.16 | 0.10 | -0.68 |
| Placebo | -0.96 | -0.20 | -0.46 | 0.00 | -0.93 |
Change in 24-item Hamilton Rating Scale for Depression (HAMD) scores from baseline to Week 48: HAMD measures depression severity based on a series of 24 items items. The range of HAMD total score is 0-74; 0 indicates no depressive symptoms and a maximum HAMD score is a 74, where the greater the score indicates more significant psychopathology. In this study, moderate to severe depression is considered a HAMD-24 greater than 14. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | scores on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | -15.2 |
Change in Selective Reminding Test-Delayed Recall scores from baseline to Week 48: SRT Delay is administered 15 minutes after the immediate recall portion. Patients are asked to remember as many of the words as they can from the 6 trials. Maximum raw score is a 12 for free recall. If a patient is unable to recall a word, they are given a chance to recognize it among three incorrect word choices. Maximum raw score for recognition is 12. The greater the score on the delayed recall portion, the better the patient does on the assessment. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 1.2 |
Change in Selective Reminding Test-Total Immediate Recall (SRT-IR) scores from baseline to Week 48: Measures word recall (maximum 12 words per trial, across 6 trials). Maximum total recall score across 6 trials is 72; minimum recall is 0 across 6 trials. The higher the raw score, the better the patient did at recalling the target words. The unit of measure is the raw score, or the sum of the number of words recalled across all 6 trials. (NCT01876823)
Timeframe: baseline, 48 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 7.5 |
Change in Trails A scores from baseline to Week 48: Measures attention and executive function. It asks patients to connect numbers from 1-25 in numerical order as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | seconds (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 1.9 |
Change from baseline to Week 48 on Trails B: Measures attention and executive function. It asks patients to connect numbers and letters in numerical to alphabetical order from (1-13 and A-L) as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers and letters, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | seconds (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | -36.3 |
Change in Wechsler Memory Scale-III scores from baseline to Week 48: The WMS-III Visual Reproduction sub-test was used to measure visual working memory and delayed memory. Patients were shown pictures of four drawings and were asked to reproduce them from memory immediately after seeing them, and 25 minutes after seeing them. The four scores are summed and the greater the total raw score, the better the patient did on the assessment. The maximum raw score for this test is a 41 on both the immediate and delayed portions (the overall range is 0-82 points). The change score is calculated using the total scores of both the immediate and delayed portions. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 9.9 |
The CDR is a numeric rating scale that is used to quantify the severity of one's cognitive function. The scale goes from 0=normal; 0.5=mild cognitive impairment; 1 to 3=mild to moderate/severe dementia. CDR was used a dichotomous outcome measure (no=0; yes=1). (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | participants (Number) |
|---|---|
| Es-citalopram and Memantine Treatment | 1 |
The CGI Cognitive Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses from the entire group were calculated. Mean at final visit and baseline is reported below. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| CGI-Cognitive Change (Baseline) | Clinical Global Impression-Cogntive Change (WK 48) | |
| Es-citalopram and Memantine Treatment | 3.6 | 2.7 |
The CGI Depression Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses were calculated for the entire group. Mean at final visit has been reported below. Higher mean at baseline indicates a decrease in depression scores. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Cognitive Global Impression at Baseline | Cognitive Global Impression at Final Visit (WK 48) | |
| Es-citalopram and Memantine Treatment | 4.1 | 2.1 |
"Somatic side effect rating scale which includes 26 common somatic side effects associated with previous medication clinical trials; rated by the study physician. Factors were dichotomized to yes or no responses on this scale, which equated to the symptom being either present or not present. Yes and no responses were given a value of 0 (no) or 1 (yes). Responses from the entire group were calculated and the mean at baseline and the last visit is reported below." (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Treatment Emergent Side Effects (Baseline) | Treatment Emergent Side Effects (WK 48) | |
| Es-citalopram and Memantine Treatment | 6.6 | 3.2 |
A secondary assessment of the safety and tolerability of 2 paradigms for switching from donepezil to rivastigmine patch in patients with Alzheimer's disease (AD) was the number of participants who discontinued from the study due to any reason during extension phases of the study. (NCT00428389)
Timeframe: From week 5 through the end of extension phase (25 weeks)
| Intervention | Participants (Number) |
|---|---|
| Immediate Switch | 32 |
| Delayed Switch | 26 |
A secondary assessment of the safety and tolerability of 2 paradigms for switching from donepezil to rivastigmine patch in patients with Alzheimer's disease (AD) was the number of participants who discontinued from the study due to an AE during the combined core and extension phases of the study. (NCT00428389)
Timeframe: Baseline through the end of study (25 weeks)
| Intervention | Participants (Number) |
|---|---|
| Immediate Switch | 23 |
| Delayed Switch | 15 |
The primary objective of the study was to evaluate the safety and tolerability of 2 paradigms for switching from donepezil to rivastigmine patch in patients with Alzheimer's disease (AD). The primary variable to assess tolerability of switching was the number of participants who discontinued from the study due to any reason during the core phase. (NCT00428389)
Timeframe: Baseline through the end of the core phase of the study (Week 5)
| Intervention | Participants (Number) |
|---|---|
| Immediate Switch | 11 |
| Delayed Switch | 10 |
The MMSE is a brief, practical screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement. (NCT00428389)
Timeframe: Baseline and Week 25 (end of the extension phase) and at the end of study
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| At Week 25 (n= 96, 106) | At the End of Study (n= 115, 118) | |
| Delayed Switch | -0.4 | -0.3 |
| Immediate Switch | -0.7 | -0.5 |
The NPI-10 assesses a wide range of behavior problems encountered in dementia patients. The 10 behavioral domains comprising the NPI-10 are evaluated through an interview of the caregiver by a mental health professional. The scale includes both frequency and severity ratings of each domain as well as a composite domain score (frequency x severity). The sum of the composite scores for the 10 domains yields the NPI total score, which ranges from 0 to 120, the lower the score the less severe the symptoms. A negative change score from baseline indicates improvement. (NCT00428389)
Timeframe: Baseline, Week 25 (end of the extension phase) and at End of Study
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| At week 25 (n= 95, 107) | At the End of Study (n= 114, 118) | |
| Delayed Switch | 0.4 | 0.5 |
| Immediate Switch | -0.1 | -0.8 |
The ADCS-ADL scale is composed of 23 items to assess the basic and instrumental activities of daily living such as those necessary for personal care, communicating and interacting with other people, maintaining a household, conducting hobbies and interests, making judgments and decisions. Responses for each item are obtained through a caregiver interview. The total score is the sum of all items and sub-questions. The range for the total ADCS-ADL score is 0 to 78; a higher score indicates a more self-sufficient individual. A positive change from baseline indicates improvement. (NCT00428389)
Timeframe: Baseline, Week 25 (end of the extension phase) and at the end of Study
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| At Week 25 (n= 95, 107) | At the End of Study (n= 113, 117) | |
| Delayed Switch | -4.2 | -4.2 |
| Immediate Switch | -3.9 | -3.1 |
"The CGIC is an assessment tool used by a skilled clinician to make a judgment of the severity or a change of a patient's condition. The clinician relies solely on information obtained from the patient at the Baseline visit as well as clinical information obtained throughout the study period. The clinician does not have access to any post-baseline cognitive testing data. The CGIC is rated on a seven-point scale, ranging from (1) very much improved to (4) no change to (7) very much worse." (NCT00428389)
Timeframe: Baseline, Week 5 (end of the core phase) and Week 25 (end of the extension phase)
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| At Week 5 (n= 116, 114) | At Week 25 (n= 105, 109) | |
| Delayed Switch | 4.0 | 4.3 |
| Immediate Switch | 3.9 | 4.1 |
This is a measure of adaptive functioning that integrates information from 13 different domains (e.g., gross motor, social interaction, eating, toileting, dressing, personal self-care, etc.). It is in a questionnaire format, which a caregiver can complete while the participant is being tested. Standard scores for all indices will be derived from age norms that extend from birth to age 80, as these were used as dependent variables. We report here on the Broad Independence Score recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value of the SIB-R Score Scale in this study was -24 (this number is below 0 because -24 was the minimum value for the worst performing participant in the trial) and the maximum value of this scale is 153; higher scores mean better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 6.88 |
| Memantine | 3.23 |
The primary efficacy measure is focused on episodic memory. The CVLT-II short form assesses supraspan word learning ability as an index of episodic verbal long-term memory. We hypothesize that treatment with memantine will produce significant improvements in this test. The main dependent variable selected, based on prior literature was the total number of target items correct summed across learning trials 1-4. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). Scale Range: from 0 to 36; higher scores represent better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 3.3 |
| Memantine | 3.49 |
This is a measure of non-verbal memory that requires the participant to learn associations between an abstract visual pattern and its location. Two dependent variables have been selected: Total number of items correct on the first trial of each stage, and total number of stages completed. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value of the PAL Memory Score Scale is 0 and the maximum value is 21; higher scores mean better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 1 |
| Memantine | 0.67 |
This is a measure of non-verbal memory. Total number correct across the two series of items presented was used as the dependent variable. We used the PRM total scale in this study, which represents the sum of the PRM correct scores (ranging from 0 to 24) and the PRM delayed scores (ranging from 0 to 24). Therefore, the range of the PRM total scale is from 0 to 48; higher values mean better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 0.45 |
| Memantine | -0.05 |
This is a measure of rote short-term verbal memory. Total number of items correct were used as the dependent variable. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value for this scale is 0 and the maximum value is 38; higher scores mean a better outcome. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 0.03 |
| Memantine | -0.01 |
This measure is a computerized version of the Corsi Blocks task, a long-standing neuropsychological test. The main dependent variables selected for this test was the span length, which is the longest sequence of numbers recalled accurately. The minimum value of the Spatial Span Length Score Scale is 0 and the maximum value is 9; higher scores mean better outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 0.13 |
| Memantine | 0.03 |
"The test requires participants to search under a series of colored boxes to locate a blue token hidden underneath one of them. During a series of trials, the participant is told that the token will be in a new location each time and that they should not go back to a location he or she has looked in previously. The main dependent variable was the total number of errors (between errors), which indexes the number of times a participant went back to a box where a token had already been found, lower scores mean better performance. The minimum value of the Spatial Working Memory scale is 0 and the maximum value is 137 (which was computed as the equivalent to -4 standard deviations from the mean of this measure); higher scores mean worse outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2)." (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | -0.09 |
| Memantine | -1.4 |
"This is a measure of inhibitory control, often used as a marker for prefrontal-striatal function integrity. Specifically, it measures the participant's ability to inhibit pre-potent behavioral responses that have been established by provision of prior go or no-go cues in a classical conditioning paradigm. The main dependent variables selected was speed of response of execution to Go targets. The minimum value of the speed of response of execution to Go targets is 280 milliseconds (ms) and the maximum value is 1000 ms; higher scores mean worse outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2)." (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | ms (Mean) |
|---|---|
| Placebo | -2.52 |
| Memantine | 0.22 |
This test provides a measure of non-verbal reasoning ability that requires subjects to visually inspect a matrix of 4 or 9 pictures that has a missing piece. Participants have to infer a rule or pattern in the stimuli and select the appropriate response from a range of 4-6 possibilities. Since age norms are not available for individuals older than 17y11m, the ability score will be used as the dependent variable. This is an intermediate score based on Rasch modeling that corrects for different items set being administered to participants. The minimum value of the DAS-II Rasch Score Scale is 0 and the maximum value is 153; higher scores mean better outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 0.75 |
| Memantine | 2.66 |
This is a measure of receptive semantics, whereby the participant is asked to point to a picture (out of 4) that corresponds to a word spoken by the examiner. As this test has a 0.85 correlation with composite measures of Verbal IQ (i.e. from the Wechsler Intelligence Scale series), it can be used in conjunction with the Matrices subtest to estimate overall intellectual functioning. The total number of items correct was used as the dependent variable, following the administration manual's rules for basals and ceilings. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value for this scale is 0 and the maximum value is 192, higher scores mean a better outcome. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 4.46 |
| Memantine | 5.63 |
This is a measure of receptive syntax skills (Bishop, 1983). Participants are asked to point to a picture (out of 4) that corresponds to a phrase or sentence spoken by the examiner. The total number of items correct (rather than blocks passed) will be used as the dependent variable, following the administration manual's ceiling rule. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value of the scores is 0 and the maximum value is 40; with higher scores considered to be a better outcome. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 0.49 |
| Memantine | 0.89 |
Incidence of adverse events was monitored by clinical history, physical examinations, electrocardiograms (ECGs), clinical laboratory tests, the Screen for Childhood Anxiety Related Emotional Disorders (SCARED). Here, we report the analysis of the effect of memantine treatment on QTc intervals because of its clinical importance for this analysis for potential drug toxicity. QTc intervals ≥ 450 ms are generally considered long, and drug-induced QTc interval prolongations ≥ 60 ms are generally considered clinically relevant. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | ms (Mean) |
|---|---|
| Placebo | -1.30 |
| Memantine | -0.11 |
Estimated mean changes in total HCV (NCT00862940)
Timeframe: Baseline to 1 year
| Intervention | mm^3/year (Mean) |
|---|---|
| Memantine 10 mg Tablets Twice Daily | -218 |
| Placebo Tablets Twice Daily | -220 |
Adjusted mean change from baseline on cognitive and behavioural scores. COWAT: Verbal fluency test. The patient was asked to, during 1 minute, generate as many words as possible beginning with three pre-specified letters. The total score was calculated as the sum of acceptable words generated, with higher scores indicating lower cognitive impairment (NCT00862940)
Timeframe: Baseline to 1 year
| Intervention | Scale scores (Least Squares Mean) |
|---|---|
| Memantine 10 mg Tablets Twice Daily | 0.78 |
| Placebo Tablets Twice Daily | -0.90 |
Adjusted mean change from baseline on cognitive and behavioural scores. MMSE: Brief, structured examination of mental status that assesses orientation, memory, attention, naming, comprehension, and praxis. The range is 0 to 30, with a lower score indicating a worse mental state (NCT00862940)
Timeframe: Baseline to 1 year
| Intervention | Scale scores (Least Squares Mean) |
|---|---|
| Memantine 10 mg Tablets Twice Daily | -0.50 |
| Placebo Tablets Twice Daily | -0.74 |
Measures direct changes in total brain volume per visit interval (screening to Week 4, 42, or 52 or from Week 4 to Week 42 or 52) (NCT00862940)
Timeframe: Baseline to 1 year
| Intervention | mL/year (Mean) |
|---|---|
| Memantine 10 mg Tablets Twice Daily | 15.24 |
| Placebo Tablets Twice Daily | 15.32 |
The ADCS-ADL (Alzhemier's Disease Cooperative Study-Activities of Daily Living) is a 19-item assessment scale used to measure a patient's basic functional abilities, such as walking, grooming, and bathing.Scores range from 0 to 54, with a higher score indicating greater functional ability. (NCT00478205)
Timeframe: Baseline and Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Donepezil SR 23 mg | -1.2 |
| Donepezil IR 10 mg | -1.2 |
The MMSE (Mini-Mental State Examination) is a 30-item test that evaluates 5 domains of cognitive function (orientation to time and place, immediate and delayed recall, attention, calculation, and language). The scores range from 0 (most impaired) to 30 (no impaiment). (NCT00478205)
Timeframe: Baseline and Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Donepezil SR 23 mg | 0.6 |
| Donepezil IR 10 mg | 0.4 |
The SIB is an assessment of cognitive dysfunction across nine domains such as memory, language, and orientation. The score ranges from 0 (worst) to 100 (best). This outcome was calculated using the LOCF (last observation carried forward) method. (NCT00478205)
Timeframe: Baseline and Week 24
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Donepezil SR 23 mg | 2.6 |
| Donepezil IR 10 mg | 0.4 |
The CIBIC+ is a rating scale derived from an interview with the patient and caregiver with an independent rater designed to measure several domains of patient function, such as mental/cognitive state, behavior, and activities of daily living. The scores range from 1 (marked improvement) to 7 (marked worsening). (NCT00478205)
Timeframe: Baseline and Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Donepezil SR 23 mg | 4.23 |
| Donepezil IR 10 mg | 4.29 |
Ratios of myo-inositol (mI), N-acetylaspartate (NAA), total creatine (Cr), and choline (Cho) by single voxel 1H MRS (proton magnetic resonance spectroscopy). Mean (± SD) metabolite levels (normalized to T2-corrected water signal intensity) and metabolite ratios for Alzheimer's disease subjects at baseline (t0), after 24 weeks of ongoing monotherapy with stable-dose cholinesterase inhibitor (t1), and after another 24 weeks of combination therapy with memantine in addition to stable-dose cholinesterase inhibitor (t2). The Wilcoxon signed-rank test was used to examine whether the change between t0 and t1 differed from the change between t1 and t2 [(t2 - t1) - (t1 - t0)]. (NCT00551161)
Timeframe: Baseline, 24 weeks, and 48 weeks
| Intervention | ratio (normalized to T2-corrected water (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change in NAA [(t2-t1) - (t1-t0)] | Change in Cr [(t2-t1) - (t1-t0)] | Change in Cho [(t2-t1) - (t1-t0)] | Change in mI [(t2-t1) - (t1-t0)] | Change in NAA/Cr [(t2-t1) - (t1-t0)] | Change in Cho/Cr [(t2-t1) - (t1-t0)] | Change in mI/Cr [(t2-t1) - (t1-t0)] | Change in NAA/Cho [(t2-t1) - (t1-t0)] | Change in NAA/mI [(t2-t1) - (t1-t0)] | |
| Memantine | -54 | -2 | 9 | 16 | -0.09 | 0.02 | 0.04 | -0.26 | -0.35 |
SRT-CLTR (range 0-72; higher scores indicate better memory), and 7-24 Spatial Memory Test (range 0-35; scores are summed across the 5 learning trials, with higher scores indicating better memory) scores will be assessed across the first (baseline) and third (post-open label memantine) testing sessions. These measures are considered to be scores on a scale, rather than standard units. The hypothesis was that subjects randomized to memantine would demonstrate sustained improvement from baseline, while the placebo group would demonstrate improvements after taking open label memantine (compared to baseline). (NCT01054599)
Timeframe: 26 weeks
| Intervention | scores on a scale (Mean) | |||
|---|---|---|---|---|
| SRT CLTR Baseline | SRT CLTR Post-Open Label | 7-24 Total Learning Baseline | 7-24 Total Learning Post-Open Label | |
| Memantine | 32.67 | 40.33 | 30.33 | 31.67 |
| Sugar Pill | 22.71 | 40.29 | 28.14 | 32.43 |
Change scores from pre- to post-treatment/placebo were calculated for the primary outcome measures, the Selective Reminding Test Continuous Long-Term Retrieval (range 0-72; higher scores indicate better memory) and 7-24 Spatial Recall Test Total Learning (range 0-35; total correct across 5 learning trials are summed, with higher scores indicating better memory) scores. These measures are scores on a scale, rather than representing standard units. (NCT01054599)
Timeframe: 13 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| 7-24 Spatial Recall Tests Learning Change Score | SRT Continuous Long-Term Retrieval Change Score | |
| Memantine | 1.00 | 4.38 |
| Sugar Pill | 1.78 | 8.11 |
NPI:12-domain caregiver assessment of behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, appetite/eating, nighttime behavior. A screening question is asked about each sub-domain. If the responses to these questions indicate that the patient has problems with a particular sub-domain of behavior, the caregiver is only then asked all the questions about that domain, rating the frequency of the symptoms on a 4-point scale, their severity on a 3-point scale, and the distress the symptom causes them on a 5-point scale. Severity(1=Mild to 3=Severe),frequency(1=occasionally to 4=very frequently) scales recorded for each domain; frequency*severity=each domain score(range 0-12). Total score=sum of each domain score(range 0-144);higher score=greater behavioral disturbances;negative change score from baseline=improvement. (NCT00545974)
Timeframe: Baseline, 26 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Memantine | -1.9 |
| Placebo | 0.3 |
The scale is rated on a 7-point scale, using a range of responses from 1 (very much improved) through 7 (very much worse). The clinician compares the participant's current condition to the condition at admission to the project. (NCT00545974)
Timeframe: 26 Weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Memantine | 4.4 |
| Placebo | 4.8 |
(NCT00545974)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Memantine | 1 |
| Placebo | 2 |
"Clinical dementia rating sum of boxes CDR-SB (0-18) high scores indicate high impairment.~Functional activities questionnaire FAQ (0-30) high scores indicate high impairment.~Texas functional living scale TFLS (0 to 52) high scores suggest better instrumental activities of daily living functioning.~Mini-Mental State Examination MMSE (0-30) low scores indicate low cognition. The executive interview EXIT25 (0 to 50) high scores indicate more executive impairment.~A modified unified Parkinson's disease rating scale UPDRS (0-199) high scores indicate worse disability.~Boston naming test (0-15) low scores indicate more retrieval difficulties." (NCT00545974)
Timeframe: Baseline and 26 Weeks
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| CDR-SB | FAQ | TFLS | MMSE | EXIT25 | UPDRS | Boston naming test | |
| Memantine | 1.5 | 4.3 | -3.7 | -1.2 | 1.9 | 1.7 | -1.4 |
| Placebo | 1.5 | 2.9 | -2.8 | -0.9 | 0.7 | 1.4 | 0.7 |
"Letter fluency, score is number of words recalled starting with a specified letter for 60 seconds. There are 3 trials, with 3 different letters. The total number of correct responses is totaled for all 3 trials for the score. Low scores indicate high impairment~Category fluency, score is number of items generated belonging to a specific category (such as animals) in 60 seconds, low scores indicate high impairment.~Digit symbol, score is number of symbols that correctly corresponded to the random numerals entered in the form in 90 seconds. Participants are given a table of numerals with matching symbols, and a form with random numerals with open spaces. Low scores indicate high impairment.~Digits backwards, score is number of digits backwards recalled (range: 0-14), The participant hears a list of digits and is asked to repeat the digits backwards. Low scores indicate high impairment." (NCT00545974)
Timeframe: Baseline and 26 Weeks
| Intervention | number of items recalled (Mean) | |||
|---|---|---|---|---|
| Letter fluency | Category fluency | Digit symbol | Digits backwards | |
| Memantine | -0.1 | -0.5 | -3.9 | 0.1 |
| Placebo | -0.3 | -0.7 | 4.2 | -0.2 |
283 reviews available for memantine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Multi-target design strategies for the improved treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Chelating Agents; Clinical Trials as Topic; Enzyme Inhibitors; Humans; N | 2019 |
Alzheimer's Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Indans; | 2022 |
Digging Deeper: Advancements in Visualization of Inhibitory Synapses in Neurodegenerative Disorders.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Brain; Humans; Huntington Disease; Levodo | 2021 |
Cholinesterase inhibitors and memantine for the treatment of Alzheimer and non-Alzheimer dementias.
Topics: Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Humans; Memantine; Quality of Life | 2021 |
Comparative Efficacy and Acceptability of Cholinesterase Inhibitors and Memantine Based on Dosage in Patients with Vascular Cognitive Impairment: A Network Meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Galantamine; Humans; | 2022 |
Challenges and Approaches of Drugs Such as Memantine, Donepezil, Rivastigmine, and Aducanumab in the Treatment, Control and Management of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Antibodies, Monoclonal, Humanized; Donepezil; Indans; Memantine; Patents | 2022 |
Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis.
Topics: Adult; Alzheimer Disease; Donepezil; Galantamine; Humans; Memantine; Network Meta-Analysis; Nootropi | 2022 |
The Role of the Microbiota-Gut-Brain Axis in the Development of Alzheimer's Disease.
Topics: Alzheimer Disease; Brain-Gut Axis; Cholinergic Agents; Humans; Memantine; Microbiota; Quality of Lif | 2022 |
Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Human | 2021 |
Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews.
Topics: Alzheimer Disease; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti- | 2022 |
Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Donepezil; Humans; Memantine; Patient-Centered Ca | 2022 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer's Disease.
Topics: Alzheimer Disease; Humans; Memantine; N-Methylaspartate; Neurodegenerative Diseases; Receptors, N-Me | 2023 |
NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer's Disease.
Topics: Alzheimer Disease; Humans; Memantine; N-Methylaspartate; Neurodegenerative Diseases; Receptors, N-Me | 2023 |
NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer's Disease.
Topics: Alzheimer Disease; Humans; Memantine; N-Methylaspartate; Neurodegenerative Diseases; Receptors, N-Me | 2023 |
NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer's Disease.
Topics: Alzheimer Disease; Humans; Memantine; N-Methylaspartate; Neurodegenerative Diseases; Receptors, N-Me | 2023 |
Clinical Indications of Memantine in Psychiatry-Science or Art?
Topics: Alzheimer Disease; Autism Spectrum Disorder; Humans; Memantine; Off-Label Use; Psychiatry | 2023 |
Esmethadone-HCl (REL-1017): a promising rapid antidepressant.
Topics: Alzheimer Disease; Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagoni | 2023 |
[Anti-Dementia Drugs (Anti-Alzheimer's Disease Drugs)].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Memantine; Receptors, | 2023 |
Insights into role of microRNA in Alzheimer's disease: From contemporary research to bedside perspective.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Humans; Memantine; MicroRNAs; tau Pr | 2023 |
Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Amyloid beta-Peptides; Antibodies, Monoclonal; Humans | 2023 |
The chemistry toolbox of multitarget-directed ligands for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Chemistry Techniques, Synthetic; Donepezil; Dopamine Agents; Drug Design | 2019 |
Study of the strength of the evidence and the redundancy of the research on pharmacological treatment for Alzheimer's disease: a cumulative meta-analysis and trial sequential analysis.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Evidence-Based | 2019 |
NMDA Receptor Antagonists: Repositioning of Memantine as a Multitargeting Agent for Alzheimer's Therapy.
Topics: Alzheimer Disease; Drug Repositioning; Humans; Memantine; Receptors, N-Methyl-D-Aspartate | 2019 |
Diagnosis and Management of Dementia: Review.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Excitatory Amino Acid Antagonists; Humans; M | 2019 |
Excitotoxicity as a Target Against Neurodegenerative Processes.
Topics: Alzheimer Disease; Glutamic Acid; Humans; Memantine; Neurons | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Combination Drug Therapy for the Management of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Biomarkers; Cholinesterase Inhibitors; Clinical Trials as Topic; Disease | 2020 |
Transdermal Drug Delivery Systems and their Potential in Alzheimer's Disease Management.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Delivery Systems; Humans; Memantine; R | 2020 |
Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Drug Therapy, Combination; Excitatory Amino Acid Antag | 2020 |
Therapeutic potentials of neural stem cells in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cell Differentiation; Cholinesterase Inhibitors; Humans; Memantine; Neural | 2020 |
Memantine Derivatives as Multitarget Agents in Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Cholinesterase Inhibitors; Drug Design; Humans; Memantine; | 2020 |
Memantine, Donepezil, or Combination Therapy-What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis.
Topics: Alzheimer Disease; China; Donepezil; Humans; Memantine; Network Meta-Analysis | 2020 |
Topics: Alzheimer Disease; Animals; Cognitive Dysfunction; Crocus; Donepezil; Humans; Memantine | 2021 |
Memantine in neurological disorders - schizophrenia and depression.
Topics: Alzheimer Disease; Antidepressive Agents; Antipsychotic Agents; Clinical Trials as Topic; Depression | 2021 |
[Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Excitatory Amino Acid Antagonists; Humans; Meman | 2017 |
Alzheimer Disease: Monotherapy vs. Combination Therapy.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Drug Therapy, Combination; | 2017 |
An Overview of New Possible Treatments of Alzheimer's Disease, Based on Natural Products and Semi-Synthetic Compounds.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Apolipoproteins E; Biological Products; Cholinesterase Inh | 2017 |
Classics in Chemical Neuroscience: Memantine.
Topics: Alzheimer Disease; Animals; Excitatory Amino Acid Antagonists; Humans; Memantine; Molecular Structur | 2017 |
Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis.
Topics: Alzheimer Disease; Donepezil; Drug Therapy, Combination; Humans; Indans; Memantine; Nootropic Agents | 2017 |
AChE Inhibitors and NMDA Receptor Antagonists in Advanced Alzheimer's Disease.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; | 2017 |
Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis.
Topics: Alzheimer Disease; Excitatory Amino Acid Antagonists; Humans; Memantine | 2017 |
[Treatment of dementia].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia, Vascular; Humans; Memantine | 2017 |
Recent Progress in the Pharmacotherapy of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cholinesterase Inhibitors; Excitatory Amino Ac | 2017 |
Comparisons between traditional medicines and pharmacotherapies for Alzheimer disease: A systematic review and meta-analysis of cognitive outcomes.
Topics: Alzheimer Disease; Asia, Eastern; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Huma | 2018 |
Memantine for the Treatment of Dementia: A Review on its Current and Future Applications.
Topics: Alzheimer Disease; Animals; Humans; Memantine; Neuroprotective Agents | 2018 |
Studies on the interaction of NMDA receptor antagonist memantine with cell membranes: A mini-review.
Topics: Alzheimer Disease; Cell Membrane; Erythrocytes; Humans; Memantine; Microscopy, Electron, Scanning; R | 2018 |
Memantine in Japanese patients with moderate to severe Alzheimer's disease: meta-analysis of multiple-index responder analyses.
Topics: Alzheimer Disease; Asian People; Databases, Factual; Excitatory Amino Acid Antagonists; Humans; Japa | 2018 |
Monotherapy Is Good Enough for Patients with Mild-to-Moderate Alzheimer's Disease: A Network Meta-analysis of 76 Randomized Controlled Trials.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dopamine Agents; Humans; Memantine; Network Meta-Analy | 2019 |
A Systematic Review and Meta-Analysis of the Effectiveness of Acetylcholinesterase Inhibitors and Memantine in Treating the Cognitive Symptoms of Dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Dopamine Agents; Humans | 2018 |
Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer's disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Dopamine Agents; Double-Blind Method; Forecasti | 2018 |
Memantine for the treatment of ischemic stroke: experimental benefits and clinical lack of studies.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Humans; Memantine; Stroke; Tissue Plasminogen Activator; | 2019 |
The efficacy and safety of memantine for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Drug Therapy, Combination; Excit | 2018 |
An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combina | 2018 |
Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients.
Topics: Alzheimer Disease; China; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Humans; Meman | 2018 |
Identification of the optimal cognitive drugs among Alzheimer's disease: a Bayesian meta-analytic review.
Topics: Alzheimer Disease; Antiparkinson Agents; Bayes Theorem; Cholinesterase Inhibitors; Cognition; Donepe | 2018 |
Chromones: privileged scaffolds for the production of multi-target-directed-ligand agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Chromones; Drug Development; Excitatory Amino | 2018 |
Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Female; Humans; Male; Memantine; Network Meta-Analysis | 2018 |
Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Dopami | 2018 |
Memantine for dementia.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Akathisia, Drug-Induced; Alzheimer Disease; Cog | 2019 |
[Drug treatment of Alzheimer's dementia : Status quo and perspectives].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Memantine; Neurodegenerative Diseases | 2019 |
Diagnosis and treatment of cognitive impairment.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Dementia; Humans; Memanti | 2019 |
Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis.
Topics: Activities of Daily Living; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Cogn | 2019 |
Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
Topics: Aging; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Excitatory Amino Acid Antagonists; G | 2013 |
A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Behavior; Cholinesterase Inhibitors; Cognition; Data Interpretation, Statis | 2013 |
[Cholesterol inhibitor and memantine in symptomatic dementia therapy].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cooperative Behavior; Dementi | 2013 |
Aspects of communication in Alzheimer's disease: clinical features and treatment options.
Topics: Alzheimer Disease; Antiparkinson Agents; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; | 2013 |
Alzheimer disease pharmacologic treatment and treatment research.
Topics: Alzheimer Disease; Antipsychotic Agents; Biomedical Research; Cholinesterase Inhibitors; Drug Approv | 2013 |
Effectiveness and safety of memantine treatment for Alzheimer's disease.
Topics: Alzheimer Disease; Cognition; Excitatory Amino Acid Antagonists; Humans; Memantine; Treatment Outcom | 2013 |
Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Drug Therapy, Combination; Excitatory | 2013 |
[Effectiveness and limitation of newly approved drugs for Alzheimer's disease].
Topics: Alzheimer Disease; Clinical Trials as Topic; Galantamine; Humans; Japan; Memantine; Phenylcarbamates | 2013 |
Synthesis and comparison of the meta-analyses evaluating the efficacy of memantine in moderate to severe stages of Alzheimer's disease.
Topics: Alzheimer Disease; Clinical Trials as Topic; Excitatory Amino Acid Antagonists; Humans; Memantine; M | 2013 |
Memantine hydrochloride in the treatment of dementia subtypes.
Topics: Alzheimer Disease; Dementia; Excitatory Amino Acid Antagonists; Humans; Memantine; Parkinson Disease | 2013 |
Drugs for cognitive loss and dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Cogniti | 2013 |
Memantine in patients with moderate to severe Alzheimer's disease: meta-analyses using realistic definitions of response.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Diagnostic and Statistical Manual of Mental D | 2014 |
Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer's disease: a review of clinical trials.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Female; Humans; Indans; Male; Memantine; Pipe | 2013 |
Disease-modifying drugs in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Disease Progression; D | 2013 |
New treatment strategies for Alzheimer's disease: is there a hope?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cognitive Dysfunction; Dementia | 2013 |
[Pharmacological and non-pharmacological treatment of Alzheimer's dementia].
Topics: Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Combined Modality Therapy; Disea | 2013 |
Reciprocal disruption of neuronal signaling and Aβ production mediated by extrasynaptic NMDA receptors: a downward spiral.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Calcium Signaling; C | 2014 |
Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014.
Topics: Alzheimer Disease; Biomarkers; Cholinesterase Inhibitors; Dopamine Agents; Drug Monitoring; Humans; | 2014 |
Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Noo | 2014 |
Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Excitatory Amino Acid Antagonists; Glutamic Acid; | 2014 |
Changes in gait variability with anti-dementia drugs: a systematic review and meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Gait; Galantamine | 2014 |
Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Disease Progression | 2014 |
[Vitamin D and Alzheimer's disease: from an intriguing idea to a therapeutic option].
Topics: Acetylcholine; Alzheimer Disease; Amyloid; Animals; Anti-Inflammatory Agents; Antioxidants; Atrophy; | 2014 |
[Progress of dementia medicine: Special reference to Alzheimer's disease].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Brain; Cholinesterase Inhibitors; Donepezil; D | 2014 |
[Proposal of endogenous anticholinergic hypothesis in Alzheimer disease].
Topics: Acetylcholine; Alzheimer Disease; Animals; Cholinergic Antagonists; Humans; Memantine; Receptors, N- | 2013 |
[Pharmacological treatment of behavioral symptoms in dementia patients].
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents; | 2014 |
Improving the predictive value of interventional animal models data.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Data Mining; Databases, Factual; Disease Mode | 2015 |
Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Cholin | 2014 |
A review on Alzheimer's disease pathophysiology and its management: an update.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Drugs, Investigational; Humans; | 2015 |
EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Drug Therapy, Combination; Excitatory Amino Acid Antag | 2015 |
Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis.
Topics: Activities of Daily Living; Alzheimer Disease; Humans; Memantine; Publication Bias; Randomized Contr | 2015 |
Efficacy and adverse effects of memantine treatment for Alzheimer's disease from randomized controlled trials.
Topics: Alzheimer Disease; Humans; Memantine; Nootropic Agents; Randomized Controlled Trials as Topic | 2015 |
Memantine extended release (28 mg once daily): a review of its use in Alzheimer's disease.
Topics: Alzheimer Disease; Delayed-Action Preparations; Drug Therapy, Combination; Excitatory Amino Acid Ant | 2015 |
Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Donepezil; Galant | 2015 |
Hypothesis of Endogenous Anticholinergic Activity in Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Cholinergic Antagonists; Cholinesterase Inhibitors; D | 2015 |
Namzaric--a combination of 2 old drugs for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Drug Com | 2015 |
Time to Treatment Initiation in People With Alzheimer Disease: A Meta-Analysis of Randomized Controlled Trials.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavior Control; Cholinesterase Inhibitors; Dopamine Ag | 2016 |
Potential drug-drug interactions in Alzheimer patients with behavioral symptoms.
Topics: Aged; Alzheimer Disease; Anti-Arrhythmia Agents; Antidepressive Agents; Antipsychotic Agents; Benzod | 2015 |
Benefits and risks of add-on therapies for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Drug Therapy, Combination; Excitatory Amino Acid Antag | 2015 |
Memantine ER/Donepezil: A Review in Alzheimer's Disease.
Topics: Alzheimer Disease; Clinical Trials, Phase III as Topic; Drug Combinations; Humans; Memantine; Nootro | 2015 |
Memantine and Kynurenic Acid: Current Neuropharmacological Aspects.
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Kynurenic Acid; Memant | 2016 |
Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Cognitive Behavioral Th | 2016 |
Pharmacotherpy and Alzheimer's Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach.
Topics: Alzheimer Disease; Animals; Benzhydryl Compounds; Cognitive Dysfunction; Humans; Melatonin; Memantin | 2016 |
Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews.
Topics: Activities of Daily Living; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Complementary | 2016 |
Memantine and donepezil: a fixed drug combination for the treatment of moderate to severe Alzheimer's dementia.
Topics: Alzheimer Disease; Donepezil; Drug Therapy, Combination; Humans; Indans; Memantine; Piperidines; Pra | 2016 |
Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Humans; Indans; Memantine; Piper | 2016 |
Symptomatic treatments in Alzheimer's disease in 2016: a study from Memory centers in France.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; D | 2016 |
Pharmacological treatments of behavioral and psychological symptoms of dementia in Alzheimer's disease: role of acetylcholinesterase inhibitors and memantine.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Humans; Memantine; | 2016 |
A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease.
Topics: Adolescent; Adult; Alzheimer Disease; Biological Availability; Cholinesterase Inhibitors; Cognition; | 2016 |
[Memantine as add-on medication to acetylcholinesterase inhibitor therapy for Alzheimer dementia].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Drug Administration Schedule; Drug Monitoring; Drug Th | 2017 |
Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Aspartic Ac | 2016 |
Cholinesterase inhibitors and non-steroidal anti-inflammatory drugs as Alzheimer's disease therapies: an updated umbrella review of systematic reviews and meta-analyses.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inhibitors; Humans; Meman | 2016 |
Management of Depression in Patients with Dementia: Is Pharmacological Treatment Justified?
Topics: Alzheimer Disease; Antidepressive Agents; Antipsychotic Agents; Cholinesterase Inhibitors; Dementia; | 2017 |
Update on Alzheimer's Disease Therapy and Prevention Strategies.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Excitatory Amin | 2017 |
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Combined Modality Therapy; Dementia; Humans; Memantine | 2017 |
Pharmacological Therapy for Apathy in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Topics: Alzheimer Disease; Apathy; Central Nervous System Stimulants; Cholinesterase Inhibitors; Clinical Tr | 2017 |
Alzheimer's disease in the zebrafish: where can we take it?
Topics: Alzheimer Disease; Animals; Dementia; Disease Models, Animal; Donepezil; Humans; Indans; Memantine; | 2017 |
Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Double-Blind Method; Excitatory Amino Acid Antagonists | 2008 |
Behavioral effects of current Alzheimer's disease treatments: a descriptive review.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Excitatory Amino Acid Antago | 2008 |
Pharmacological treatment in moderate-to-severe Alzheimer's disease.
Topics: Alzheimer Disease; Donepezil; Double-Blind Method; Humans; Indans; Memantine; Phenylcarbamates; Pipe | 2008 |
[Therapy of Alzheimer's disease: current status and future development].
Topics: Alzheimer Disease; Alzheimer Vaccines; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; | 2008 |
Cholinesterase inhibitors and memantine: best practices.
Topics: Aging; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Memantine; Practice Patterns, Physician | 2008 |
Three-year follow-up of a patient with early-onset Alzheimer's disease with presenilin-2 N141I mutation - case report and review of the literature.
Topics: Age of Onset; Alzheimer Disease; Cholinesterase Inhibitors; Codon; Donepezil; Electrophysiology; Exc | 2008 |
Memantine for dementia in people with Down syndrome.
Topics: Alzheimer Disease; Down Syndrome; Humans; Memantine; Receptors, N-Methyl-D-Aspartate | 2009 |
Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Behavior; Excitatory Amino Acid Antagonists; Female; Humans; Male; Memantin | 2009 |
Discontinuing Alzheimer's disease drug therapy: why, when, and how.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Approval; Drug Monitoring; Excitatory | 2008 |
Treatment of Alzheimer's disease in the long-term-care setting.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Galantamine; Humans; Indan | 2009 |
[Antidementia drugs].
Topics: Aged; Alzheimer Disease; Amyloidosis; Cholinesterase Inhibitors; Dementia; Dementia, Vascular; Dose- | 2009 |
Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions.
Topics: Aged; Aggression; Alzheimer Disease; Anticonvulsants; Antidepressive Agents, Second-Generation; Anti | 2009 |
[Therapy of Alzheimer disease].
Topics: Alzheimer Disease; Alzheimer Vaccines; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; | 2009 |
Memantine: a review of its use in moderate to severe Alzheimer's disease.
Topics: Alzheimer Disease; Clinical Trials as Topic; Humans; Memantine; Severity of Illness Index | 2009 |
Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias.
Topics: Alzheimer Disease; Dementia; Dopamine Agents; Humans; Memantine; Severity of Illness Index; Treatmen | 2009 |
A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors.
Topics: Aged; Akathisia, Drug-Induced; Alzheimer Disease; Cholinesterase Inhibitors; Dizziness; Drug Interac | 2010 |
The dysregulation of intracellular calcium in Alzheimer disease.
Topics: Alzheimer Disease; Amyloid; Animals; Apoptosis; Calcium; Calcium Channels; Calcium Signaling; Electr | 2010 |
[Anti-dementia drugs for dementia syndromes--just unkept promises?].
Topics: Alzheimer Disease; Clinical Trials as Topic; Dopamine Agents; Galantamine; Ginkgo biloba; Humans; Me | 2006 |
Combination treatments in Alzheimer's disease: risks and benefits.
Topics: Alzheimer Disease; Animals; Antioxidants; Cholinesterase Inhibitors; Clinical Trials as Topic; Cogni | 2010 |
Clinical practice. Early Alzheimer's disease.
Topics: Age of Onset; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Diagnosis, Differential; Disease P | 2010 |
[Drug therapy for Alzheimer's disease].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase In | 2010 |
Current treatments for patients with Alzheimer disease.
Topics: Aggression; Alzheimer Disease; Behavior Therapy; Cholinesterase Inhibitors; Depression; Excitatory A | 2010 |
Modern care for patients with Alzheimer disease: rationale for early intervention.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cognition; Donepezil; Excitator | 2010 |
Late onset Alzheimer's disease in older people.
Topics: Age Factors; Age of Onset; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Hu | 2010 |
[Memantine: the value of combined therapy].
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Drug Therapy, Combination; | 2011 |
Alzheimer's disease and age-related memory decline (preclinical).
Topics: Aging; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Histamine H3 A | 2011 |
Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Continuity of Patient Care; Donep | 2011 |
Memantine in dementia: a review of the current evidence.
Topics: Alzheimer Disease; Economics, Pharmaceutical; Excitatory Amino Acid Antagonists; Humans; Memantine; | 2011 |
[Daily functioning in dementia: pharmacological and non-pharmacological interventions demonstrate small effects on heterogeneous scales].
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Angiotensin-Converting Enzyme Inhibitors; Careg | 2011 |
Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
Topics: Alzheimer Disease; Cognition Disorders; Evidence-Based Medicine; Excitatory Amino Acid Antagonists; | 2011 |
Combination therapy for Alzheimer's disease.
Topics: Alzheimer Disease; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Memantine; Time Fact | 2011 |
Dementia.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inhibitors; Dementia; Gal | 2010 |
Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dopamine Agents; Frontotemporal Dementia; Humans; Mema | 2011 |
Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Brain; Cholinesterase Inhibitors; Cognition; Donepezil; Ga | 2011 |
[Newly approved drugs for Alzheimer disease: effectiveness and limitation].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans; Memantine; Phenylcarbamates; Rece | 2011 |
New drugs for Alzheimer's disease in Japan.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Discovery; Excitatory Amino Acid Antag | 2011 |
N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.
Topics: Alzheimer Disease; Animals; Dementia, Vascular; Humans; Memantine; Neuroprotective Agents; Parkinson | 2012 |
Use of memantine for the treatment of dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Dopamine Agents; Humans; Indans; | 2011 |
A review of the effects of memantine on clinical progression in Alzheimer's disease.
Topics: Activities of Daily Living; Alzheimer Disease; Clinical Trials as Topic; Cognition; Communication; D | 2012 |
Pharmacological treatment of Alzheimer disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Galantamine; Humans; I | 2011 |
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.
Topics: Alzheimer Disease; Clinical Trials as Topic; Donepezil; Drug Discovery; Excitatory Amino Acid Antago | 2012 |
Management of moderate to severe Alzheimer's disease: focus on memantine.
Topics: Alzheimer Disease; Dopamine Agents; Excitatory Amino Acid Antagonists; Humans; Memantine; Receptors, | 2011 |
Effective pharmacological management of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dementia; Disease Progression; Donepezil; G | 2011 |
The costs of Alzheimer's disease and the value of effective therapies.
Topics: Age Factors; Aging; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Ga | 2011 |
Possibility of a new anti-alzheimer's disease pharmaceutical composition combining memantine and vitamin D.
Topics: Alzheimer Disease; Animals; Drug Combinations; Glutamic Acid; Humans; Memantine; Neuroprotective Age | 2012 |
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
Topics: Alkaloids; Alzheimer Disease; Amino Acids; Animals; Cholinesterase Inhibitors; Dietary Supplements; | 2012 |
Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.
Topics: Alzheimer Disease; Cost-Benefit Analysis; Donepezil; Dopamine Agents; Drug Costs; Economics, Pharmac | 2012 |
[Intended pharmacotherapeutical approaches of Alzheimer's disease therapy].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Memantine; N-Methylaspartate | 2012 |
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; | 2012 |
Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Dopamine Agents; Glutamic Acid; Humans; Memantine; Recepto | 2012 |
Alzheimer's disease: early diagnosis and treatment.
Topics: Alzheimer Disease; Antioxidants; Antipsychotic Agents; Cholinesterase Inhibitors; Dopamine Agents; H | 2012 |
Pharmacological prevention and treatment of vascular dementia: approaches and perspectives.
Topics: Alzheimer Disease; Antihypertensive Agents; Aspirin; Cholinesterase Inhibitors; Cognition; Dementia, | 2012 |
Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Excitatory Amino Acid Antagonists; Glutami | 2013 |
Pharmacological treatment of dementia.
Topics: Alzheimer Disease; Antidepressive Agents; Antipsychotic Agents; Cholinesterase Inhibitors; Dementia; | 2012 |
Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer's disease patients.
Topics: Alpha Rhythm; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cognition; Electroencephalograp | 2013 |
Effectiveness of antidementia drugs in delaying Alzheimer's disease progression.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Dopamine Agents; Evidence-B | 2013 |
Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Drug Therapy, Combin | 2013 |
Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Evidence-Based Medicine; Humans | 2013 |
[Assessment of benefits of drug therapies: memantine for Alzheimer's disease as an example].
Topics: Alzheimer Disease; Clinical Trials as Topic; Excitatory Amino Acid Antagonists; Humans; Memantine; M | 2012 |
Once-daily memantine: a guide to its use in moderate to severe Alzheimer's disease in the EU.
Topics: Alzheimer Disease; Cost-Benefit Analysis; Drug Administration Schedule; European Union; Humans; Mema | 2013 |
Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Humans; Memantine; Neuroprotective Agents; Re | 2012 |
Immunotherapy against amyloid pathology in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Excitatory Amino Acid Antagonis | 2013 |
Non-cholinergic strategies for treating and preventing Alzheimer's disease.
Topics: Alzheimer Disease; Amino Acids; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroi | 2002 |
Glutamate receptors as a target for Alzheimer's disease--are clinical results supporting the hope?
Topics: Aged; Alzheimer Disease; Excitatory Amino Acid Antagonists; Humans; Memantine; Receptors, Glutamate | 2002 |
[Anti-dementia drugs for Alzheimer disease in present and future].
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Carbamates; Cholinesterase Inhibitors; Done | 2002 |
Memantine for dementia.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Dementi | 2003 |
Alzheimer's disease: emerging noncholinergic treatments.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cholinesterase Inhib | 2003 |
Memantine.
Topics: Alzheimer Disease; Animals; Clinical Trials as Topic; Dementia; Humans; Memantine; Receptors, N-Meth | 2003 |
[Memantine].
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Brain; Glutamic Acid; Humans; Memantine | 2003 |
The glutamatergic system and Alzheimer's disease: therapeutic implications.
Topics: Alzheimer Disease; Cell Death; Excitatory Amino Acid Agents; Glutamic Acid; Humans; Learning; Memant | 2003 |
Memantine for dementia.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Dementi | 2003 |
The search for better noncholinergic treatment options for Alzheimer's disease.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Dizocilpine Maleat | 2003 |
The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence.
Topics: Aged; Alzheimer Disease; Drug Evaluation, Preclinical; Excitatory Amino Acid Antagonists; Humans; Me | 2003 |
Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer's disease?
Topics: Alzheimer Disease; Clinical Trials as Topic; Humans; Memantine; Receptors, N-Methyl-D-Aspartate; Sev | 2003 |
The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Electrophysiology; Excitatory Amino Acid Antagonists; Humans; Memantine; | 2003 |
Alzheimer's disease and the glutamate NMDA receptor.
Topics: Aged; Alzheimer Disease; Excitatory Amino Acid Antagonists; Humans; Memantine; Receptors, N-Methyl-D | 2003 |
[Current therapy of patients with dementia].
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Controlled Cli | 2003 |
Memantine for dementia?
Topics: Aged; Alzheimer Disease; Dementia; Excitatory Amino Acid Antagonists; Humans; Memantine; Nootropic A | 2003 |
[Dementia].
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; | 2003 |
[Mechanisms of action of Alzheimer medications].
Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Cognition; Donepezil; Excitatory | 2003 |
Evaluation of memantine for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Antiparkinson Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Me | 2003 |
NMDA-antagonism (memantine): an alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia.
Topics: Alzheimer Disease; Clinical Trials as Topic; Dementia, Vascular; Dose-Response Relationship, Drug; D | 2004 |
[Memantine (Ebixa), glutaminergic modulator].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Excitatory Amino Acid Antagonists; Glutamic | 2004 |
Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Down Syndrome; Galantamine; Hum | 2004 |
Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.
Topics: Activities of Daily Living; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Clinical Trial | 2004 |
What are the treatment options for patients with severe Alzheimer's disease?
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Galantamine; Hum | 2004 |
NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Excitatory Amino Acid | 2004 |
Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Brain; Caregivers; Cell Death; Cholinesteras | 2004 |
[Memantine: a therapeutic drug for Alzheimer's disease and the comparison with MK-801].
Topics: Alzheimer Disease; Binding Sites; Controlled Clinical Trials as Topic; Dizocilpine Maleate; Drug Des | 2004 |
The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Animals; Basal Ganglia Diseases; Bradycardia; Central Nervous System Diseas | 2004 |
The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cognition; Dopamine Agents; Humans; Memantine; | 2004 |
[Diagnosis and treatment of vascular dementia].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Dementi | 2004 |
Memantine: pharmacological properties and clinical uses.
Topics: Alzheimer Disease; Cost-Benefit Analysis; Dementia; Dementia, Vascular; Excitatory Amino Acid Antago | 2004 |
Memantine for dementia.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Dementi | 2004 |
Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
Topics: Alzheimer Disease; Animals; Clinical Trials as Topic; Humans; Memantine; Neurodegenerative Diseases; | 2005 |
[Role of magnesium ions on the regulation of NMDA receptor--a pharmacopathology of memantine].
Topics: Alzheimer Disease; Binding Sites; Brain Ischemia; Dizocilpine Maleate; Humans; Magnesium; Memantine; | 2004 |
Dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Donepezil; Galantamin | 2004 |
[New options for the pharmacotherapy of Alzheimer's disease after the registration of memantine?].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dopamine Agents; Drug Therapy, Combination; Humans; Me | 2005 |
Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.
Topics: Alzheimer Disease; Clinical Trials as Topic; Cost-Benefit Analysis; Costs and Cost Analysis; Economi | 2005 |
Is there a double standard when it comes to dementia care?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Europe; Humans; Memantine; Neuroprotective Agents; Qua | 2005 |
Memantine for dementia.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Dementi | 2005 |
Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Double-Blind Method; Excitatory Ami | 2005 |
Dementia.
Topics: Alzheimer Disease; Dementia; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Nootr | 2004 |
[Assessment of dementia and use of anti-dementia drugs in nursing homes].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Dopamine Agents; Humans; Memantine; Norway; | 2005 |
Efficacy and tolerability of memantine in the treatment of dementia.
Topics: Aged; Alzheimer Disease; Clinical Trials as Topic; Dementia, Vascular; Humans; Memantine; Receptors, | 2004 |
Combination drug therapy for Alzheimer's disease: what is evidence-based, and what is not?
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cholinesterase Inhibitors; | 2005 |
The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
Topics: Alzheimer Disease; Animals; Excitatory Amino Acid Antagonists; Humans; Memantine; Nervous System Dis | 2005 |
Measuring treatment response in Alzheimer's disease clinical trials.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Antiparkinson Agents; Clinical Trials as Topic; | 2005 |
Mild cognitive impairment and preclinical Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Aging; Alzheimer Disease; Antiparkinson Agents; | 2005 |
Refining treatment guidelines in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Clinical Trials as Topic; | 2005 |
Alzheimer's disease care management plan: maximizing patient care.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Management; Disease Progression; Excitatory Am | 2005 |
Pharmacologic treatment options in Alzheimer's disease: optimizing disease management.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Disease Manag | 2005 |
Memantine for dementia.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Dementi | 2005 |
[Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Excitatory Amino Acid Antagonists; Galantamine; | 2005 |
Drug therapy of dementia in elderly patients. A review.
Topics: Aged; Alzheimer Disease; Dementia; Donepezil; Galantamine; Humans; Indans; Memantine; Neuroprotectiv | 2005 |
Memantine: a therapeutic approach in treating Alzheimer's and vascular dementia.
Topics: Alzheimer Disease; Animals; Dementia, Vascular; Excitatory Amino Acid Antagonists; Glutamic Acid; Hu | 2005 |
[Efficacy of memantine in the treatment of Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dopamine Agents; Drug Therap | 2005 |
Mechanism of action of memantine.
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Ion Channel Gating; Ke | 2006 |
Treatment of Alzheimer's disease: current and future therapeutic approaches.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Cholinesterase Inhibitors; | 2004 |
The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cost-Benefit Analysis; Donepezil; Dopamine Agents; Evide | 2006 |
Alzheimer's treatment in nursing homes: room for improvement.
Topics: Activities of Daily Living; Aged; Algorithms; Alzheimer Disease; Cholinesterase Inhibitors; Clinical | 2006 |
A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Behavior; Clinical Trials as Topic; Cost-Benefit Analysis; Dopamine Agents; | 2006 |
Dementia.
Topics: Alzheimer Disease; Benzodiazepines; Dementia; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; | 2005 |
Memantine for dementia.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Dementi | 2006 |
Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
Topics: Acetylcholine; Alzheimer Disease; Calcium Channels; Cholinergic Fibers; Cognition Disorders; Excitat | 2006 |
Navigating patients and caregivers through the course of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Doub | 2006 |
Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Drug Synergi | 2006 |
Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
Topics: Acetylcholine; Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Drug Therapy, Combinati | 2006 |
Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Drug Synergism; D | 2006 |
Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: part I.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Alzheimer Disease; Brain; Dopamine Agents; Humans; Mema | 2006 |
Altered synaptic function in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Humans; Memantine; Mice; | 2006 |
Memantine: a review of its use in Alzheimer's disease.
Topics: Alzheimer Disease; Clinical Trials as Topic; Dopamine Agents; Humans; Memantine; Treatment Outcome | 2006 |
New pathways in drug discovery for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Drug Desig | 2006 |
Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine.
Topics: Alzheimer Disease; Animals; Brain; Cell Death; Excitatory Amino Acid Antagonists; Glutamic Acid; Hum | 2006 |
[Pharmacotherapy for Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Neu | 2006 |
Shedding light on Alzheimer's.
Topics: Aged; Alzheimer Disease; Causality; Cholinesterase Inhibitors; Excitatory Amino Acid Antagonists; Ge | 2006 |
From tau to toxicity: emerging roles of NMDA receptor in Alzheimer's disease.
Topics: Activation Analysis; Alzheimer Disease; Antiparkinson Agents; Humans; Memantine; Receptors, N-Methyl | 2006 |
Treatment of dementia: anything new?
Topics: Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Dementia; Dopamine Agents; Human | 2006 |
[Medical treatment of Alzheimer's disease].
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; | 2006 |
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Combined Modality Therapy; Consensus Development | 2006 |
Disease-modifying therapies in Alzheimer's disease: how far have we come?
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor | 2006 |
Added therapeutic value of memantine in the treatment of moderate to severe Alzheimer's disease.
Topics: Alzheimer Disease; Excitatory Amino Acid Antagonists; Humans; Memantine; Severity of Illness Index; | 2006 |
Memantine in the treatment of mild-to-moderate Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Calcium; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Huma | 2007 |
A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Memantine; Randomized | 2007 |
Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Men | 2007 |
Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.
Topics: Aged; Alzheimer Disease; Brain; Dopamine Agonists; Humans; Memantine; Randomized Controlled Trials a | 2007 |
Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
Topics: Adamantane; Alzheimer Disease; Animals; Dementia, Vascular; Humans; Memantine; Neuroprotective Agent | 2007 |
[Management of Alzheimer disease].
Topics: Aged; Alzheimer Disease; Animals; Antipsychotic Agents; Caregivers; Case Management; Cholinesterase | 2007 |
Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies.
Topics: Alzheimer Disease; Amyloid; Cholinesterase Inhibitors; Cognition; Combined Modality Therapy; Disease | 2007 |
Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Disability Evaluation; Disea | 2007 |
Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis.
Topics: Alzheimer Disease; Cost-Benefit Analysis; Disease Progression; Donepezil; Galantamine; Humans; Indan | 2007 |
[Alzheimer Disease].
Topics: Alzheimer Disease; Central Nervous System Agents; Humans; Memantine; Risk Factors; Vascular Diseases | 2007 |
Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.
Topics: Alzheimer Disease; Dose-Response Relationship, Drug; Excitatory Amino Acid Agents; Homeostasis; Huma | 2007 |
[Are anti-dementia drugs worthwhile?].
Topics: Activities of Daily Living; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Cost | 2007 |
Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis.
Topics: Aged; Alzheimer Disease; Behavioral Symptoms; Dementia; Excitatory Amino Acid Antagonists; Female; H | 2008 |
Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Behavioral Symptoms; Excitatory Am | 2008 |
Practical clinical use of therapeutic agents for Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Behavioral Symptoms; Cholinesterase Inhibitors; Cognition D | 2007 |
Glutamatergic approaches to the treatment of cognitive and behavioural symptoms of Alzheimer's disease.
Topics: Alzheimer Disease; Behavioral Symptoms; Cognition Disorders; Glutamic Acid; Humans; Memantine; Neuro | 2008 |
Pharmacologic management of Alzheimer disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Galantamine; Hum | 2008 |
The use of the hippocampal slice preparation in the study of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Excitatory Amino Acid Antagonists; Glycogen Synthase Kinase 3; Glycogen | 2008 |
Current and future therapy in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cholinesterase Inhi | 2008 |
[New therapeutic possibilities with low-affinity NMDA receptor antagonists].
Topics: Aged; Alzheimer Disease; Amantadine; Antiparkinson Agents; Excitatory Amino Acid Antagonists; Glutam | 1996 |
Evaluation of memantine for neuroprotection in dementia.
Topics: Alzheimer Disease; Animals; Dementia; Humans; Memantine; Neuroprotective Agents | 2000 |
Drugs for treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Anti-Inflammatory Agents; Antiparkinson Agents; Cholinesterase Inhibitors; Estrog | 2001 |
[Current strategies of pathogenetic therapy of Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Amino Acids; Aminoquinolines; Carbamates; Cholinesterase Inhibitors; Clinic | 2001 |
96 trials available for memantine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Impact of Donepezil and Memantine on Behavioral and Psychological Symptoms of Alzheimer Disease: Six-month Open-label Study.
Topics: Alzheimer Disease; Behavioral Symptoms; Donepezil; Humans; Indans; Memantine; Piperidines; Prospecti | 2021 |
Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.
Topics: Activities of Daily Living; Alzheimer Disease; Humans; Memantine; Thiazoles | 2023 |
Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Female; | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
[Efficacy and tolerance of Memantine monotherapy and combination therapy with Reinhartdt And Sea Cucumber Capsule on agitation in moderate to severe Alzheimer disease].
Topics: Alzheimer Disease; Animals; Humans; Memantine; Neuropsychological Tests; Psychomotor Agitation; Sea | 2017 |
Combined application of tenuigenin and β-asarone improved the efficacy of memantine in treating moderate-to-severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Allylbenzene Derivatives; Alzheimer Disease; Anisoles; Drug Therap | 2018 |
Effectiveness of Anti-Dementia Drugs in Extremely Severe Alzheimer's Disease: A 12-Week, Multicenter, Randomized, Single-Blind Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Female; Follow-Up Studies; Humans; Male; Mema | 2018 |
Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Donepezil; Dopamine Agents; Double-Blind M | 2019 |
A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antiparkinson Agents; Double-Blind Method; F | 2013 |
Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antioxidants; Double-Blind Method; Excitatory Amino Acid | 2014 |
The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.
Topics: Aged; Alzheimer Disease; Argentina; Cholinesterase Inhibitors; Delayed-Action Preparations; Dose-Res | 2013 |
Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Brain; Chi-Square Distribution; China; C | 2013 |
Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Cholinesterase Inhibitors; Dementia | 2014 |
Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Female; Follow-Up S | 2013 |
Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antioxidants; Caregivers; Ch | 2014 |
The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Brief Psychiatric Rating Scale; Ce | 2014 |
Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; C | 2014 |
Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Double-Blind Method; Europe; Excitatory Amino | 2014 |
Tolerability and efficacy of the long-term administration of memantine hydrochloride (Memary®) in patients with moderate to severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Drug Tolerance; Female; Humans; Long-Term Care; Male; Me | 2014 |
Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Delayed-Action Pre | 2014 |
Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Delayed-Action Pre | 2014 |
Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Delayed-Action Pre | 2014 |
Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Delayed-Action Pre | 2014 |
Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial.
Topics: Aged; Alzheimer Disease; Crocus; Double-Blind Method; Female; Humans; Iran; Male; Memantine; Phytoth | 2014 |
Role of the extended MAPT haplotype in the worsening of psychotic symptoms and treatment response in Alzheimer disease.
Topics: Aged; Alleles; Alzheimer Disease; Antipsychotic Agents; Delusions; Disease Progression; Excitatory A | 2014 |
Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease.
Topics: Aged; Alleles; Alzheimer Disease; Apolipoprotein E4; Butyrylcholinesterase; Female; Genetic Testing; | 2015 |
A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cross-Over Studies; Dose-Response | 2015 |
Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Case-Control Studies; Dopamine Age | 2015 |
A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer's disease: two phase I studies in healthy volunteers.
Topics: Adult; Alzheimer Disease; Biological Availability; Cross-Over Studies; Donepezil; Drug Therapy, Comb | 2015 |
The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients.
Topics: Alzheimer Disease; Behavioral Symptoms; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; E | 2015 |
Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Caregivers; Cholinesterase Inhibit | 2015 |
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Donepezil; Double-Blind Method; Female; Homes | 2015 |
[A comparison of the efficacy and safety of memantal and original memantine in the treatment of mild and moderate dementia in Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Cognition; Drugs, Generic; Female; Humans; Male; Memantine; Personality Inv | 2015 |
The effect of memantine on sleep architecture and psychiatric symptoms in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dose-Response Relationship, Drug; Female; Humans; Male; | 2016 |
Effects on agitation with rivastigmine patch monotherapy and combination therapy with memantine in mild to moderate Alzheimer's disease: a multicenter 24-week prospective randomized open-label study (the Korean EXelon Patch and combination with mEmantine
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Dose-Response Relationship, D | 2017 |
Anti-Dementia Drugs, Gait Performance and Mental Imagery of Gait: A Non-Randomized Open-Label Trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Female; Gait; | 2016 |
Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; C | 2017 |
Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Disability Evaluation; Double | 2016 |
Comprehensive, Individualized, Person-Centered Management of Community-Residing Persons with Moderate-to-Severe Alzheimer Disease: A Randomized Controlled Trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Case Management; | 2017 |
Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine.
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Biomarkers; Disease Progression; Double-Blind Method; | 2008 |
Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study.
Topics: Aged; Alzheimer Disease; Apolipoprotein E4; Cognition; Dementia; Excitatory Amino Acid Antagonists; | 2009 |
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.
Topics: Alzheimer Disease; Donepezil; Dopamine Agents; Evidence-Based Medicine; Humans; Indans; Memantine; N | 2009 |
Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Cholinesterase Inhibitors; Donepez | 2010 |
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Algorithms; Alzheimer Disease; Antiparkinson Age | 2010 |
[Memantine for treatment of behavioural disturbances and psychotic symptoms in moderate to moderately severe Alzheimer dementia: a naturalistic study in outpatient services in Austria].
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Ambulatory Care; Austria; Ca | 2010 |
[Memantine in the pharmacologic treatment of moderately severe to severe Alzheimer's disease in Spain (MEMORY study)].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dopamine Agents; Female; Humans; Memantine; Psychiatric | 2010 |
Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Diagnostic Im | 2011 |
Effect of memantine on resting state default mode network activity in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Memantine; Neurops | 2011 |
Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Communi | 2011 |
Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study.
Topics: Aggression; Alzheimer Disease; Caregivers; Dopamine Agents; Female; Humans; Long-Term Care; Male; Me | 2011 |
Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Drug Th | 2011 |
Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Cognition Disorders; D | 2011 |
Memantine and functional communication in Alzheimer's disease: results of a 12-week, international, randomized clinical trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Communication; Double-Blind | 2012 |
MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Mapping; Creatine; Double-Blind Met | 2011 |
Alzheimer's disease--input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholecalciferol; Clinical Protocols; Cognition; Double-Blind Method; Humans | 2011 |
Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Alzheimer Disease; Cognition; Dementia; Double-Blind Method; Down Syndrome; Female; Humans; M | 2012 |
Memantine in everyday clinical practice: a comparison of studies in Germany and Greece.
Topics: Activities of Daily Living; Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson A | 2011 |
Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Atrophy; Brain; Cholinesterase Inh | 2012 |
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Metho | 2012 |
Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; alpha-Tocopherol; Alzheimer Disease; Amyloid be | 2012 |
Tracking cognitive change over 24 weeks with longitudinal functional magnetic resonance imaging in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Brain Mapping; Cognition; Donepezil; Dopamine Agents; Female; Humans; Indan | 2012 |
Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open-label, single-arm, multicenter clinical study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Austria; Disability Evaluati | 2013 |
Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Female; Humans; Male; Memantine; Psychomotor A | 2012 |
Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Dose-Response Rel | 2012 |
A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI.
Topics: Aged; Alzheimer Disease; Amnesia; Cholinesterase Inhibitors; Cognition; Cognitive Dysfunction; Cohor | 2012 |
[Efficacy, safety and tolerability of a single dose of akatinol memantine in comparison to two-doses in patients with moderately expressed and moderately severe dementia in Alzheimer's disease].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dose-Response Relationship, Drug; Drug Administration Sc | 2012 |
Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Analysis of Variance; Apolipoproteins E; Donepezil; Dopamine Agents; Dose-R | 2012 |
Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Apolip | 2012 |
Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Caregivers; Cognition; Costs and Cost Analysis; | 2003 |
Memantine in moderate-to-severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavior; Cognition; Disease Progression; Excit | 2003 |
Memantine in moderate-to-severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavior; Cognition; Disease Progression; Excit | 2003 |
Memantine in moderate-to-severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavior; Cognition; Disease Progression; Excit | 2003 |
Memantine in moderate-to-severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavior; Cognition; Disease Progression; Excit | 2003 |
Memantine in moderate-to-severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavior; Cognition; Disease Progression; Excit | 2003 |
Memantine in moderate-to-severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavior; Cognition; Disease Progression; Excit | 2003 |
Memantine in moderate-to-severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavior; Cognition; Disease Progression; Excit | 2003 |
Memantine in moderate-to-severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavior; Cognition; Disease Progression; Excit | 2003 |
Memantine in moderate-to-severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavior; Cognition; Disease Progression; Excit | 2003 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine enhances autonomy in moderate to severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Double-Blind Method; Excitatory Amino Acid Anta | 2004 |
Memantine approved to treat moderate to severe Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; Mem | 2004 |
Memantine hydrochloride: pharmacological and clinical profile.
Topics: Alzheimer Disease; Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; | 2004 |
Memantine in vascular dementia.
Topics: Aged; Alzheimer Disease; Brain; Dementia, Vascular; Dopamine Agents; Humans; Magnetic Resonance Imag | 2003 |
Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study.
Topics: Adult; Alzheimer Disease; Diabetes Mellitus, Type 2; Drug Combinations; Drug Interactions; Female; G | 2005 |
A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Disease Progression; Double-Blind Method; Excitatory Ami | 2006 |
A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Disease Progression; Double-Blind Method; Excitatory Ami | 2006 |
A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Disease Progression; Double-Blind Method; Excitatory Ami | 2006 |
A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Disease Progression; Double-Blind Method; Excitatory Ami | 2006 |
Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.
Topics: Aged; Alzheimer Disease; Antiparasitic Agents; Cholinesterase Inhibitors; Drug Therapy, Combination; | 2006 |
A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine | 2006 |
Observations from a 14-week open-label trial with memantine suggest variable response on behavioral symptoms and cognition, depending on former treatment of AD.
Topics: Aged; Alzheimer Disease; Behavior; Caregivers; Cognition; Dopamine Agents; Humans; Memantine; Mental | 2006 |
[Clinical efficacy and safety of akatinol memantine in treatment of mild to moderate Alzheimer disease: a donepezil-controlled, randomized trial].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Excitatory Amino Acid Antagonists; Fe | 2006 |
Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Behavi | 2006 |
Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.
Topics: Aged; Alzheimer Disease; Cognition; Double-Blind Method; Drug-Related Side Effects and Adverse React | 2006 |
A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI).
Topics: Age Factors; Aged; Alzheimer Disease; Amnesia; Attention; Double-Blind Method; Excitatory Amino Acid | 2007 |
Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anxiety; Dopamine Agents; Double-Blind Method; Drug Admi | 2007 |
Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Double-Blind Method; Drug Therapy, | 2007 |
Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Attention; Cholinesterase Inhibitors; Cognition; Cogniti | 2007 |
Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Double-Blind Method; Excitatory Amino Acid Antagonists; | 2007 |
Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Donepez | 2007 |
Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; D | 2008 |
Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; D | 2008 |
Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
Topics: Aged; Aggression; Alzheimer Disease; Delusions; Dopamine Agents; Female; Hallucinations; Humans; Mal | 2008 |
Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.
Topics: Aged; Alzheimer Disease; Dopamine Agents; Double-Blind Method; Female; Follow-Up Studies; Humans; Ma | 2008 |
Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry.
Topics: Administration, Oral; Adult; Alzheimer Disease; China; Chromatography, Liquid; Dopamine Agents; Dose | 2008 |
A prospective PMS study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cognition; Excitatory Amino Acid Antagonists; F | 2000 |
Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Dementia, Vascular; Disabled Persons; Dopamine | 1999 |
Alzheimer's congress. Drug shows promise for advanced disease.
Topics: Alzheimer Disease; Disease Progression; Excitatory Amino Acid Antagonists; Humans; Memantine; Recept | 2000 |
[Akatinol memantin in Alzheimer's disease: clinico-immunological correlates].
Topics: Aged; Alzheimer Disease; Chronic Disease; Excitatory Amino Acid Antagonists; Female; Humans; Interle | 2000 |
Memantine in the treatment of senile dementia of the Alzheimer type.
Topics: Aged; Alzheimer Disease; Amantadine; Clinical Trials as Topic; Female; Humans; Male; Memantine; Rand | 1986 |
460 other studies available for memantine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid; Cholinesterase Inhibitors; Humans; Inhibitory Conc | 2008 |
Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
Topics: Alzheimer Disease; Butyrylcholinesterase; Carbolines; Cholinesterase Inhibitors; Excitatory Amino Ac | 2010 |
Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cell Proliferation; Cerebral Cortex; Cholinesteras | 2012 |
Identification of small molecule inhibitors of amyloid β-induced neuronal apoptosis acting through the imidazoline I(2) receptor.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Cells, Cultured; | 2012 |
Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Cells, Cultured; Cotinine; Humans; | 2014 |
New azepino[4,3-b]indole derivatives as nanomolar selective inhibitors of human butyrylcholinesterase showing protective effects against NMDA-induced neurotoxicity.
Topics: Alzheimer Disease; Azepines; Butyrylcholinesterase; Cell Line, Tumor; Cholinesterase Inhibitors; Hum | 2017 |
Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT
Topics: Administration, Oral; Alzheimer Disease; Animals; Drug Discovery; Humans; Indoles; Male; Piperazines | 2017 |
Substituent effect of N-benzylated gramine derivatives that prevent the PP2A inhibition and dissipate the neuronal Ca
Topics: Alkaloids; Alzheimer Disease; Calcium; Calcium Channel Blockers; Cell Line, Tumor; Humans; Indole Al | 2018 |
A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
Topics: Acetylcholinesterase; Adamantane; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitor | 2019 |
Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Behavior, Animal; Binding Sites; Ce | 2020 |
Evaluation of γ-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Carbolines; Cholinesterase Inhibitor | 2021 |
Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Caenorhabditis elegans; Disease Models, Animal; Memantine; Mice; Recepto | 2022 |
Rational Design of a Theranostic Agent Triggered by Endogenous Nitric Oxide in a Cellular Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Humans; Memantine; Nitric Oxide; Oxidative Stress; Precision Medicine | 2022 |
Spectroscopic, calorimetric and in silico insight into the molecular interactions of Memantine with human transferrin: Implications of Alzheimer's drugs.
Topics: Alzheimer Disease; Calorimetry; Computer Simulation; Fluorescence; Humans; Hydrogen Bonding; Memanti | 2021 |
Using Biomarkers to Predict Memantine Effects in Alzheimer's Disease: A Proposal and Proof-Of-Concept Demonstration.
Topics: Aged; Alzheimer Disease; Biomarkers; Cognition; Double-Blind Method; Excitatory Amino Acid Antagonis | 2021 |
The Effect of Oxidative Stress and Memantine-Incorporated Reactive Oxygen Species-Sensitive Nanoparticles on the Expression of
Topics: Alzheimer Disease; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; | 2021 |
Automated multi-dose dispensing in persons with and without Alzheimer's disease-impacts on pharmacotherapy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Female; Finland; | 2022 |
An Overview of Combination Treatment with Citicoline in Dementia.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cytidine Diphosphate Choli | 2022 |
Effects of Memantine and High Dose Vitamin D on Gait in Male APP/PS1 Alzheimer's Disease Mice Following Vitamin D Deprivation.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Gait Analysis; Male; Memantine; Mice; Mice, Tran | 2022 |
The listed, delisted, and sustainability of therapeutic medicines for dementia patients: the study is specific to South Korea.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Indans; Memantine; Phenylcarbamates; Piperidin | 2022 |
Bryostatin Placebo-Controlled Trials Indicate Cognitive Restoration Above Baseline for Advanced Alzheimer's Disease in the Absence of Memantine1.
Topics: Alzheimer Disease; Animals; Bryostatins; Clinical Trials, Phase II as Topic; Cognition; Controlled C | 2022 |
Racial/ethnic disparities in initiation and persistent use of anti-dementia medications.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Healthcare Disparities; Humans; | 2022 |
Pharmacotherapeutic combinations for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Drug Therapy, Combination; Huma | 2022 |
Insoluble Salt of Memantine with a Unique Fluorescence Phenomenon.
Topics: Alzheimer Disease; Humans; Memantine; Powders; Sodium Chloride; X-Ray Diffraction | 2022 |
Drug delivery of memantine with carbon dots for Alzheimer's disease: blood-brain barrier penetration and inhibition of tau aggregation.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Carbon; Memantine; Quantum Dots; tau Proteins; Zebr | 2022 |
APOE ε4 Carrier Status as Mediator of Effects of Psychotropic Drugs on Clinical Changes in Patients With Alzheimer's Disease.
Topics: Activities of Daily Living; Alzheimer Disease; Anticonvulsants; Apolipoprotein E4; Cholinesterase In | 2022 |
Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer's dementia using OMOP CDM.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Phe | 2022 |
Computational Modeling of Therapy with the NMDA Antagonist in Neurodegenerative Disease: Information Theory in the Mechanism of Action of Memantine.
Topics: Alzheimer Disease; Computer Simulation; Humans; Information Theory; Memantine; N-Methylaspartate; Ne | 2022 |
Long-term use of pharmacological treatment in Alzheimer's disease: a retrospective cohort study in real-world clinical practice.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Humans; Mem | 2022 |
Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer's Disease Predementia.
Topics: Alzheimer Disease; Animals; Humans; Memantine; Rats; Tauopathies | 2022 |
Antitumor effect of memantine is related to the formation of the splicing isoform of GLG1, a decoy FGF‑binding protein.
Topics: Alzheimer Disease; Carrier Proteins; Humans; Memantine; Protein Isoforms; Receptors, Fibroblast Grow | 2022 |
Propolis Promotes Memantine-Dependent Rescue of Cognitive Deficits in APP-KI Mice.
Topics: Adenosine Triphosphate; Alzheimer Disease; Animals; Calcium; Calcium-Calmodulin-Dependent Protein Ki | 2022 |
Hypoxic and Hypercapnic Responses in Transgenic Murine Model of Alzheimer's Disease Overexpressing Human AβPP: The Effects of Pretreatment with Memantine and Rivastigmine.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Disease Models, Animal; Humans; Hypercapnia; Hypox | 2022 |
NMDA receptor antagonists reduce amyloid-β deposition by modulating calpain-1 signaling and autophagy, rescuing cognitive impairment in 5XFAD mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Autophagy; Calpain; Cognitive Dysfunction; Female | 2022 |
Boron Nitride Nanoparticles Loaded with a Boron-Based Hybrid as a Promising Drug Carrier System for Alzheimer's Disease Treatment.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Boron; Boron | 2022 |
A novel multi-target strategy for Alzheimer's disease treatment via sublingual route: Donepezil/memantine/curcumin-loaded nanofibers.
Topics: Alzheimer Disease; Animals; Brain-Derived Neurotrophic Factor; Curcumin; Donepezil; Glycogen Synthas | 2022 |
Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Clozapine | 2022 |
Drugs for cognitive loss and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dementia; Humans; Indans; Memantine | 2022 |
Comparison table: Drugs for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Indans; Memantine | 2022 |
Neuronal network-based biomimetic chip for long-term detection of olfactory dysfunction model in early-stage Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomimetics; Biosensing Techniques; Dizocilpine Maleate; H | 2022 |
Neuroprotective effects of combined therapy with memantine, donepezil, and vitamin D in ovariectomized female mice subjected to dementia model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Donepezil; Female; Hippocampus; Interleukin-4; Me | 2023 |
Glial cell reactivity and oxidative stress prevention in Alzheimer's disease mice model by an optimized NMDA receptor antagonist.
Topics: Alzheimer Disease; Animals; Arginase; Brain-Derived Neurotrophic Factor; Calcineurin; Calcium; Chiti | 2022 |
Combination of Donepezil and Memantine Attenuated Cognitive Impairment Induced by Mixed Endocrine-Disrupting Chemicals: an In Silico Study.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Humans; Indans; Mema | 2022 |
A Preliminary Pharmacodynamic Study for the Management of Alzheimer's Disease Using Memantine-Loaded PLGA Nanoparticles.
Topics: Aged; Alzheimer Disease; Brain; Drug Carriers; Humans; Memantine; Nanoparticles; Particle Size | 2022 |
A Preliminary Pharmacodynamic Study for the Management of Alzheimer's Disease Using Memantine-Loaded PLGA Nanoparticles.
Topics: Aged; Alzheimer Disease; Brain; Drug Carriers; Humans; Memantine; Nanoparticles; Particle Size | 2022 |
A Preliminary Pharmacodynamic Study for the Management of Alzheimer's Disease Using Memantine-Loaded PLGA Nanoparticles.
Topics: Aged; Alzheimer Disease; Brain; Drug Carriers; Humans; Memantine; Nanoparticles; Particle Size | 2022 |
A Preliminary Pharmacodynamic Study for the Management of Alzheimer's Disease Using Memantine-Loaded PLGA Nanoparticles.
Topics: Aged; Alzheimer Disease; Brain; Drug Carriers; Humans; Memantine; Nanoparticles; Particle Size | 2022 |
A Preliminary Pharmacodynamic Study for the Management of Alzheimer's Disease Using Memantine-Loaded PLGA Nanoparticles.
Topics: Aged; Alzheimer Disease; Brain; Drug Carriers; Humans; Memantine; Nanoparticles; Particle Size | 2022 |
A Preliminary Pharmacodynamic Study for the Management of Alzheimer's Disease Using Memantine-Loaded PLGA Nanoparticles.
Topics: Aged; Alzheimer Disease; Brain; Drug Carriers; Humans; Memantine; Nanoparticles; Particle Size | 2022 |
A Preliminary Pharmacodynamic Study for the Management of Alzheimer's Disease Using Memantine-Loaded PLGA Nanoparticles.
Topics: Aged; Alzheimer Disease; Brain; Drug Carriers; Humans; Memantine; Nanoparticles; Particle Size | 2022 |
A Preliminary Pharmacodynamic Study for the Management of Alzheimer's Disease Using Memantine-Loaded PLGA Nanoparticles.
Topics: Aged; Alzheimer Disease; Brain; Drug Carriers; Humans; Memantine; Nanoparticles; Particle Size | 2022 |
A Preliminary Pharmacodynamic Study for the Management of Alzheimer's Disease Using Memantine-Loaded PLGA Nanoparticles.
Topics: Aged; Alzheimer Disease; Brain; Drug Carriers; Humans; Memantine; Nanoparticles; Particle Size | 2022 |
Effects of Pharmacological Treatments in Alzheimer's Disease: Permutation Entropy-Based EEG Complexity Study.
Topics: Aged; Alzheimer Disease; Brain; Electroencephalography; Entropy; Humans; Memantine | 2023 |
Effects of Pharmacological Treatments in Alzheimer's Disease: Permutation Entropy-Based EEG Complexity Study.
Topics: Aged; Alzheimer Disease; Brain; Electroencephalography; Entropy; Humans; Memantine | 2023 |
Effects of Pharmacological Treatments in Alzheimer's Disease: Permutation Entropy-Based EEG Complexity Study.
Topics: Aged; Alzheimer Disease; Brain; Electroencephalography; Entropy; Humans; Memantine | 2023 |
Effects of Pharmacological Treatments in Alzheimer's Disease: Permutation Entropy-Based EEG Complexity Study.
Topics: Aged; Alzheimer Disease; Brain; Electroencephalography; Entropy; Humans; Memantine | 2023 |
Effects of Pharmacological Treatments in Alzheimer's Disease: Permutation Entropy-Based EEG Complexity Study.
Topics: Aged; Alzheimer Disease; Brain; Electroencephalography; Entropy; Humans; Memantine | 2023 |
Effects of Pharmacological Treatments in Alzheimer's Disease: Permutation Entropy-Based EEG Complexity Study.
Topics: Aged; Alzheimer Disease; Brain; Electroencephalography; Entropy; Humans; Memantine | 2023 |
Effects of Pharmacological Treatments in Alzheimer's Disease: Permutation Entropy-Based EEG Complexity Study.
Topics: Aged; Alzheimer Disease; Brain; Electroencephalography; Entropy; Humans; Memantine | 2023 |
Effects of Pharmacological Treatments in Alzheimer's Disease: Permutation Entropy-Based EEG Complexity Study.
Topics: Aged; Alzheimer Disease; Brain; Electroencephalography; Entropy; Humans; Memantine | 2023 |
Effects of Pharmacological Treatments in Alzheimer's Disease: Permutation Entropy-Based EEG Complexity Study.
Topics: Aged; Alzheimer Disease; Brain; Electroencephalography; Entropy; Humans; Memantine | 2023 |
Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer's Disease.
Topics: Acoustic Stimulation; Aged; Alzheimer Disease; Cognition; Double-Blind Method; Female; Humans; Male; | 2023 |
Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer's Disease.
Topics: Acoustic Stimulation; Aged; Alzheimer Disease; Cognition; Double-Blind Method; Female; Humans; Male; | 2023 |
Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer's Disease.
Topics: Acoustic Stimulation; Aged; Alzheimer Disease; Cognition; Double-Blind Method; Female; Humans; Male; | 2023 |
Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer's Disease.
Topics: Acoustic Stimulation; Aged; Alzheimer Disease; Cognition; Double-Blind Method; Female; Humans; Male; | 2023 |
Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer's Disease.
Topics: Acoustic Stimulation; Aged; Alzheimer Disease; Cognition; Double-Blind Method; Female; Humans; Male; | 2023 |
Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer's Disease.
Topics: Acoustic Stimulation; Aged; Alzheimer Disease; Cognition; Double-Blind Method; Female; Humans; Male; | 2023 |
Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer's Disease.
Topics: Acoustic Stimulation; Aged; Alzheimer Disease; Cognition; Double-Blind Method; Female; Humans; Male; | 2023 |
Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer's Disease.
Topics: Acoustic Stimulation; Aged; Alzheimer Disease; Cognition; Double-Blind Method; Female; Humans; Male; | 2023 |
Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer's Disease.
Topics: Acoustic Stimulation; Aged; Alzheimer Disease; Cognition; Double-Blind Method; Female; Humans; Male; | 2023 |
[Capabilities of combined therapy of Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Memantin | 2022 |
[Capabilities of combined therapy of Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Memantin | 2022 |
[Capabilities of combined therapy of Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Memantin | 2022 |
[Capabilities of combined therapy of Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Memantin | 2022 |
[Capabilities of combined therapy of Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Memantin | 2022 |
[Capabilities of combined therapy of Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Memantin | 2022 |
[Capabilities of combined therapy of Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Memantin | 2022 |
[Capabilities of combined therapy of Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Memantin | 2022 |
[Capabilities of combined therapy of Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Memantin | 2022 |
The Differential Diagnosis and Treatment of Mild Cognitive Impairment and Alzheimer Disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Diagnosis, Differential; Diseas | 2022 |
Anti-dementia drugs: a descriptive study of the prescription pattern in Italy.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Italy; Memantine | 2023 |
Aminoadamantanes: from treatment of Parkinson's and Alzheimer's disease to symptom amelioration of long COVID-19 syndrome?
Topics: Alzheimer Disease; Amantadine; COVID-19; Humans; Memantine; Parkinson Disease; Post-Acute COVID-19 S | 2023 |
Extemporaneous combination of donepezil and memantine to treat dementia in Alzheimer disease: evidence from Italian real-world data.
Topics: Alzheimer Disease; Donepezil; Female; Humans; Italy; Male; Memantine; Retrospective Studies | 2023 |
Memantine induced encephalopathy in chronic kidney disease: a case report.
Topics: Alzheimer Disease; Brain Diseases; Humans; Memantine; Renal Insufficiency, Chronic | 2023 |
Sundowning in Patients with Dementia: Identification, Prevalence, and Clinical Correlates.
Topics: Alzheimer Disease; Anxiety; Delirium; Dementia; Humans; Memantine; Prevalence | 2023 |
Mitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Memantine; Mice; Mice, Transgenic; Mitochondr | 2023 |
Using artificial intelligence to learn optimal regimen plan for Alzheimer's disease.
Topics: Alzheimer Disease; Artificial Intelligence; Cholinesterase Inhibitors; Humans; Learning; Memantine | 2023 |
Prevalence of Chronic Pain Among People with Dementia: A Nationwide Study Using French Administrative Data.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Chronic Pain; Cross-Sectional Studies; Humans; Memanti | 2023 |
Edaravone Improves Streptozotocin-Induced Memory Impairment via Alleviation of Behavioral Dysfunction, Oxidative Stress, Inflammation, and Histopathological Parameters.
Topics: Alzheimer Disease; Animals; Antioxidants; Disease Models, Animal; Donepezil; Edaravone; Inflammation | 2023 |
Alzheimer's and Dementia Guidelines and Tables.
Topics: Alzheimer Disease; Antipsychotic Agents; Depressive Disorder, Major; Hallucinations; Humans; Memanti | 2023 |
Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; COVID-19; Donepezil; Female; Galantamine; Humans; Inda | 2023 |
Psychopharmacological Medication Use in Frontotemporal Dementia at the Time of Diagnosis: Comparison with Alzheimer's Disease.
Topics: Alzheimer Disease; Delayed Diagnosis; Female; Frontotemporal Dementia; Humans; Memantine; Neurodegen | 2023 |
pH-influenced self-assembled stealth nanoscaffolds encapsulating memantine for treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Hydrogen-Ion Conce | 2023 |
A causal inference study: The impact of the combined administration of Donepezil and Memantine on decreasing hospital and emergency department visits of Alzheimer's disease patients.
Topics: Alzheimer Disease; Donepezil; Emergency Service, Hospital; Hospitals; Humans; Memantine | 2023 |
Galantamine-memantine hybrids for Alzheimer's disease: The influence of linker rigidity in biological activity and pharmacokinetic properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Galantamine; Humans; Me | 2023 |
The Role of NMDA Receptor Subunits in the Effect of Memantine on the Brain of Healthy Animals.
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Memantine; Rats; Receptors, N- | 2023 |
Memantine administration prevented chorea movement in Huntington's disease: a case report.
Topics: Aged; Alzheimer Disease; Chorea; Dyskinesias; Female; Humans; Huntington Disease; Iofetamine; Male; | 2023 |
Consumption of drugs for Alzheimer's disease on the Brazilian private market.
Topics: Alzheimer Disease; Brazil; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Memantine; Phenylca | 2023 |
Effects of thymoquinone and memantine alone and in combination on memory and hippocampal morphology in rats with streptozotocin-induced Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Hippocampus; Male; Maze Learning; Memantine; Neu | 2023 |
Impact of Anti-Dementia Medication on the Risk of Death and Causes of Death in Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Cause of Death; Cholinesterase Inhibitors; Cognition; Early Medical Interve | 2019 |
Effects of the drug combination memantine and melatonin on impaired memory and brain neuronal deficits in an amyloid-predominant mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cholineste | 2019 |
Lactoferrin Coupled Lower Generation PAMAM Dendrimers for Brain Targeted Delivery of Memantine in Aluminum-Chloride-Induced Alzheimer's Disease in Mice.
Topics: Aluminum Chloride; Alzheimer Disease; Animals; Brain; Cognition; Dendrimers; Disease Models, Animal; | 2019 |
Gamma radiation preparation of chitosan nanoparticles for controlled delivery of memantine.
Topics: Acetic Acid; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antiparkinson Agents; Brain; Chitosa | 2020 |
Cholinesterase as a Target for Drug Development in Alzheimer's Disease.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Develo | 2020 |
Current and Emerging Solutions to Challenges in the Management of Alzheimer's Disease.
Topics: Adaptation, Psychological; Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cognition | 2019 |
Concomitant memantine and
Topics: Alzheimer Disease; Animals; Animals, Genetically Modified; Biomarkers; Choline; Cognitive Dysfunctio | 2020 |
Pharmacological Characterizations of anti-Dementia Memantine Nitrate via Neuroprotection and Vasodilation
Topics: Alzheimer Disease; Animals; Brain; Dementia, Vascular; Glutamic Acid; Memantine; Neurons; Neuroprote | 2020 |
Asthma and Chronic Obstructive Pulmonary Disease as a Comorbidity and Association with the Choice of Antidementia Medication Among Persons with Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Asthma; Cholinesterase Inhibitors; Drug Prescriptions; F | 2020 |
The pharmacokinetic parameters and the effect of a single and repeated doses of memantine on gastric myoelectric activity in experimental pigs.
Topics: Administration, Oral; Alzheimer Disease; Animals; Disease Models, Animal; Electromyography; Excitato | 2020 |
Neuroprotective Effect of New Nanochelating-Based Nano Complex, ALZc3, Against Aβ
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Caspase 3; Glutathione; Hippocampus; Magnesium; M | 2020 |
Medical interventions suppressed progression of advanced Alzheimer's disease more than mild Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Disease Progressio | 2020 |
Donepezil plus memantine versus donepezil alone for treatment of concomitant Alzheimer's disease and chronic obstructive pulmonary disease: a retrospective observational study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Asian People; Cholinesterase | 2020 |
Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors enhance procognitive effects of conventional anti-Alzheimer drugs in scopolamine-treated rats.
Topics: Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Animals; Choliner | 2020 |
Multiple target-based combination therapy of galantamine, memantine and lycopene for the possible treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Lycopene; Mema | 2020 |
Ethnic disparities in the uptake of anti-dementia medication in young and late-onset dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cross-Sectional Studies; Dementia; Humans; Lewy Body D | 2023 |
Usage and adherence of antidementia drugs in a memory clinic cohort in Chongqing, Southwest China.
Topics: Aged; Alzheimer Disease; China; Donepezil; Dopamine Agents; Humans; Medication Adherence; Memantine; | 2020 |
Pharmaceutical Treatment for Alzheimer's Disease and Related Dementias: Utilization and Disparities.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Dopamine | 2020 |
Effect of memantine on expression of Bace1-as and Bace1 genes in STZ-induced Alzheimeric rats.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Antiparkins | 2020 |
Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record study.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Memantine; Retrospective | 2021 |
Magnetic nanoemulsions as candidates for Alzheimer's disease dual imaging theranostics.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Dopamine Agents; Drug Carriers; Emulsions; Humans; Magneti | 2020 |
Effects of homocysteine and memantine on oxidative stress related TRP cation channels in
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Calcium; Caspase 3; Caspase 9; Female; | 2021 |
Chronic Memantine Treatment Ameliorates Behavioral Deficits, Neuron Loss, and Impaired Neurogenesis in a Model of Alzheimer's Disease.
Topics: Administration, Oral; Alzheimer Disease; Animals; Anxiety; Behavior, Animal; CA1 Region, Hippocampal | 2021 |
Anti-Amnesic and Neuroprotective Effects of Fluoroethylnormemantine in a Pharmacological Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Behavior, Animal; Disease Models, Animal | 2021 |
Alzheimer's drug Memantine inhibits metastasis and p-Erk protein expression on 4T1 breast cancer cells.
Topics: Alzheimer Disease; Apoptosis; Breast Neoplasms; Cell Proliferation; Dopamine Agents; Extracellular S | 2020 |
Synthetic analogues of memantine as neuroprotective and influenza viral inhibitors: in vitro and physicochemical studies.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Dogs; Glutamic Acid; Humans; Influenza, Human; Ma | 2020 |
Dementia Diagnoses and Treatment in Geriatric Ward Patients: A Cross-Sectional Study in Poland.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cross-Sectional Studies; Dementia; | 2020 |
The Importance of Citicoline in Combined Treatment in Dementia: What did the Citimem Study Teach us?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Cytidine Diphosphate Choline; Humans; Memanti | 2021 |
Topics: Alzheimer Disease; Amyloid beta-Peptides; Benzothiazoles; Dizocilpine Maleate; Excitatory Amino Acid | 2020 |
The Tetramethylpyrazine Analogue T-006 Alleviates Cognitive Deficits by Inhibition of Tau Expression and Phosphorylation in Transgenic Mice Modeling Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Autophagy; Autophagy-Related Protein-1 H | 2021 |
Post-market utilization patterns of Alzheimer's disease treatments in South Korea: comparison with countries with universal health coverage.
Topics: Alzheimer Disease; Australia; Cholinesterase Inhibitors; Donepezil; Galantamine; Global Health; Huma | 2021 |
Hippocampal Degeneration and Behavioral Impairment During Alzheimer-Like Pathogenesis Involves Glutamate Excitotoxicity.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Dentate Gyrus; Disks Large Homolog 4 Protein; Excitato | 2021 |
Memantine ameliorates cognitive impairment induced by exposure to chronic hypoxia environment at high altitude by inhibiting excitotoxicity.
Topics: Altitude; Altitude Sickness; Alzheimer Disease; Animals; Cell Death; Cognition; Cognitive Dysfunctio | 2021 |
A Retrospective Study on the Benefits of Combined Citicoline, Memantine, and Acetylcholinesterase Inhibitor Treatments in Older Patients Affected with Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cholinesterase Inhibitors; Cytidin | 2021 |
The CITIMERIVA Study: CITIcoline plus MEmantina plus RIVAstigmine in Older Patients Affected with Alzheimer's Disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cholin | 2021 |
Effect of memantine, an anti-Alzheimer's drug, on rodent microglial cells in vitro.
Topics: Alzheimer Disease; Animals; Excitatory Amino Acid Antagonists; Memantine; Mice, Inbred C57BL; Microg | 2021 |
Effect of Memantine Treatment and Combination with Vitamin D Supplementation on Body Composition in the APP/PS1 Mouse Model of Alzheimer's Disease Following Chronic Vitamin D Deficiency.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Body Composition; Dietary Supplements; D | 2021 |
Early Start of Anti-Dementia Medication Delays Transition to 24-Hour Care in Alzheimer's Disease Patients: A Finnish Nationwide Cohort Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Fe | 2021 |
Therapeutic efficacy of novel memantine nitrate MN-08 in animal models of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Memantine; Mice; Mice, Transgenic | 2021 |
Memantine ameliorates cognitive deficit in AD mice via enhancement of entorhinal-CA1 projection.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; CA1 Region, Hippocampal; Cognitive Dysfu | 2021 |
Safety of Memantine in Combination with Potentially Interactive Drugs in the Real World: A Pharmacovigilance Study Using the Japanese Adverse Drug Event Report (JADER) Database.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Alzheimer Disease; Databases, Fact | 2021 |
[Effects of Yokukansankachimpihange on Memantine-induced Dizziness in Mice with Memory Impairment].
Topics: Administration, Oral; Alzheimer Disease; Animals; Disease Models, Animal; Dizziness; Drug Therapy, C | 2021 |
Global trends in symptomatic medication use against dementia in 66 countries/regions from 2008 to 2018.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cross-Sectional Studies; Humans; Indans; Memantine; Ph | 2021 |
Potentiation of cognitive enhancer effects of Alzheimer's disease medication memantine by alpha7 nicotinic acetylcholine receptor agonist PHA-543613 in the Morris water maze task.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Animals; Bridged Bicyclo Compounds, Hete | 2021 |
Novel conjugates of aminoadamantanes with carbazole derivatives as potential multitarget agents for AD treatment.
Topics: Alzheimer Disease; Amantadine; Carbazoles; Carboxylesterase; Cholinesterase Inhibitors; Drug Design; | 2017 |
Spatial recognition test: A novel cognition task for assessing topographical memory in mice.
Topics: Alzheimer Disease; Animals; Cognition; Disease Models, Animal; Donepezil; Indans; Levetiracetam; Mal | 2017 |
Ameliorating effect of anti-Alzheimer's drugs on the bidirectional association between type 2 diabetes mellitus and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Biomarkers; Diabetes Mellitus, Type 2; Female; Humans; M | 2017 |
The cost-effectiveness implications of suboptimal treatment for different severities of Alzheimer's disease in the UK.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Delivery of Health Care; | 2018 |
Effects of acute administration of donepezil or memantine on sleep-deprivation-induced spatial memory deficit in young and aged non-human primate grey mouse lemurs (Microcebus murinus).
Topics: Aging; Alzheimer Disease; Animals; Cheirogaleidae; Disease Models, Animal; Donepezil; Indans; Male; | 2017 |
Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; Disease Progression; Female; | 2018 |
Use of antidementia drugs in German patients with Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Cross-Sectional S | 2018 |
Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzodioxoles; Maze Learning; Memantine; Mice; Mi | 2018 |
Tramadol ameliorates behavioural, biochemical, mitochondrial and histological alterations in ICV-STZ-induced sporadic dementia of Alzheimer's type in rats.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Dementia; Disease Models, Animal; Dose-Response Relati | 2018 |
Efficacy of tenuigenin and β-asarone as augmentations for memantine in the treatment of Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Allylbenzene Derivatives; Alzheimer Disease; Anisoles; Cognition; | 2018 |
Loss of kallikrein-related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Astrocytes; Brain; Cell Line, Tumor; Cul | 2018 |
Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Body Weight; Cognition; Diet, High-Fat; Disease M | 2018 |
Impact of cholinesterase inhibitors or memantine on survival in adults with Down syndrome and dementia: clinical cohort study.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Comorbidity; Down Syndrome; Exci | 2018 |
Elderly woman presenting with unusual propriospinal myoclonus triggered by drug-induced nausea and vomiting.
Topics: Aged, 80 and over; Alzheimer Disease; Bupropion; Dopamine Agents; Dopamine Uptake Inhibitors; Female | 2018 |
Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antiparkinson Agents; Astro | 2018 |
Mechanism of NMDA receptor channel block by MK-801 and memantine.
Topics: Alzheimer Disease; Animals; Binding Sites; Crystallography, X-Ray; Dizocilpine Maleate; Ion Channel | 2018 |
[Therapy of Dementia: State of the Art].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Humans; Memantine; Parkinson Disease; Risk F | 2018 |
The Impact of Cholinesterase Inhibitors with or without Memantine on Antipsychotic Prescribing.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Cogniti | 2018 |
In Depth Analysis of Pressure-Sensitive Adhesive Patch-Assisted Delivery of Memantine and Donepezil Using Physiologically Based Pharmacokinetic Modeling and in Vitro/in Vivo Correlations.
Topics: Administration, Cutaneous; Alzheimer Disease; Animals; Biological Availability; Donepezil; Drug Deli | 2018 |
Application value of serum biomarkers for choosing memantine therapy for moderate AD.
Topics: Aged; Alzheimer Disease; Area Under Curve; Biomarkers; Brain-Derived Neurotrophic Factor; Drug Resis | 2018 |
A pharmacoeconomic evaluation of cholinesterase inhibitors and memantine for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dopamine Agents; Economics, Pharmaceutical; Humans; Me | 2018 |
Drawing on the brain's resilience to fight Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Cognitive Remediation; Cognitive Reserve; Donepezil; Female; Humans; Male; | 2018 |
Setbacks and promises for drugs against Alzheimer's disease: As pharmaceutical companies are retreating from drug development for Alzheimer's, new approaches are being tested in academia and biotech companies.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Aspartic Ac | 2018 |
Current approaches to the pharmacological treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Anti-Inflammatory Agents; Australia; Cholinesterase Inhibitors; Estrogens; Fatty | 2018 |
N-methyl-D-aspartate receptor-mediated calcium influx connects amyloid-β oligomers to ectopic neuronal cell cycle reentry in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Calcium; Cell Cycle; Cells, Cultured; Disease Mod | 2018 |
Pore-former enabled seeding of tau in rats: Alleviation by memantine and lithium chloride.
Topics: Alzheimer Disease; Animals; CA1 Region, Hippocampal; Disease Models, Animal; Lithium Chloride; Male; | 2019 |
Memantine mediates astrocytic activity in response to excitotoxicity induced by PP2A inhibition.
Topics: Alzheimer Disease; Animals; Astrocytes; Cognitive Dysfunction; Glial Fibrillary Acidic Protein; Hipp | 2019 |
Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Drug T | 2019 |
[Antidementia Drug Therapy of Alzheimer's Dementia: Status 2018 and Outlook].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia, Vascular; Humans; Lewy Body Disease; Memanti | 2019 |
Combined vildagliptin and memantine treatment downregulates expression of amyloid precursor protein, and total and phosphorylated tau in a rat model of combined Alzheimer's disease and type 2 diabetes.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Diabetes Mellitus, Experimental; Diabete | 2019 |
The role of LINC00094/miR-224-5p (miR-497-5p)/Endophilin-1 axis in Memantine mediated protective effects on blood-brain barrier in AD microenvironment.
Topics: 3' Untranslated Regions; Adaptor Proteins, Signal Transducing; Alzheimer Disease; Amyloid beta-Pepti | 2019 |
Combination of Memantine and 6-Chlorotacrine as Novel Multi-Target Compound against Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Capillary Permeability; Cell | 2019 |
Association of Antidementia Therapies With Time to Skilled Nursing Facility Admission and Cardiovascular Events Among Elderly Adults With Alzheimer Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cardiovascular Diseases; Cholinesterase Inhibitors; Drug | 2019 |
Memantine prodrug as a new agent for Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Autophagy; Cell Line; Humans; Hydrogen Sulfide; I | 2019 |
A pharmaceutical answer to nonadherence: Once weekly oral memantine for Alzheimer's disease.
Topics: Administration, Oral; Alzheimer Disease; Animals; Biological Availability; Delayed-Action Preparatio | 2019 |
Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Female; Ginkgo biloba; Humans; Memant | 2019 |
Trends of antidementia drugs use in outpatients with Alzheimer's disease in six major cities of China: 2012-2017.
Topics: Aged; Alzheimer Disease; China; Cholinesterase Inhibitors; Donepezil; Female; Humans; Male; Memantin | 2019 |
Merging memantine and ferulic acid to probe connections between NMDA receptors, oxidative stress and amyloid-β peptide in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Survival; Coumaric Acids; Dose-Response Relationship, | 2019 |
One-Year Persistence with Donepezil, Memantine, and Rivastigmine in More than 66,000 Elderly Patients Followed in Poland.
Topics: Aged; Alzheimer Disease; Donepezil; Drug Utilization Review; Female; Humans; Male; Medication Adhere | 2019 |
Two cases of loss of consciousness after long-term memantine treatment.
Topics: Aged; Alzheimer Disease; Excitatory Amino Acid Antagonists; Humans; Male; Memantine; Middle Aged; Un | 2013 |
Is drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centres.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Dementia, Vascular; Donepezil; Female; Galanta | 2013 |
Memantine-associated renal impairment in a patient with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Dopamine Agents; Humans; Male; Memantine; Renal Insufficiency | 2013 |
Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Cell Line; Excitatory Amino Acid An | 2013 |
The impact of memantine and cholinesterase inhibitor initiation for Alzheimer disease on the use of antipsychotic agents: analysis using the Régie de l'Assurance Maladie du Québec database.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Cohort | 2013 |
Drugs to treat Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Contraindications; Ergoloid Mesylates; Humans; Isoxsuprine; Memantine; Noot | 2013 |
Memantine is associated with longer survival than donepezil in a Veterans Affairs prescription database, 1997 to 2008.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Databases, Factual; Donepezil | 2013 |
[Cognitive decline in Alzheimer's disease. A follow three or more years of a sample of patients].
Topics: Activities of Daily Living; Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase | 2013 |
Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: comparison with memantine.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Avoidance Learning; Cytokines; Disease Models, An | 2013 |
The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Drug Costs; Drug Therapy, | 2014 |
Reduced CNS exposure of memantine in a triple transgenic mouse model of Alzheimer's disease assessed using a novel LC-MS technique.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Brain; Chromatography, Liquid; Disease Models, Anim | 2013 |
Combination of memantine and vitamin D prevents axon degeneration induced by amyloid-beta and glutamate.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Axons; Cells, Cultured; Drug Synergism; Drug Ther | 2014 |
[Exacerbation of psoriasiform lesions by a gamma-secretase inhibitor].
Topics: Adrenal Cortex Hormones; Aged; Alanine; Alzheimer Disease; Amyloid Precursor Protein Secretases; Aze | 2013 |
Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer's disease.
Topics: Aged; Alleles; Alzheimer Disease; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; C | 2014 |
Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Antip | 2014 |
Medication for Alzheimer's disease and associated fall hazard: a retrospective cohort study from the Alzheimer's Disease Neuroimaging Initiative.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoprotein E4; Case-Contr | 2014 |
Vitamin E, memantine, and Alzheimer disease.
Topics: Alzheimer Disease; Antioxidants; Dopamine Agents; Female; Humans; Male; Memantine; Vitamin E | 2014 |
Protein profiles associated with context fear conditioning and their modulation by memantine.
Topics: Alzheimer Disease; Animals; Cell Nucleus; Cerebral Cortex; Conditioning, Classical; Cytosol; Fear; H | 2014 |
Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Diagnostic an | 2014 |
Souvenaid®: a new approach to management of early Alzheimer's disease.
Topics: Alzheimer Disease; Choline; Cholinesterase Inhibitors; Disease Progression; Docosahexaenoic Acids; D | 2014 |
The value of vitamin E as a treatment for Alzheimer's disease remains unproven despite functional improvement, due to a lack of established effect on cognition or other outcomes from RCTs.
Topics: Alzheimer Disease; Antioxidants; Dopamine Agents; Female; Humans; Male; Memantine; Vitamin E | 2014 |
Is memantine + acetylcholinesterase inhibitor treatment superior to either therapy alone in Alzheimer's disease?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Female; Humans; Male; Memantine; Nootropic Agents | 2014 |
Effects of anti-Alzheimer drugs on phosphorylation and assembly of microtubules from brain microtubular proteins.
Topics: Alzheimer Disease; Aminoquinolines; Animals; Brain; Memantine; Microtubule-Associated Proteins; Micr | 2014 |
Memantine improves spatial learning and memory impairments by regulating NGF signaling in APP/PS1 transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloidosis; Animals; Avoi | 2014 |
[Vitamin E delays Alzheimer disease progression only slightly].
Topics: Aged; Alzheimer Disease; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Humans | 2014 |
Efficacy of memantine hydrochloride once-daily in Alzheimer's disease.
Topics: Activities of Daily Living; Alzheimer Disease; Cognition Disorders; Excitatory Amino Acid Antagonist | 2014 |
QT prolongation associated with memantine in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; | 2015 |
Protection of Radial Glial-Like Cells in the Hippocampus of APP/PS1 Mice: a Novel Mechanism of Memantine in the Treatment of Alzheimer's Disease.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Apoptosis; Bromodeoxyuridine; Cel | 2015 |
Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Do | 2015 |
Memantine overdose in a non-demented older adult.
Topics: Aged, 80 and over; Alzheimer Disease; Diagnosis, Differential; Drug Overdose; Excitatory Amino Acid | 2015 |
Stuart Lipton: UFOs and flying tigers.
Topics: Alzheimer Disease; Drug Discovery; Excitatory Amino Acid Antagonists; History, 20th Century; History | 2015 |
Potential natural products for Alzheimer's disease: targeted search using the internal ribosome entry site of tau and amyloid-β precursor protein.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cell Line, Tumor; Central Nervous System | 2015 |
Neuroprotective effect of memantine on the retinal ganglion cells of APPswe/PS1ΔE9 mice and its immunomodulatory mechanisms.
Topics: Alzheimer Disease; Analysis of Variance; Animals; Disease Models, Animal; Electroretinography; Epend | 2015 |
Memantine-associated hyperkalaemia in a patient with Alzheimer's disease.
Topics: Aged, 80 and over; Alzheimer Disease; Blood Urea Nitrogen; Creatinine; Excitatory Amino Acid Antagon | 2013 |
Syndrome of inappropriate antidiuretic hormone secretion due to excessive intake of memantine.
Topics: Aged, 80 and over; Alzheimer Disease; Humans; Inappropriate ADH Syndrome; Male; Memantine; Nootropic | 2015 |
Discontinuation of memantine standard release and its impact on patient therapy.
Topics: Alzheimer Disease; Caregivers; Consultants; Delayed-Action Preparations; Drug Liberation; Excitatory | 2015 |
Calcium flux-independent NMDA receptor activity is required for Aβ oligomer-induced synaptic loss.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Calcium; Dendritic Spines; Dizocilpine Maleate; E | 2015 |
Memantine for treatment of moderate or severe Alzheimer's disease patients in urban China: clinical and economic outcomes from a health economic model.
Topics: Alzheimer Disease; China; Cost Savings; Disease Progression; Excitatory Amino Acid Antagonists; Huma | 2015 |
Memantine-associated corneal endothelial dysfunction.
Topics: Aged, 80 and over; Alzheimer Disease; Corneal Diseases; Descemet Stripping Endothelial Keratoplasty; | 2015 |
A Legal Test for the Pharmaceutical Company Practice of "Product Hopping".
Topics: Alzheimer Disease; Drug Industry; Drugs, Generic; Economic Competition; Humans; Legislation, Drug; M | 2015 |
Pharmacokinetics of Memantine after a Single and Multiple Dose of Oral and Patch Administration in Rats.
Topics: Administration, Cutaneous; Administration, Intravenous; Administration, Oral; Alzheimer Disease; Ani | 2016 |
Postmortem memantine concentration in a non-intoxication case, and the possibility of postmortem redistribution: A case report.
Topics: Alzheimer Disease; Dopamine Agents; Female; Forensic Toxicology; Humans; Liver; Memantine; Middle Ag | 2015 |
Clinical Benefits of Memantine Treatment for Alzheimer's Disease in the Okayama Memantine Study II (OMS II).
Topics: Aged, 80 and over; Alzheimer Disease; Female; Humans; Japan; Male; Memantine; Neuropsychological Tes | 2015 |
Clinical Benefits for Older Alzheimer's Disease Patients: Okayama Late Dementia Study (OLDS).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Donepezil; Female; Follow-Up Studi | 2015 |
Protective effects of NMDA receptor antagonist, memantine, against senescence of PC12 cells: A possible role of nNOS and combined effects with donepezil.
Topics: Aging; Alzheimer Disease; Animals; beta-Galactosidase; Cholinesterase Inhibitors; Cognition; Disease | 2015 |
Use of Anti-Dementia Drugs in Relation to Change in Cognition, Behavior, and Functioning in Alzheimer's Disease over a Three-Year Period: Kuopio ALSOVA Study.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Disease Progression; Drug Therapy, Co | 2015 |
Amyloid beta modulation of neuronal network activity in vitro.
Topics: Action Potentials; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cells, Cultured; Drug Evaluati | 2015 |
Anti-autophagic and anti-apoptotic effects of memantine in a SH-SY5Y cell model of Alzheimer's disease via mammalian target of rapamycin-dependent and -independent pathways.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Apoptosis; Autophagy; Cell Line, Tumor; Excitatory Amino A | 2015 |
Long-term effects of Alzheimer's disease treatment.
Topics: Alzheimer Disease; Female; Homes for the Aged; Humans; Indans; Male; Memantine; Nootropic Agents; Nu | 2015 |
Real-world evaluation of compliance and preference in Alzheimer's disease treatment.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Asia; A | 2015 |
Memantine Attenuates Alzheimer's Disease-Like Pathology and Cognitive Impairment.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Blotting, Western; Cognition Disorders; Dependovirus; | 2015 |
Why has therapy development for dementia failed in the last two decades?
Topics: Alzheimer Disease; Biomarkers; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Drug D | 2016 |
Alzheimer disease. Donepezil and nursing home placement--benefits and costs.
Topics: Alzheimer Disease; Female; Homes for the Aged; Humans; Indans; Male; Memantine; Nootropic Agents; Nu | 2016 |
Elevated glucose and oligomeric β-amyloid disrupt synapses via a common pathway of aberrant protein S-nitrosylation.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Case-Contr | 2016 |
Toxicological Differences Between NMDA Receptor Antagonists and Cholinesterase Inhibitors.
Topics: Adverse Drug Reaction Reporting Systems; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Meman | 2016 |
Memantine Exacerbates Corrected QT Interval Prolongation in Alzheimer's Disease: A Case Report from an Unintentional Rechallenge.
Topics: Aged; Alzheimer Disease; Delirium; Dopamine Agents; Drug Substitution; Electrocardiography; Humans; | 2016 |
NMDA receptor is involved in neuroinflammation in intracerebroventricular colchicine-injected rats.
Topics: Alzheimer Disease; Animals; Cell Adhesion; Colchicine; Cytotoxicity, Immunologic; Disease Models, An | 2016 |
Therapeutic advances and risk factor management: our best chance to tackle dementia?
Topics: Alzheimer Disease; Antibodies, Monoclonal, Humanized; Australia; Cholinesterase Inhibitors; Dementia | 2016 |
Cognitive benefits of memantine in Alzheimer's 5XFAD model mice decline during advanced disease stages.
Topics: Alzheimer Disease; Animals; Cognition Disorders; Disease Models, Animal; Dopamine Agents; Memantine; | 2016 |
Drug Product Life-Cycle Management as Anticompetitive Behavior: The Case of Memantine.
Topics: Alzheimer Disease; Delayed-Action Preparations; Drug Industry; Drug Substitution; Drugs, Generic; Ec | 2016 |
[Clinical experience of the use of memantal in patients with moderate and severe Alzheimer's disease].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Drugs, Generic; Female; Humans; Male; Memanti | 2016 |
The importance of high quality trials of cognitive interventions in Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Humans; Memantine | 2016 |
Neuroprotective and neurorestorative potential of xenon.
Topics: Alzheimer Disease; Cells, Cultured; Dicarboxylic Acids; Humans; Memantine; Neurons; Neuroprotective | 2016 |
Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Humans; Memantine; Practice Guidelines as To | 2016 |
Treatment Patterns with Antidementia Drugs in the United States: Medicare Cohort Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Drug Utilizat | 2016 |
Use of Cholinesterase Inhibitors Increases Initiation of Urinary Anticholinergics in Persons with Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Drug Therapy, Combination; | 2016 |
The combination of memantine and galantamine improves cognition in rats: The synergistic role of the α7 nicotinic acetylcholine and NMDA receptors.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Animals; Antiparkinson Agents; Cholinest | 2016 |
Immunomodulation by memantine in therapy of Alzheimer's disease is mediated through inhibition of Kv1.3 channels and T cell responsiveness.
Topics: Alzheimer Disease; CD4-Positive T-Lymphocytes; Cells, Cultured; Excitatory Amino Acid Antagonists; H | 2016 |
Microglia-Based Phenotypic Screening Identifies a Novel Inhibitor of Neuroinflammation Effective in Alzheimer's Disease Models.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cognition; Disease Models, Animal; Donepez | 2016 |
Racial and Ethnic Differences in Initiation and Discontinuation of Antidementia Drugs by Medicare Beneficiaries.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Black People; Cholinesterase Inhibitors; Cross-Cultural | 2016 |
In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Drug Evaluation, Preclini | 2016 |
In Vitro Effects of Cognitives and Nootropics on Mitochondrial Respiration and Monoamine Oxidase Activity.
Topics: Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Ind | 2017 |
Blockade of the K
Topics: Alzheimer Disease; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Dendrites; Disease M | 2018 |
Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Finland; Galanta | 2017 |
Memantine-induced chorea and dystonia.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Chorea; Dystonia; Female; Humans; Memantine | 2017 |
In vitro effects of the anti-Alzheimer drug memantine on the human erythrocyte membrane and molecular models.
Topics: Alzheimer Disease; Calorimetry, Differential Scanning; Dimyristoylphosphatidylcholine; Dose-Response | 2017 |
Cognitive changes under memantine according to vitamin D status in Alzheimer patients: An exposed/unexposed cohort pilot study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Body Mass Index; Cognition; Excita | 2018 |
Influence of Memantine on Continuous Treatment with Rivastigmine Patches-Retrospective Study Using the Logistic Regression Analysis.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Drug Therapy, Combination; Female; Humans; Logistic Mode | 2017 |
Trends in the Prescription and Long-Term Utilization of Antidementia Drugs Among Patients with Alzheimer's Disease in Spain: A Cohort Study Using the Registry of Dementias of Girona.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Drug Utilizat | 2017 |
Longitudinal lipid profile variations and clinical change in Alzheimer's disease dementia.
Topics: Alzheimer Disease; Apolipoprotein E4; Cholinesterase Inhibitors; Cognition; Female; Humans; Hydroxym | 2017 |
Different clinical effect of four antidementia drugs for Alzheimer's disease patients depending on white matter severity.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Donepezil; Female; Galantamine; Humans; Male; M | 2017 |
Galantamine-induced pisa syndrome: memantine as an alternative.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Dystonic Disorders; Female; Galantamine; Humans; | 2008 |
Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials.
Topics: Aged; Alzheimer Disease; Clinical Trials as Topic; Electrocardiography; Excitatory Amino Acid Antago | 2008 |
Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Disease Models, Animal; Exploratory Beha | 2008 |
Symptomatic therapeutic aspects in Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Excitatory Amino Acid Antagonists; Humans; Memantine | 2008 |
Alzheimer's disease--towards more patient-centred and meaningful clinical outcomes.
Topics: Activities of Daily Living; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Clinical Trial | 2008 |
[Alzheimer type dementia].
Topics: Alzheimer Disease; Apolipoprotein E4; Diagnosis, Differential; Disease Progression; Donepezil; Human | 2008 |
Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database.
Topics: Aged; Alzheimer Disease; Anti-Anxiety Agents; Antipsychotic Agents; Databases, Factual; Dopamine Age | 2008 |
Effect of tacrine, amiridine, akatinol memantine, and triazolam on phosphorylation, structure, and assembly of microtubules from brain microtubular proteins in Alzheimer diseases.
Topics: Alzheimer Disease; Aminoquinolines; Brain; Dopamine Agents; GABA Modulators; Humans; Memantine; Micr | 2008 |
Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Caspase 3; Cells, Cultured; Cerebral Cortex; Cycl | 2008 |
The Alzheimer's disease drug memantine increases the number of radial glia-like progenitor cells in adult hippocampus.
Topics: Aging; Alzheimer Disease; Animals; Biomarkers; Bromodeoxyuridine; Cell Differentiation; Cell Divisio | 2009 |
Psychosis in the elderly.
Topics: Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents | 2009 |
Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Drug Therapy, Combination; Ex | 2009 |
Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine.
Topics: Alzheimer Disease; Cells, Cultured; Data Interpretation, Statistical; Electrophysiology; Excitatory | 2009 |
[Treatment of degenerative dementia disorders--who should be treated?].
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Dopamine Agents; | 2009 |
New developments in the treatment of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Atrophy; Biomarkers; Brain; Choli | 2009 |
Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cognition; Data Interpretation, Statistical; Di | 2009 |
Memantine and acetylcholinesterase inhibitor treatment in cases of CDR 0.5 or questionable impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Black People; Cholinesterase Inhibitors; Cognition Disor | 2009 |
Memantine (Namenda, Forest Pharmaceuticals).
Topics: Alzheimer Disease; Excitatory Amino Acid Antagonists; Humans; Memantine; Neurotoxins | 2009 |
Treatment practices of mild cognitive impairment in California Alzheimer's Disease Centers.
Topics: Aged; Alzheimer Disease; Antioxidants; California; Chi-Square Distribution; Cholinesterase Inhibitor | 2009 |
Drugs to treat Alzheimer's disease.
Topics: Alzheimer Disease; Central Nervous System Agents; Cholinesterase Inhibitors; Contraindications; Ergo | 2009 |
Memantine in moderately-severe-to-severe Alzheimer's disease: a postmarketing surveillance study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Excitatory Amino Acid Antagonists; Female; Hum | 2009 |
Two cases of discontinuation syndrome following cessation of memantine.
Topics: Aged; Alzheimer Disease; Humans; Male; Memantine; Substance Withdrawal Syndrome; Syndrome; Treatment | 2009 |
Increased expression of PAD2 after repeated intracerebroventricular infusions of soluble Abeta(25-35) in the Alzheimer's disease model rat brain: effect of memantine.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; CD11b Antigen; Disease Models, Animal; Hyd | 2009 |
Memantine inhibits calpain-mediated truncation of GSK-3 induced by NMDA: implications in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Calpain; Cells, Cultured; Cerebral Cortex; Dose-Response | 2009 |
Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology.
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Biomarkers; Brain; Cognition Disorders; Female; Human | 2009 |
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).
Topics: Activities of Daily Living; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Antipa | 2010 |
Effects of memantine on soluble Alphabeta(25-35)-induced changes in peptidergic and glial cells in Alzheimer's disease model rat brain regions.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Biomarkers; Brain; CD11 Antigens; Disease Models, | 2009 |
International price comparisons of Alzheimer's drugs: a way to close the affordability gap.
Topics: Aged; Alzheimer Disease; Cross-Cultural Comparison; Developing Countries; Donepezil; Drug Costs; Eco | 2009 |
Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cross-Sectional Studies; Donepezil; | 2009 |
Memantine: heart failure: harmful drug.
Topics: Alzheimer Disease; Europe; Heart Failure; Humans; Memantine | 2009 |
Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Disability Evaluation; Dopam | 2009 |
Current Alzheimer's disease clinical trials: methods and placebo outcomes.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Apolipoproteins E; Cholinest | 2009 |
Dual action of memantine in Alzheimer disease: a hypothesis.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Chlorocebus aethiops; COS Cells; Dopamin | 2009 |
[Final report is now available. IQWiG doubts the effectiveness of memantine].
Topics: Aged; Alzheimer Disease; Brain; Germany; Humans; Memantine; Nootropic Agents; Product Surveillance, | 2009 |
Variability in the prescription of cholinesterase inhibitors and memantine.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Drug Costs; Drug | 2009 |
Alzheimer's disease: Seeing the signs early.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Galantamine; Humans; Memantine; N | 2009 |
GluN2B subunit-containing NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Analysis of Variance; Animals; Dose-Response Relationship, | 2009 |
[Alzheimer dementia. Memantine: value for patient and caregivers].
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Caregivers; Cognition; Cost of Illness; Dopamin | 2009 |
Memantine: "hypothesis testing" not "disease modifying" in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid; Animals; Antiparkinson Agents; Clinical Trials as Topic; Concept Formati | 2010 |
Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice.
Topics: Age Factors; Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antiparkinson Agents; Cogniti | 2010 |
Prescribing of drugs for Alzheimer's disease: a South African database analysis.
Topics: Aged; Alzheimer Disease; Cohort Studies; Cost-Benefit Analysis; Costs and Cost Analysis; Donepezil; | 2010 |
Pharmacological treatment of Alzheimer's disease: effect of race and demographic variables.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Black or African American; Choline | 2010 |
Off-label medication use in frontotemporal dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; California; Cholinesterase Inhibitors; Dopamine Agents; | 2010 |
Folic Acid potentiates the effect of memantine on spatial learning and neuronal protection in an Alzheimer's disease transgenic model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Avoidance Learnin | 2010 |
Effect of memantine treatment on regional cortical metabolism in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Cortex; Dopamine Agents; Female; Humans; Male; | 2010 |
Lower Barthel Index scores predict less prescription of pharmacological therapy in elderly patients with Alzheimer disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; C | 2010 |
Simultaneous determination of memantine and amantadine in human plasma as fluorescein derivatives by micellar electrokinetic chromatography with laser-induced fluorescence detection and its clinical application.
Topics: Acetonitriles; Alzheimer Disease; Amantadine; Antiparkinson Agents; Chemical Fractionation; Chromato | 2010 |
[Cost of illness in Alzheimer's disease].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cost-Benefit Analysis; Disability Evaluation; Drug Costs | 2010 |
Cost effectiveness of memantine in Alzheimer's disease in the UK.
Topics: Alzheimer Disease; Cost-Benefit Analysis; Dopamine Agents; Female; Health Services; Humans; Male; Ma | 2010 |
Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Delayed-Action Preparations; Drug Administration Schedule; Excitatory Amino Acid | 2010 |
How do we treat people with dementia in Croatia.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Croatia; Cross-Cultural Comparison; Cross-Sectio | 2010 |
Predictors of adherence among Alzheimer's disease patients receiving oral therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Dopamine Agents; Female | 2010 |
[Variability and trends in dementia drug consumption in Castile-La Mancha (Spain). Estimated prevalence of Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Galantamine; Ginkgo | 2010 |
Effects of the uncompetitive nmda receptor antagonist memantine on recognition memory in rats.
Topics: Alzheimer Disease; Animals; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Hum | 2010 |
Direct costs of Alzheimer's disease in Germany.
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Cost-Benefit Analysis; Female; Germany; Health Care C | 2011 |
Memantine-related psychotic symptoms in a patient with bipolar disorder.
Topics: Alzheimer Disease; Antimanic Agents; Bipolar Disorder; Donepezil; Drug Interactions; Excitatory Amin | 2010 |
Prescribing trends in cognition enhancing drugs in Australia.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Australia; Cholinesterase Inhibitors; Donep | 2011 |
Effect of memantine in Alzheimer's disease evaluated by visual-evoked potentials to pattern-reversal, motion-onset, and cognitive stimuli.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Evoked Potentials; Evoked Potentials, Visual; | 2010 |
Determining the minimum clinically important differences for outcomes in the DOMINO trial.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Data Interpretation, Stati | 2011 |
Once-daily memantine: pharmacokinetic and clinical considerations.
Topics: Administration, Oral; Aged; Alzheimer Disease; Dopamine Agents; Dose-Response Relationship, Drug; Dr | 2010 |
Memantine discontinuation and the health status of nursing home residents with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Health Status; Humans; Medical Aud | 2010 |
Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Brain; Brain-Derived Neurotrophic Factor; Calcium; Cognition; Dizocilpin | 2011 |
Memantine benefits functional abilities in moderate to severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Double | 2010 |
Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Dementia; Excitatory Amino Acid Antagonists; | 2011 |
[Treatment of dementia].
Topics: Aged; Alzheimer Disease; Antidepressive Agents; Central Nervous System Stimulants; Cholinesterase In | 2010 |
High-performance liquid chromatographic determination of memantine hydrochloride in rat plasma using sensitive fluorometric derivatization.
Topics: Alzheimer Disease; Animals; Chromatography, High Pressure Liquid; Dopamine Agents; Fluorenes; Humans | 2011 |
S 18986 reverses spatial working memory impairments in aged mice: comparison with memantine.
Topics: Aging; Alzheimer Disease; Animals; Behavior, Animal; Benzothiadiazines; Excitatory Amino Acid Antago | 2011 |
Subchronic memantine administration on spatial learning, exploratory activity, and nest-building in an APP/PS1 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Avoidance Learning; Discrimination, Psyc | 2011 |
CDR state transition probabilities in Alzheimer's disease with and without cholinesterase inhibitor intervention in an observational cohort.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Disease Progr | 2011 |
Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Databases, Factual; Donepezil; Dopamine Agents; | 2011 |
Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Algorithms; Alzheimer Disease; Cognition; Cognition Disorders; Dopamine Age | 2012 |
Antidementia drug prescription sources and patterns after the diagnosis of dementia in Germany: results of a claims data-based 1-year follow-up.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Ambulatory Care; Cholinesterase Inhibitors; | 2011 |
[Prescription differences of dementia drugs in urban and rural areas in Germany].
Topics: Aged; Alzheimer Disease; Ambulatory Care; Donepezil; Galantamine; General Practice; Germany; Humans; | 2011 |
Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Female; Humans; Male; Memantine; Product Surveillance, P | 2011 |
Measuring therapeutic efficacy in patients with Alzheimer's disease: role of instruments.
Topics: Alzheimer Disease; Disease Progression; Excitatory Amino Acid Antagonists; Humans; Memantine; Meta-A | 2011 |
Diagnosis of Alzheimer's disease patients with rapid cognitive decline in clinical practice: interest of the Deco questionnaire.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disord | 2011 |
Alternative drug therapies for dementia.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents; Antioxidants; Cholinesterase Inhibitors; Estrogen | 2011 |
Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: a post-marketing surveillance study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anxiety; Apathy; Depression; Dopamine Agents; Feeding Be | 2012 |
Treatment of Alzheimer disease.
Topics: Aged; Aged, 80 and over; Algorithms; Alzheimer Disease; Cholinesterase Inhibitors; Evidence-Based Me | 2011 |
Drugs: a tangled web of targets.
Topics: Alanine; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; An | 2011 |
AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Cholinesterase Inhibito | 2011 |
Dementia with cardiac problems.
Topics: Adaptation, Psychological; Alzheimer Disease; Anecdotes as Topic; Arrhythmias, Cardiac; Dopamine Age | 2011 |
Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cost-Benefit Analysis; Disease Progression; Excitatory A | 2012 |
The impact of patient and public involvement in the work of the Dementias & Neurodegenerative Diseases Research Network (DeNDRoN): case studies.
Topics: Alzheimer Disease; Biomedical Research; Community Participation; Dementia; Donepezil; Humans; Indans | 2013 |
Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease.
Topics: Alzheimer Disease; Canada; Cholinesterase Inhibitors; Drug Costs; Drug Therapy, Combination; Health | 2011 |
Does memantine improve the gait of individuals with Alzheimer's disease?
Topics: Aged, 80 and over; Alzheimer Disease; Excitatory Amino Acid Antagonists; Female; Follow-Up Studies; | 2011 |
Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoprotein E4; Cholinesterase Inhibitors; Cohort Stu | 2012 |
Effects of the uncompetitive NMDA receptor antagonist memantine on spatial memory in medial septal lesioned rats.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Male; | 2011 |
Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Dopamine Agents; Ger | 2012 |
Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Databases, Bibliographic; Drug Therapy | 2012 |
Discontinuing donepezil or starting memantine for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Excitatory Amino Acid Antagonists; Female; | 2012 |
Drugs for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Drug Design; Excitatory Amino Acid Antagonists; Galant | 2012 |
Alzheimer disease: Treatment of Alzheimer disease in Down syndrome.
Topics: Alzheimer Disease; Dopamine Agents; Down Syndrome; Executive Function; Humans; Memantine; Memory; Ra | 2012 |
Synergistic effects of antidementia drugs on spatial learning and recall in the APP23 transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Drug Syner | 2012 |
Memantine facilitates memory consolidation and reconsolidation in the day-old chick.
Topics: Alzheimer Disease; Animals; Animals, Newborn; Avoidance Learning; Chickens; Excitatory Amino Acid An | 2012 |
False recognition in a mouse model of Alzheimer's disease: rescue with sensory restriction and memantine.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Disease Models, Animal; Electric Stimula | 2012 |
Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Disease Progression; Double-Blind Method; Excitatory Ami | 2012 |
Is delay of clinical worsening a valuable goal in the treatment of Alzheimer's disease?
Topics: Alzheimer Disease; Excitatory Amino Acid Antagonists; Female; Humans; Male; Memantine | 2012 |
Pretreatment with memantine prevents Alzheimer-like alterations induced by intrahippocampal okadaic acid administration in rats.
Topics: Alzheimer Disease; Animals; Carcinogens; Chromatography, High Pressure Liquid; Cyclin-Dependent Kina | 2012 |
[New anti-AD drugs--their possibilities and issues].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans; Memantine; N-Methylaspartate; Phe | 2012 |
Use of antidementia drugs in frontotemporal lobar degeneration.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cross-Sectional Studies; Fema | 2012 |
Discontinuing donepezil or starting memantine for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Excitatory Amino Acid Antagonists; Female; Humans; Ind | 2012 |
Discontinuing donepezil or starting memantine for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Excitatory Amino Acid Antagonists; Female; Humans; Ind | 2012 |
Use of drug treatments for Alzheimer's disease in France: a study on a national level based on the National Alzheimer's Data Bank (Banque Nationale Alzheimer).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cross-Sectional Studies; Data | 2012 |
Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Excitatory Amino Acid Antagonists; Female; Humans; Ind | 2013 |
Combination therapy no advantage in Alzheimer's treatment.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Drug Therapy, Combination; | 2012 |
Drugs for Alzheimer's disease: best avoided. No therapeutic advantage.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Memantine | 2012 |
Memantine in Alzheimer's disease: experience in an Alzheimer's disease assessment unit.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; E | 2012 |
Alzheimer's disease biomarkers.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dopamine Agents; Humans; Immunotherapy; Memantine | 2012 |
Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Cognition Disorders; Drug Therapy, Combinatio | 2012 |
Racial and ethnic disparities in Alzheimer's disease pharmacotherapy exposure: an analysis across four state Medicaid populations.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Ethnicity; Excit | 2012 |
Beneficial effects of lysosome-modulating and other pharmacological and nanocarrier agents on amyloid-beta-treated cells.
Topics: Acetylcarnitine; Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Cell Survival; Drug Car | 2012 |
Combination therapy with galantamine and memantine improves behavioral and psychological symptoms of dementia (BPSD) in patients with early-onset Alzheimer's disease.
Topics: Alzheimer Disease; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Galantamine | 2013 |
[Anti-dementia drugs].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Memantine; Receptors, N-Methyl-D-Aspartate | 2012 |
Alzheimer's disease: development of disease-modifying treatments is the challenge for our generation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Antiparkinson Agents | 2012 |
Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cost-Bene | 2012 |
Clinical effectiveness of rivastigmine monotherapy and combination therapy in Alzheimer's patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Drug Therapy, Combination; Fe | 2013 |
Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine.
Topics: Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Cyclic AMP Response Element-Binding Pr | 2013 |
Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Cohort S | 2013 |
New therapies. New Alzheimer's treatments that may ease the mind.
Topics: Alzheimer Disease; Alzheimer Vaccines; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; | 2002 |
[Case report. Dementia with apathy].
Topics: Administration, Oral; Aged; Alzheimer Disease; Amantadine; Bronchopneumonia; Confusion; Dehydration; | 2002 |
Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40).
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Cell Death; Dentate Gyrus; Ectodyspla | 2002 |
Defining the role of the caregiver in Alzheimer's disease treatment.
Topics: Activities of Daily Living; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Clinical Trial | 2002 |
[The challenge of Alzheimer dementia].
Topics: Alzheimer Disease; Clinical Trials as Topic; Excitatory Amino Acid Antagonists; Humans; Memantine; R | 2003 |
[Prevention of dementias: state of the art].
Topics: Aged; Alzheimer Disease; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Ste | 2003 |
[Early diagnosis and treatment of Alzheimer's disease. Implementation in the doctor's office].
Topics: Aged; Alzheimer Disease; Brief Psychiatric Rating Scale; Carbamates; Cholinesterase Inhibitors; Dihy | 2002 |
[Treatment with NMDA antagonist controls neuron death. Even in severe dementia it is not too late].
Topics: Aged; Alzheimer Disease; Brain; Cell Death; Clinical Trials as Topic; Excitatory Amino Acid Antagoni | 2003 |
Comparison of the effect of NT-0409 and antidementia drugs on learning and memory in rats with chronic cerebral cholinergic deficiency.
Topics: Alzheimer Disease; Animals; Aziridines; Brain; Choline; Excitatory Amino Acid Agonists; Male; Maze L | 2003 |
[Early treatment with anti-dementia drugs when possible. These signs reveal Alzheimer disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Drug Therapy, Combination; Excitatory Amino Acid Antag | 2003 |
Memantine in moderate-to-severe Alzheimer's disease.
Topics: Alzheimer Disease; Excitatory Amino Acid Antagonists; Homocysteine; Humans; Hyperhomocysteinemia; Me | 2003 |
[Drug therapy of Alzheimer dementia].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Denmark; Excitatory Amino Acid Antagonists; Humans; Me | 2003 |
Treatment of Alzheimer's disease: current status and new perspectives.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents; Chelation Therapy; Cholinesteras | 2003 |
Memantine for Alzheimer's disease.
Topics: Alzheimer Disease; Dizziness; Dopamine Agents; Drugs, Investigational; Humans; Memantine; Randomized | 2003 |
Does this patient have Alzheimer disease? Diagnosing and treating dementia.
Topics: Activities of Daily Living; Aged; Aging; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Dis | 2003 |
[Antibodies, antihypertensive drugs, antioxidants. Can they prevent Alzheimer disease?].
Topics: Alzheimer Disease; Antibodies, Monoclonal; Antihypertensive Agents; Antioxidants; Excitatory Amino A | 2003 |
[Memantine brakes Alzheimer's dementia. The NMDA antagonist is effective in severe cases, too].
Topics: Activities of Daily Living; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Dopami | 2003 |
[Anti-dementia therapy pays at every stage of the disease. Patients with Alzheimer's disease stay all-day fit longer].
Topics: Activities of Daily Living; Alzheimer Disease; Controlled Clinical Trials as Topic; Dopamine Agents; | 2003 |
Diagnosis and management of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inhibitors; Female; | 2003 |
Erotomania variants in dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Bipolar Disorder; Delusions; Dementia, Vascular; Dopamin | 2003 |
New Alzheimer's drug approved.
Topics: Alzheimer Disease; Humans; Memantine; Nootropic Agents | 2003 |
Alzheimer's disease: a progress report, Part II. The continuing search for treatments and persistent hopes for prevention.
Topics: Alzheimer Disease; Blood Glucose; Cardiovascular Diseases; Caregivers; Cholesterol, LDL; Depression; | 2003 |
Into the darkness of the mind.
Topics: Aged; Alzheimer Disease; Alzheimer Vaccines; Clinical Trials as Topic; Drug Approval; Humans; Memant | 2003 |
FDA approves groundbreaking Alzheimer's drug.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Drug Approval; Excitatory Amino Acid Antagonists | 2004 |
Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cost-Benefit Analysis; Demen | 2003 |
Academic highlights: emerging therapeutic strategies in Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Combined Modality Therapy; Diagnosis, Differential; Disease Progression; D | 2004 |
Drug for moderate to advanced Alzheimer's approved.
Topics: Alzheimer Disease; Excitatory Amino Acid Antagonists; Humans; Memantine | 2004 |
Memantine hydrochloride.
Topics: Aged; Alzheimer Disease; Excitatory Amino Acid Antagonists; Humans; Memantine; Receptors, N-Methyl-D | 2004 |
Questions & answers. We've been told that my wife has multi-infarct dementia and that the new drug memantine may help. How is her condition different from Alzheimer's disease, and what could memantine do for her?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia, Multi-Infarct; Diagnosis, Differential; Dopa | 2004 |
Memantine (Namenda) for moderate to severe Alzheimer's disease.
Topics: Alzheimer Disease; Excitatory Amino Acid Antagonists; Humans; Memantine; Receptors, N-Methyl-D-Aspar | 2004 |
Memantine for patients with Alzheimer disease.
Topics: Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Dopamine | 2004 |
The presence of the APP(swe) mutation in mice does not increase the vulnerability of cholinergic basal forebrain neurons to neuroinflammation.
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Choline O-Acetyltransfera | 2004 |
Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration.
Topics: 2-Amino-5-phosphonovalerate; Alzheimer Disease; Animals; Calcium-Calmodulin-Dependent Protein Kinase | 2004 |
Effect of memantine on the levels of glial cells, neuropeptides, and peptide-degrading enzymes in rat brain regions of ibotenic acid-treated alzheimer's disease model.
Topics: Alzheimer Disease; Animals; Blotting, Western; Brain; Disease Models, Animal; Dopamine Agents; Elect | 2004 |
Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease.
Topics: Aggression; Alzheimer Disease; Animals; Dopamine Agents; Humans; Male; Maze Learning; Memantine; Mic | 2004 |
[Effect of drugs against dementia].
Topics: Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Humans; Memantine; Ner | 2004 |
What is the rationale for new treatment strategies in Alzheimer's disease?
Topics: Acetylcholine; Alzheimer Disease; Brain; Cholinergic Fibers; Cholinesterase Inhibitors; Cognition Di | 2004 |
Understanding the latest advances in pharmacologic interventions for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Top | 2004 |
Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Caregivers; Cost of Illness; Double-Blind Metho | 2004 |
Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cost-Benefit Analysis; Excitatory Amino Acid Antagonists | 2004 |
Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cholinesterase Inhibitors; Cognition; Di | 2005 |
Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
Topics: Alzheimer Disease; Apoptosis; Brain; Calcium Channels; Cell Death; Clinical Trials as Topic; Cogniti | 2004 |
NICE proposes to withdraw Alzheimer's drugs from NHS.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Drug Costs; England; | 2005 |
Memantine for treatment of moderate to severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Canada; Cholinesterase Inhibitors; Dementia; Diffusion o | 2005 |
19F and 1H MRI detection of amyloid beta plaques in vivo.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloidosis; | 2005 |
Another perspective on the memantine graphs: clinical vs. statistical significance.
Topics: Alzheimer Disease; Data Interpretation, Statistical; Dopamine Agents; Humans; Memantine; Randomized | 2005 |
Alzheimer disease, in living color.
Topics: Alzheimer Disease; Animals; Disease Progression; Humans; Magnetic Resonance Imaging; Memantine; Mice | 2005 |
Development of subtle psychotic symptoms with memantine: a case report.
Topics: Aged; Alzheimer Disease; Confusion; Dreams; Female; Humans; Memantine; Psychoses, Substance-Induced | 2005 |
[Pharmacological treatment in severe dementia].
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Antidepressive Agents; Caregivers; Cholinestera | 2005 |
[Music and art therapy--a taboo topic in therapy of dementia?].
Topics: Aged; Alzheimer Disease; Art Therapy; Clinical Trials as Topic; Cognitive Behavioral Therapy; Combin | 2005 |
[Effectiveness and tolerance of memantine in general practice].
Topics: Aged; Alzheimer Disease; Clinical Trials as Topic; Family Practice; Humans; Memantine; Multicenter S | 2005 |
Combination drug therapies for AD: progress is slow, but we must keep trying.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cholinesterase Inhibitors; | 2005 |
Health utilities in Alzheimer's disease and implications for cost-effectiveness analysis.
Topics: Alzheimer Disease; Antiparkinson Agents; Cost-Benefit Analysis; Health Services Needs and Demand; Hu | 2005 |
Antidementia agents: what is important in this class.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Economics, Pharmaceutical; Fe | 2005 |
[Modern therapy for dementia].
Topics: Aged; Algorithms; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Comorbidity; De | 2005 |
Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Ger | 2005 |
Antipsychotic dose-sparing effect with addition of memantine.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Dopamine Agents; Drug Therapy, Combinatio | 2005 |
Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Cholinesterase Inh | 2006 |
Spontaneous bruising as a possible adverse reaction to memantine.
Topics: Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Ecchymosis; Female; Humans; Memantine | 2005 |
Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cognition; Cost-Benefit Analysis; Disease Progr | 2005 |
UK government guidance on Alzheimer's drugs postponed.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Excitatory Amino Aci | 2005 |
Rationalizing therapeutic approaches in Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; I | 2005 |
[Little behavior improvement with memantine].
Topics: Alzheimer Disease; Clinical Trials as Topic; Excitatory Amino Acid Antagonists; Humans; Memantine | 2005 |
Exacerbation of Lewy bodies dementia due to memantine.
Topics: Aged; Alzheimer Disease; Dopamine Agonists; Hallucinations; Humans; Lewy Body Disease; Male; Memanti | 2005 |
Drugs for Alzheimer disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dopamine Agents; Humans; Memantine; Nootropic Agents | 2005 |
What we can learn from open-label extensions of randomized clinical trials.
Topics: Alzheimer Disease; Double-Blind Method; Drug Evaluation; Excitatory Amino Acid Antagonists; Humans; | 2006 |
[New options for the pharmacotherapy of Alzheimer disease after the approval of memantine? Re the article from DMW 8/2005].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dopamine Agents; Drug Therapy, Combination; Excitatory | 2006 |
Managing discontinuation syndrome in patients with dementia.
Topics: Aged; Alzheimer Disease; Dopamine Agents; Health Promotion; Humans; Memantine; Syndrome; Treatment R | 2006 |
Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Depressive Disorder; E | 2005 |
[Also consider non-cognitive disorders].
Topics: Aged; Alzheimer Disease; Brain; Cognition Disorders; Depressive Disorder; Excitatory Amino Acid Anta | 2005 |
I remember.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Canada; Cholinesterase Inhibitors; Dopamine Agents; Huma | 2006 |
Nationwide use of medicines for Alzheimer's disease by community-dwelling persons in Finland.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; | 2006 |
Low doses of memantine disrupt memory in adult rats.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Brain Edema; Disease Models, Animal; Excitatory Am | 2006 |
Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain.
Topics: Alzheimer Disease; Cost-Benefit Analysis; Dopamine Agents; Humans; Markov Chains; Memantine; Randomi | 2006 |
Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dopamine Agonists; Drug Inte | 2006 |
[Advances in Alzheimer's disease treatment].
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Donepezi | 2006 |
Magnesium supplementation in the treatment of dementia patients.
Topics: Alzheimer Disease; Autopsy; Calcium; Dementia; Dietary Supplements; Drug Synergism; Excitatory Amino | 2006 |
Memantine: the next trend in academic performance enhancement?
Topics: Alzheimer Disease; Cognition; Dopamine Agents; Excitatory Amino Acid Antagonists; Glutamic Acid; Hum | 2006 |
Use of memantine to treat Alzheimer's disease.
Topics: Alzheimer Disease; Canada; Dopamine Agents; Evidence-Based Medicine; Humans; Memantine; Randomized C | 2006 |
In vitro galantamine-memantine co-application: mechanism of beneficial action.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolep | 2006 |
Shift shown in influenza A adamantane resistance.
Topics: Adamantane; Alzheimer Disease; Antiviral Agents; Drug Resistance, Viral; Excitatory Amino Acid Antag | 2006 |
Visual hallucinations and agitation in Alzheimer's disease due to memantine: report of three cases.
Topics: Aged; Alzheimer Disease; Excitatory Amino Acid Antagonists; Female; Hallucinations; Humans; Memantin | 2007 |
Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane.
Topics: Alzheimer Disease; Animals; Brain-Derived Neurotrophic Factor; Cyclopentanes; Dose-Response Relation | 2006 |
Cholinesterase inhibitors and memantine have a role in the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Excitatory Amino Acid Antagonists; Humans; Memantine | 2006 |
Anti-Alzheimer drugs: life-threatening adverse effects.
Topics: Alzheimer Disease; Cardiovascular Diseases; Cholinesterase Inhibitors; France; Galantamine; Humans; | 2007 |
Memantine in the treatment of dementia.
Topics: Alzheimer Disease; Dementia; Dementia, Vascular; Excitatory Amino Acid Antagonists; Humans; Memantin | 2007 |
[Use of specific drugs for Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Drug Utilization; Excitatory Amino Acid Antagoni | 2007 |
Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Clinical Trials, Phase III as Topic; Cost-Benefit Analys | 2007 |
Therapies for Alzheimer's disease.
Topics: Alzheimer Disease; Alzheimer Vaccines; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; | 2007 |
Postmortem memantine concentrations.
Topics: Alzheimer Disease; Cause of Death; Drug Overdose; Excitatory Amino Acid Antagonists; Forensic Toxico | 2007 |
Memantine (Ebixa) in clinical practice - results of an observational study.
Topics: Activities of Daily Living; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Alzhei | 2007 |
Exacerbation of myoclonus by memantine in a patient with Alzheimer disease.
Topics: Aged; Alzheimer Disease; Donepezil; Excitatory Amino Acid Antagonists; Female; Humans; Indans; Meman | 2007 |
Alzheimer's disease: will advances made in the past turn the tide?
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Cholinest | 2007 |
Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Excitatory Amino Acid Antagonists; Female; Humans; Male; | 2007 |
Different conclusions about memantine.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Canada; Dose-Response Relationship, Drug; Drug Administr | 2007 |
[Alzheimer drugs for mild cognitive impairment].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Early Diagnosis; Galantamin | 2007 |
Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Canada; Cost-Benefit Analysis; Diagnostic and S | 2007 |
Incidence of cholinergic and memantine treatment in Alzheimer's disease in Finland.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Cholinergic Agents; Dopamine Agents; Drug Utilization; | 2007 |
Memantine acts as a cholinergic stimulant in the mouse hippocampus.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Central Nervous System Stimulants; Cholinergic Fib | 2007 |
Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study.
Topics: Adult; Aged; Aging; Alzheimer Disease; Cognition Disorders; Excitatory Amino Acid Antagonists; Femal | 2008 |
Psychosis and agitation in dementia: should general psychiatrists care?
Topics: Aged; Alzheimer Disease; Dementia; Excitatory Amino Acid Antagonists; Humans; Memantine; Psychotic D | 2008 |
Memantine-induced hepatitis with cholestasis in a very elderly patient.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chemical and Drug Induced Liver Injury; Cholestasis; Fem | 2008 |
Effects of memantine on neuronal structure and conditioned fear in the Tg2576 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Axons; Behavior, Animal; Brain; Conditioning, Psychological; Disease Mod | 2008 |
Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Area Under Curve; Benzylamines; Cholinesterase Inhibitor | 2008 |
Stroke, Alzheimer's patients may benefit from AIDS dementia drug.
Topics: AIDS Dementia Complex; Alzheimer Disease; Cerebrovascular Disorders; Clinical Trials as Topic; Excit | 1997 |
Clinical issues in current drug therapy for dementia.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Dopamine Antagonists; Ginkgo biloba; H | 2000 |
Weighing the benefits of new Alzheimer's treatments.
Topics: Alzheimer Disease; Clinical Trials as Topic; Ethics, Medical; Excitatory Amino Acid Antagonists; Hum | 2000 |
Promising vaccine treatment for alzheimer disease found.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Dopamine Agents; Humans; Memantine; Vaccines | 2000 |
[Drug therapy of dementia. Improving cognitive performance].
Topics: Aged; Alzheimer Disease; Cognition Disorders; Dementia, Vascular; Humans; Memantine; Neuropsychologi | 2001 |
[Geriatric assessment in 3 steps. Often mental decline is not correctly assessed].
Topics: Aged; Alzheimer Disease; Controlled Clinical Trials as Topic; Dementia; Dopamine Agents; Follow-Up S | 2002 |